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A B STR A C T
Naturally-acquired immunity (NAI) to malaria develops first to the m ost severe form o f 
disease followed by uncomplicated m alaria episodes. NAI is never com pletely achieved 
therefore asymptomatic P. falciparum  infections are often detected in adults living in 
m alaria endemic areas. The timing and sequential acquisition o f  im munity to the three 
distinct m anifestations o f  an infection suggests that different targets and m echanisms o f 
protection are involved. Immunity is thought to be partly mediated by antibodies 
directed to blood-stage antigens. This thesis explores the potential m erozoite targets and 
mechanisms o f  immunity to severe m alaria and to uncomplicated malaria episodes in 
Kenyan children.
First, using a well-studied cohort o f  children aged 1-12 years recruited during a period 
o f  high malaria transmission (Chonyi), IgG responses to five m erozoite antigens were 
quantified using a standard reference reagent. Thereafter, protective threshold 
concentrations were derived using a statistical approach and applied to a separate age- 
matched cohort (Junju) in which antibodies to the same antigens were not associated 
with protection using a conventional cu toff o f  seropositivity. Children who achieved 
antibody concentrations above the proposed thresholds had a reduced risk o f  developing 
clinical episodes o f m alaria during the subsequent 6 -months o f  follow-up.
Second, using a matched case-control design nested within a birth cohort o f  children 
followed up every three months for the first two years o f  life, I examined the targets and 
mechanisms o f  protection against severe malaria. Children admitted to Kilifi County 
hospital with well-defined severe malaria were identified and matched to controls who 
were never admitted to hospital with severe malaria. Antibody responses to five 
merozoite antigens were measured in all the three-monthly samples from the cases and 
controls and prospectively associated with the odds o f  developing severe m alaria. The
ability o f  antibodies to inhibit parasite growth in the Growth Inhibition Activity (GIA) 
assay and m ediate antibody dependent respiratory burst (ADRB) by neutrophils was 
also investigated and prospectively associated with the odds o f  developing severe 
malaria. Dynamic antibody patterns were observed with transient peaks in antibody 
titres occurring during asymptomatic infections in some children. Overall, antibody 
levels were sim ilar in the cases and controls and were not associated w ith a reduced 
odds o f  developing severe malaria with the exception o f  anti-A M A l antibodies. 
Interestingly, children who had a combination o f antibodies that m ediated both GIA and 
ADRB, had a significantly reduced odds o f developing severe malaria.
This thesis provides direct evidence o f an association between achieving specific 
antibody thresholds and protection against uncom plicated episodes o f  malaria. M y 
findings also highlight the possible involvement o f  multiple antibody-m ediated effector 
functions in protection against severe m alaria in young children. These findings 
enhance our knowledge o f  the acquisition o f immunity to malaria and provide insights 
that may be valuable for advancing m alaria vaccine developm ent and testing.
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CHAPTER ONE
1.0 Introduction
M alaria is a global public health scourge affecting approximately 3.4 billion people 
worldwide. The W orld Health Organization estimates that in the year 2012, 
approximately 207 million cases were reported accounting for 627,000 deaths (W HO 
2013). A disproportionate num ber o f  the malaria-related deaths occur in sub-Saharan 
Africa with pregnant women and children under the age o f 5 being m ost severely 
affected. Despite the grave outlook, a trem endous achievem ent towards reducing the 
m alaria burden has been reported in several countries over the past decade, with 
mortality rates declining by 42% globally in all age groups and by 54% in African 
children aged five and below, since the year 2000 (W HO 2013). Huge financial 
investments in expansion and coverage o f  m alaria control programmes particularly in 
resource-poor settings have contributed to this reduction, although changing clim ate 
patterns, improved living conditions, increased urbanization and human settlement, 
have also played a role (Noor et al. 2014). Large-scale deploym ent o f  insecticide treated 
bed nets (ITNs) has risen significantly from 3% to 54% between the year 2000 and 2013 
contributing to an increase in the proportion o f  protected populations. Am ong 
individuals seeking care at health facilities, accurate diagnosis o f  suspected m alaria 
cases has risen from 44%  to 64% and this is attributable to the availability o f  rapid 
diagnostic tests (RDTs) for screening. In the year 2007, the W HO recom m ended the 
uptake o f  highly effective artemisinin based com bination (ACT) drugs in health 
facilities as first-line treatm ent for malaria and this has been adopted by at least seventy 
nine countries (W HO 2013).
Although the benefits o f  the existing m alaria control measures are unprecedented, only 
52 out o f  103 countries are on track towards realizing the goal o f  the Global M alaria
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Action Plan initiative, which is to reduce malaria incidence rates by three quarters, by 
the year 2015 (W HO 2013). Furthermore, these countries accounted for only 8 m illion 
(3.5%) o f  the 226 million reported m alaria cases in the year 2000, which is an indication 
that the war against m alaria is far from being achieved. In addition, several countries 
have also reported the emergence o f  parasites resistant to ACT drugs (W ongsrichanalai 
and M eshnick 2008, Noedl et al. 2008, Dondorp et al. 2009) and increased resistance o f  
m alaria vectors to commonly used pyrethroids (Ranson et al. 2011, Butler 2011), w hich 
threatens the ability to sustain m alaria control interventions. A multifaceted approach 
involving the sustenance and expansion o f  available malaria control approaches, the 
search for more effective drugs, m onitoring o f  em erging drug resistance to the available 
ACTs, better vector m anagement tools and the search for more effective preventative 
options such as vaccines, is key to achieving the current drive towards m alaria 
elimination and eradication.
To date, vaccination remains the m ost cost effective method o f reducing the burden o f  
diseases particularly in areas with limited resources (Ehreth 2003). W idespread 
vaccination programmes have led to the eradication o f  small pox and are currently 
successful against the prevention o f  polio, measles, hepatitis and Haemophilus 
influenzae, amongst others. Despite concerted efforts over the years to develop vaccines 
against parasitic infections, there is as yet no licensed m alaria vaccine. This is not 
surprising given the complex life cycle o f the m alaria parasite both in hum an and 
mosquito hosts and the numerous proteins expressed during the different developm ental 
stages. The most advanced malaria vaccine, currently undergoing Phase III trials in 
paediatric populations in Africa has only achieved m odest efficacy o f  30% and 50% 
against severe and clinical episodes o f  malaria, respectively (Agnandji et al. 2011, 
Agnandji et al. 2012) with waning protective efficacy over a four-year follow-up period 
(Olotu et al. 2013).
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1.1 Life cycle of Plasmodium spp
M alaria is caused by infection with the obligate intracellular parasites o f  the 
Plasmodium species transm itted via the bite o f  an infected female anopheline mosquito. 
The four species o f  Plasmodium that infect humans are Plasmodium falciparum, 
Plasmodium ovale, Plasmodium vivax and Plasmodium malariae. Recently, the monkey 
parasite P. knowlesi (that is morphologically indistinguishable from P. malariae) was 
identified in individuals living in close proximity to macaque m onkeys (Singh et al. 
2004) and has since been established as the fifth hum an Plasmodium species (W hite
2008).
The life cycle o f  Plasmodium spp involves an asexual cycle in the human host and a 
sexual cycle, in the mosquito vector (Figure 1.1). Infection in the human host begins 
with the bite o f  an infected female anopheline mosquito, which injects sporozoites 
under the skin. The motile sporozoites penetrate the blood vessels and are carried to the 
liver where they cross the liver endothelium and invade hepatocytes (Sinnis and Coppi 
2007). Quantitative imaging studies using fluorescently labelled P. berghei parasites in 
mice have shown that a proportion o f sporozoites also migrate from the dermis to the 
proximal draining lymph node and are subsequently destroyed by resident dendritic 
cells (Amino et al. 2006). Inside the liver, a clinically silent stage, sporozoites m ultiply 
and differentiate into thousands o f m erozoites enclosed within liver schizonts. 
Following schizont rupture, the merozoites are confined within vesicles known as 
merosomes, which bud o ff from the hepatocytes into the liver sinusoids releasing the 
merozoites into circulation (Sturm et al. 2006). P. vivax and P. ovale infections are 
characterized by dormant hypnozoites which persist in the liver causing relapses that 
occur upto a year after the primary infection (W hite 2011).
Once the merozoites are released into circulation, they attach to and invade red blood
cells to initiate the intra erythrocytic phase o f developm ent that lasts upto 48 hours for 
P. falciparum, P. vivax and P. ovale, 72 hours for P. malariae and a shorter period o f  24 
hours for P. knowlesi. Upon erythrocyte invasion, the merozoite differentiates into the 
ring-stage, then the trophozoite stage and finally undergoes asexual replication to form 
mature schizonts containing merozoites. The schizonts rupture and release free 
m erozoites which re-invade erythrocytes to initiate a repeat cycle o f  erythrocytic 
development. A  small proportion o f  blood-stage parasites differentiate into sexual forms 
(male and female ganietocytes) that can be taken up by female anopheles mosquitoes 
during feeding. In the mosquito gut, the male and female gametocytes are released from 
infected red blood cells and develop into male and female gametes. The male and 
female gametes fuse to form diploid zygotes, which develop into m otile ookinetes that 
traverse the mosquito midgut wall and form oocyts. The oocysts undergo division to 
produce thousands o f  haploid sporozoites, which are released upon oocyst rupture and 
migrate to the salivary glands. The cycle o f  human infection is re-initiated when the 
mosquito takes a blood meal, injecting the sporozoites from  its salivary glands into the 
dermis o f the skin.
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Figure 1.1 T he life cycle o f Plasmodium spp. The diagram shows the developmental stages 
of the parasite in the human and mosquito hosts. The estimated numbers o f  parasites at each 
stage o f  the life cycle are shown in boxes. Figure adopted from (White et al. 2014b).
1.2 The epidem iology o f P. falciparum  m a laria
During the past decade, the epidemiology o f  malaria has been changing with substantial 
reductions in malaria transmission (Noor et al. 2014) and the number o f  clinical cases 
reported in some countries (Okiro et al. 2007, O'Meara et al. 2008, Ceesay et al. 2010, 
Brasseur et al. 2011, Bouyou-Akotet et al. 2009, Mmbando et al. 2010, Otten et al.
2009), although this phenomenon is not homogenous in all countries (Okiro et al. 2009, 
Okiro et al. 2011, Okiro et al. 2013, Roca-Feltrer et al. 2012). For instance, in Malawi,
sampling o f  four hospitals revealed that the number o f  admissions with m alaria 
increased or remained unchanged over a ten-year period, despite uptake o f  m alaria 
intervention measures (Okiro et al. 2013). A sim ilar scenario o f increase in m alaria 
admissions from 1999 to 2009 o f  between 47%  and 350% in five hospitals in U ganda 
has also been reported (Okiro et al. 2011).
Recent parasite prevalence estimates compiled from African countries show that at least 
26.7% o f  people have transitioned into a lower endemicity class in the year 2010 
compared to 2000 (Figure 1.2). The proportion o f  individuals living in areas o f  high 
transm ission (classified as hyper or holoendem ic) has also declined by 16.1% and most 
strikingly, the m ajority (87%) o f  the total population living in the two highest 
endemicity classes are concentrated in only ten countries (Noor et al. 2014). It is clear, 
therefore, that despite the improvements generally noted in the continent in terms o f  
declining m alaria transmission, these findings cannot be extrapolated to all endemic 
settings.
Spatial variations in malaria transm ission at the m icroepidemiological level have been 
reported in several countries classified as having low (Noor et al. 2011) or m oderate to 
high transmission (Bousema et al. 2010, Bejon et al. 2010, Kobayashi et al. 2012, 
Gaudart et al. 2006). These studies have found that particular regions/villages have 
relatively more febrile malaria cases, higher parasite prevalence or higher antibody 
seropositivity, classifying them as “hotspots” o f  malaria transmission. Some o f  the 
hotspots are stable over time (Bejon et al. 2010, Ernst et al. 2006) whereas others have 
only been identified during a single survey (Bousem a et al. 2010, Bejon et al. 2011b). 
Targeted intervention strategies in “hotspot” areas should have a greater im pact on 
m alaria transmission.
Reflecting the decline in transmission that has occurred, there has been a significant
decrease in the overall num ber o f  clinical cases reported in several national health 
facilities. For instance, in Senegal, there was a 30-fold decrease in num ber o f  episodes 
over a 15-year period (Brasseur et al. 2011). Similarly, in Kenya and The Gambia, the 
num ber o f paediatric admissions with malaria fell from 18.43 per 1000 children in 2003 
to 3.42 in 2007 (O 'M eara et al. 2008) and by 74%, 69% and 27% at three sites (Ceesay 
et al. 2010), respectively. However, the incidence o f  m alaria in some countries still 
remains high and appears to be increasing (Okiro et al. 2011, Okiro et al. 2009, Okiro et 
al. 2013). The changes in m orbidity have been paralleled by changes in the age-pattern 
o f m alaria admissions with a shift in cases to older ages (O 'M eara et al. 2008). The 
pattern o f clinical disease varies by age and transm ission intensity, whereby in areas o f 
high endemicity, the burden o f disease is greatest in children under the age o f 5 years 
whereas in areas o f  low transm ission intensity, both children and adults bear the brunt 
o f  disease (Carneiro et al. 2010). Using mathematical models o f  data collected from  9 
countries, Griffin et a l  predicted that 57% o f malaria cases were observed in children 
under 5 years o f  age in areas o f  high transmission (60% parasite prevalence in 2-10 year 
olds) whereas the estimates were reduced to 10% in areas o f low transm ission (5% 
parasite prevalence in 2-10 year olds) (Griffin, Ferguson and Ghani 2014). A  sim ilar 
pattern has also been reported in a systematic review and pooled analysis o f  29 studies 
showing that this trend is independent o f  the seasonality patterns observed in the 
different settings (Carneiro et al. 2010). The general consensus therefore is that the 
brunt o f  disease continues to be borne by the younger age groups and intervention 
strategies need to be tailored depending on the epidemiological context taking into 
account the observed age-patterns o f mortality and m orbidity as m alaria transm ission 
continues to decline.
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Figure 1.2. E stim ated  Plasmodium falciparum  p a rasite  prevalence endem icity  m aps in 
the y ea r 2000 (A) and  2010 (B) in A frica. The parasite prevalence rate in children aged 2 
-  10 years (P/PR2-10) was used to define the different endemicity classes as follows: >75% 
P/PR 2-10 (holoendemic), >50% - 75% P/PRi-io (hyperendemic), >10% - 50% P /PR 2-10 
(mesoendemic), 1% - 10% P/PR 2-10 (hypoendemic) and <1% P/PR 2-10 (low stable 
endemic). Figure adopted from (Noor et al. 2014).
1.3 C linical fea tu res o f P. fa lciparum  m a laria
After the onset o f  an infection, several host, parasite and environmental related factors
influence disease progression and outcome (Miller et al. 2002). The initial symptoms o f
malaria are variable, non-specific and clinically indistinguishable from those o f  flu and
other common causes o f  fever. Patients often present with intermittent fever, headache,
malaise, muscle aches and occasionally abdominal pains and diarrhea. In very young
children, there's increased irritability, vomiting and refusal to eat (Crawley et al. 2010).
In the absence o f  proper diagnosis and treatment, P. falciparum infections can progress
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to severe life-threatening m alaria characterized by impaired consciousness (prostration 
or coma), seizures, respiratory distress, severe anemia, hypoglycaemia, metabolic 
acidosis and hyperlactataemia (M arsh et al. 1995, W HO 2012). These symptoms are 
frequently seen in both children and adults but pulm onary oedema, renal failure and 
severe jaundice are mainly restricted to adults. The spectrum o f clinical symptoms o f 
severe m alaria varies depending on host age and m alaria transmission intensity. In areas 
o f  high m alaria transm ission intensity, severe disease occurs in children less than 2 
years often presenting with severe m alaria anemia (Hb <5g/dL) whereas in areas o f 
moderate to low transmission, severe m alaria peaks at a later age (3-5 years) often 
presenting as cerebral m alaria (CM) (impaired consciousness, com a or prostration) in 
this age group (Roca-Feltrer et al. 2010, Reyburn et al. 2005, Snow et al. 1994). 
According to the W HO guidelines, cerebral malaria is defined as unarousable com a 
after 1 hour o f term ination o f  a seizure in a patient with P. falciparum  parasitem ia, 
excluding other causes o f  encephalopathy (W HO 2012). The depth o f com a in patients 
is assessed based on the verbal, m otor and gaze responses on a scale o f  0 to 5, referred 
to as the Blantyre com a score (BCS). Unarousable coma is defined as a BCS<3 and 
impaired consciousness as a BCS<5. Histological sections obtained from postm ortem  
samples o f  fatal CM cases demonstrated the sequestration o f  infected red blood cells 
within the brain blood vessels in a m ajority and thus associated with hypoxia, 
hypovolem ia and brain hemorrhages (Taylor et al. 2004). However, am ongst the 
clinically diagnosed CM cases, 23% o f  those who died showed no evidence o f  parasite 
sequestration underscoring the lack o f  specificity o f  clinical diagnosis o f  cerebral 
malaria. Recent descriptions o f retinal changes can reliably confirm CM cases and have 
successfully correlated severity o f the retinal signs with fatal disease outcom e (Beare et 
al. 2004, Lewallen et al. 1996, Hero et al. 1997). Prolonged multiple seizures are a 
prominent feature o f  cerebral m alaria that often result in death occurring w ithin 24
hours o f  admission in 20% o f  cases or residual neurological sequelae that includes 
ataxia, speech and hearing disorders, epilepsy, cortical blindness or hemiplegia 
occurring in 10% o f the cases (Carter et al. 2005, Idro, Jenkins and Newton 2005, Idro 
et al. 2007). Severe malarial anemia (SMA) defined as a hem oglobin concentration o f 
<5g/dL o f blood in the presence o f  detectable P. falciparum  parasites is the m ost 
frequent presenting feature in very young children (aged 1 year) in areas o f high 
transm ission and in children aged 2 years in areas o f  low and stable transm ission 
(Reyburn et al. 2005). The pathophysiology o f  SMA could directly or indirectly involve 
destruction o f  infected and non-infected red blood cells, suppression o f erythropoiesis 
or dysregulation o f  inflammatory mediators (Reviewed in (Perkins et al. 2011). 
Respiratory distress, a m anifestation o f  severe malaria which is characterized by deep 
breathing with in-drawing o f  the bony structures o f  the lower chest walls is a clinical 
indicator o f  metabolic acidosis (M arsh et al. 1995). Owing to increased metabolic 
demands, children with metabolic acidosis also develop hypoglycaem ia (blood glucose 
<2.2mmol/l). Impaired vaso perfusion that is thought to occur due to sequestration o f 
parasites in the microcirculation leads to accumulation o f  lactic acid, released during 
anaerobic glycolysis. The prognosis is often fatal particularly in children who also 
present with impaired consciousness (Dondorp et al. 2008, M arsh et al. 1995). The 
clinical features o f pulmonary oedema in adults are similar to acute respiratory distress 
syndrome. Patients present with increased respiratory rates, increased pulm onary 
capillary permeability and reduced arterial oxygen levels, which results in hypoxia 
related signs such as convulsions and impaired consciousness. Pulm onary oedema has a 
case fatality rate o f greater than 80%. Acute renal failure, a fairly common com plication 
seen in adults and older children presenting to hospital with severe m alaria (Dondorp et 
al. 2008) occurs due to tubular necrosis, a reversible condition in those who survive. 
Since severe malaria is a multi-organ, multi-system  disorder, patients frequently present
with overlapping symptoms, o f  which, respiratory distress is the leading prognostic 
marker for fatal outcome (Marsh et al. 1995. Dondorp et al. 2008, Kendjo et al. 2013).
Malaria without 
impaired conscious­
ness, severe respira­
tory distress, or severe 
’ anemia (1027) 
0 .6%
Malaria with 
severe anemia 
(506)
Malaria with 
impaired
consciousness 
(332)
Malaria with 
severe 
respiratory 
distress 
(132)
F igure  1.3 The prevalence, overlap  and  m orta lity  o f the m a jo r clinical sym ptom s o f 
severe m alaria  in a ru ra l hospital in coastal K enya. Figure adopted from (Marsh et al. 
1995).
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M alaria in pregnancy is also common in m alaria endemic areas particularly during first 
pregnancies, predisposing the infant to congenital malaria, low birth weight, premature 
delivery and stillbirth (Desai et al. 2007, Shulman and Dorm an 2003). The risk o f  infant 
death is greater if  maternal m alaria occurs during the final trim ester o f  pregnancy. 
Maternal anemia is the m ost frequent symptom seen during pregnancy although 
hypoglycem ia and pulmonary oedema are also observed in a proportion o f  cases.
1.4 Pathogenesis o f severe P. falciparum  malaria
Host age, level o f  immunity, parasite virulence, parasite multiplication rate, antigenic 
variation, human genetic and environmental factors are important determ inants o f  
disease outcome and progression following an infection (M iller et al. 2002). The 
pathophysiology o f  severe malaria is complex and often comprises multiple and/or ill- 
defined mechanisms although the most consistent observations involve sequestration o f  
mature parasites in the micro vasculature o f  the m ost vital organs (Taylor et al. 2004, 
M acPherson et al. 1985, Silamut et al. 1999) and inflammation related pathology 
(reviewed in (Schofield and Grau 2005, M ackintosh, Beeson and M arsh 2004, M iller et 
al. 2002). Opinions are divided over which o f these two represent the m ajor driving 
force leading to disease and death.
Parasite proteins expressed on the surface o f  mature infected red blood cells, o f  which
P. falciparum  erythrocyte membrane protein -1 (P fE M P l) is the most studied, mediate
binding to receptors expressed on the endothelial lining o f  various organs such as the
brain, kidney, lung, liver and also modify the RBC surface reducing its flexibility and
ability to circulate (Dondorp, Pongponratn and W hite 2004). In the brain and placenta,
upregulation o f  expression o f  intercellular adhesion m olecule 1 (ICAM 1) (Turner et al.
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1994) and chondroitin sulfate A (CSA) (Fried and Duffy 1996, Salanti et al. 2003) 
respectively, promotes cytoadherence o f  infected red blood cells. Parasites that 
sequester in the placenta express a unique variant o f  P/EMP1 known as var2csa. 
Sequestration also leads to widespread endothelial activation via m echanisms that are 
not fully understood but several authors have identified angiogenic factors such as 
angiopoietin-2, Von W illebrand factor (both released from secretory vesicles known as 
weibel-palade bodies), soluble ICAM1 and vascular endothelial growth factor (VEGF) 
as important markers o f  disease severity (Kim et al. 2001, Oh et al. 1999, Yeo et al. 
2008, Tchinda et al. 2007). In in vitro experiments, addition o f  VEFG increased 
expression o f  ICAM-1 and Ang-2 in endothelial cells (Oh et al. 1999, Kim et al. 2001). 
Increased levels o f angiopoeietin-2 were also associated w ith fatal outcome, increased 
parasite biomass, increased levels o f  ICAM1 and increased endothelial activation in 
Thai adults (Yeo et al. 2008, Lovegrove et al. 2009), Ugandan children (Lovegrove et 
al. 2009) and M alawian children (Conroy et al. 2012) with cerebral malaria. Plasm a 
levels o f  Von W illebrand factor, a m arker o f  endothelial activation were also elevated in 
children with severe malaria and were positively correlated with lactate levels, a 
biochemical m arker o f  disease severity (Hollestelle et al. 2006). Endothelial activation 
can be reversed by L-arginine and nitric oxide in in vitro experiments (De Caterina et al.
1995) whereas in vivo, low levels o f  both are associated with disease severity in 
children (Anstey et al. 1996, Lopansri et al. 2003) and adults (Yeo et al. 2007). These 
findings suggest that nitric oxide and L-arginine could be potential therapeutic agents 
for treatment o f cerebral malaria but clinical trials o f  both as possible adjunct therapies 
have not been successful (reviewed in (John et al. 2010).
Parasite toxins and red blood cell (RBC) debris released during schizont rupture such as 
glycosylphosphatidylinositol (GPI) and hem ozoin (product o f  heme breakdown) interact 
with toll like receptors on macrophages and dendritic cells m ediating excessive release
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o f inflammatory mediators TNF-a, IL-12, IL-18 and nitric oxide (Coban et al. 2005, 
Gowda 2007, Nebl, De Veer and Schofield 2005). The accumulation o f  monocytes, 
m acrophages (Patnaik et al. 1994), platelet and fibrinogen deposition (Grau et al. 2003) 
and microparticles (vesicles released from the cell membrane o f  apoptotic or activated 
cells) in the brain m icrovasculature leads to inflammation-mediated pathology, w hich is 
thought to contribute to disease severity both in human and experimental animal models 
(reviewed in (Schofield and Grau 2005)). For instance, release o f  TN F-a by 
inflammatory cells upregulates the expression o f  ICAM1 to which infected red blood 
cells bind (Turner et al. 1994, Turner et al. 1998) and platelets enhance cytoadherence 
o f  infected erythrocytes (IEs) by bridging the interaction between IEs and endothelial 
cells in the brain through CD36 binding (W assm er et al. 2004). In addition, platelet 
derived microparticles may increase binding o f  leukocytes and IEs to the endothelium, 
enhance endothelial permeability and promote apoptosis (reviewed in (Schofield and 
Grau 2005)). Elevated expression o f  inflammatory cytokine genes such as TN F-a and 
IL-1 has been demonstrated in autopsy brain tissues from fatal cases o f  CM (Brown et 
al. 1999, Turner et al. 1994). Levels o f  pro inflammatory cytokines such as TN F-a, IL- 
1, IL-8, IL-12 and IL-6 m easured in serum are also significantly elevated in severe 
m alaria (SM) patients (Lyke et al. 2004, Kwiatkowski et al. 1990, Day et al. 1999) 
whereas IL-10 and TGF-p are present at low levels (Day et al. 1999). Linking these 
findings together, presence o f  mature sequestered parasites leads to recruitm ent o f 
leukocytes and the ensuing inflammatory environment present in the brain veiy likely 
contributes to the pathology o f  cerebral malaria.
The pathophysiology o f severe malarial anemia may in part involve destruction o f  both 
infected and uninfected red bloods cells, bone marrow suppression o f  erythropoiesis and 
altered patterns o f inflammatory mediators (reviewed in (Ekvall 2003)). There is a 
consensus that the clearance o f infected red blood cells only plays a m inor role towards
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severe anemia pathology. Elevated levels o f  TN F-a and low levels o f  IL-10 have been 
reported in young children with severe malarial anemia (Othoro et al. 1999, Kurtzhals et 
al. 1998). The exact mechanisms o f  action o f  cytokines that lead to developm ent o f 
severe anemia are not fully known although in vitro experiments suggest that TN F-a 
(Dufour et al. 2003) and IFNy (Felli et al. 2005) could play a role in suppression o f 
eiythropoiesis. In a study conducted in The Gambia, children presenting w ith chronic 
anemia had impaired erythropoiesis and reduced reticulocyte counts (Abdalla and 
Pasvol 2004) thought to occur due to impaired production o f erythropoietin during 
severe malaria. However, follow up studies showed that the levels o f  erythropoietin 
were normal in children with severe anemia (Newton et al. 1997) and m ore recently in 
vitro  experiments demonstrated that decreased responsiveness o f  erythrocyte precursors 
in the bone marrow to erythropoietin could explain these findings (Chang, Tam and 
Stevenson 2004). The clearance o f uninfected RBCs by the spleen (Looareesuwan et al. 
1987) has been shown to contribute to the developm ent o f  severe anemia. Impaired 
RBC deformability is a strong predictor for m ortality in children and adults w ith severe 
m alarial anemia (Dondorp et al. 1997, Dondorp et al. 2002). These cells also undergo 
intrinsic changes such as oxidation, externalization o f  phosphatidylserine and increased 
com plem ent deposition, which targets them for splenic clearance by m acrophages 
(reviewed in (Lamikanra et al. 2007)).
Obstruction o f  blood flow as a result o f  parasite sequestration precipitates the 
developm ent o f  metabolic acidosis. Tissues undergo anaerobic glycolysis, w hich leads 
to accumulation o f lactic acid (Day et al. 2000) although lactate production by parasites 
also augments these levels.
Taken together, the studies above illustrate the pathophysiological diversity o f  the 
different malaria syndromes and the complex multifactorial processes that precipitate 
developm ent o f severe disease.
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1.5 Management of severe malaria
According to the W HO guidelines, the recommended drug o f  choice for the treatm ent o f 
severe falciparum  m alaria is intravenous (IV) or intram uscular (IM) artesunate (W HO
2010). This policy was informed by the largest trial conducted in Africa, com paring the 
efficacy o f artesunate versus quinine in severely ill children. The study showed a 
significant reduction in mortality from 10.9% to 8.5% o f  artesunate versus quinine 
(Dondorp et al. 2010). For both children and adults, artesunate 2.4 m g/kg o f  body is 
administered IV or IM on admission, then at 12 hours and 24 hours. Thereafter, doses 
are given once a day (W HO 2012). In the absence o f  parenteral artesunate, artem ether 
or quinine are given as alternative drugs. For patients presenting to hospital with 
convulsions, treatment with intravenous or rectal benzodiazepines such as diazepam  is 
recommended (W HO 2012). The airways should also be maintained open and breathing 
support provided if  necessary. Use o f  prophylactic anticonvulsants is not advised 
following results o f  a large double-blind placebo trial o f  20 mg/kg phenobarbital in 
Kenyan children that demonstrated doubled mortality rates in children presenting with 
cerebral m alaria who received phenobarbital, possibly due to respiratory arrest (Crawley 
et al. 2000). In acute renal failure, fluid balance and urinary sodium levels should be 
checked and patients started on hemofiltration or hemodialysis (Phu et al. 2002). Blood 
glucose levels should be monitored every four hours particularly in unconscious patients 
and cases o f hypoglycemia (blood glucose levels < 2.2 mmol/1) treated immediately 
with 0.3-0.5 g/kg body weight o f  bolus glucose. In areas o f  high m alaria transm ission, 
blood transfusion for severe anemia is recommended for children with hem oglobin 
levels <5 g/lOOmL (hematocrit <15%) whereas in areas o f  low transm ission, the 
threshold is 7 g/lOOmL (hematocrit <20%) (W HO 2010). However, these 
recommendations are based on opinions o f  physicians, as adequate trials to ascertain 
these practices are lacking. According to the W HO guidelines, patients presenting to
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hospital with shock, hypovolem ia and respiratory distress particularly with acidotic 
breathing should receive fluid resuscitation in addition to standard care (W HO 2013). 
However, results o f  a large randomized trial in African children comparing fluid 
resuscitation with albumin or saline against receiving no bolus demonstrated increased 
m ortality in children who received bolus fluids (M aitland et al. 2011) providing strong 
evidence against this com m on practice and challenging the existing W HO policy o f 
fluid administration in shock patients (Kiguli et al. 2014). Rapid bolus infusion is 
contraindicated in individuals o f  all ages as it could lead to pulmonary oedema. Severe 
m alaria in pregnancy, associated with >50%  m ortality should be treated with parenteral 
artesunate over quinine due to recurrent hypoglycaem ia associated with quinine. The 
clinical status o f  patients with severe m alaria deteriorates very rapidly, therefore 
frequent observation for vital signs, m onitoring o f  blood glucose and hemoglobin levels 
and parasite counts every 12-24 hours is recommended (W HO 2013).
1.6 Malaria control interventions
The WHO recommends a multifaceted approach for malaria prevention, com prising o f  
(i) vector control using indoor residual spraying (IRS), larval control and use o f  
insecticide treated nets (ITNs), (ii) chemoprevention for the most vulnerable 
populations by means o f  intermittent preventive therapy (IPT) and seasonal m alaria 
treatment, (iii) accurate and prompt diagnosis and treatm ent with highly active 
artemisinin based combination therapy (W HO 2013).
1.6.1 Vector control strategies
The goal o f  vector control interventions is to m inim ize hum an-vector contact and to 
lower m alaria transm ission intensity by reducing the average lifespan o f  vector
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populations (Beier et al. 2008, W HO 2013). In sub-Saharan Africa, scale-up in 
distribution o f  ITNs has increased the proportion o f  the population with access from 
10% in 2005 to 42% in 2013 and as a result, many deaths have been averted (W HO 
2013). Lengeler et al summarized results o f  individual and cluster randomized trials o f  
ITN usage and showed a protective efficacy o f 17% and approximately 50% reduction 
in incidence o f  uncomplicated m alaria am ong ITN users (Lengeler 2004). However, 
although the WHO recommends that all individuals at risk o f  m alaria should sleep 
under a treated net, current coverage is way below the target required to reduce malaria 
burden and mortality. In a recent meta analysis o f  strategies for delivering ITNs at scale 
for m alaria control, the range o f  ITN usage am ong children under the age o f  five was 
12% to 94% (W illey et al. 2012).
Approximately forty African countries have adopted indoor residual spraying as a tool 
for m alaria control (W HO 2013). Four general chemical classes o f insecticides are 
recommended for IRS and their uptake in different areas depends on safety profiles, 
data on insecticide resistance, residual efficacy, cost, community acceptance and types 
o f surfaces to be sprayed. According to the W HO, IRS efficacy against m alaria- 
attributable m ortality and reducing malaria transm ission in targeted com m unities can 
only be achieved if  >80%  o f  houses and shelters are treated (WHO 2013). Selection 
pressure due to widespread use o f  pyrethroids for agriculture and treatm ent o f  bed nets 
has contributed to emergence o f  resistance (Ranson et al. 2011, Brouqui, Parola and 
Raoult 2012, Himeidan et al. 2011). Larval treatm ent which involves regular treatm ent 
o f  water bodies with a biological or chemical compound to reduce the num ber o f  
mosquito larvae is difficult to achieve in rural settings since mosquito breeding sites are 
often temporary, widely spaced and difficult to enumerate. Larviciding is therefore 
mostly feasible in urban areas where the breeding sites are few, easy to find and 
permanent.
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1.6.2 Chemoprevention and chemoprophylaxis
In areas o f  moderate to high malaria transmission, the W HO recommends 
administration o f  a full course o f sulphadoxine-pyrimethamine (SP) to all pregnant 
wom en at each scheduled antenatal visit after the first trim ester (W HO 2004). Each dose 
should be administered at least one month apart up to the time o f  delivery. This 
approach has also been extended to infants (intermittent preventive treatm ent in in fan ts- 
iPTi) through the routine expanded immunization programme. Regardless o f  the 
presence or absence o f  parasitemia, infants receive three doses o f SP in total, each given 
along with the second and third doses o f  DPT and measles vaccines. Pooled data 
obtained from six randomized trials o f iPTi with SP demonstrated partial protection 
against uncomplicated m alaria (30%), anemia (21%) and hospital adm issions with 
malaria parasitem ia (38%), but no effect on mortality (Aponte et al. 2009). The WHO 
also recommends seasonal m alaria chemoprevention (SMC) to all children aged 3-59 
months in areas o f highly seasonal m alaria transmission (W HO 2013). Children receive 
four doses o f amodiaquine plus SP, each administered monthly from the start o f  the 
m alaria transmission season. Results from a meta analysis o f  twelve studies showed an 
overall protective efficacy o f 82% during the malaria transm ission season and 57% 
against all-cause mortality (W ilson 2011), suggesting that SMC is a highly effective 
control approach in areas with markedly seasonal m alaria transmission.
1.7 Malaria vaccines
The unprecedented success o f vaccines against polio, tetanus, diphtheria and the
successful eradication o f  small pox and rinderpest demonstrates w ithout doubt the
potential o f  this approach in alleviating the burden o f infectious diseases (Andre et al.
2008, Levine and Robins-Browne 2009). O f note however, is the unavailability o f
vaccines against parasitic infections including malaria, despite more than 30 years o f
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ongoing efforts to develop one. M ore than 40 vaccine-testing projects are currently 
underway (reviewed in (Schwartz et al. 2012)) and there are renewed efforts to identify 
additional candidates from the over 5,200 parasite proteins (Gardner et al. 2002). 
Vaccine targets are based on the pre-erythrocytic, erythrocytic and sexual stages o f 
parasite developm ent in the human host.
1.7.1 Pre-erythrocytic stage vaccines
Experiments conducted in the 1970s demonstrated that vaccination with radiation-
attenuated sporozoites could induce sterile protection in humans (Clyde et al. 1973) and
animals (Nussenzweig et al. 1967, Gwadz et al. 1979). Despite this dem onstration, there
has been relatively slow progress towards advancem ent o f  this vaccination approach,
until recently, owing to i) the requirem ent o f  a high dose o f irradiated sporozoites
(>10,000) to induce sterile protection that is difficult to achieve technically, in large
quantities and to good manufacturing practice (GMP) standards and ii) the num ber o f
mosquito bites required to inoculate such a high sporozoite dose (5-19 biting sessions).
The challenge o f  producing large doses o f  aseptic and purified sporozoites (P /3PZ ) has
been resolved recently (Hoffman et al. 2010, Epstein et al. 2011) and in a subsequent
clinical trial, Epstein et a l  demonstrated that the route o f  adm inistration o f  viable
PJSPZs was crucial in achieving protective efficacy. Volunteers who received the dose
via subcutaneous or intradermal injection using a needle and syringe mounted
suboptimal immune responses and achieved inadequate protection (Epstein et al. 2011)
in comparison to individuals who were immunized with non-irradiated sporozoites via
mosquito bites followed by a prophylactic regimen o f  chloroquine (Roestenberg et al.
2011). This could be attributed to inadequate antigen presentation since m ost o f  the
sporozoites are dead after cryopreservation (Chakravarty et al. 2007).
Given the challenges o f  deploying a vaccine in the field using m osquito bites,
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determination o f  an optimal route o f administration o f  the sporozoites is crucial and in 
experiments conducted in non-human primate models, intravenous adm inistration o f 
P/SPZ elicited potent and durable sporozoite-specific T cell responses (Epstein et al.
2011). Recently in a human trial, repeated intravenous administration o f  i /S P Z  using 
needle and syringe elicited high level, dose-dependent protection against controlled 
human m alaria infection (CHM I) (Seder et al. 2013) suggesting that this inoculation 
approach may be effective in future.
Other research groups have focused on development o f subunit sporozoite vaccines and 
currently the candidates under clinical developm ent are CSP, LSA-1, Exp-1 and 
SSP2/TRAP. The m ost advanced malaria vaccine, the RTS,S vaccine from 
GlaxoSmithKline (GSK), is based on the NANP central repeats o f the circum sporozoite 
protein (CSP) plus T-helper epitopes from the C-terminal region fused to hepatitis B 
surface antigen (RTS). This component is co-expressed with more free hepatitis B 
surface antigen in a 1:4 ratio to form the RTS,S virus-like particle (reviewed in (Cohen 
et al. 2010)). RTS,S antigen formulated with the liposome-based (AS01) or oil-in-water 
based (AS02) adjuvant systems together with m onophosphoryl lipid A (Baldridge and 
Crane 1999) and QS21 (Kensil, Wu and Soltysik 1995) as immunostim ulants have been 
extensively evaluated. Comparative studies o f  RTS,S/AS01 and RTS,S/A S02 have 
demonstrated superior anti-CS responses and efficacy with RTS,S/AS01 when three 
doses are administered both in adults (Kester et al. 2009, Polhemus et al. 2009) and 
children (Agnandji et al. 2011). In Phase III trials o f  RTS, S/AS01 in African children, 
the overall efficacy against clinical episodes o f m alaria was 30.1% (Agnandji et al.
2012) and 50.4% (Agnandji et al. 2011) in infants aged 6 - 1 2  weeks and 5 - 1 7  
months, respectively. A follow-up study also showed that the RTS, S vaccine does not 
induce durable protection against clinical episodes o f m alaria over a four-year follow-up 
period (Olotu et al. 2013). Substantial age-dependent differences in efficacy were
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observed possibly due to interference by co-administered expanded program on 
immunization (EPI) vaccines, presence o f  maternal antibodies or inherently lower 
immune responses in infants compared to older children. Admittedly, the protective 
efficacy o f  RTS,S falls short o f  the goals o f  the original malaria vaccine technology 
roadmap which is to develop and license a first-generation m alaria vaccine that has a 
protective efficacy o f  greater than 50% against severe m alaria and death and lasts longer 
than one year, by 2015 (W HO 2013). Therefore, improvements on the RTS,S vaccine, 
for instance, by combining it with antigens targeting other stages o f  the parasite life 
cycle may confer better protection.
Although contemporary approaches have assessed responses to single antigens, 
formulations comprising o f  multiple pre-erythrocytic epitopes or target antigens are also 
being evaluated. For instance, the m ulti-epitope TRAP (consisting o f  CD4+ and CD8+ 
T cell epitopes from six antigens; LSA1, CSP, STARP, LSA3, E xpl and TRAP) fused 
to the TRAP antigen (M oorthy et al. 2003) and the DNA vaccine polyepitope DNAEPI 
1300 (consisting o f CSP, SSP2/TRAP, LSA-1, E x p l) adm inistered through 
electroporation. Vaccination with the ChAd63-M VA-TRAP prim e-boost regim en 
demonstrated a highly favorable safety profile and robust im m unogenicity in both 
m alaria naive volunteers (Ewer et al. 2013) and malaria exposed Gambian and Kenyan 
adults (Ogwang et al. 2013).
1.7.2 Erythrocytic vaccines
Seminal studies demonstrating marked reduction o f  parasitemia and resolution o f
clinical symptoms o f malaria in children receiving purified IgG obtained from m alaria
exposed adults (Cohen, Me and Carrington 1961) have provided the impetus for
developm ent o f  vaccines against the blood-stage o f  infection. The specificities o f these
antibodies are not completely known but antigens expressed at the m erozoite stage and
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those inserted on the surface o f the infected red blood cell are attractive options due to 
their accessibility to the immune system. At present, vaccines based on antigens 
exported to the m erozoite surface during invasion such as AMA1 (Thera et al. 2010, 
Thera et al. 2011), EBA-175 region II (El Sahly et al. 2010) and those expressed at the 
surface o f  the merozoite such as MSP-1 (Ogutu et al. 2009), MSP-3 (Belard et al. 2011), 
SERA5 (Horii et al. 2010), GLURP (Belard et al. 2011) and MSP-2 (Genton et al. 2002) 
are being evaluated in clinical trials. AMA1 and MSP1 proteins are the m ost advanced 
blood-stage candidates, tested using various formulations such as AMA1-C1 (3D7 and 
FVO) alhydrogel w ith or without CpG (Sagara et al. 2009, Dicko et al. 2008, Ellis et al.
2009), FM P2.1/AS02A or AS01B (Spring et al. 2009, Thera et al. 2008, Thera et al.
2010), FM P1/AS02A (M SP142) (Stoute et al. 2007, Ogutu et al. 2009, W ithers et al. 
2006), ChAd63-M VA/M SP 1 (Sheehy et al. 2011) and combining MSP1 and AMA1 
(M alkin et al. 2008, Sheehy et al. 2012b). Disappointingly, neither AMA1 (Thera et al.
2011) nor MSP1 (Ogutu et al. 2009) has demonstrated adequate clinical efficacy when 
tested in paediatric populations in Africa, possibly due to the extensive antigenic 
polymorphism exhibited by these antigens and the induction o f predom inantly low to 
m odest antibody titres. The focus has also been extended to combinations o f blood- 
stage antigens or blood-stage antigens together w ith other developmental stages. For 
instance, the combination B vaccine comprising o f  RES A, MSP-1 and M SP-2 (3D7) 
formulated with an oil-based adjuvant, M ontanide ISA 720 conferred a 62% reduction 
in parasite density in Papua New  Guinean children who did not receive SP drugs, but 
increased carriage with parasites containing the alternate M SP-2 allele (Genton et al. 
2002). However, testing o f  this vaccine was discontinued. The GM Z2 vaccine 
combining the MSP-3 and GLURP antigens with aluminum hydroxide was safe, well 
tolerated and immunogenic when tested in Gabonese children (Belard et al. 2011). Thus 
far, there is no indication that these combination blood-stage vaccines confer superior
protection compared to single antigen vaccines although evidence from immuno- 
epidemiological studies increasingly shows the importance o f  the breadth o f  responses 
in terms o f the num ber o f  antigens an individual responds to, in inducing higher 
protective natural immunity compared to responses to single antigens (O sier et al. 2008, 
John et al. 2005).
Antigens expressed on the surface o f  the infected red blood cell are plausible but 
challenging vaccine targets to develop due to their temporal switching o f  gene 
expression patterns and high m olecular mass (Fried et al. 2013). However, identification 
o f conserved domains or domain combinations within the widely studied PfEM Pl 
protein that are im munogenic and induce broadly cross neutralizing antibodies could 
circumvent this difficulty. Efforts to identity conserved regions (Avril et al. 2010), 
highly immunogenic domains and domain combinations (Saveria et al. 2013, Fried et al.
2013) are currently underway for var2CSA, a PfEM Pl variant associated with 
pregnancy malaria by m ediating placental sequestration.
1.7.3 Transmission blocking vaccines
Transmission blocking vaccines (TBV) are designed to block developm ent o f  infectious 
sporozoites in the mosquito vector but not to protect the vaccinated individual from 
infection. Such vaccines target antigens expressed on gametocytes, zygotes or 
ookinetes. The demonstration that individuals living in m alaria endemic areas acquire 
potent transm ission-blocking antibodies (Bousema et al. 2006) forms the basis fo r ' 
development o f transm ission-blocking vaccines, a tool that could contribute towards 
malaria elimination and eradication.
The three leading TBV targets for P. falciparum  induce antibody responses against the
parasite antigens Pfs230, Pfs48/45 and Pfs25. Pfs48/45 and Pfs230 are expressed on the
surface o f  gametocytes and play a role in fertilization o f  m acrogam etes by
50
m icrogametes (Vermeulen et al. 1985, Rener et al. 1983, Kum ar and Carter 1984), 
whereas Pfs25 is expressed on the surface o f ookinetes (Pradel 2007, Verm eulen et al. 
1985). Both Pfs48/45 and Pfs230 are attractive vaccine candidates because they are 
expressed in the human host and antibody responses to these antigens could potentially 
be boosted by natural infection unlike Pfs25. A Phase 1 human trial using a recom binant 
Pfs25H formulated with M ontanide ISA51 demonstrated that human Pfs25 specific 
antibodies block parasite infectivity to m osquitoes (W u et al. 2008), although some 
subjects reported serious adverse reactions to the vaccine.
Evidence from m athematical m odeling studies suggest that an effective TBV would 
need to induce very high antibody levels (Saul 2008) and such a vaccine would only be 
efficacious in areas o f  high m alaria transm ission intensity if  administered together w ith 
other interventions such as bednets (Carter et al. 2000). However, the com bination o f  a 
TBV with other candidates such as blood-stage or pre-erythrocytic antigens would be an 
ideal vaccination strategy because, if  effective, it would reduce transm ission and also 
provide protection against infection or disease to the vaccinated individuals.
There is renewed interest to apply systematic approaches for identifying and prioritizing 
antigens to put forward for vaccine development. These include i) use o f  state-of-the art 
techniques such as functional genomics to screen novel antigens and ii) accelerating the 
timelines for clinical development by including controlled human m alaria infections 
studies. Towards this end, the full genome sequence o f  P. falciparum  genes has 
increased the range o f targets available for study (Gardner et al. 2002) coupled with 
high throughput screening approaches involving assembly o f multiple proteins on arrays 
which are used to screen specific responses (Doolan et al. 2008, Crompton et al. 2010a, 
Trieu et al. 2011). In addition, development o f  eukaryotic expression systems to express 
full-length proteins preserving their structural conformation and function has enabled
high throughput testing o f  protein functions such as protein-receptor interactions 
(Crosnier et al. 2013, Crosnier et al. 2011, Bartholdson et al. 2013). Such platforms 
have led to the identification o f PJRh5 as a promising second-generation blood-stage 
vaccine candidate that has been shown to induce strain-transcending neutralizing 
antibodies in pre-clinical studies (Douglas et al. 2011, Reddy et al. 2014).
1.8 Naturally-acquired immunity to malaria
Individuals living in m alaria endemic areas who do not succumb to severe m alaria
during the first few years o f life remain susceptible to clinical episodes o f  m alaria to
which they acquire immunity during early adulthood. Therefore, adults rarely i f  ever
suffer clinical attacks but often harbor asymptomatic infections (reviewed in (M arsh and
Kinyanjui 2006, Langhorne et al. 2008)). In the early 20th century, blood-stage parasite
inoculations were used to treat neurosyphyllis patients by induction o f  high fevers that
killed the Treponema pallidum  spirochetes. Re-analysis o f  patient records by Collins
and Jeffery in the 1990s showed a reduction o f  the frequency o f fever, parasitem ia and
gametocyte carriage in patients exposed to secondary infections, suggesting that
immunity against m alaria could be induced in humans (Collins and Jeffery 1999a).
The key features o f  naturally-acquired immunity (NAI) are, first, it develops after
frequent exposure to infections, evidenced by the high burden o f  m orbidity and
mortality to severe life-threatening episodes in relatively naive young children having
little exposure (Marsh and Kinyanjui 2006, Langhorne et al. 2008) and in m alaria naive
travelers. By the age o f  five, children acquire immunity to severe episodes but remain
susceptible to clinical episodes o f m alaria until early adulthood. M odeling studies have
suggested that immunity to severe non-cerebral episodes may develop after one or two
infections (Gupta et al. 1999). Second, NAI is not sterile, demonstrated by the frequent
parasitization seen in older children and adults living in an endemic area (M arsh and
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Kinyanjui 2006, Tran et al. 2013) and the ability to maintain chronic asymptomatic 
infections in some individuals. In their study, Tran et a l followed up 251 children and 
adults aged 4 - 2 5  years over a 6 month period for development o f  clinical episodes o f 
malaria and PCR confirmed infections and revealed no age-related differences in the 
risk o f  infection (Tran et al. 2013). A limitation o f  this study was the narrow age range 
o f adults selected. One may argue that individuals aged 25 years (the upper age limit in 
this study) are in fact very young adults and their findings would have been more 
conclusive had they showed the risk o f  infection in relatively older individuals. 
M aintenance o f  chronic infections was also demonstrated in neurosyphyllis patients 
inoculated with P. falciparum  who had persistent low-grade asymptomatic infections 
over an extended period after recovery from m alaria symptoms accom panied by 
successive waves o f parasitem ia (Collins and Jeffery 1999b).
Third, NAI diminishes upon interruption o f  exposure (M atteelli et al. 1999, Jelinek et al. 
2002). In the highlands o f  M adagascar, DDT was successfully used in the 1950s to 
eradicate malaria. However, a sudden resurgence occurred in 1980, which resulted in 
epidemics that killed over 40,000 adults and children (M ouchet et al. 1997, Deloron and 
Chougnet 1992). O f note, adults aged 40 years and above who had spent their childhood 
years under continuous m alaria exposure were more protected than younger children 
and they also had stronger humoral responses suggesting some degree o f  im munological 
mem ory (Deloron and Chougnet 1992). This latter finding is corroborated by 
observational studies dem onstrating that some degree o f  immunity to clinical m alaria is 
achieved in immigrants compared to malaria naive adults (Bouchaud et al. 2005, 
M ascarello et al. 2008). In the study by Bouchaud et al, African immigrants w ho had 
lived in Europe for at least four years had lower parasite densities, faster parasite 
clearance times and higher antibody levels compared to Europeans, following short 
visits to sub-Saharan Africa (Bouchaud et al. 2005). Therefore, although m alaria
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immunity wanes in the absence o f  continuous exposure, this is only partial. Such 
findings have important implications in the current era o f  a m ove towards malaria 
eradication and the observed decline in m alaria transmission intensity in some areas. 
History has taught us that if  current elimination and eradication efforts are successful 
but not long-term and sustainable, a population o f susceptible individuals would emerge 
leading to future epidemic attacks.
The slow acquisition o f  immunity to m alaria can be attributed in part to the need to 
accumulate responses against multiple independent parasite strains. In classical 
experiments done by Brown and Brown in the 1960s, monkeys were resistant to re­
inoculation with hom ologous parasite strains but were susceptible to clinical episodes 
when challenged with a heterologous strain (Brown and Brown 1965). In line with these 
findings, experiments done in neurosyphyllis patients revealed that individuals were 
resistant to infection with a hom ologous parasite strain but susceptible to a different 
strain (Collins and Jeffery 1999a). Indeed, antigens expressed on the infected red blood 
cell surface have been shown to vary antigenically (reviewed in (Scherf, Lopez-Rubio 
and Riviere 2008)). This is further exacerbated by the presence o f  extensive genetic 
diversity in many P. falciparum  antigens (Takala et al. 2009) to which individuals 
induce variant specific (M arsh and Howard 1986, Bull et al. 1998) and allele-specific 
(Osier et al. 2007, Osier et al. 2010b, Osier et al. 2010a, Cortes et al. 2005, Genton et al. 
2002) responses. Adults and older children have a broad repertoire o f  responses to the 
different variants, which is associated with natural acquisition o f  immunity to m alaria 
(Marsh and Howard 1986, Bull et al. 1998).
The rate at which naturally-acquired immunity develops in malaria endemic areas is 
thus dependent on the degree o f  exposure, with immunity developing more rapidly in 
areas o f high malaria transmission intensity compared to areas o f  low m alaria 
transmission, with children bearing the brunt o f disease.
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In summary, the clear picture that emerges from epidemiological observations is that 
developm ent o f  immunity to m alaria is dependent on both age and exposure, two factors 
that are difficult to disentangle given that increasing age results in increased cumulative 
exposure. However, in cross-sectional surveys o f  non-im m une Indonesian 
transmigrants, children and adults had a sim ilar incidence o f  parasitem ia after three 
months o f residence in a holo-endemic area but when prospectively examined after 20 
months, the adults had less frequent and less severe infections compared to children 
(Baird 1995, Baird et al. 1993). These observations suggest that acquisition o f  immunity 
is in part determined by intrinsic age-related factors independent o f  the degree o f 
exposure to infection (Doolan, Dobano and Baird 2009).
1.8.1 The role o f antibody and cellular responses in naturally-acquired immunity 
to malaria
Passive transfer studies conducted in 1960 by Cohen et al. demonstrated that
immunoglobulins purified from immune adults could be successfully used to treat
children with episodes o f  m alaria (Cohen et al. 1961). Consistent with these findings,
IgG from African adults administered to Thai children led to resolution o f  clinical
symptoms and clearance o f parasites (Sabchareon et al. 1991). These findings suggest
that naturally-acquired antibodies, particularly o f the IgG subclass play an im portant
role in protection against malaria. The underlying mechanisms o f  protection, why they
are acquired only after repeated infections and the plausible targets from over 5,400
parasite proteins (Gardner et al. 2002) are incompletely understood.
The potential targets o f  antibodies include antigens exposed to the immune system
during the merozoite and mature stages o f asexual development. Prospective
longitudinal studies measuring responses to specific antigens at the start o f  a m alaria
transmission season and following individuals through the rainy season for developm ent
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o f m alaria have been pivotal in objectively identifying protective targets o f  naturally- 
acquired antibodies. Out o f a total o f 33 studies included in a m eta-analysis o f  the risk 
o f developing clinical episodes o f malaria in the presence o f  antibodies to 
approximately 10 P. falciparum  m erozoite antigens, only antibodies directed to the C- 
term inus o f MSP-3 and M S P -I19 and to a somewhat lesser extent, AMA1 and GLURP 
were consistently associated with protection across all studies (Fowkes et al. 2010). 
This is not surprising given the differences in methodologies between studies such as 
choice and preparation o f  antigens, antibody quantification methods, follow up time for 
clinical disease and definitions o f  clinical endpoints. Standardization o f  methodologies 
for measurem ent and reporting o f  protective efficacies o f specific antibodies across 
settings is important in order to accurately determine the contribution o f  antibodies to 
blood stage targets in naturally-acquired immunity to malaria.
Antibodies are thought to function by blocking merozoite dispersal after schizont 
rupture (Green et al. 1981), blocking merozoite invasion into red blood cells (Blackm an 
et al. 1990, Kocken et al. 2002), opsonizing merozoites for phagocytosis (Hill et al.
2012), antibody-dependent cellular inhibition (ADCI) by monocytes (Bouharoun- 
Tayoun et al. 1995) or antibody-dependent respiratory burst (ADRB) by neutrophils 
(Joos et al. 2010).
Some immuno-epidemiological studies investigating the association between antibodies 
expressed on the surface o f  the infected erythrocyte and risk o f  m alaria have 
demonstrated that PfEM Pl is the major target (Chan et al. 2012), and antibodies to 
some PfEM Pl variants are associated with a reduced risk o f  developing m alaria (M arsh 
et al. 1989, Chan et al. 2012, Giha et al. 2000, M ackintosh et al. 2008b, Dodoo et al. 
2001) albeit inconsistently (Bull et al. 2002). Several studies have shown that children 
rarely have antibodies to the variant surface antigens (VSAs) expressed by the infecting 
isolates but these are quickly acquired after infection, and subsequent disease episodes
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will be caused by parasites with VSA types that are not already recognized by the 
individual (M arsh and Howard 1986, Bull et al. 1998, Ofori et al. 2002). Although 
PfEM Pl undergoes rapid antigenic switching suggesting that the acquisition o f  a broad 
repertoire o f  antibodies is necessary to mediate immunity, there is evidence that cross­
reactive antibodies are present in immune individuals (M arsh and Howard 1986, Bull et 
al. 2000, Chattopadhyay et al. 2003), which may confer broad protection against a 
diverse num ber o f  phenotypes (Aguiar et al. 1992, N ielsen et al. 2004). Furthermore, 
some studies have shown that only limited subsets o f  common PfEM Pl variants are 
associated with severe disease (Rottmann et al. 2006, Jensen et al. 2004) and are more 
frequently recognized by sera from malaria-exposed individuals, including young 
children, than parasite antigens from older children with mild m alaria (Bull et al. 2000, 
N ielsen et al. 2002). These studies taken together beg the question whether immunity to 
severe disease is rapidly acquired (Gupta et al. 1999) because only a limited num ber o f 
variants are associated with severe disease and if  so, narrowing down on conserved, 
cross-reactive epitopes or the small proportion o f  PfEM Pl variants associated with 
severe disease may improve our understanding o f  the contribution o f  anti-PfEM Pl 
antibodies in m ediating naturally-acquired immunity. Antibodies directed to the 
infected erythrocyte surface have also been shown to mediate their function by 
opsonizing infected erythrocytes for uptake by m onocytes (Celada, Cruchaud and Perrin 
1982, Chan et al. 2012, Ghumra et al. 2011), preventing/disrupting rosette formation 
(Carlson et al. 1990, Barragan et al. 1998) and inhibiting parasite sequestration on 
receptors expressed on endothelial cells (Udeinya et al. 1981).
Antigens expressed at the pre-erythrocytic stage are targets o f  antibodies that block 
invasion o f  hepatocytes. Anti-sporozoite antibodies are detectable in sera collected from 
individuals living in malaria endemic areas (Nardin et al. 1979, Druilhe et al. 1986) 
predominantly against CSP, the major antigen expressed on the surface o f  sporozoites.
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CSP (Del Giudice et al. 1987, M arsh et al. 1988), LSA (John et al. 2003) and TRAP 
(Scarselli et al. 1993) antibodies are acquired in an age-dependent m anner but have been 
inconsistently associated with protection against infection or clinical episodes o f 
malaria. Some studies report a decreased risk o f  infection (John et al. 2005) or clinical 
episodes o f  malaria (John et al. 2008, Nebie et al. 2008b, M igot-Nabias et al. 2000) 
whereas others have reported lack o f  protection (Kitua et al. 1999, John et al. 2003). 
Individuals who mount high antibody levels against multiple pre-erythrocytic stage 
antigens (John et al. 2008, John et al. 2005) have a reduced risk o f developing a clinical 
episode o f  m alaria compared to those who make responses to single antigens.
Both animal (W eiss et al. 1988, Schmidt et al. 2008, Rodrigues et al. 1997, Tsuji et al. 
1990, O liveira et al. 2008) and experimental hum an challenge models (Roestenberg et 
al. 2011, B ijker et al. 2014, Pombo et al. 2002) have demonstrated an im portant role for 
both CD4+ and CD8+ T cells in protective immunity against malaria. Although the T 
cell correlates o f  immunity to m alaria are not com pletely understood, there is a 
consensus that the tim ing and fine balance between pro-and anti-inflammatory cytokine 
secretion is important for the successful resolution o f  an infection (Riley et al. 2006). 
Some field-based studies have shown that IFN-gam m a induced by T-cells against liver- 
stage (Reece et al. 2004, Luty et al. 1999, Todryk et al. 2008) and blood-stage antigens 
(Robinson et al. 2009, Luty et al. 1999, M oorm ann et al. 2013, D 'Ombrain et al. 2008, 
M cCall and Sauerwein 2010, Dodoo et al. 2002) is associated with resistance to 
reinfection or clinical episodes o f  malaria. IFNy production by T h l cells and other 
lymphocytes may therefore be a potential m ediator o f protective immunity.
A population o f  lFNy/IL-10 co-producing CD4+ T cells has been recently defined in
children living under intense malaria exposure (Jagannathan et al. 2014) and those
encountering re-exposure to P. falciparum  parasites after a recent febrile episode o f
m alaria (Portugal et al. 2014). These cells have been described as “self-regulating” T h l
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effector cells (O 'Garra and Vieira 2007) acting to limit excessive production o f pro- 
inflammatory m ediators while enhancing effector mechanisms that control parasite 
replication. Failure to detect a significant num ber o f  circulating IFNy/IL-10 co­
producing CD4+ cells at the time o f  acute infection in a separate study conducted in an 
area o f  m oderate m alaria transm ission suggests that these cells are produced in an 
exposure-dependent m anner (Gitau et al. 2012). Furthermore, the presence o f  pre­
existing lFNy/IL-10 co-producing CD4+ cells was not associated w ith protection from 
future episodes o f  m alaria (Jagannathan et al. 2014) suggesting that they may not play 
an important role in protective immunity, but these findings remain to be confirmed in 
other settings.
1.8.2 Antibodies to blood-stage antigens and risk o f severe malaria
The observation that children living in m alaria endemic areas who survive the first five 
years o f  life develop lifelong immunity to severe malaria but remain susceptible to 
clinical episodes o f  m alaria suggests that the dominant factors or targets conferring 
protection against severe illness may be different from those m ediating immunity to 
clinical episodes o f m alaria or parasitization, which is seen in older children and adults. 
Nonetheless, there is a potential overlap between the mechanisms and targets that 
mediate the different phases o f  immunity because the ability to limit parasite 
m ultiplication to very low levels is crucial in preventing the parasites from 
overwhelming an individual and leading to developm ent o f  clinical symptoms. There 
are very limited epidemiological data defining the targets and m echanisms o f  protection 
against severe malaria owing to the fact that such studies require recruitm ent and 
follow-up o f  a large number o f  children for the relatively rare outcom e o f  severe 
malaria. For instance, in a study conducted at the Kenyan coast, am ong 4,783 children
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recruited at the start o f  a m alaria transm ission and followed up over a period o f  8 
months during two transm ission seasons, only 21 cases o f  severe m alaria were 
identified (Bull et al. 1998, Ndungu et al. 2002). In this section o f the thesis, 1 review 
the existing literature on the role o f  antibodies in protection against severe m alaria and 
highlight the gaps in knowledge that form the basis o f  this thesis.
First, studies designed to investigate the importance o f  antibodies to specific targets 
have been largely hospital-based, comparing antibody responses in children adm itted to 
hospital with severe malaria against healthy or uncomplicated m alaria controls (Table 
1). Responses measured at the time o f  acute infection comprise those generated in 
response to the current infection as well as pre-existing ones, which m akes it difficult to 
infer a causal relationship between antibodies and the outcome o f  severe malaria. 
Prospective studies in which pre-existing antibodies are analyzed in relation to the 
subsequent risk o f  malaria are preferable but thus far, such studies have been few, small 
in size, inadequate in the definition o f  severity and only evaluated a limited num ber o f  
antigens (Bull et al. 2002, Ndungu et al. 2002, Osier et al. 2008, Bull et al. 1998). In the 
study by Ndungu et a l and Bull et al, only 21 well-defined severe m alaria cases were 
examined and antibodies to non-specific antigens contained in a crude schizont extract 
(Ndungu et al. 2002) and those to the surface o f  three infecting parasite isolates (Bull et 
al. 2002) were measured. In these studies, IgG l against crude schizont extract was 
associated with a decreased risk o f  developing severe m alaria (Ndungu et al. 2002) 
whereas agglutinating antibodies directed to the infected red blood cell surface were not 
associated with a reduced risk o f developing severe malaria (Bull et al. 2002).
In the studies by Bull et al and Osier et al, severe m alaria was defined as m alaria severe 
enough to warrant admission to hospital (Bull et al. 1998, Osier et al. 2008) with no 
indication o f whether specific severe malaria symptoms were present and in w hat 
proportion o f  children. The study by Osier et al, demonstrated that the antibody
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concentration and responses to combinations o f  P. falciparum  merozoite antigens could 
be more important in protection against admission to hospital with malaria (Osier et al. 
2008), but this remains to be validated for well-defined severe m alaria as a clinical 
endpoint.
Second, hospital-based studies have often reported conflicting results with some studies 
showing no differences in antibody levels between severe m alaria cases and mild 
m alaria cases (Erunkulu et al. 1992, Al-Yaman et al. 1997), whereas others report 
significantly higher antibody levels in mild malaria cases compared to severe malaria 
cases (Okech et al. 2006, Perraut et al. 2005a). Conversely, others have reported higher 
antibody levels in severe malaria cases compared to mild m alaria cases (Dobano et al. 
2008). The inconsistencies in findings have arisen partly due to lack o f  standardized 
methodologies for m easuring and reporting data across studies. Table 1 below 
summarises the findings from 18 hospital-based studies comparing antibody responses 
against several P. falciparum  m erozoite and variant surface antigens in severe m alaria 
cases, uncomplicated m alaria cases and healthy controls. The key differences identified 
in these studies that lead to inconsistent findings include i) varying definitions o f severe 
m alaria with some studies either focusing on the specific severe m alaria manifestations 
o f  cerebral malaria, hyperparasitemia, hypotension, severe anemia and respiratory 
distress and others considering any o f  the above symptoms; ii) the choice o f  controls to 
compare against ranging between healthy controls, uncomplicated m alaria controls, 
controls with asymptomatic infections and other unrelated severe illnesses; iii) 
differences in antigens selected for study ranging between conserved and polym orphic 
merozoite antigens, crude parasite lysate and variant surface antigens; iv) differences in 
age inclusion ranging from children to adults depending on transmission intensity; and 
v) the antibody response measured ranging from total IgG, IgM to IgG subclasses. 
Therefore, despite the large body o f  literature from hospital-based studies, the evidence
for a role o f  antibodies and their targets in protection against severe m alaria remains 
inconclusive.
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2UM, uncomplicated malaria 
JCM, cerebral malaria 
4SMA, severe malaria anemia 
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6The standard WHO defined criteria for severe malaria includes severe malaria anemia, impaired 
consciousness or coma, prostration, multiple seizures, hyperlactatemia or metabolic acidosis, dark 
urine, hypoglycemia, jaundice, respiratory distress, shock, and/or renal failure (WHO, 2000)
7AS, asymptomatic P. falciparum  infections
Although many studies have been conducted comparing antibody responses between severe malaria 
cases, uncomplicated malaria cases and healthy controls, the evidence that antibodies protect for any 
given antigen is inconclusive.
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1.9 Plasmodium falciparum merozoite antigens
The studies conducted in this thesis focus on merozoite targets o f  protective antibodies. A 
panel o f  merozoite antigens, which are currently under development as potential vaccine 
candidates, were selected and are reviewed in this section. The importance o f  these antigens as 
putative targets o f protective antibodies has been demonstrated in in vitro experiments, animal 
model studies, population genetic studies, prospective cohort studies and human vaccine trials. 
Nevertheless, the prospective cohort studies and human vaccine trials conducted thus far have 
focused on uncomplicated episodes o f  malaria and infection as endpoints o f interest, therefore 
there is a paucity o f  data demonstrating the potential or lack thereof o f these antigens as 
targets o f  immunity to well defined severe episodes o f malaria.
1.9.1 Apical Membrane antigen 1 (AMA1)
AMA1 is an 83kDa type 1 integral protein synthesized during the late schizont stage o f 
parasite development (Narum and Thomas 1994) and localized to the micronemes o f  the 
merozoite (Healer et al. 2002, Bannister et al. 2003). The ectodomain o f  the protein is made 
up o f an N-terminal pro-sequence and three domains (DI, DII and D ili) linked together by 
eight disulphide bonds (Hodder et al. 1996). During schizont rupture, the prosequence is 
proteolytically cleaved and the mature 66 kDa form o f  AMA1 is translocated to the merozoite 
surface (Narum and Thomas 1994) where it undergoes further cleavage by the membrane- 
bound P . falciparum  subtilisin-like protease 2 (P/SUB2) ‘sheddase’ to form the 44 and 48 kDa 
soluble fragments (Howell et al. 2001).
AMA1 has over 60 polymorphic sites, with the majority o f  them concentrated near a 
hydrophobic trough in domain 1 o f the protein (Bai et al. 2005). In a study conducted in Mali, 
a total o f  214 AMA1 haplotypes were identified among 506 predominant-clone infections
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(Takala et al. 2009). Similarly, among 50 Thai (Polley, Chokejindachai and Conway 2003a) 
and 129 Kenyan isolates (Osier et al. 2010b) sequenced, 27 and 78 AMA1 haplotypes were 
identified, respectively, highlighting the highly polymorphic nature o f  the antigen. There is 
strong evidence suggesting that mutations on the AMA1 gene arise due to diversifying 
selection driven by immune pressure (Polley and Conway 2001, Polley et al. 2003a, Osier et 
al. 2010b).
AMA1 is thought to play a role in the process o f RBC invasion through reorienting the 
merozoite after initial contact with the erythrocyte (Mitchell et al. 2004) and through initiating 
tight junction formation by associating with the RON proteins. In particular, the surface 
exposed ectodomain o f  RON2 binds to the conserved hydrophobic trough o f  AMA1 to form 
the moving junction (Richard et al. 2010, Alexander et al. 2006, Lamarque et al. 2011, Tonkin 
et al. 2011). Antibodies against AMA1 (Hodder, Crewther and Anders 2001, Healer et al. 
2004, Kocken et al. 2002) or short peptides such as R1 that bind to the hydrophobic groove o f 
AMA1 (Richard et al. 2010) block invasion into erythrocytes.
Individuals living in malaria endemic areas develop antibodies against AMA1 and these have 
been associated with a reduced risk o f developing a clinical episode o f malaria in some studies 
(Fowkes et al. 2010, Polley et al. 2004, Osier et al. 2008). Protective immunization in mice 
and monkeys has also been achieved (Collins et al. 1994, Anders et al. 1998, Stowers et al. 
2002, Dutta et al. 2009) although such studies demonstrate a high degree o f  strain-specific 
protection against challenge with homologous parasite strains. Consistent with these findings, 
the most advanced AMA1 trial conducted in Malian children demonstrated limited overall 
protective efficacy against clinical episodes o f  malaria but conferred 64.3% protection against 
infection with homologous parasites (Thera et al. 2011). These observations suggest that 
induction o f broad protection by an AMA1 vaccine requires inclusion o f  multiple haplotypes 
representative o f circulating parasite strains. However, with more than 200 circulating AMA1
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haplotypes (Takala et al. 2009), development o f a multi-allelic AMA1 vaccine seems 
unachievable, although some studies have provided evidence that only a limited fraction o f 
alleles are necessary for inclusion into a vaccine to offer broad coverage o f the existing 
diversity and induction o f strain-transcending protection (Duan et al. 2008, Drew et al. 2012, 
M iura et al. 2013b), or by increasing the immunogenicity o f conserved epitopes within the 
protein (Dutta et al. 2013). These studies provide renewed hope that an effective AMA1 
vaccine is attainable and the rational selection o f the important haplotypes for inclusion will 
inform design o f future AMA1 vaccines.
1.9.2 Merozoite surface protein -2 (MSP-2)
MSP-2 is a 45 to 52 kDa protein anchored on the surface o f the merozoite by a 
glycosylphosphatidylinositol (GPI) anchor. MSP-2 consists o f  a central variable region, which 
is flanked by highly conserved N and C terminal regions (Smythe et al. 1991, Fenton et al. 
1991). The central repeat region is highly polymorphic, varying in length, num ber and 
sequence among isolates, flanked by non-repetitive dimorphic sequences that define two m ajor 
allelic families -  3D7-like and FC27-like (Smythe et al. 1991). The 3D7-like family contains 
4-8 amino acid repeats with five different amino acids being used whereas the FC27-like 
family has 12 and 32 amino acids repeated up to 4 times (Felger et al. 2003).
The observation that this gene is highly polymorphic suggests that this is driven by immune 
pressure, a hypothesis that has been confirmed by some population genetic studies (Barry et al. 
2009, Conway 1997). For instance, in the study by Conway et al., MSP-2 alleles from three 
geographical locations were tested using the Ewens-Wattersons test o f neutrality and the F 
statistic from this test was lower than that obtained under neutrality, demonstrating evidence 
o f positive selection on this gene (Conway 1997). In early studies, monoclonal antibodies
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raised against asexual blood-stage parasites were able to recognize MSP-2 and inhibit parasite 
growth in vitro suggesting that this protein plays a role during the process o f  invasion (Epping 
et al. 1988). Such studies paved the way for further characterization o f  the protein as a 
potential vaccine candidate. Mice immunized with the N- and C-terminal regions o f  MSP-2 
were partially protected against lethal P. chabaudi challenge (Saul et al. 1992). 
Naturally-acquired antibodies to MSP-2 are present in individuals living in malaria endemic 
areas (Taylor et al. 1995, Polley et al. 2006) with a predominance o f the IgG3 subclass (Taylor 
et al. 1995, M etzger et al. 2003, Tongren et al. 2005) and mainly directed to the central 
variable repeat region (Taylor et al. 1995). These antibodies are associated with protection 
against clinical episodes o f  malaria or infection in some immuno-epidemiological studies 
(Polley et al. 2006, Osier et al. 2008, Taylor et al. 1998) and not others (Scopel et al. 2007) but 
no clear evidence o f allele-specific protection has been observed (Osier et al. 2010a, Stanisic 
et al. 2009). Further testing o f MSP-2 as a component o f  a combination vaccine in a Phase 1/2 
trial in Papua New Guinea, revealed protection against infection with parasite strains 
contained in the vaccine (Genton et al. 2002). This observed strain-specific protection led to 
testing o f a vaccine containing both MSP-2 alleles in healthy malaria naive adults resident in 
Australia, a trial that was halted due to reactogenicity to the vaccine formulation (M cCarthy et 
al. 2011). However, analyses o f  serum samples collected from vaccinees in this trial showed 
induction o f high antibody levels to both forms o f MSP-2 and these antibodies had potent 
ADCI but not GIA activity (McCarthy et al. 2011), suggesting that MSP-2 is a potential target 
o f  functional antibodies that could induce protection.
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1.9.3 Merozoite Surface Protein 3 (MSP-3)
MSP-3 is a soluble polymorphic antigen associated with the merozoite surface. At the 
sequence level, it has twelve copies o f  heptad repeats (AXXAXXX) in three blocks in the N- 
terminus forming an alpha helical coil/coil m otif and a leucine zipper sequence at the C- 
terminus (McColl et al. 1994). Polymorphisms within the N-terminal domain arise due to 
insertions and deletions in non-repetitive sequences within and flanking the alanine heptad- 
repeat domain (McColl et al. 1994) and the polymorphisms are mainly driven by selection 
pressure (Polley et al. 2007). MSP-3 sequences can be classified into two m ajor allelic 
classes, the 3D7 and K1 types (Huber et al. 1997).
M anipulation o f the MSP-3 gene leading to loss o f  the leucine zipper m otif interfered with 
trafficking o f  MSP-3 and a related protein (acidic-basic repeat antigen) to the merozoite 
surface resulting in reduced invasion into erythrocytes (Mills et al. 2002), findings that imply 
that MSP-3 is not very essential during invasion and intra-erythrocytic development. However, 
antibodies from malaria immune adults directed to MSP-3 inhibited parasite growth in vitro  in 
the presence o f  monocytes (Oeuvray et al. 1994) and field studies have also demonstrated that 
anti-MSP-3 antibodies are associated with a reduced risk o f  developing malaria (Polley et al. 
2007, Osier et al. 2007, Soe et al. 2004, Meraldi et al. 2004). Similarly, studies done in saimiri 
and aotus monkeys have demonstrated protection against lethal P. falciparum  challenge in 
animals immunized with MSP-3. These observations provide evidence that MSP-3 is a target 
o f  protective antibodies. Currently, MSP-3 trials in humans are underway, testing the C- 
terminal domain in combination with GLURP antigen and results from Phase l/2b  trials 
demonstrate a good safety profile and induction o f high levels o f  functional antibodies in 
adults and children living in a malaria endemic area (M ordmuller et al. 2010, Jepsen et al. 
2013, Belard et al. 2011).
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1.9.4 Merozoite surface protein 1 (MSP-1)
MSP-1 is the most abundant protein on the surface o f the merozoite. It is synthesized during 
the schizont stage o f development as a 190 kDa precursor protein and undergoes proteolytic 
cleavage by P. falciparum  subtilisin 1 (P/SUB 1) into four polypeptides (p83, p30, p38 and 
p42), which remain non-covalently linked and anchored to the merozoite surface by GPI 
residues (McBride and Heidrich 1987, Holder et al. 1992). At the time o f invasion, the 42 kDa 
protein undergoes secondary processing into 33 and 19 kDa fragments by the P. falciparum  
subtilisin 2 (P/SUB2) enzyme (Blackman and Holder 1992, Blackman et al. 1990). M SP-133 is 
shed from the surface together with associated proteins and the other MSP-1 polypeptides, 
whereas M SP-119 remains membrane bound and is carried into erythrocytes during invasion 
(Blackman, Whittle and Holder 1991).
MSP-1 consists o f  seventeen distinct blocks that are either variable, conserved or semi­
conserved (Tanabe et al. 1987). The N-terminal block 2 region displays the greatest sequence 
variability (Miller et al. 1993) with the different variants at this locus grouped into 3 classes 
(K l, MAD20 and R 033) based on the parasite strain from which the sequences were first 
identified. For the purpose o f this thesis, antibody responses to the conserved 19 Kda C- 
terminal fragment were measured, but there is evidence that other regions o f  MSP-1 can elicit 
protective immune responses. For instance, naturally-acquired antibodies to the N-terminal 
block 2 are associated with a reduced risk o f developing malaria in some studies (Conway et 
al. 2000, Polley et al. 2003b) but not others (Gray et al. 2007, Osier et al. 2008), and in a 
primate model o f malaria, immunization with the N-terminal domain elicited partial protection 
against lethal challenge with the FVO parasite strain (Cavanagh et al. 2014).
Polyclonal (Chang et al. 1992) and monoclonal antibodies (Blackman et al. 1990, Chappel and 
Holder 1993) and sera from immune adults (Egan et al. 1999, O'Donnell et al. 2001) targeting
M SP-1 19 can inhibit parasite growth in vitro by blocking secondary processing o f  M SP-142
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(Blackman et al. 1994). O f note also is that antibodies to different epitopes o f  M SP-119 can 
either be inhibitory, blocking or neutral, with blocking antibodies interfering with the binding 
o f inhibitory ones hence allowing secondary processing o f the protein (Blackman et al. 1994, 
Uthaipibull et al. 2001). I f  M SP-119 is the specific target o f  antibodies that inhibit secondary 
processing o f the protein, what is the contribution o f  responses to the MSP-142 fragment as a 
whole? Do these responses exhibit superior protection than those directed at M SP-119? There 
is some evidence that M SP-119 has limited T-cell epitopes (Egan et al. 1997) whereas the 
region upstream o f  M SP-119 that is present in MSP-142 contains dominant T-cell epitopes 
(Udhayakumar et al. 1995) suggesting that M SP-142 could be a better immunogen. Studies to 
address this question have yielded conflicting findings, for instance, in a primate model o f  
malaria, monkeys immunized with M SP-142 were protected from lethal challenge with malaria 
(Stowers et al. 2001, Chang et al. 1996) but immunization with M SP-119 in the same study 
(Stowers et al. 2001) and others (Burghaus et al. 1996, Kumar et al. 2000) was not protective 
due to induction o f very low antibody titres. The opposite effect has been reported in other 
studies, where immunization with M SP-119 yielded better protection than immunization with 
MSP-1 42 (Kumar et al. 1995). Thus far, it is not clear whether MSP-142 is more protective than 
M SP-119.
Surprisingly, out o f  nine immuno-epidemiological studies assessing the protective efficacy o f  
antibodies to the C-terminus o f MSP-1 in malaria exposed populations (Stanisic et al. 2009, 
Egan et al. 1996, Osier et al. 2008, Conway et al. 2000, Cavanagh et al. 2004, al-Yam an et al. 
1996, Nebie et al. 2008a, Dodoo et al. 2008, Perraut et al. 2005b) only one study specifically 
looked at naturally-acquired antibodies to MSP-142 and demonstrated a protective effect o f  
these antibodies (al-Yaman et al. 1996). All other studies have examined responses to M SP-119 
albeit yielding conflicting findings. In half o f  the studies, antibodies to M SP-119 were 
associated with a significant reduction in risk o f  developing malaria (Perraut et al. 2005b,
Egan et al. 1996, Dodoo et al. 2008, Stanisic et al. 2009) and in the other half; M SP-119 
antibodies were not protective (Osier et al. 2008, Conway et al. 2000, Cavanagh et al. 2004, 
Nebie et al. 2008a). In a recent meta-analysis o f  merozoite targets o f  protective immunity, 
M SP-119 was significantly associated with an overall protective efficacy o f  18% from pooled 
analyses (Fowkes et al. 2010). In view o f the fact that immuno-epidemiological studies are 
important tools used to inform the candidate antigens to put forward for vaccine development, 
studies examining responses to M SP-1 19 seem to outcompete those testing M SP-I42 but 
surprisingly, the latter has preferentially been taken forward for testing in human trials. To the 
best o f  my knowledge, there’s a paucity o f  field studies to support the importance o f M SP-I42 
as a target o f  protective immunity and it is not surprising therefore that although the vaccine 
was safe and immunogenic when tested in adults in Kenya (Withers et al. 2006), United States 
(Ockenhouse et al. 2006) and Mali (Thera et al. 2006), it did not elicit protection in a 
paediatric trial in Kenya (Ogutu et al. 2009). It is thought that vaccine failure was due to lack 
o f  strain-transcending protection given that only one allele (3D7) o f M SP-I42 was included in 
the vaccine. M SP-119 has been tested together with AMA1 but although the vaccine was safe 
and immunogenic (Hu et al. 2008), the growth inhibition activity o f  these antibodies was 
suboptimal (Malkin et al. 2008) and the current status o f  trials o f  this chimeric protein is 
inactive (Schwartz et al. 2012).
1.9.5 Plasmodium falciparum  reticulocyte binding-like homologue protein 2 {Pf&hl)
PJRh2 is a hydrophilic protein expressed during the merozoite stage o f  parasite development 
and localized to the rhoptries. It shares 500 amino acid sequence homology with its P. vivax 
homologue, FVRh2 (Rayner et al. 2000). The PJRhla, and /yR h2b genes are identical at the 5’ 
end for approximately 8kb o f  their sequences but are highly divergent at the 3 ’ end, presumed
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to have arisen due to evolutionary duplication. The unique sequences span part o f  the 
ectodomain, a putative transmembrane domain and the cytoplasmic tail region (Rayner et al. 
2000, Triglia et al. 2001). The N-terminal region o f the P ftlh l gene is highly polymorphic 
(Rayner et al. 2005, Reiling et al. 2010) and some evidence suggests that this region is under 
diversifying selective pressure (Reiling et al. 2010).
In an earlier study, the erythrocyte binding capacity o f PfKh2 could not be detected (Triglia et 
al. 2001) but more recently, there’s evidence that PfKh2 binds erythrocytes via a sialic acid- 
independent, chymotrypsin-sensitive and trypsin-resistant pathway (Sahar et al. 2011, 
Duraisingh et al. 2003). Using gene knockout experiments, Duraisingh et al. demonstrated that 
PfRh2b but not PfRh2a mediates invasion o f erythrocytes (Duraisingh et al. 2003) and 
blocking this ligand impairs invasion capacity. These observations, together with limited data 
from epidemiological studies showing that PfRh2 antibodies are significantly associated with 
protection against high density parasitemia and clinical episodes o f malaria (Reiling et al. 
2010), suggest that it could be an important target o f protective immunity. For the purpose o f 
this thesis, I examined antibody responses to Rh2A9, a fragment o f Pf Rh2 spanning the 2030 -  
2528 amino acid positions, which was demonstrated to induce high antibody titres and had the 
highest seroprevalence among Papua New Guinean children (Reiling et al. 2010).
1.10 Aims and scope of the thesis
Naturally-acquired malaria immunity has many determinants and in the absence o f well- 
defined targets and correlates o f  protection against P. falciparum, the studies presented in this 
thesis have focused separately on the clinical endpoints o f uncomplicated and severe malaria 
incidence as an approach towards defining acquisition o f  immunity. The overall aim is to 
identify the potential merozoite targets o f  antibodies and the protective mechanisms associated 
with NAI.
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Below, I outline the aims, rationale and a brief summary o f the findings presented in the 
results chapters o f  this thesis.
In C h ap te r T hree, the initial aim was to compare two widely used ELISA methods o f  
quantifying antibody responses to blood-stage antigens. I demonstrate the limited utility o f 
measuring and reporting the magnitude o f antibody responses as ELISA OD values 
particularly in settings o f high malaria transmission intensity, and outline a quantification 
method using a standard reference reagent to standardize measurement o f  antibody titres.
In C h ap te r F our, I set out to define threshold antibody concentrations against specific
merozoite antigens that are associated with a reduced risk o f developing a clinical episode o f
malaria and their application to prospective cohort studies. Although there is extensive
literature supporting several merozoite antigens as targets o f  immunity, for any given antigen,
there has been conflicting data with some studies demonstrating protection while others do not
(Fowkes et al. 2010). The numerous potential reasons for these discrepancies have been
elaborated in this thesis but the finding in our own setting that antibodies to merozoite antigens
were associated with protection in one cohort but not in another, provided the rationale to
explore possible explanations for this paradox. Using the ELISA quantification method
outlined in chapter three, antibodies to similar antigens were quantified in a high transmission
cohort where antibodies were shown to be protective and a low transmission cohort where
similar antibodies were not associated with protection, all based on a cutoff o f responses above
the reactivity o f  malaria naive sera (seropositivity). Using a statistical model, threshold
concentrations associated with a reduced risk o f  developing a clinical episode o f  malaria to
various antigens were defined in the high transmission cohort and applied to the low
transmission cohort. Children who achieved these thresholds had a lower risk o f developing
malaria, providing evidence that differences in transmission intensities notwithstanding,
achieving particular thresholds are more important for protection and may be useful correlates
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o f protection for future studies. I extended this work in post-hoc analyses and outline an 
interesting finding o f  similar threshold concentration cutoffs derived independently in three 
cohorts (Chonyi, Junju and Tanzania). This observation suggests that achieving the proposed 
threshold levels may be clinically and/or biological relevant and could form useful correlates 
o f protection, given the demonstration that achieving these titres was associated with a 
reduced risk o f  developing uncomplicated malaria in two geographically distinct populations.
C h ap te r Five focuses on immunity to severe malaria. Using a case-control approach nested 
within a longitudinally monitored birth cohort o f  children followed up every three months 
from birth upto two years o f  age for development o f severe malaria, I have i) described the 
dynamics o f  antibodies to a panel o f merozoite antigens and ii) determined the association 
between specific antibodies with protection against severe malaria during the first two years o f 
life.
First, as outlined in section 1.5.2 above, the paucity o f epidemiological data on the role o f 
antibodies in protection against well-characterized severe episodes and more importantly, the 
protective targets from the numerous /^p ro te in s  provided the rationale for this study. Second, 
there have been few longitudinal studies investigating the acquisition o f  antibodies to malarial 
antigens during childhood using repeated antibody measurements over time. Antibodies are 
relatively short-lived in children and the measurement o f antibody responses at a single time 
point may therefore inaccurately reflect the ability o f an individual to mount an immune 
response. The longitudinal sampling o f this cohort o f children provided the unique opportunity 
to evaluate, to my knowledge, the first description o f the association between an individual’s 
overall response in protection against severe malaria. There was no evidence o f  an association 
between antibodies against the five merozoite antigens tested in reducing the risk o f 
developing severe malaria during the first two years o f life with the exception o f  AMA1.
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Antibodies to AMA1 alleles were associated with a significant reduction in risk o f  disease 
using samples collected immediately prior to the disease episode and a general trend towards 
reduced risk when the mean response o f all samples collected from an individual were 
analysed. I also demonstrate the prevalence o f low and stable antibody titres over time in this 
group o f  children, boosted in the presence o f  concurrent parasitemia. This finding may be 
explained by inadequate exposure following the decline in malaria transmission intensity 
during the period o f the study and possibly due to intrinsic factors associated with low host 
age.
C h ap te r Six focuses on passively transferred maternal antibodies with the specific aim o f 
describing the decay o f maternal antibodies against a panel o f merozoite antigens and 
determining the role o f these antibodies in protection against severe malaria and infection 
during the first six months o f  life. The rarity o f  clinical episodes o f m alaria in infants during 
the first few months o f  life is thought to be mediated in part by the presence o f  antibodies 
transferred to the infant from the mother. However, the evidence for a role o f these antibodies 
in protection has been inconsistent between studies. In addition, no study so far, to the best o f  
my knowledge has specifically evaluated protection against severe episodes o f  malaria. The 
key findings from this chapter are i) transplacentally acquired anti-merozoite antibodies have a 
half-life o f  between 1 month and 34 months, varying depending on the antigen tested; ii) the 
rate o f decay o f maternal antibodies differs according to the level o f  antibodies - high titre 
antibodies were shown to decay relatively faster than low titre antibodies; and iii) maternal 
antibodies were markers o f exposure to infection and not associated with protection against 
asymptomatic infection or severe malaria.
C h ap te r Seven examines the role o f antibody-mediated functional activity in protection 
against severe malaria using the GIA and ADRB assays. The lack o f  in vitro measures that
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correlate with in vivo protection against malaria have partly hampered the identification o f  
potential targets associated with naturally-acquired immunity. This, together with the lack o f 
prospective studies examining the association between the functional activity o f  antibodies and 
protection against severe malaria, provided the rationale for conducting this study. I have 
described the optimization o f  a recently described ADRB assay that was shown to correlate 
with immunity against clinical malaria in Senegal and also showed an interesting and novel 
finding that children who had a combination o f antibodies mediating both GIA and ADRB had 
significantly reduced odds o f developing severe malaria. Previously, most studies have only 
concentrated on one functional mechanism. These findings therefore highlight the need to 
assess multiple mechanisms in concert and provide a useful platform to evaluate their 
antigenic targets as potential vaccine candidates.
Finally, in C h ap te r eight I provide a summary o f  the findings generated in this thesis and 
recommendations for future studies.
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CHAPTER TWO
Materials and Methods
2.0 Study area
The study was conducted in Kilifi County, situated 60 km north o f M ombasa city, along the 
Kenyan coast. According to the Kenya population and housing census report released in 
August 2010, the county has a population o f 1,109,735 residents and covers an area o f  12,609 
km2 (http://www.knbs.or.ke/counties.php). The majority o f the inhabitants belong to the 
Giriama subgroup, one o f  the nine subgroups o f  the M ijikenda ethnic group. The area 
experiences two annual rainy seasons, April-July and November-December during which most 
o f  the malaria transmission occurs. The main vectors that transmit malaria are Anopheles 
gamble s.I. and Anopheles fnnestus species (Mbogo et al. 2003).
2.1 Study population
Participants in this study were children drawn from the Kilifi Health and Demographic 
Surveillance System (KHDSS) which was established in the year 2000 and covers 
approximately 900km2 around Kilifi District Hospital (KDH). The area covered by the 
KHDSS consists o f 15 administrative locations, 40 sub locations, 186 enumeration zones and 
34,795 households (Figure 2.1) (Scott et al. 2012). The KHDSS was established to provide a 
link between data collected from the hospital and the demographic characteristics o f  residents 
in order to i) provide a sampling framework for epidemiological studies; ii) m onitor deaths, 
births and migration patterns; iii) describe the burden o f  local childhood illness; and iv) 
evaluate the impact o f  interventions against the m ost prevalent childhood infections. The 
KHDSS tracks a population o f 260,000 residents who are monitored quarterly for births,
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household/homestead characteristics, deaths, fertility rates and migration patterns (Scott et al. 
2012). On the other hand, KDH serves as the primary health care and referral facility to a 
population of 500.000 people. Approximately 65% of the paediatric admissions reside within 
the KHDSS area (Scott et al. 2012). Standard clinical and laboratory data obtained from 
individuals attending the hospital are entered into a database and linked using a unique 
identifier to the patient’s demographic details in the KHDSS register.
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Figure 2.1: M ap o f Kilifi D istrict showing the adm in istra tive  locations covered by the 
KHDSS. Adopted from http://\vww.kemri-vvellcomc.on>/sites/kemriwellcome.ore/files/KHDSS
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2.2 Study design
2.2.1 Kilifi Birth Cohort
The study was a matched case-control nested within a longitudinally monitored birth cohort
(Kilifi Birth Cohort) set up in 2001 to establish the risk factors for invasive pneumococcal
disease in young children. Ethical approval was granted by the Kenya National Ethics Review
Com m ittee (SCC 613 - A cohort study o f susceptibility to invasive pneumococcal disease 
1
among children aged 0-23 months). Infants born to mothers resident within the KHDSS were 
recruited at birth (at the maternity clinic) or within their first month o f  life during their visit to 
the vaccination clinic. At recruitment, 2ml o f cord blood was collected and the child was given 
a unique identifying number (Kilifi Birth Cohort number), which was used to identify the child 
during subsequent visits. No blood was collected from infants recruited during their visit to the 
vaccination clinic. After every 3 months, the children were seen at the outpatient clinic where 
1.5ml o f saliva and 2ml o f  venous blood was collected regardless o f  whether the child was ill 
or well. These follow-up visits were concluded when the child reached 2 years o f  age. 
Children who did not attend a scheduled 3-monthly visit were followed up at home by a 
fieldworker the following day and re-invited to attend the clinic. Those who were unavailable 
during the home visit and did not attend the subsequent appointment were sought at home and 
similarly re-invited to attend the clinic. I f  they did not attend two consecutive 3-monthly visits, 
they were withdrawn from the study and replaced with a new recruit.
Children from within the cohort who developed an illness requiring hospital admission were 
identified using the unique Kilifi Birth Cohort number assigned to them during recruitment. 
Detailed clinical and laboratory investigations were carried out to ascertain the cause o f  illness
using well-defined case definitions as per the national and WHO clinical guidelines for 
management and referral o f  common conditions at level 4 - 6  hospitals (WHO 2009).
2.2.2 Matched case-control study
A matched case-control study was nested within the Kilifi birth cohort. Children from the 
cohort who were admitted to the high dependency unit between April 2002 and January 2010 
with well-defined severe malaria were selected as cases. Severe malaria was defined as 
admission to hospital with detectable parasites by microscopy and either one o f  the following 
symptoms: i) hemoglobin <5g/dL; ii) Blantyre coma score <5; or iii) deep breathing or chest 
indrawing (Marsh et al. 1995). Children fulfilling the criteria for severe malaria but in addition 
having positive cultures from blood or cerebrospinal fluid and/or a white blood cell count 
>10/pil, were excluded from the study to avoid misclassification with other potential causes o f  
severe illness in which case the parasitemia may have been coincidental.
Cases were individually matched to at least three controls by age (+/- 4 months); residence and 
cohort visit dates (+/- 4 months) to minimize potential confounding due to differences in 
cumulative exposure to infection which influences the levels o f antibodies and also increases 
the risk o f developing disease. At least three controls per case were selected to increase the 
statistical power o f the study (Miettinen 1969). Controls were selected from cohort 
participants who were never admitted to hospital with severe malaria up to the time o f 
admission o f the index case.
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2.2.3 Adult serum samples
For the well-studied merozoite antigens, adults living in malaria endemic areas have high 
antibody prevalence and a large proportion mount high titre responses compared to young 
children (Polley et al. 2004, Taylor et al. 1998, Ramasamy, Nagendran and Ramasamy 1994, 
McCallum et al. 2008). Adults were therefore recruited to allow for comparison o f antibody
levels and function with infants recruited in the case-control study.
!
Tvjo cross-sectional surveys were conducted in December 2007 and August 2008 in which 26 
and 75 individuals were recruited; respectively. The adults were aged between 18 -  65 years 
and residing within Junju sub-location, Kilifi County. Following informed consent, individuals 
were requested to attend the outpatient department o f Kilifi District Flospital for a physical 
examination performed by the study clinician and to donate 15ml o f venous blood drawn into 
15ml falcon tubes containing heparin. A small volume o f blood (1ml) was also transferred into 
EDTA tubes for complete blood counts. Thick and thin blood smears were also performed to 
detect P. falciparum  infections. The blood samples were processed immediately after 
collection. Serum and peripheral blood mononuclear cells (PBMCs) were separated and either 
used fresh in assays or stored at -80°C.
2.3 Laboratory methods
2.3.1 Recombinant P. falciparum  antigens
The recombinant antigens used in the study were based on allelic sequences o f  various P. 
falciparum  parasite strains and were expressed in Escherichia coli or Pichia pastoris. MSP-2 
antigens were based on the Dd2 and C H I50/9 parasite strains and were expressed as 
glutathione S'-transferase (GST) fusion proteins in E. coli. The 19-KDa fragment o f  M SP-119
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was expressed as a GST-fusion protein and was based on the Wellcome parasite strain. 
Transformed E coli cells containing the MSP-2 and M SP-119 genes were generously provided 
by Dr. Kevin Tetteh (London School o f Hygiene and Tropical Medicine). Full-length MSP-3 
antigens were expressed as maltose binding protein (MBP) -  fusion proteins in E. coli and 
were based on the 3D7 and K1 parasite strains. Full-length recombinant AMA1 ectodomains 
based on the FVO and 3D7 parasite strains were generously provided by Dr. Edmond 
Remarque (Biomedical Primate Research Centre, Netherlands). The AMA1 antigens were 
expressed in Pichia pastoris as His-tagged proteins. A fragment o f P/Rh2 based on the 3D7 
parasite strain was expressed in E. coli as a GST-fused protein (Reiling et al. 2010). 
Transformed E coli cells containing the f^Rh2 fragment were generously provided by 
collaborators in Prof. James Beeson’s laboratory (Burnet Institute o f Medical Research, 
Australia). A P. falciparum  schizont lysate based on the A4 parasite line was also tested. The 
lysate was prepared by sonicating a highly synchronous culture containing mature schizonts at 
high speed. The lysate was stored frozen at -80°C.
T able 2.1: D etails o f the recom binan t P. falciparum  antigens used in the study
A ntigen Sequence
Region
Tag E xpression
System
R eference
MSP-2 (Dd2) 22-247 GST E. coli (Taylor et al. 1995)
MSP-2 (C H I50/9) 1-184 GST E. coli (Taylor e ta l. 1995)
MSP-3 (3D7) 2-354 MBP E. coli (Polley et al. 2007)
MSP-3 (K l) 2-379 MBP E. coli (Polley et al. 2007)
AMA1 (3D7) 83-531 His P. pastoris (Dutta et al. 2002)
AMA1 (FVO) 25-544 His P. pastoris (Kocken et al. 2002)
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P jRh2 2030-2528 GST E. coli (Reiling et al. 2010)
M SP-1 , 9 1631-1726 GST E. coli (Burghaus and Holder 1994)
2.3.2 Enzyme Linked Immunosorbent Assay (ELISA)
Two different ELISA techniques were used to measure antibody titres in serum samples and 
are described below:
2.3.2.1 Standard ELISA
A well-established standard ELISA protocol was used to measure antibody titres against the 
recombinant antigens (Polley et al. 2004, Polley et al. 2006, Osier et al. 2008) and P. 
falciparum  schizont extract (Ndungu et al. 2002). Wells o f  Dynex 4HBX Immunolon plates 
(Dynex technologies Inc) were coated with lOOpI o f  0.5pg/ml recombinant antigen diluted in 
coating buffer (15mM Na2C0 3 , 35mM NaHC 0 3 , pH 9.4-9.6) or lOOpl o f  schizont extract 
diluted 1:1000 as previously described (Ndungu et al. 2002). After an overnight incubation at 
4°C, plates were washed four times in IX  PBS containing 0.05% Tween-20 (wash buffer) and 
blocked for 5 hours at room temperature with 1% skimmed milk diluted in PBS Tween-20 
(blocking buffer). The plates were washed four times in wash buffer and lOOpl o f  serum 
diluted 1:1000 in blocking buffer added to each well. Following an overnight incubation at 
4°C, wells were washed and incubated for 3 hours at room temperature with lOOpl o f  HRP 
conjugated polyclonal rabbit anti-human IgG (Dako) diluted 1:5000 in blocking buffer. The 
wells were washed four times and incubated at room temperature with lOOpl o f  development 
buffer (0.1M citric acid, 0.2M Na2HPC>4 , 4mg o-Phenylenediamine dihydrochloride tablets
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(Sigma), 8pl hydrogen peroxide and 5ml distilled water). After 25mins, the reaction was 
stopped with 25 pi H2SO4 and absorbance read at 492nm. Eleven serial dilutions o f a purified 
immunoglobulin reagent prepared from a pool o f Malawian adults presumed to be malaria- 
immune (Taylor et al. 1992) were included for every antigen tested to obtain a standard 
dilution curve that allows conversion o f optical density readings to relative antibody 
concentrations. A pool o f sera obtained from Kilifi adults was included on a single well in 
each plate as a positive control to allow for standardization o f  day-to-day and plate-to-plate 
variation. Twenty sera obtained from m alaria non-exposed UK adults were also included as 
negative controls for each antigen tested. All samples were assayed in duplicate and those that 
had a coefficient o f  variation (CV) greater than 20% were repeated.
2.3.2.2 Multiplex bead-based antibody assay
A multiplex bead-based ELISA assay was used to simultaneously quantify antibodies against
multiple P. falciparum  merozoite antigens (Fouda et al. 2006). Antigens were coupled onto
different M agPlex® microspheres (Luminex corporation) each bearing a unique spectral
address. The coupling reaction was performed using the Bio-Plex amine coupling kit
(BioRad). An aliquot o f  one million beads was washed in lOOpl wash buffer by vortexing for
30 seconds and resuspended in 80pl o f bead activation buffer. lOpl o f  a 50mg/ml solution o f
sulfo-N-hydroxysulfosuccinimide (S-NHS) and lOpl o f  a 50mg/ml solution o f l-ethyl-3-[3-
dimethylaminopropyl) carbodiimide hydrochloride (EDAC) diluted in bead activation buffer
were each added to the beads and incubated at room temperature in the dark for 20min on a
rotator. The activated beads were washed and resuspended in lOOpl o f IX  PBS pH 7.4
followed by addition o f lp g  o f recombinant antigen per million beads. The beads were
incubated for 2 hours at room temperature on a rotator, washed with IX  PBS pH 7.4 and
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blocked with 250pl o f blocking buffer for 30min at room temperature. The coupled beads 
were washed once in storage buffer, resuspended in 150pl o f  the same buffer and stored 4°C.
M icrospheres were resuspended by vortexing and diluted to 100 beads/pl using PBS with 1% 
bovine serum albumin (BSA) (dilution buffer). 50pl o f diluted beads and 50pil o f  plasma 
(diluted 1:1000 in dilution buffer) were added to individual wells o f  Bio-Plex pro flat bottom 
plates (BioRad). The plates were incubated on a microplate shaker (rotation 500 rpm) for 1 
hour at ro im  temperature. The plates were washed five times with IX  PBS containing 0.05% 
Tween-20 (wash buffer) and resuspended in lOOpl o f  R-phycoerythrin-conjugated, f(ab ’)2  
fragment-specific, goat anti-human immunoglobulin G (Jackson Immunoresearch, West 
Grove, PA) diluted 1:300 in dilution buffer. After 30 min incubation at room temperature on a 
microplate shaker, the plates were washed five times with wash buffer. The beads were 
resuspended in lOOpl o f dilution buffer and analyzed on a Magpix® (Luminex corporation) 
platform using the xPONENT® software. The reader was programmed to measure 
fluorescence intensity o f  100 beads per spectral address and the readings are expressed as 
median fluorescent intensity (MFI). Eleven serial dilutions o f the purified immunoglobulin 
reagent mentioned in section 2.3.2.1 above (Taylor et al. 1992) were included for every 
antigen tested to obtain a standard dilution curve that allowed the conversion o f  MFI readings 
to relative antibody concentrations. A pool o f sera obtained from Kilifi adults was included on 
a single well in each plate as a positive control to allow for standardization o f  day-to-day and 
plate-to-plate variation. Twenty sera obtained from malaria non-exposed UK adults were also 
included as negative controls for each antigen tested. All samples were assayed in duplicate 
and those that had a coefficient o f variation (CV) greater than 20% were repeated.
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2.3.3 In vitro P. falciparum parasite culture
Parasite strains were frozen in glycerolyte and stored in liquid nitrogen at the Jenner Institute, 
University o f  Oxford and KEMRI, Kilifi laboratories. To establish parasite cultures for 
antibody-mediated functional assays, parasites were retrieved from liquid nitrogen, allowed to 
thaw at room temperature and transferred to 50ml falcon tubes. Two hundred microlitres o f 
12% sodium chloride solution was added dropwise while gently shaking the tube. After 5 
minutes incubation at room temperature, 10ml o f 1.8% sodium chloride solution was added 
dropwise while gently shaking the tube, followed by incubation for 5 mins at room 
temperature. A final 10ml volume o f 0.9% sodium chloride solution was added to the tube and 
the cells pelleted by centrifugation at 830 x g for 5 mins. The supernatant was discarded and 
the cell pellet washed twice with RPMI-1640 medium (pH 7.2) supplemented with Im M  L- 
glutamine, 37.5mM HEPES, 200mg/ml glucose, lOOpM hypoxanthine and 25pg/m l 
gentamicin (incomplete media). After the final wash, 10ml o f incomplete media supplemented 
with 10% pooled human serum was added and the parasites transferred to a sterile culture 
flask. A gas mixture containing 92% N 2, 5% O2 and 3% CO2 was also added to the parasites 
and the flask transferred to an incubator maintained at 37°C. Parasite cultures were routinely 
maintained at 1-2 % parasitemia and 2% hematocrit by adding fresh O+ erythrocytes from 
healthy malaria non-exposed donors.
To obtain highly synchronized parasites, culture pellets were either treated with warm 5% D- 
sorbitol (Sigma) solution for 10 mins at 37°C to obtain ring stage parasites or resuspended in 
incomplete media and passed through a magnetic column (varioMACS™) to allow separation 
o f trophozoite stage parasites. Alternatively, a lm l culture pellet was overlayed on a gradient 
containing 65% percoll (diluted in PBS) and centrifuged at 1,870 x g for 5 mins at room 
temperature. The brown layer containing trophozoites and schizonts between the culture
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medium and the percoll solution was collected and washed twice in incomplete media at 830 x 
g for 5 mins at room temperature.
2.3.4 Isolation of parasitophorous enclosed merozoite structures from P. falciparum  
cultures
Parasites were maintained at 10 -  15% parasitemia and 2% hematocrit and synchronized by 
sorbitol lysis, as described in section 2.3.3 above, for two consecutive cycles. Synchronous 
ring-stage parasites were allowed to mature to trophozoite stage and enriched on a 65% percoll 
gradient, as described in section 2.3.3 above. The parasites were pelleted and washed twice 
with incomplete media at 830 x g for 5 mins. The cell pellet was resuspended in 10ml o f 
complete media containing lOpM trans-epoxysuccinlyl-L-leucylamido-(4-guanidino) butane 
(E-64) (Sigma), transferred to a sterile culture flask and incubated for six to eight hours at 
37°C to obtain schizont stage parasites. Schizonts were pelleted by centrifugation at 2000 rpm 
for 5 mins and resuspended in IX  PBS. Ten microlitres o f  resuspended parasites was 
transferred to a FastRead™ hemocytometer slide (Immune Systems Ltd) and the number o f 
schizonts estimated as follows (http://fastread.co.uk): -
No. o f  schizont/ml = No. o f  schizonts in 16 squares x 104
The resuspended parasites were aliquoted into eppendorf tubes, each containing approximately 
lm l o f  18.5 x 105 schizonts/ml and frozen at -20°C.
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2.3.5 Antibody function assays
Two different assays were performed to measure the functional activity o f  human antibodies 
using the P. falciparum  3D7 laboratory isolate. The one-cycle growth inhibition and antibody 
dependent respiratory burst (ADRB) assays were performed at the Jenner Institute, whereas 
the two-cycle growth inhibition assay was performed in Kilifi at the KEMRI Wellcome Trust 
laboratories.
2.3.5.1 Growth Inhibition Assays
The ability o f human serum to inhibit in vitro growth o f parasites was measured after one or 
two cycles o f parasite replication according to previously established protocols (Persson et al. 
2006, Malkin et al. 2005). Fifty microlitres o f sera were dialyzed to remove antimalarial drugs 
prior to assay set-up using 20KDa M W CO slide-A-lyzer mini dialysis tubes (Thermo fisher 
scientific). Sera were dialyzed against two changes o f  IX  PBS each lasting 1 hour and a final 
overnight dialysis at 4°C. After dialysis, the samples were transferred to Amicon Ultra - 0.5 
centrifugal filter devices, 100,000 MWCO (Millipore) and reconstituted back to the original 
volume by centrifuging at 10,000rpm for 20mins. Thereafter, sera were heat-inactivated by 
incubating in a water bath for 30mins at 56°C.
In the two-cycle GIA, highly synchronous trophozoite parasites were obtained (as described 
above) and adjusted to 0.3- 0.5% parasitemia by addition o f  fresh O+ erythrocytes. Parasites 
were resuspended at 1% hematocrit in incomplete media supplemented with 10% pooled 
human serum. 45pl o f parasite suspension was added to individual wells o f  sterile 96-well U- 
bottom plates (Falcon) excluding the outer wells o f  the plate, which were filled with sterile 
water for humidification purposes. Thereafter, 5pl o f  dialyzed test sera were added into the
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wells in duplicate and the plates placed in a well-sealed humidified gas chamber and incubated 
at 37°C. Duplicate wells with a pool o f sera from non-immune UK adults were included as a 
negative control and lOmg/ml o f a pool o f purified IgG obtained from healthy Malawian adult 
donors (MIG) as a positive control. Several wells containing untreated cultures were also 
included on every plate to monitor the growth o f  parasites. After 40 hours incubation, lOpl o f 
fresh complete media was added to the wells and the plates incubated for a further 40 hours. 
At the end o f the second growth-cycle, lOOpl of10pg/m l ethidium bromide (molecular grade) 
diluted in IX  PBS was added to each well and the plates incubated for 30 mins at room 
temperature in the dark. The plates were centrifuged at 1200rpm for 1 min and the pellet 
resuspended in 200pl o f IX  PBS. Parasitemia was determined by analyzing 70,000 events 
acquired on an FC500 (Beckman Coulter) flowcytometer.
Results were analyzed using FlowJo (Treestar) software and expressed as follows (Rono et al. 
2012): -
% G IA =  100% - Average parasitemia o f  test sample x 100 
Average parasitemia o f negative control
In the one-cycle GIA, trophozoite stage parasites were obtained as described above and
adjusted to 0.5% parasitemia by adding fresh 0 +  erythrocytes. The cells were pelleted and
resuspended at 1% hematrocrit in complete media. 36pl o f  parasite suspension was added to
individual wells o f sterile half area 96-well flat-bottom plates (Corning). Thereafter 4pl o f
dialyzed and heat-inactivated test sera were added to the wells in triplicate and incubated in an
improvised humidified gas chamber at 37°C. In every plate, triplicate wells containing a pool
o f sera from non-immune UK adults were included as a negative control and lOmg/ml o f
purified MIG as a positive control. Wells containing uninfected 0 +  erythrocytes in complete
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m edia were also included on every plate. The outer wells and inter-well spaces were filled 
with sterile water to minimize evaporation. After 40 hours incubation, the wells were washed 
once with lOOpl o f ice-cold IX  PBS. Parasitemia was determined by a biochemical assay that 
measures the amount o f parasite lactate dehydrogenase (pLDH) present in mature stage 
parasites. Fifty millilitre stocks o f LDH substrate buffer were prepared by mixing 5ml 1M Tris 
HC1 (pH 8.0), 45ml dH20, 0.28g sodium L-lactate (Sigma) and 0.125ml Triton X-100 
(Sigma). The stocks were stored at -20°C. On the day prior to usage, a lOmg/ml Nitro Blue 
Tetrazolium (NBT) tablet (Sigma) was dissolved in 50ml o f LDH buffer. The substrate was 
prepared by mixing 10ml o f LDH substrate buffer, 200pl o f 50units/ml diaphorase solution 
(Sigma), 50pl o f  lOmg/ml 3-Acetylpyridine Adenine Dinucleotide (APAD) solution (Sigma), 
and added to individual wells (lOOpl each). The plates were incubated on a Titramax 100™flat 
bed shaker (Heidolph) for 15 minutes. Optical density readings were measured at 650nm on a 
Varioskan flash multimode reader (Thermo Scientific). Growth inhibition was calculated as 
follows (Williams et al. 2012): -
% G IA =  100% —
■<
OD o f test sample -  OD o f uninfected RBCs x 100 
OD o f negative control -  OD o f  uninfected RBCs
2.3.5.2 Isolation of polymorphonuclear (PMN) leukocytes from whole blood
Whole blood was collected in EDTA vacutainer tubes and layered over polymorphprep™ 
(Axis-Shield Diagnostics) in a sterile 15ml falcon tube at a ratio o f 1:1. The tubes were 
centrifuged at 500 x g without brakes for 40mins at room temperature. The layer containing 
PMNs was carefully aspirated and transferred to a 15ml falcon tube containing 10ml o f  ice-
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cold sterile PMN buffer (0.1% bovine serum albumin (BSA) and 1% D-(+)-Glucose Hybri 
Max (Sigma) in hanks buffered saline solution). The cells were pelleted at 500 x g for lOmins 
at 4°C and resuspended in 10ml ice cold 0.2% sodium chloride for 30secs to lyse residual 
RBCs, followed by addition o f 10ml ice-cold 1.6% sodium chloride. After a final spin at 250 x 
g for 6 mins at 4°C, the cell pellet was resuspended in 0.5ml PMN buffer. Thereafter, 15pl o f  
PMN suspension diluted 1:10 in trypan blue was transferred onto a FastRead 102™ (Immune 
systems Ltd) disposable hemocytometer and the concentration o f isolated PMNs estimated as 
follows (http://fastread.co.uk): -
No. o f  cells/ml = No. o f  viable cells in 16 squares x 104 x 10(dilution factor)
The percentage o f  neutrophils amongst the PMNs was estimated by smearing 5pi o f  PMN 
suspension on a glass slide, fixing in methanol for 10 seconds, staining with 5% Giemsa for 
lOmins and observing under X I 00 magnification on a light microscope.
2.3.5.3 Antibody dependent respiratory burst (ADRB) assay
Merozoite lysates comprising o f merozoites and debris from lysed schizonts were thawed at 
room temperature and resuspended by vortexing. Microplate 96 well polystyrene fluorescence 
Maxisorp surface white (Thermo Scientific Nunc) wells were coated with either lOOpl o f  
recombinant protein at lOpg/ml (diluted in IX  PBS) or lOOpl o f 18.5 x 105 schizonts/ml lysate 
and incubated overnight at room temperature. The wells were washed three times with 200pl 
o f  IX  PBS and blocked with 200pl blocker™ casein in PBS (Thermo scientific) for 1 hour at 
room temperature. One hundred microlitres o f test serum diluted 1:50 in 1XPBS was added to 
individual wells in duplicate and incubated for 1 hour at 37°C. The wells were washed three 
times with 200pl o f IX  PBS followed by addition o f 50pl o f  4-Aminophthalhydrazide (Sigma)
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at 0.04mg/ml. Thereafter, 50pl o f human neutrophils (prepared as described in section 2.3.5.2) 
diluted to 5x105 PMNs/well in PMN buffer were added to individual wells and the plates 
immediately read on a Varioskan flash multimode reader (Thermo Scientific). 
Chemiluminescence readings from each well were obtained for one second every minute over 
an hours’ duration.
2.4 Cohort description
Following are details o f  the characteristics o f  the Kilifi Birth Cohort (KBC) used to study the 
targets and mechanisms associated with protection against severe malaria. Details o f  the 
cohorts used for the clinical endpoint o f  uncomplicated malaria are described in Chapter Four.
2.4.1 General characteristics of the KBC cohort
A total o f  5,949 infants were recruited between 2001 and 2008 either at the Kilifi District 
Hospital’s maternity ward (4,229 (71.1%)) or at the maternal and child health clinic (1678 
(28.2%)) (Figure 2.2). Recruitment information o f 42 (0.7%) infants was not entered into the 
database. 842 (14%) infants were not linked to the KHDSS register (Fig 2.2) because 
matching o f KBC recruits to the population register began much later in April 2002 (Scott et 
al. 2012). The mean maternal age was 26.7 years (range 17 -  59). The median num ber o f  
siblings was 2 (range 0-11). A total o f  20, 219 cohort visits were recorded during the study 
period. A total o f 222 children were selected for the matched case-control study comprising o f  
61 well-defined severe malaria cases and 161 controls. The baseline characteristics o f  the 
study participants are summarized in Table 2.2.
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2.4.2 Summary of severe malaria cases and controls
A total o f  93 children fulfilled the criteria for well-defined severe malaria (Marsh et al. 1995). 
Sixty one cases had three-monthly follow-up serum samples available (Figure 2.2). The 
distribution o f  clinical symptoms o f  severe malaria amongst the 61 cases is summarized in 
Figure 2.3. The median age o f index cases at the time o f  admission was 14.8 months (IQR 7.5 
-  24.7) and four cases had fatal outcomes. The median parasitemia was 26,691parasites/pl 
(IQR 4 ,020- 260,000). The localities within the KHDSS from which the severe m alaria cases 
were drawn are shown in Figure 2.4.
A total o f  161 controls were selected (Figure 2.2), 58 o f whom had a history o f admission to 
hospital with uncomplicated malaria (11 (19%)), lower respiratory tract infections (13 (22%)), 
gastroenteritis (12 (21%)) or other illnesses (22 (38%)) such as neonatal sepsis, bronchiolitis, 
neonatal jaundice, bums, malnutrition and febrile convulsions.
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Fig 2.2: A schematic diagram of the Kilifi Birth Cohort illustrating the selection of cases 
and controls for the matched case-control study.
1 Total num ber o f  admissions during the follow-up period. Some children were admitted to 
hospital more than once.
2 Unique admissions during the follow-up period.
3 Parasite positive refers to presence o f  detectable parasites by microscopy.
4 Thirty two cases were excluded because their 3-m onthly follow-up visit serum samples were 
depleted.
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Table 2.2: Baseline characteristics of selected cases and controls illustrating the 
success of matching.
Cases
(N=61)
Controls
(N=161) P-value
Sex, female/N (%) 31/61 (50.8) 78/161 (48.4) 0.76
No. o f  visit samples, mean (range) 4 .36(1-8) 4 .49(1-9) 0.49
Age at the time o f  index case admission, 14.83 16.36 0.81
median age in months (IQR) (7 .5 -2 4 .5 3 ) (7 .3 -2 4 .8 )
Proportion parasite positive3 during 21/170 36/458 0.08
visits, n/N  (%) (12) (7.8)
Proportion o f  individuals with fever 14/153 37/443 0.90
during visits, n/N (%) (9.1) (8.3)
Proportion o f  individuals with fever and 5/165 12/427 0.95
parasites during visits, n/N (%) (3%) (2.8%)
aParasite positive either by m icroscopy or PCR
105
Impaired consciousness 
(32) ^
Respiratory distress
\  (35)
15  (24.6%) 9 (14.8%) 19 (31%)
5 (8.2%)
3 (4.9%) 2 (3.3%)
8  (13.1%)
Severe anemia
(18)
F ig u re  2.3: The prevalence and overlap o f  the m ajor severe m alaria sym ptoms amongst 
the cases.
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F igure 2.4: Map o f  KHDSS showing the number o f  KBC severe malaria eases recorded from 
each administrative location during the follow-up period (map kindly provided by Mark 
Otiende, KHDSS data manager).
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CHAPTER THREE
Comparison of ELISA methods for quantifying malaria-specific antibody amounts
3.0 Introduction
Quantification o f m alaria-specific antibodies is important for determ ining the level o f  
antibodies that m ay be associated w ith protection from episodes o f  malaria in 
immunoepidemiological studies and for evaluating the immunogenicity o f  m alaria 
vaccines. Enzyme Linked Imm unosorbent Assay (ELISA) based approaches have been 
widely used to quantify antibodies and have replaced traditional methods such as the 
radioimmunoassay. The ELISA method was developed simultaneously and independently 
in 1971 by Engvall and Perlm ann (Engvall and Perlmann 1971) and by van W eemen and 
Schuurs (Van W eemen and Schuurs 1971). Although this method is reliable, sensitive, 
reproducible and fairly low cost, considerable differences exist between studies in the 
reporting o f  the magnitude o f responses.
In the field o f  malaria, some studies report ELISA optical density (OD) values as a 
measure o f  the magnitude o f  responses (Osier et al. 2008, Kinyanjui et al. 2007, A gak et al. 
2008, Polley et al. 2006, Polley et al. 2004) whose accuracy is limited by the non-linear 
relationship observed between OD values and antibody concentration outside specific 
ranges o f  a standard curve. In my studies, the linear range o f  a standard curve is limited to 
about one order o f magnitude, ranging between an OD o f  0.2 -  2, while the actual 
concentration in a sample could range over five to six orders o f  magnitude. This is a 
concern when measuring antibody titers o f  individuals living in high m alaria transm ission 
settings or those mounting effective responses after vaccination, since such individuals 
would induce anti-merozoite antibody levels that fall above the linear range o f  a standard 
curve with the possibility that their antibody titres would be underestimated. Above this
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range, a two-fold difference in OD readings does not equal to a two-fold difference in the 
absolute antibody amount (Engvall and Perlmann 1972, Plested, Coull and Gidney 2003).
To overcome this limitation, the determination o f  end point titers from dilution curves o f 
individual sera has been adopted in some studies (Dutta et al. 2009, Dodoo et al. 2011). 
Here, titers are defined as the highest dilution o f  serum that gives an OD reading above a 
specified cutoff. Some studies employ a cu to ff o f  two or three standard deviations o f  the 
mean o f  the negative control or background (Stowers et al. 2001, Genton et al. 2007) or an 
arbitrary OD value (M iura et al. 2008a, Dutta et al. 2009). Given that this method requires 
a full dilution curve o f  individual sera, which is labor-intensive and requires a lot o f 
reagents, it is not suited for large cohort studies. An attem pt has been made to standardize 
end point titer cutoffs by employing statistical methods (Frey, Di Canzio and Zurakowski 
1998).
Other studies have reported relative antibody units with reference to the units assigned to a
pool o f  sera from malaria-exposed individuals (Dodoo et al. 2000, Corran et al. 2008,
Nebie et al. 2008b) or a standard commercial reagent (Nebie et al. 2008a, Lusingu et al.
2005, Sirima et al. 2007, Sirima et al. 2009). Antibody amounts in test sera are then
reported as arbitrary units since the actual antigen-specific am ount in the standard is
unknown and, thus far, there is a lack o f m alaria-specific reference reagents (with known
antigen-specific antibody concentrations) to determine absolute antigen-specific antibody
amounts. In a study by Yoon et a l , the developm ent o f  an M SP-I42 specific reference
standard o f known absolute concentration has been described (Yoon et al. 2005) and
employed in the quantification o f M SP-142-specific antibodies (Ogutu et al. 2009).
However, this is one o f  hundreds o f merozoite antigens and a sim ilar standard would be
needed for all the remaining antigens and for each species to be studied.
\
In the absence o f a known antigen-specific reference reagent to determ ine absolute
antibody concentrations, M iura et al. have demonstrated that arbitrary units can be
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converted into absolute concentrations (in pg/m l) using a mathematical conversion factor 
(M iura et al. 2009). A lthough this approach is mainly limited by the quantity o f  antigen 
and serum that is required to perform antigen-specific antibody affinity purification, it has 
been adopted by several studies assessing vaccine-induced immunity against MSP-1 and 
AMA1 (Sheehy et al. 2011, Sheehy et al. 2012a, Ellis et al. 2010, Ellis et al. 2012, Pierce 
et al. 2010). Another method o f  antibody quantification known as the calibration-free 
concentration analysis (CFCA) has been described and utilized for absolute quantification 
o f  merozoite-specific antibody concentrations (W illiams et al. 2012). CFCA m easures the 
rate o f binding o f specific antibodies to their target antigens by surface plasm on resonance 
(SPR). A fully quantitative and standardized measure o f antibody responses would allow 
better comparison o f  data from different studies.
The heterogeneity in the methods used to quantify antibodies to m alaria antigens by 
different studies has hindered accurate comparison o f findings across studies and the 
standardization o f  methods o f  expressing ELISA data is essential in this regard.
3.1 Rationale
In this chapter, I sought to determine the best method to adopt for quantification o f
antibodies against P. falciparum  merozoite antigens that could replace the use o f  OD
values (limitations outlined above) which have previously been w idely applied as a
m easure o f  the magnitude o f  responses in several cohorts in Kilifi (Agak et al. 2008, Osier
et al. 2008, Kinyanjui et al. 2007, Polley et al. 2004, Polley et al. 2006). Towards this end,
I tested a quantification method outlined by M iura et al, which reliably estim ates arbitrary
units using a single dilution o f sera (M iura et al. 2008a). Titres o f  test sera are determ ined
from a serially diluted hyperimmune serum pool and defined as the reciprocal dilution that
gives an OD equal to 1.0. Titres obtained by this method are identical to those derived
from a full dilution curve o f  individual samples at this cutoff. I com pared antibody titres
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obtain by this method with those obtained by interpolating relative amounts from a 
standard curve derived from a purified immunoglobulin pool assigned an arbitrary 
concentration o f  50mg/ml. Evaluating the best quantification method would enable 
comparison o f data from different cohorts in Kilifi and in other settings if  the same method 
were applied.
3.2 Objective
• To evaluate and compare two ELISA methods for the quantification o f  malaria- 
specific antibodies.
3.3 Methods
3.3.1 Recombinant antigens and standard ELISA
Antibody titres against AM A1, M SP-2, MSP-3 and M S P -I19 OD were evaluated using a 
standard ELISA protocol as outlined in section 2.3.2.1.
3.3.2 Semi-immune adult sera
Relative antibody amounts were interpolated from standard curves generated from  two 
independent serum pools prepared from m alaria-exposed adults who are known to be semi- 
immune to clinical episodes o f malaria.
3.3.2.1 Pool of sera from malaria exposed Kilifi adults (PHIS)
Serum samples collected between 1995 and 2008 during annual cross-sectional surveys 
from healthy adults resident in Kilifi County were pooled and aliquoted into 1ml vials. The
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samples were stored at -80°C. Eleven doubling dilutions o f the pooled serum were used in 
the ELISA assay to generate a standard curve.
3.3.2.2 Malaria Immune Globulin (MIG)
A commercially purified immunoglobulin reagent o f  known concentration (50mg/ml) was 
also provided for use as a malaria-specific reference standard (Central Laboratory Blood 
Transfusion Service SRC, Switzerland). The preparation contains immunoglobulins (98% 
IgG) purified from a plasm a pool o f  eight hundred and thirty four healthy M alawian adults 
and was originally manufactured to test its potential use as an adjunct therapy to quinine in 
the treatm ent o f  cerebral m alaria (Taylor et al. 1992). The absolute concentration o f  
antibodies to specific malaria antigens in this reagent has thus far not been determ ined and 
therefore this pool was assigned an arbitrary concentration o f  50mg/ml.
3.3.3 Assigning antibody units to the pooled semi-immune serum (PHIS) and MIG
Eleven two-fold serial dilutions o f  PHIS were prepared, starting at 1:250 to 1:256,000. 
ELISA OD values were determined at each dilution against AM A1, M SP-3, M SP-2 and 
MSP-1 19. The OD values were plotted against the reciprocal dilution to generate a standard 
curve fitted using the four-param eter logistic function in GraphPad Prism software, version 
6.0 (GraphPad Software, San Diego, CA). Antibody units for each antigen tested were 
assigned to PHIS as the reciprocal dilution giving an OD 492 equal to 1. These were 
invariably used as the antibody units contained in the semi-immune serum pool against 
these antigens in subsequent assays.
The M alaria Immune Globulin (Central Laboratory Blood Transfusion Service SRC,
Switzerland) was commercially prepared and packaged in 50mg/ml vials. The absolute
antigen-specific antibody concentrations contained in M IG has not been determ ined thus
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far and it was therefore assumed to be 50mg/ml for every antigen tested to enable 
interpolation o f relative antibody amounts from a standard curve.
3.3.4 Determining antibody units o f test samples from a standard curve o f PHIS and 
MIG
One hundred and thirty one adult serum samples were screened for the range o f  ELISA OD 
values obtained at a serum dilution o f  1:1000 against four merozoite antigens using a 
standard ELISA protocol. Serum samples with high OD values (OD >2.5), intermediate 
OD values (OD 1 -  2.5) and low OD values (OD <1) were selected for each antigen tested 
to capture the range o f  OD values obtained from a standard ELISA in our setting. Serial 
dilutions o f PHIS and MIG were included for every antigen to generate a standard curve 
which was used to convert ELISA OD values to relative antibody units.
3.3.5 End point titration of individual test sera
Twelve two-fold serial dilutions o f  individual test sera were prepared starting at 1:1,000 to 
1:1,024,000 dilution. The samples were tested for reactivity to AM A1, M SP-3, M SP-2 and 
MSP-1 19. Individual curves o f  test samples were fitted using the four-param eter logistic 
function, as described above. The end point titer for each sample was defined as the 
reciprocal dilution that gave an OD492 equal to 1.
3.3.6 Statistical analysis
Spearman correlation coefficients were calculated using GraphPad prism version 6.0 
(GraphPad software, San Diego, California, USA). A  four-param eter logistic function was
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used to tit standard curves in GraphPad Prism software, version 6.0 (GraphPad Software, 
San Diego, CA).
3.4 R esults
3.4.1 Assigning an tibody  units to PH IS  and  M IG
The antibody units assigned to PHIS were 11700AU. 3070AU, 3540AU and 3250AU for 
AMA1, MSP-3, MSP-2 and M SP-119 respectively (Figure 3.1). These were invariably used 
as the total antibody concentrations o f  the hyperimmune pools for these antigens in 
subsequent assays. The antibody concentration o f MIG was assumed to be 50mg/ml for all 
antigens.
PHIS - Antibody units
AMA1 
MSP3 
MSP2 
MSP1 19
Q
O
10° 105 106
Reciprocal dilution
Figure 3.1 Standard curves o f a semi-immune serum pool (PHIS) against AMA-1. MSP- 
3, MSP-2 and M S P -I 1 9 . Antibody units contained in the pool for each antigen were 
determined as the reciprocal dilution that gave an O D 4 9 2  equal to 1 .0 .
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3.4.2 End point titration
To ensure that the quantification method was accurate across the range o f ELISA O D  
values obtained in our setting, twenty two adult samples with low, intermediate or high O D  
values were selected for each antigen. Test sera were diluted 1:1000. Thereafter, full 
dilution curves were generated for the 22 adult samples. All samples exhibited the 
expected sigmoid shape (Figure 3.2). The end point titer was defined as the reciprocal 
dilution that gave an OD492 equal to 1. Titers for 4 (18%), 9 (41%), 10 (45%), and 1 2  
(55%) samples tested against AM A1, M SP-3, M SP-2 and M S P -I19 respectively could not 
be determined using this method because the O D  observed at the maximum concentration 
was below the end point titer cutoff (defined as OD492 =1).
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F igure  3.2: End point titration curves o f  22 sera tested against (A) AMA-1 (B) MSP-3 (C) MSP- 
2 and (D) M S P-119 Two-fold serial dilutions were generated for every sample starting at 1:1000 to 
1:1024000. A curve o f each sample was fitted using the four-parameter hyperbolic function. End 
point titers were defined as reciprocal dilution giving an OD492 equal to 1 .0 .
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3.4.3 Comparison of antibody units derived from a single dilution (1:1000) versus a 
full dilution curve
Based on the method described by M iura et al, antibody amounts extrapolated from  the 
serially diluted standard (PHIS) at a single dilution are similar to those obtained using the 
end point titer method (M iura et al. 2008a). End point titers are defined as the reciprocal 
dilution that gives an OD492 equal to 1. The correlations between amounts derived from a 
single serum dilution o f  1 : 1 0 0 0  were compared to those obtained from a full dilution curve 
(1:1000 to 1:1024000) o f  individual samples. For all antigens tested, there was a 
significant positive correlation between end point titers obtained by both methods 
(Spearman correlation coefficient o f  0.987, 0.968, 0.936 and 0.991 for AM A1, M SP-3, 
M SP-2 and M S P -l^ , respectively) (Figure 3.3). However, there was a large difference in 
antibody units assigned by both m ethods in 13 (59%), 13 (59%), 12 (54%) and 10 (45%) 
samples tested against AM A1, M SP-3, M SP-2 and M S P -I19, respectively, for sam ples that 
had an OD 492 greater than 2.07, 1.95, 1.91 and 2.12, or less than 0.05, 0.245, 0.07 and 
0.101, respectively. These OD 492 values thus define the limits within w hich reliable 
estimation o f  antibody amounts from a standard curve at a serum dilution o f  1:1000 could 
be obtained. Since more than h a lf o f the samples tested were assigned incorrect antibody 
amounts at this dilution, the determination o f a single dilution that gave OD values closest 
to 1 was essential.
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F ig u re  3.3. Comparison o f end point titers calculated from a single dilution point (1:1000) 
versus a full dilution curve o f  individual samples. The end point titre was defined as the OD 492 
that gave an OD equal to 1. Representative graphs o f responses to (A) AMA1 (B) M SP-3 (C) 
M SP-2 and (D) M S P l -19  are shown.
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3.4.4 Determining an optimal single serum dilution for estimating accurate antibody 
concentrations from a standard curve
Having determined that a single dilution could accurately reflect the titres measured using 
a full end point titration, I then sought to determine what that optimal serum dilution ought 
to be. To do this, end point titers derived from  full dilution curves o f  individual test sera 
were plotted against titers interpolated from the standard PHIS curve at five doubling 
serum dilutions (1 :2000 -  1:32000) and the correlation coefficients for each pair compared.
There was a significant positive correlation between the end point titers derived from full 
dilution curves and from single dilutions at all the serial dilutions tested for all antigens 
(Spearman correlation coefficient >0.9; p<0.0001), (Figure 3.4.1 -  3.4.4). There was an 
increase in the correlation coefficient with increasing serum dilution for all antigens tested 
(Figure 3.4.1 -  3.4.4). Based on these findings, a dilution o f  1:16000 was selected as the 
optimal serum dilution for determining antibody concentrations from the standard PHIS 
curve as it gave the highest correlation coefficient for all antigens tested (Spearm an 
correlation coefficient = 1, 0.998, 0.992 and 0.991 for AM A1, M S P -I19, M SP-2 and M SP- 
3, respectively).
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F ig u re  3.4.1: AMA-1 end point antibody titers estimated from individual full dilution curves o f  test 
sera (x-axis) versus titers derived from a standard curve o f  PHIS (y-axis). Serum samples were diluted 
at (A) 1:2000 (B) 1:4000 (C) 1:8000 (D) 1:16000 and (E) 1:32000 and titers interpolated from the 
standard PHIS curve. End point titres were defined as the reciprocal dilution that gave an OD 492 equal
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F ig u re  3.4.2: M S P -I19 end point antibody titers estimated from individual full dilution curves o f  test 
sera (x-axis) versus titers derived from a standard curve o f  PHIS (y-axis). Serum samples were diluted at 
(A) 1:2000 (B) 1:4000 (C) 1:8000 (D) 1:16000 and (E) 1:32000 and titers interpolated from the standard 
PHIS curve. End point titres were defined as the reciprocal dilution that gave an OD 492 equal to 1.
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Figure 3.4.3: M SP-2 end point antibody titers estimated from individual full dilution curves o f  test 
sera (x-axis) versus titers derived from a standard curve o f PHIS (y-axis). Serum samples were 
diluted at (A) 1:2000 (B) 1:4000 (C) 1:8000 (D) 1:16000 and (E) 1:32000 and titers interpolated from 
the standard PHIS curve. End point titres were defined as the reciprocal dilution that gave an O D 492
equal to 1 .
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F ig u re  3.4.4: MSP-3 end point antibody titers estimated from individual full dilution curves o f  test 
sera (x-axis) versus titers derived from a standard curve o f  PHIS (y-axis). Serum samples were diluted 
at (A) 1:2000 (B) 1:4000 (C) 1:8000 (D) 1:16000 and (E) 1:32000 and titers interpolated from the 
standard PHIS curve. End point titres were defined as the reciprocal dilution that gave an OD 492 equal
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3.4.5. D eterm ining  rela tive an tibody  am ounts from  a s ta n d a rd  curve o f M IG
Having optimized the method o f accurately determining arbitrary antibody amounts from a 
standard PHIS curve using a single serum dilution, a purified immunoglobulin pool (MIG) 
o f  known concentration was also used to obtain arbitrary antibody concentrations (in 
fig/ml) based on the assumption that the MIG pool contains 50mg/ml arbitrary units o f  
antibody against each antigen. Twelve two-fold serial dilutions o f MIG were prepared, 
starting at 160pg/ml to 0.078pg/ml and tested against AMA1, MSP-2 (Dd2 and C H I 50/9 
allelic types), MSP-3 (K1 and 3D7 allelic types), GLURP-RO, GLURP-R2 and M S P -fo  
(Figure 3.5).
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Figure 3.5. Serial dilution curves o f  MIG tested against eight merozoite antigens. Each line 
represents a dilution curve for an individual antigen.
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A prerequisite for correct estimation o f relative antibody concentrations from a standard is 
the confirmation that the shape o f the standard curve is similar to that o f  individual test 
samples (Miura, 2008). The dilution curves for MIG were parallel to those o f  the test 
samples when tested against AMA-1 and MSP-3 (Figure 3.6); therefore correct relative 
estimates o f  concentrations could be determined in this population using MIG as a 
standard. Thereafter, relative antibody amounts o f  22 adult samples were determined from 
a standard curve o f  MIG generated using the four-parameter logistic function. Samples 
were assayed at a single serum dilution o f 1:16000.
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F igure 3.6. Individual dilution curves (1:1000 to 1:1024000) o f  twenty two adult serum samples 
and a malaria specific standard reference reagent (MIG) represented as a black bold line. 
Responses to (A) A M A 1 and (B) MSP-3 are shown.
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3.4.6. C om parison  o f an tibody  am o u n ts  derived  from  a  s ta n d a rd  cu rve o f P H IS  
versus M IG
End point titers obtained using a standard curve o f PHIS were compared to relative 
antibody amounts derived from a standard curve o f  MIG, assuming a concentration o f  
50mg/ml in the M IG pool. There was a significant positive correlation between results 
obtained by both approaches for anti-A M A l and MSP-3 antibodies (spearm an correlation 
coefficient = 0.998 and 0.984; respectively), (Figure 3.7).
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F ig u re  3.7. Comparison o f  end point titers derived from a standard curve o f  PHIS and relative 
amounts derived from a standard curve o f  MIG. Representative graphs o f  responses to (A) 
AMA1 and (B) MSP-3 are shown.
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3.4.7 R eproduc ib ility  o f the  E L IS A  d a ta
Serum samples (n=22) were tested on two separate days, at an interval o f  one month, to 
determine the reproducibility o f  the ELISA data (end point titers) generated from  a 
standard curve o f  PHIS. There was a significant positive correlation between antibody 
amounts obtained on two separate days for AMA1 and MSP-3 (spearm an correlation 
coefficient = 0.985 and 0.971; respectively), (Figure 3.8).
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F ig u re  3.8. Reproducibility o f ELISA data. The assays were performed on different days and 
the antibody amounts interpolated from a standard curve o f  PHIS. Representative graphs o f 
responses to (A) AMA1 and (B) MSP-3 are shown.
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3.5 Discussion
In the absence o f  a reference reagent o f  known antigen-specific concentration, to provide 
an estimate o f  relative antibody concentrations in test sera, antibody amounts can be 
quantified relative to a pool o f sera from individuals with high antibody titers to a panel o f  
antigens. The end point titers o f 22 Kilifi adults derived from a standard curve o f  PHIS are 
in agreem ent with the findings o f  M iura et a l ,  and show that the use o f  a pool o f  sera from 
malaria exposed individuals or vaccinated subjects can reliably estim ate arbitrary antibody 
units for samples using a single serum dilution (M iura et al. 2008a). This approach has 
been adopted by several studies to quantify vaccine-induced antibodies (Dicko et al. 2008, 
M alkin et al. 2005, M ullen et al. 2008, El Sahly et al. 2010, Sagara et al. 2009) naturally- 
acquired antibodies (W eiss et al. 2010, M iura et al. 2008b, M iura et al. 2013a) or 
antibodies to other infectious agents (Seo et al. 2013). The amounts determined above were 
strongly correlated with relative antibody titres estimated from a standard curve o f  a 
purified immunoglobulin preparation obtained from m alaria exposed M alawian adults. 
Both approaches o f  determ ining the magnitude o f  an antibody response are superior to 
presenting raw OD values by i) assigning accurate titers to samples with OD readings that 
fall outside the linear range o f  the OD reading and ii) correcting for normal test variations 
in antibody quantification. The standard curve run at different times will not yield the exact 
same OD values for every run and the same also applies to the test samples. However, 
since the concentration o f  the sample is calculated using the standard curve generated for 
every run, any variability can be negated. In addition, OD readings obtained in different 
settings are dependent on the ELISA protocol used and it is therefore unlikely that two 
different assays will yield the same OD readings.
Standardization o f  results could be achieved by worldwide distribution o f  a standard 
serum, leading to a better ability to compare results between research groups when
assessing the magnitude o f  antigen-specific antibody responses.
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A serum dilution o f 1:16000 was selected as the optimal dilution to test adult serum 
samples in this population. At this dilution, the OD 492 o f  all samples fell within the linear 
range o f  the standard curve hence allowing accurate determination o f relative antibody 
concentrations. In addition, the minimum and maximum detectable concentration o f  
specific-antibodies at this serum dilution was determined for each antigen. A part from 
allowing the correct assessment o f antibody concentrations with fewer dilutions compared 
to the end point titer method, testing serum at a 1:16000 dilution is ideal for cohorts w ith 
limited volumes o f sera such as those obtained from very young children. Inevitably, some 
individuals had very low antibody titres which could not be quantified at this dilution. 
These samples were retested at 1:1000 and 1:500 dilutions and those that were not 
quantifiable at these dilutions were assigned the m inim um  concentration recorded at the 
lower limit o f  detection o f  the assay.
To obtain reliable data, the standard curve must fulfill several criteria for acceptable 
quality (M iura et al. 2008a). First, the R-squared value approached unity indicating a good 
fit o f  the data to the curve, in all assays. It was also shown that the shape o f  the dilution 
curves o f  all test sera were sim ilar to that o f  the standard (Figure 3.2). Second, the standard 
serum pool (PHIS) was obtained from a population sim ilar to the test population. I f  each 
sample had a different dilution curve from the standard curve, the antibody units calculated 
from the OD values would be incorrect, due to the fact that at one dilution the antibody 
units derived from the standard curve would be different from the units calculated at 
another dilution (W ernette et al. 2003). Similarly, w e’ve shown that the dilution curve o f  a 
pool o f  IgG obtained from a M alawian adult population (MIG) had a shape sim ilar to that 
o f  Kilifi adults tested here suggesting that a standard pool generated from the same species 
as the test population can be used to reliably determine antibody amounts.
Although the quantification method tested in this chapter yielded reproducible results on 
different days (Figure 3.8), the robustness o f  the assay which is defined as the variability o f
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antibody units with varying experim ental conditions such as varying incubation times for 
antigen coating, serum binding, secondary antibody binding and substrate development 
was not assessed. Second, a recent study has described a method o f  converting end point 
titers into absolute antibody concentrations using a conversion factor (M iura et al. 2009). 
This approach has been adopted by several animal and human studies (M iura et al. 2009, 
M ullen et al. 2008, Ellis et al. 2010, Pierce et al. 2010, Sheehy et al. 2011, Sheehy et al. 
2012a) but was not explored in this chapter due to the limitation o f  recom binant antigens to 
perform affinity-purification o f  antigen-specific IgG antibodies.
The results in this chapter do not dem onstrate superiority o f  the use o f  end point titers that 
can be determined from a single serum dilution (M iura et al. 2008a) over those determ ined 
relative to a standard reference reagent prepared from a pool o f individuals w ith high titre 
antibodies to a panel o f  antigens o f interest. However, the use o f  a com m on reference 
serum with these ELISA quantification m ethods across study sites is recom m ended in 
order to standardize readings obtained on different days, using different ELISA protocols 
between and within different geographical settings. For other infectious diseases, for 
instance pneumococcal infection, a standard reference reagent is available to enable 
harmonization o f antibody measurem ent (Quataert et al. 1995). The use o f  sim ilar antigens 
across studies for malaria antigens would also allow for better comparison o f  findings.
In subsequent chapters o f  this thesis, I used the m alaria immune globulin preparation as the 
standard reference reagent to titrate the standard curves across assays, assum ing an 
arbitrary antibody concentration o f  50AU against all antigens tested. This facilitated direct 
quantitative comparison o f  anti-merozoite IgG responses in different cohorts in Kilifi 
revealing significant differences in antibody amounts in cohorts recruited during varying 
m alaria transmission intensities.
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CHAPTER FOUR
A threshold concentration of anti-merozoite antibodies is required for protection
from clinical episodes of malaria
4.0 Introduction
Antibodies play an important role in m ediating protection against clinical malaria. Purified 
total IgG obtained from m alaria-imm une African adults was successfully used to treat 
children and adults hospitalized w ith malaria, while control sera from adults not exposed to 
m alaria had no protective effect (Cohen et al. 1961, Sabchareon et al. 1991). Identifying 
the target(s) o f  these “protective” antibodies continues to be a priority for m alaria vaccine 
development. Im m uno-epidemiological studies are widely used to assess the potential 
protective efficacy o f antibodies against Plasmodium falciparum  antigens in humans. 
However, such studies have often yielded inconsistent results w ith some studies 
demonstrating a protective role for antibodies to a specific antigen, while others do not 
(Fowkes et al. 2010). One important reason for this may be the lack o f  a standardized 
approach to the reporting o f  antibody concentrations, and the methods used for their 
analysis (Fowkes et al. 2010, John et al. 2005). W hile there is reasonable agreem ent that 
high levels o f  antibodies are better indicators o f protection than sero-positivity, the 
definition o f “high” varies considerably between studies (John et al. 2005, O sier et al. 
2008, Courtin et al. 2009, Reiling et al. 2010, Richards et al. 2010, Stanisic et al. 2009), 
making it difficult to compare findings from different sites.
Here, we investigated why antibodies appeared to be protective in some settings but not in 
others. Specifically, we tested the hypothesis that a threshold concentration o f  antibody 
was required for protection and that in some settings, although antibodies were present, 
their concentrations were below the thresholds required for protection. Q uantitative
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correlates o f  protection have been reported for vaccine-induced antibodies against many 
infectious diseases (Plotkin 2008). For malaria, although antibodies to several specific 
antigens have been shown to correlate w ith protection from clinical episodes o f m alaria 
(Fowkes et al. 2010), similar quantitative correlates have not yet been defined. In one 
study, the concept o f  an antigen-specific threshold concentration o f  antibodies that 
correlated best with protection against P. falciparum  infection was explored (John et al. 
2005) but not applied in subsequent studies (John et al. 2008, M cCarra et al. 2011). In this 
chapter, we develop this concept by using data from one cohort to identify “protective 
thresholds”, defined as the antibody concentrations against specific antigens that best 
correlate w ith protection from clinical episodes o f  malaria. We subsequently tested the 
validity o f  these thresholds in an independent cohort.
Our previous studies have shown that antibodies to specific m erozoite antigens were 
associated with protection from clinical episodes o f  m alaria in the Chonyi cohort (Osier et 
al. 2007, Osier et al. 2008, Polley et al. 2004, Polley et al. 2006). In subsequent studies 
conducted in the same geographical area along the Kenyan coast, but during a period o f  
moderate transmission, antibodies to the same panel o f  merozoite antigens were not 
associated with protection. W e used a purified IgG preparation as a reference reagent to 
quantify the relative amounts o f antibodies against specific antigens (as described in 
Chapter three) and to standardize the measurem ent o f  antibody concentrations in both 
cohorts. Statistical methods were used to determine the relative IgG concentrations against 
each antigen that best correlated with protection in the Chonyi cohort. W e show that 
antibody concentrations in the moderate transm ission cohort were below the thresholds 
required for protection.
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4.1 Methods
4.1.1 Study population
4.1.1.1 Chonyi cohort
The study was undertaken in Chonyi village in Kilifi County on the Kenyan coast. This 
cohort has been extensively studied (Polley et al. 2006, Polley et al. 2004, Osier et al. 
2007, Osier et al. 2008, A gak et al. 2008, M ackintosh et al. 2008a, M ackintosh et al. 
2008b, M wangi et al. 2005, Bejon et al. 2010, M bogo et al. 2003) and a detailed 
epidemiological description is published elsewhere (Mbogo et al. 2003, M wangi et al. 
2005). The parasite prevalence rate in children aged 2-10 years (P/PR 2-10) and the 
entomological inoculation rate (EIR) were 44%  and 10-100 bites/person/year, respectively, 
at the time o f  the study. For the current study, we analyzed 286 serum samples collected in 
October 2000 at the start o f  a m alaria transm ission season from children aged 0-10 years. 
These children were subsequently followed up for 6 months for clinical episodes o f  
m alaria by active and passive case detection. In this area, the age-specific criteria for 
defining clinical episodes o f  m alaria are established and are as follows: for children <  1 
year old, a tem perature o f >37.5°C plus any parasitemia; for children > 1 year old, a 
tem perature o f  >37.5°C plus a parasitem ia o f  >2500/pl (M wangi et al. 2005). Trained field 
workers visited the participants every week whereby children with fever (axillary 
tem perature >37.5°C) had a blood slide taken. Children with a positive test result were 
treated with antimalarial drugs. In addition, parents were advised to report to a dedicated 
outpatient clinic at Kilifi District Hospital if their child developed symptoms o f  disease at 
any time.
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4.1.1.2 Junju cohort
In a second independent cohort, children aged 1-6 years resident in Junju sub-location 
within the Chonyi area o f Kilifi county were originally recruited into a randomized 
controlled vaccine trial in 2005 (Bejon et al. 2006) and have been followed up as described 
above, for clinical episodes o f  m alaria (Bejon et al. 2006, Mwangi et al. 2005). Trained 
field workers living in the same sub-location were available to conduct passive 
surveillance. Children born into study households are continuously recruited into the 
cohort and are followed up weekly at hom e to docum ent clinical episodes o f  malaria. Peak 
m alaria transm ission occurs during the rainy months o f  M ay-July and N ovem ber to 
December. Blood samples are collected annually during a cross-sectional survey conducted 
at the beginning o f  the m alaria transm ission season in May. The P /PR 2-10 rate and EIR  in 
Junju were 29% and 21.7 bites/person/year (M idega et al. 2012) respectively, at the tim e o f  
sampling. Participants in the Junju cohort area live approximately 25km away from  those 
described above in the Chonyi cohort. We analysed 304 serum samples collected in M ay 
2008 from children aged 1-12 years at the start o f  the malaria transmission season. D ata on 
6 months o f  follow up in the subsequent m alaria transm ission season are presented here.
4.1.2 Recombinant P. falciparum  merozoite antigens
All antigens are based on P. falciparum  and include the 19 KDa C-term inal fragm ent o f  
merozoite surface protein (M SP)-l o f  the W ellcome parasite line (Burghaus and H older 
1994), full-length recombinant AMA1 o f the HB3 parasite line (Kocken et al. 2002), M SP- 
2 o f the Dd2 parasite line (Taylor et al. 1995) and MSP-3 o f  the 3D7 allelic type (Polley et 
al. 2007, Osier et al. 2007). Responses to two fragments o f G lutam ate-rich protein 
(GLURP) representing the N-terminal non-repeat region (G LU RP-R 0) and C-term inal 
repeat region (GLURP-R2) were also analyzed (Theisen et al. 1995).
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4.1.3 Enzyme-Linked Immunosorbent Assay (ELISA)
Serum IgG responses to individual antigens were measured as described in section 2.4.2. 
Eleven two-fold serial dilutions o f  a purified m alaria immune globulin (M IG) standard 
were incorporated into the assay to generate a standard ELISA curve. The four-param eter 
logistic function was used to fit the standard curve in GraphPad Prism version 4.0 
(GraphPad software, San Diego, CA). ELISA OD values o f  test samples were converted 
into relative antibody concentrations using parameters estimated from the standard curve, 
assuming the purified IgG preparation contained 50 arbitrary units o f  antigen-specific 
antibodies. A pool o f  sera from Kilifi adults was included on every plate as a positive 
control. Sera from twenty Europeans served as negative controls to determine cu toff values 
for seropositivity, defined as mean optical density plus three standard deviations.
Although antibody responses to sim ilar antigens have been measured previously in the 
Chonyi cohort (Polley et al. 2004, Polley et al. 2006, Osier et al. 2007, Osier et al. 2008), 
these serum samples were retested to include a common reference reagent (M IG) that 
allowed standardization and direct comparison o f  relative antibody concentrations in the 
two sites. Responses to AM A1, M SP-2 and MSP-3 were measured in both cohorts whereas 
those to M SP-119 and GLURP were measured in the Chonyi cohort only.
4.1.4 Statistical analysis
Data analysis was performed using Stata 11 (StatCorp, TX, USA). A modified Poisson 
regression model was used as previously described (Osier et al. 2008) to exam ine the 
effects o f  individual antibodies on the outcome, defined as a clinical episode o f  m alaria 
during six months o f follow-up. The confounding effects o f age and previous malaria 
exposure were taken into account by fitting age and reactivity to parasite schizont extract 
as covariates in multivariate analyses. Age was fitted as a categorical variable (age bands
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o f 0-3, 4-5, 6-7 and 8-12 years) while reactivity to schizont was fitted as a continuous 
variable.
4.1.4.1 Establishing the presence o f a “dose-response” relationship between antibodies 
and outcome in the Chonyi cohort
First, we evaluated the effect o f  increasing antibody titers on protection against clinical 
episodes o f  malaria. Antibody levels were divided into quartiles (25th, 50th and 75th 
respectively) based on distribution o f  antibody concentrations o f  all individuals in the 
Chonyi cohort. The 25th, 50th and 75th percentile boundaries were applied as cutoffs for 
Low, M edium and High antibody amounts, respectively. The risk o f  disease between 
individuals who had antibodies below and those above each cutoff point was determ ined 
using a generalized linear model.
4.1.4.2 Identifying the antibody concentrations associated with protection
Next, we used data from all children in the Chonyi cohort to estimate the concentration o f 
antibodies that best correlated with clinical protection for each antigen as follows; i) 
different antibody concentrations were applied as cutoffs for high versus low responders 
over a range o f  increasing concentrations up to the maximum concentration recorded 
against each antigen, ii) a modified Poisson regression model was used to calculate the risk 
ratio at each cutoff value, iii) the best fitting model was selected using the log 
pseudolikelihood (Olotu et al. 2011). The antibody concentrations that resulted in the best 
fitting models were designated as “protective thresholds” . As an independent validation, 
the protective thresholds defined in the Chonyi cohort were tested in an unrelated cohort 
(Junju).
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4.1.4.3 Comparing analyses based on protective thresholds with those based on 
conventional cutoffs
The protective thresholds were used in two ways: (i) to compare age-m atched antibody 
levels in the Chonyi versus Junju cohorts and (ii) as cutoffs, com paring the clinical 
outcome o f  children with levels above, versus below the threshold, for each antigen in the 
Junju cohorts.
Next, analyses using the protective threshold as a cu toff point were com pared to 
conventional analyses where the cutoff is defined as 1) seropositivity, defined as the mean 
plus 3 standard deviations o f  negative controls, and 2) high versus low antibody levels, 
defined as the ELISA OD level above which the risk o f  m alaria was lower than the 
population’s average risk o f  acquiring a clinical episode o f  m alaria (Osier et al. 2008). 
Importantly, analyses based on high versus low antibody levels have been defined 
differently in different immuno-epidemiological studies, but ultim ately depend on the 
range o f  ELISA OD reactivities observed in the population under test.
4.2. Results
4.2.1. Effect o f varying antibody concentration and protection against clinical 
episodes of malaria in the Chonyi cohort.
In order to determine w hether there was a “dose-response” relationship between antibodies
and the risk o f  a clinical episode o f  malaria in the Chonyi cohort, the protective efficacy o f
antibodies at different cutoff points for Low, M edium and High antibody responses was
evaluated (Fig 4.1). W hen all individuals in the cohort were considered, the risk o f  disease
gradually declined when the cutoff was shifted from Low, M edium to High antibody levels
for all antigens tested except MSP-I19, though none o f the estimates were statistically
significant (RR; 0.74 to 1.83, p>0.05) for all antigens tested.
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F igure  4.1: Protective efficacy o f  antibodies based on different cutoff levels. Antibody 
titers were divided into quartiles (25th, 50th and 75th) based on the distribution o f  antibody 
amounts in the Chonyi cohort. Low (L), Medium (M) and High (H) cutoffs were generated 
based on the 25th, 50th and 75th quartile boundaries, respectively, and applied to all 
individuals in the cohort. Risk ratio values in red are based on the conventional cutoff o f  
seropositivity defined as Mean+3SD of 20 European sera for each antigen tested.
4.2.2. P ro tective efficacy o f an tibodies to m erozoite an tigens in the C honyi co h o rt
The association between antibodies to individual merozoite antigens and the risk o f  clinical 
malaria during the follow-up period was analysed using a modified poisson regression 
model as previously described (Osier et al. 2008). Two ELISA OD cutoffs were tested, 
seropositivity (defined as mean plus three standard deviations o f  non-malaria exposed 
European sera) and high antibody levels (defined as the ELISA OD level above which the 
risk o f disease was lower than the population’s average risk o f  acquiring a clinical episode
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o f  malaria). Among the children who had microscopically detectable parasites at the time 
o f  sampling, antibody concentrations above the seropositivity and high antibody level 
cutoffs were associated with protection against developing a clinical episode o f m alaria 
during the follow-up period consistent w ith previous studies in which ELISA OD values 
had been used to analyse the data (Osier et al. 2007, Osier et al. 2008, Polley et al. 2006, 
Polley et al. 2004). Antibody responses to the GLURP-R0 and GLURP-R2 fragments were 
tested for the first time in this cohort, but neither antibody seropositivity to GLURP-R2 nor 
GLURP-R0 was associated w ith protection from malaria, in the w hole cohort (RR; 0.94, 
95% Cl 0.58-1.54; p=0.83 and RR; 0.92, 95% Cl 0.52-1.64; p=0.80, respectively). 
Following stratification by slide status at the time o f sampling, these antibodies were 
associated with a decreased risk o f  developing an episode o f  malaria, in the parasite 
positive children, although the estimates were not statistically significant in m ultivariate 
analyses (RR; 0.59, 95% Cl 0.34-1.02; p=0.06 and RR 0.56, 95%CI 0.29-1.09; p=0.09, for 
GLURP-R2 and GLURP-R0; respectively). In parasite negative individuals, antibodies to 
GLURP-R2 and GLURP-R0 were associated with an increased risk o f  disease (RR; 1.25, 
95% Cl 0.51-3.08; p=0.62 and RR; 1.29, 95% Cl 0.50-3.34; p=0.59, respectively).
4.2.3. Protective efficacy o f antibodies to merozoite antigens in the Junju cohort
Children in the Junju cohort were sampled during a period o f m oderate m alaria
transmission intensity. In spite o f the fact that m alaria transm ission intensity was low er in
the Junju area than that observed in the Chonyi area during sampling, antigen-specific
antibodies were readily detectable in this cohort, and antibody prevalence was 67%, 31%
and 26% for AM A1, M SP-2 and MSP-3, respectively. Antibody levels increased
significantly with age for all antigens tested (Pearson’s chi-square test for trend, p<0.05).
Analyses based on both seropositivity and high antibody level cutoffs (to classify
responders versus non-responders) revealed that antibodies to these antigens were not
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associated with protection from malaria, with the exception o f  MSP-3 (Table 4.1). Unlike 
the Chonyi cohort where stratification based on slide status was associated w ith a 
significant reduction in risk o f  developing an episode o f  malaria in the group o f  children 
who were parasitemic at the time o f  sampling, the same was not observed in the Junju 
cohort.
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T ab le  4 .1 . A  C o m p a riso n  o f  A n a ly se s  B ased  on  A n tib o d y  S e ro p o s itiv ity , H igh  A n tib o d y  L ev e ls  and  P ro te c tiv e  T h re sh o ld s  in th e  Ju n ju  
C oh o rt.
AMA-1 M SP -2 M SP -3
Seropositivity High
antibody
levels
Threshold Seropositivity High
antibody
levels
Threshold Seropositivity High
antibody
levels
Threshold
All ind iv iduals  
(N =304)
P revalence 67 21 6 31 25 10 26 18 8
%  (n/N ) (203/304) (65/304) (17/304) (95/304) (77/304) (29/304) (80/304) (54/304) (23/304)
IgG 42 37 6 37 35 31 30 22 13
positive1 (85/203) (24/65) (1/17) (35/95) (27/77) (9/29) (24/80) (12/54) (3/23)
IgG 40 42 43 43 43 42 45 45 43
n eg a tiv e1’ (40/101) (101/239) (124/287) (90/209) (98/227) (116/275) (101/224) (113/250) (122/281)
U n iv aria te 1.05 0.87 0.13 0.85 0.81 0.73 0.66 0.49 0.33
R R (9 5 % C I) (0.79,1.41) (0.61,1.24) (0.02,0.91) (0.62,1.16) (0.57.1.14) (0.41,1.28) (0.46,0.95) (0.29,0.82) (0.11,0.95)
M u ltiv a r ia te 1.09 0.94 0.16 0.79 0.78 0.74 0.63 0.47 0.34
R R (9 5 % C I) (0.75,1.59) (0.65,1.36) (0.02,1 12) (0.57,1.08) (0.55.1.12) (0.42,1.29) (0.42,0.94) (0 .27 ,0 .81) (0.12,0.94)
A b b rev ia tio n s : T h re sh o ld , p ro te c tiv e  th re sh o ld ; N D . no t d e te rm in e d ; R R . risk  ratio .
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The risk o f  developing a clinical episode o f  m alaria during the 6-month follow-up period was 
compared in analyses based on antibody seropositivity, high antibody levels and protective 
thresholds. D ata were fitted to modified Poisson regression models, adjusting for age and reactivity to 
parasite schizont extract in multivariate analyses. Significant results at P <0.05 are shown in bold.
aIgG seropositive, high antibody levels or above the protective threshold and developing malaria 
during follow-up. bIgG seronegative, high antibody levels or below the protective threshold and 
developing m alaria during follow-up. Protective efficacy o f  thresholds defined in the Chonyi cohort0 
versus those defined in the Junju cohortd using the log m aximum likelihood method.
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4.2.4 Identifying a threshold concentration of antibodies that best correlates with a 
reduced risk of malaria
Next, we tested the hypothesis that the apparent lack o f protection observed in the Junju 
cohort could be explained by insufficient antibody concentrations. To do this, we used data 
from all children in the Chonyi cohort where antibodies to these antigens were shown to 
correlate w ith protection from malaria. Using the purified IgG as a standard for measuring 
relative antibody concentrations, we determined for each antigen the relative IgG antibody 
concentration that best correlated with protection from malaria by selecting the model w ith 
the least log pseudolikelihood (Olotu et al. 2011). The antibody concentrations that 
resulted in the best fitting models were designated as “protective thresholds” and it varied 
for different antigens, resulting in protective efficacies ((1-RR) x 100) o f 25-56%  (Table 
4.2). Notably, the threshold concentration was higher than that defined both by 
seropositivity and by high antibody levels. Relative antibody amounts against the R0 
fragm ent o f  GLURP were highly skewed to the right and it was not possible to define high 
levels as described above. A protective threshold could not be identified for antibodies 
against M SP-119.
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T able 4.2. Cutoff Values for Antibody Seropositivity, High Antibody Levels and 
Protective Thresholds in the Chonyi Cohort.
A ntigen Seropos
c u to ff1
High
levels
cu toff1’
P rotective
th resh o ld 0
P rotective
efficacy'1
(% )
(R isk  R atio ; 
95%  C I)e
AMA-1 0.70 43.70 55.00 25 (0.75; 0.42-1.33)
M SP-2 7.40 18.50 19.00 43 (0.57; 0.32-1.00)
M SP-3 0.39 6.50 16.00 56 (0.44; 0.16-1.17)
GLURP-RO 7.90 ND 11.00 41 (0.59; 0.27-1.28)
G L U R P-R 2 4.30 5.90 8.00 40 (0.60; 0.31-1.18)
M S P -I 19 8.2 15.70 ND ND ND
Abbreviations: AU, arbitrary units; SD, standard deviation, ND, Not Determined.
“Seropositivity cutoff is defined as the mean + 3SD response o f  sera from malaria naive 
donors for each antigen tested.
bHigh antibody level cutoff is defined as the antibody concentration above which the risk 
o f  malaria was lower than the population's average risk o f developing malaria.
P rotective threshold cutoff is defined as the antibody concentration that resulted in the 
least log pseudolikelihood value in a modified Poisson regression model.
Pro tective  efficacy in analyses based on the protective threshold as a cutoff. Calculated as 
(1-RR)* 100.
eRisk ratio estimates employed to calculate protective efficacy.
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4.2.5. Antibody concentrations are below protective thresholds in Junju cohort.
We then compared antibody concentrations in age-matched children from Chonyi and 
Junju in relation to the protective thresholds for each antigen. M edian IgG levels to AM A1, 
M SP-2 and MSP-3 were significantly lower in the Junju cohort compared to those in the 
Chonyi cohort across all age groups (M ann-W hitney test p<0.01) except the youngest 
children (0-3 years), who had sim ilar m edian antibody levels to AMA1 in both cohorts 
(Figure 4.2). Importantly, the proportion o f  age-matched children that had antibody 
concentrations above the protective thresholds was also significantly lower in Junju 
compared to Chonyi for AMA1 and M SP-2 except the youngest age-group (Fisher’s exact 
test p<0.01). The proportion o f  children that had protective threshold antibody 
concentrations against MSP-3 was significantly lower in Junju compared to Chonyi only in 
the 4-5 year age group.
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Figure 4.2 : Distribution o f antibody concentrations in age-matched children reeruited from
the Chonyi and Junju (grey) cohorts against (A) AMAl ,  (B) MSP-2 and (C) MSP-3. Black
dotted and red bold lines represent the protective threshold levels and the median antibody
concentrations by age against each antigen, respectively.
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4.2.6. Protective thresholds explain apparent lack of protection in the Junju cohort
We used the protective thresholds derived in the Chonyi cohort to classify children in the 
Junju cohort as having antibodies above or below threshold concentrations for each 
antigen. We then used the modified Poisson regression model as previously described, to 
compare the outcome in Junju children classified in this manner. W e compared these 
results with those obtained from analyses based on seropositive versus seronegative, and 
high versus low levels. For antibodies against A M A l and MSP-3, we found that the 
estimates o f  risk decreased in a stepwise fashion, when the cu toff was applied as 
seropositivity, high levels, and finally as protective thresholds defined independently for 
both Chonyi and Junju. For example, using these three cutoff points in multivariate 
analyses, antibodies against A M A l were associated with relative risks (95% confidence 
intervals) o f  1.09(0.75-1.59), 0.94(0.65-1.36) and 0.16(0.02-1.12), respectively. For both 
A M A l and MSP-3, antibody concentrations at the protective thresholds were considerably 
higher than those at seropositive or high levels (Table 4.1). O f note, the proportion o f  
children with antibody concentrations above any given cu toff reduced considerably as the 
cutoff was raised from sero-positivity, to that defined by high versus low levels, through to 
protective thresholds. In the Junju cohort overall, less than 10% o f children had antibodies 
above defined threshold levels either in the Chonyi cohort (5.6%, 9.5%, and 6.9%) or Junju 
cohort (6%, 5.5% and 5%) for A M A l, M SP-2 and M SP-3, respectively.
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4.3 Discussion
An increasing body o f  evidence suggests that protection from m alaria is dependent on high 
antibody concentrations (John et al. 2005, Osier et al. 2008, Courtin et al. 2009, Reiling et 
al. 2010, Richards et al. 2010, Stanisic et al. 2009). My data build on this by using a 
standardized reference reagent to quantify relative antibody concentrations and to define 
the threshold concentration for each antigen that was associated with protection against 
clinical episodes o f  malaria, using data from a high m alaria transm ission cohort. 
Application o f  these thresholds to an independent m oderate transmission cohort provided 
an explanation for the lack o f  protection observed in the latter cohort. A ntibody levels in 
age-matched children were significantly lower in the moderate (Junju) compared to those 
observed in the high (Chonyi) transm ission cohort. Consequently, only a small proportion 
o f  children in Junju achieved antibody levels above the protective threshold concentrations. 
These data thus provide a plausible biological explanation for the observation that 
antibodies to individual antigens are associated with protection in some cohorts, but not 
others (Fowkes et al. 2010).
M ethodological differences between immuno-epidemiological studies m ake it difficult to 
interpret apparently contradictory results where antibodies to a single antigen are 
associated with protection from m alaria in one geographical setting, but not in another 
(Fowkes et al. 2010). These differences range from definition o f  end-points, w hether 
clinical malaria, time to infection, or m alaria with high parasitaemia, for example, to 
duration o f follow up, quality and allelic type o f  antigen tested, whether or not full-length 
or fragments o f  antigens were tested, right through to laboratory assays and analytical 
approaches, among others. In the current study, we minimized all these m ethodological 
differences and conducted the studies identically.
There was a clear difference in parasite prevalence rates in children aged 2-10 years
(P/PR 2-10) (Noor et al. 2009) in the Junju cohort (29%) as compared to Chonyi (44%).
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Several studies have shown that parasite prevalence rates in children aged 2-10 years are 
reliable indicators o f  m alaria endemicity (Noor et al. 2014, N oor et al. 2009, Smith et al.
2007, Smith and Hay 2009, Hay, Smith and Snow 2008). From these studies, areas o f  high 
transmission are defined by a /yPR.2-10 o f  >40%  whereas those o f  low transmission are 
defined by a 7yPR2-io o f  <5%. Areas o f intermediate/moderate transm ission which would 
experience an immediate reduction in parasite prevalence following large-scale 
deploym ent o f  insecticide- treated nets have a 7yPR.2-io o f  5 - 40% (Hay et al. 2008, Smith 
and Hay 2009).
Apart from differences in malaria transm ission intensity, the two cohorts belong to the 
same ethnic group and share sim ilar environmental factors such as cultivation practices, 
rainfall, wind direction, presence o f  streams and rivers. However, notable differences 
between both cohorts were the change in antimalarial drug policy from sulphadoxine- 
pyrimethamine to artem ether lumefantrine in 2006 (Amin et al. 2007) and the distribution 
o f  free insecticide-treated bednets by the government in the same year (Noor et al. 2007) 
increasing coverage from 6% in 1999 (M wangi et al. 2005) to more than 60% (Noor et al. 
2007). It is plausible that these factors also contributed to the decline in m alaria 
transmission. In these circumstances, and using a m alaria IgG reference serum to 
standardize antibody m easurem ents across both cohorts, we were able to show antibody 
concentrations in the Junju cohort were significantly lower than those in Chonyi.
Immuno-epidemiological studies have traditionally classified study participants as being 
seropositive or seronegative for responses to specific antigens. M ore recently, we and 
others have found that classifying individuals as having high or low levels o f  antibodies is 
a highly informative indicator o f protection am ong children (John et al. 2005, O sier et al.
2008, Courtin et al. 2009, Reiling et al. 2010, Richards et al. 2010, Stanisic et al. 2009). 
However, the actual definition o f  high versus low antibody levels varies between studies, 
making it difficult to meaningfully compare data from different sites. We had previously
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derived a definition for high versus low antibody levels that was based on the range o f 
responses observed in the cohort under study (Osier et al. 2008). By this definition, we 
found that antibody levels which we would have considered to be high in Junju cohort, 
were nevertheless lower than those required for protection in the Chonyi cohort. Thus, an 
analysis based on high versus low levels in the Junju cohort would have erroneously 
concluded that high levels o f  antibodies against these merozoite antigens were not 
associated with protection. I therefore propose an analytical approach based on the 
principle o f  “protective thresholds” in place o f (or in addition to) seropositivity, or varying 
definitions o f  high versus low antibody levels. The protective threshold concentrations for 
antibodies against each antigen are fixed and the confidence intervals around these 
estimates will not vary from one population to the next, allowing for efficient com parison 
o f  data across sites. A lthough the estimates o f  risk in the Junju cohort did not always reach 
statistical significance, I observed a clear trend in the reduction o f  risk when the analysis 
was based on protective thresholds. In effect, this was a cu toff higher than that 
conventionally used for seropositivity and/or high versus low levels o f  antibodies. An 
obvious consequence o f  raising cu toff points is a reduction in the ability to detect 
significant effects, as the numbers achieving higher antibody concentrations m ay be 
relatively small, particularly in areas o f  low m alaria endemicity. The protective threshold 
concentration I derived varied by antigen. For some antigens, for example AMA1 and 
MSP-3, this concentration was considerably higher than that defined by sero-positivity or 
high levels. For M SP-2, the protective threshold concentration was substantially higher 
than that defined by seropositivity, but was nearly equivalent to what I had previously 
defined as high levels (high antibody level cutoff was 18.5 AU whereas the protective 
threshold cutoff was 19 AU). For antibodies against GLURP, the difference between the 
protective threshold concentration and that defined by sero-positivity, and/or high levels 
(GLURP-R2) was less marked. For M S P -I19, I was not able to define a protective
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threshold by the m ethods presented here. These findings need to be validated in much 
larger cohorts, and in samples collected from different geographical settings.
Additionally several studies have shown that quality o f antibody responses, in particular 
the type o f IgG sub-classes are also important for protection (Courtin et al. 2009, Stanisic 
et al. 2009). I did not set out to study IgG subclasses in the current study. However, 
antibodies against the antigens I have analyzed here have been shown from multiple 
studies to comprise predominantly o f  the cytophilic IgG l and IgG3 subclasses (M etzger et 
al. 2003, Polley et al. 2004, Osier et al. 2007) even in areas o f  low m alaria transm ission 
intensity (Scopel et al. 2006). Thus although useful, measurem ent o f  IgG subclasses in this 
study would not have altered my interpretation o f  the data. In the present study, I measured 
responses to a single allelic variant o f each antigen and did not ascertain w hether the 
circulating parasite strains were bearing the haplotypes tested or whether the strains were 
sim ilar in the two cohorts. A lthough this may be a potential limitation, our previous studies 
conducted in the same geographical area at different time points have found a high 
correlation between antibodies against different allelic versions o f AMA1 (Osier et al. 
2008, Osier et al. 2010b), M SP-2 (Osier et al. 2008, Osier et al. 2010a) and M SP-3 (O sier 
et al. 2008, Osier et al. 2007). Furthermore, a longitudinal study conducted in The G am bia 
showed that circulating alleles remained stable over time (Conway, Greenw ood and 
M cBride 1992).
In conclusion, my data suggest that a “protective threshold” concentration o f  antibodies 
against specific merozoite antigens o f P. falciparum  needs to be achieved for protection 
from clinical episodes o f  malaria. I propose a new approach to the analysis o f  such data 
that may add value to current analytical strategies. If validated in larger studies and in 
unrelated immuno-epidemiological cohorts, this analytical approach based on “protective 
thresholds” could be usefully extended to the testing o f  immunogenicity and potential 
protective efficacy o f sub-unit vaccines currently under developm ent for malaria.
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CHAPTER FOUR (SUPPLEMENT)
Exploratory post-hoc analysis
A comparison of threshold antibody concentrations associated with protection against 
clinical episodes of malaria in two villages in Kilifi and in Tanzania
In the previous section o f  this chapter, I have demonstrated that children in the moderate 
transm ission cohort (Junju) who achieved antibody titres above the protective thresholds 
defined in the high transm ission cohort (Chonyi) had a reduced risk o f developing a 
clinical episode o f  malaria during the follow-up period. However, the protective threshold 
values were derived as point estimates, with no estimation o f the level o f  uncertainty 
around these cutoff values. Here, I sought to obtain the confidence intervals around the 
threshold estimates using the bootstrap percentile method (Efron, 1993, Hollander, 2004) 
based on at least 1000 bootstrap samples.
Additionally, the thresholds identified in the previous section were based on a specific 
primary dataset with validation o f these cutoffs in an independent cohort. Here, I also 
sought to determine whether similar threshold estimates could be obtained from an 
independent dataset to provide further evidence in favor o f  a threshold effect. I therefore 
compared the optimal cut offs generated independently in the high and low transm ission 
cohorts (Chonyi and Junju) using similar methodologies.
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Methods
In the Chonyi cohort, antibody titres were fitted into a modified poisson regression model 
and a dichotom ization point that maximized the log likelihood that antibody titres would 
predict protection from malaria was selected as the optimal fit. Bootstrapping was used to 
calculate the 95% confidence intervals around the selected cu to ff
The Chonyi cohort was used as the primary cohort to build the models. Sim ilar models 
were applied to the Junju dataset to compare and confirm the validity o f  the protective 
thresholds obtained in the Chonyi cohort.
Results
The confidence intervals around the protective thresholds previously defined in the Chonyi 
cohort were as follows: AMA1 55AU (37-63AU), M SP-2 19AU (9-26AU), MSP-3 16AU 
(12-29AU), GLURP-RO 11AU (6-22AU) and GLURP-R2 8 AU (4-15AU) (Figure 4.3). 
Protective thresholds for M SP-119 could not be estimated as the dichotom ization point that 
maximized the log likelihood that this cutoff would predict protection corresponded to the 
highest M SP-119 antibody titre (Figure 4.3 F).
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Further validation o f  the protective threshold estimates obtained in the high transmission 
Chonyi cohort was perform ed by independently running similar models in the moderate 
transmission Junju cohort (Figure 4.4). Interestingly, the protective threshold cutoffs and 
95% confidence intervals defined in the Junju cohort were consistent with those defined in 
the Chonyi cohort (50-57AU (Cl 39-64) versus 55AU (Cl 37-63) for AM A1; 20AU (Cl 9- 
22) versus 16AU (12-29) for MSP-3; and 24AU (Cl 13-31) versus 19AU (Cl 9-26) for 
M SP-2), respectively (Table 4.3).
In a recent study conducted in Tanzania, protective threshold levels to AMA1 (3D7), 
AMA1 (FVO), M SP-119, M SP-2 (CH150), M SP-2 (Dd2), MSP-3 (3D7) and MSP-3 (K l)  
were defined using a sim ilar methodological and analytical approach (Rono et al. 2013). In 
their study, Rono et al. defined the protective levels for M SP-2 (Dd2) and M SP-3 (3D7) as 
11AU and 14AU, respectively. These estimates were comparable to those defined in the 
Chonyi and Junju cohorts (19AU and 24AU for M SP-2) and (16AU and 20AU for M SP-3, 
respectively) hence strengthening the suggestion that these threshold concentrations could 
be biologically relevant and could be applied as reliable correlates o f  protection against 
development o f  clinical episodes o f  malaria.
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T able 4.3. Protective threshold concentrations and the 95% confidence interval estimates derived 
independently in the Chonyi, Junju and Tanzanian cohorts.
C honyi cohort 
T hresho ld  (95%  C l)
Ju n ju  cohort 
T hresho ld  (95%  C l)
T an zan ia  co h o rt 
T h re sh o ld 1
AM A1(HB3) 55 (37-63) 5 0 -5 7 (3 9 -6 4 ) ND*
M SP-3(3D7) 16(12-29) 24(13-31) 14
M SP-2(D d2) 19 (9-26) 20 (9-22) 11
GLURP-RO 1 1 (6 -2 2 ) ND* ND*
G L U R P-R 2 8(4-15) ND* ND*
M SP-1 , 9 ND** ND* 59
'95% confidence intervals for these threshold estimates have not been assessed 
(Rono et al. 2013).
ND Not Determined.
ND* IgG responses to these specific antigens were not measured.
ND** I could not define a threshold concentration against MSP-119 in the Chonyi cohort 
because the dichotomization point that gave the least log likelihood ratio (best fit) 
corresponded to the maximum antibody concentration measured in this cohort.
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Finally the thresholds defined for Chonyi, Junju and Tanzanian cohorts were applied in the 
respective cohorts to determine their association with subsequent risk o f  developing a 
clinical episode o f malaria. For all antigens tested, the different thresholds defined in the 
three populations were associated with a reduced risk o f developing m alaria during the 
follow-up period (Table 4.4). The reduction in risk o f  developing a clinical episode o f 
m alaria was significant in the three cohorts for individuals who had anti-M SP (Dd2) 
antibodies above the thresholds defined; (RR 0.57 (0.32-1.00), p=0.051; R R  0.26 (0.07- 
0.93), p=0.036; and RR 0.30 (0.15-0.60), for the Chonyi, Junju and Tanzanian cohorts 
(Rono et al. 2013), respectively). Similarly, antibodies above the threshold cu to ff for MSP- 
3 were associated with a significant reduction in risk o f  developing m alaria in the Junju 
and Tanzanian cohorts (RR 0.15 (0.02-1.00), p=0.05 and RR 0.46 (0.24-0.90), 
respectively) and towards reduced risk in the Chonyi cohort (RR 0.44 (0.16-1.17).
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Discussion
In the previous chapter, I demonstrated that the apparent lack o f protection associated with 
antibodies against a panel o f  merozoite antigens in a moderate transmission cohort could be 
explained by failure to achieve titres above certain protective thresholds. The thresholds were 
defined in a high transmission cohort (Chonyi) and subsequently validated in the moderate 
transmission cohort (Junju). Here, I extend the above findings by deriving the protective 
thresholds independently in each o f  the two cohorts and comparing these thresholds with those 
described in a third cohort from a geographically distinct population in Tanzania (Rono et al. 
2013). I found that the protective thresholds vary only slightly depending on the population 
they are derived from. In addition, there was an overlap o f  the confidence intervals around 
each threshold estimate when derived independently in each population. For instance, for 
MSP-2, the Chonyi cohort threshold cutoff was 19AU (95% Cl 9-26) and 20AU (95% Cl 9- 
22) for the Junju cohort. The similarities in thresholds and confidence intervals suggest that 
these estimates are a realistic reflection o f the levels o f antibodies that are associated with 
protection against clinical episodes o f malaria.
Individuals who had antibodies above the protective threshold concentrations for AMA-1, 
MSP-2 and MSP-3 defined independently in the moderate transmission Junju cohort had a 
reduced risk o f developing a clinical episode o f  malaria. Similarly, when those defined in the 
Chonyi cohort were applied to the Junju cohort, the relative risk ratio was also comparable 
(Murungi et al. 2013), a finding which may be explained by the similarity in threshold 
estimates and overlapping confidence limits.
The thresholds defined in the Chonyi and Junju cohorts were consistent with what was
observed in a geographically distinct cohort o f Tanzanian children (Rono et al. 2013),
although the age range studied was slightly wider (1-16 years) compared to the Junju and
Chonyi cohorts (1-12 years). The parasite prevalence rate in the Tanzanian cohort was
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comparable to the Chonyi cohort (PyPR2-io o f 49% versus 44%, respectively), hence 
classifying both as high transmission cohorts, whereas the Junju cohort with a P /PR 2-10 o f  29% 
was classified as a moderate transmission cohort (Noor et al. 2014, Smith et al. 2007, Hay et 
al. 2008). Differences in transmission intensities notwithstanding, the protective thresholds 
were comparable in the three cohorts studied here and also notably higher than the 
seropositivity and “high” antibody level cutoffs employed by previous studies (Osier et al. 
2008, Osier et al. 2007, Polley et al. 2004, Polley et al. 2006). The similarity in protective 
threshold cutoffs derived independently in three different settings suggests that these 
concentrations may be biologically relevant. This study offers for the first time, a range o f 
plausible concentrations that may be useful cutpoints for comparing findings between studies 
to minimize the inconsistencies in assessing the protective efficacy o f  antibodies to merozoite 
antigens.
The two-level model approach used in this chapter to infer threshold cutoffs has the 
disadvantage o f  assuming an immediate change in the risk o f  developing disease at a particular 
titre, i.e. characterizing individuals close to but on opposite sides o f the cutpoint as having 
very different rather than very similar outcomes, which might be an oversimplification. I did 
not test how abrupt the change in risk was around the threshold estimates defined here, as has 
been previously proposed (Olotu et al. 2011). Nonetheless, a linear model that assumes a 
continuous reduction in risk o f developing a clinical episode o f m alaria with increase in 
antibody titres did not fit the data better than the traditionally employed seropositivity cutoffs 
or the two-level model applied here (RR 0.98- 0.99) P>0.05 (for most antigens tested).
I cannot rule out the fact that the relatively small sample sizes and low proportion o f children 
achieving titres above the thresholds in the Chonyi and Junju cohorts contributed towards 
obtaining relatively wide confidence intervals around the defined protective thresholds. One
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approach towards resolving this would be testing in a larger dataset. Such a dataset would be 
adequately powered and would give more confidence in the results. It also remains to be 
determined whether achieving concentrations above the thresholds correlates with functional 
activity such as the inability to inhibit parasite growth in vitro or effectively bind to other cells 
such as neutrophils and monocytes to promote parasite clearance by release o f  soluble 
mediators or by phagocytosis.
Thus far, there is no immunological measurement that provides a reliable and reproducible 
measure o f  clinical protection in different endemic populations and this study has extended our 
knowledge by offering a range o f plausible cutoffs associated with a reduced risk o f 
developing uncomplicated malaria that may be applied in other geographical regions.
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CHAPTER FIVE
Antibodies against merozoite antigens and protection against severe malaria in a 
longitudinally monitored birth cohort of Kenyan children
5.0 Introduction
In malaria endemic areas, the outcome o f  a P. falciparum  infection ranges between 
asymptomatic infections to mild or severe and life-threatening malaria. The latter is 
particularly observed in children aged less than 5 years, although immunity to this severe form 
o f  disease is achieved early in life. Thereafter, these children remain susceptible to episodes o f 
non-severe malaria until early adulthood but continue to encounter asymptomatic infections to 
which immunity is non-sterilizing (Marsh and Kinyanjui 2006, Langhorne et al. 2008). 
Evidence from modeling studies suggests that immunity to severe, non-cerebral malaria occurs 
after one or two episodes o f  disease (Gupta et al. 1999). The timing and sequential acquisition 
o f  immunity first to severe malaria, then to non-severe and later to asymptomatic infections 
implies that the targets and nature o f  the immune response against these different 
manifestations o f  an infection may be distinct with limited overlap. However, immune 
responses that act to clear parasites (anti-parasitic immunity) will also reduce the risk o f 
clinical disease. It is unclear whether the same targets and immune responses are equally 
important for the different outcomes o f a malaria infection.
A protective role o f antibodies against malaria has been directly demonstrated through the
transfer o f purified gammaglobulin from immune African adults to Gambian (Cohen et al.
1961 1963) and Thai (Sabchareon et al. 1991) children during an acute episode o f  m alaria
leading to a substantial reduction in parasite density and clinical symptoms. In addition, cord
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blood obtained from mothers during delivery was successfully used to treat children with 
malaria (Edozien, Gilles and Udeozo 1962). Recent studies conducted in malaria endemic 
populations have also demonstrated a role for pre-existing anti-merozoite antibodies (reviewed 
in (Fowkes et al. 2010)) and antibodies to the infected red blood cell surface (Chan, Fowkes? 
and Beeson 2014) in protection against clinical episodes o f malaria. These studies have largely 
focused on the non-severe form o f malaria as the primary outcome and have also relied on 
antibody measurements taken at a single time-point prior to the disease episode. Although 
useful, the latter may not adequately reflect an individual’s ability to mount an antibody 
response, as such responses are largely driven by factors which vary over time such as 
concurrent parasitemia, number o f  previous infections and age (Kinyanjui et al. 2009). Studies 
in humans to determine the protective mechanisms underlying immunity to severe malaria 
have been largely conducted at the time o f acute infection (reviewed in the Introduction). 
Although such studies are well suited for studying the quality o f immune responses induced by 
parasites during the acute phase o f the disease, it is difficult to establish a causal relationship 
between the particular immune response and protection from severe disease. As such, 
prospective studies are ideal but have so far been few (Bull et al. 1998, Bull et al. 2002, 
Ndungu et al. 2002, Osier et al. 2008), limited in sample size (Ndungu et al. 2002, Bull et al. 
2002), used inadequate definitions o f severe malaria (Bull et al. 1998, Osier et al. 2008) and 
largely focused on antibody titres measured at a single time-point (Bull et al. 1998, Bull et al. 
2002, Ndungu et al. 2002, Osier et al. 2008).
A key and as yet unsolved question is whether pre-existing antibody responses (measured at 
multiple time-points) play a role in acquisition o f immunity to severe malaria and if  so, what 
the specific target antigens are.
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5.1 Objectives
To use a case-control approach nested within a longitudinally monitored birth cohort o f 
children aged between 0 - 2  years to:-
• Describe the factors that influence antibody titres against a panel o f  P. falciparum
merozoite antigens in infants.
• Describe and compare the longitudinal dynamics o f anti-merozoite antibodies from
birth until the incidence o f severe malaria for cases and their corresponding controls.
• Compare the protective efficacy o f  anti-merozoite antibodies measured at a single
time-point with those measured at several time-points prior to an episode o f  severe 
malaria.
5.2 Methods
5.2.1 Recombinant antigens and Multiplex ELISAs.
Antibody levels to a panel o f  recombinant merozoite antigens; AMA1 (FVO and 3D7 allelic 
types), MSP-2 (Dd2 and CHI 50/9 allelic types), MSP-3 (3D7 and K1 allelic types), P /R h2 and 
M SP-119 were measured using a multiplex bead:based ELISA platform, as previously 
described in Chapter two. IgG responses to schizont extract were measured using a standard 
ELISA technique as previously described (Ndungu et al. 2002)
5.2.2 Serum and red blood cell pellet samples
Serum and red blood cell pellet samples collected consecutively at three-monthly intervals 
from birth until the occurrence o f a severe malaria episode (for the cases) were assayed and
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compared with those collected from matched control subjects who did not develop an episode 
o f  severe malaria.
5.2.3 Detection of P. falciparum  infections by microscopy and PCR
Thin blood smears were prepared from finger prick blood samples, stained with giemsa and 
examined under a light microscope. Parasites were enumerated against 500 uninfected RBCs 
or 200 leukocytes. Blood films were independently scored by two expert microscopists. 
Parasite DNA was extracted from the red blood cell pellets followed by genotyping at the 
MSP-2 gene locus using a capillary electrophoresis method (Lundblom et al. 2013, Liljander 
et al. 2009).
5.2.4 Statistical analysis
Continuous variables were compared using the Kruskal-Wallis and M ann-W hitney U rank 
sum tests. Proportions were compared using the Chi-squared test. The association between 
antibody titres and age, year o f  birth, location, concurrent parasitemia and previous exposure 
to infection (measured by reactivity to schizont extract) were analysed using generalized 
estimating equation models in a univariate analysis. This model accounts for clustering as a 
result o f  multiple antibody measurements obtained per child using an exchangeable correlation 
structure. Repeated observations on the same subject are not independent so a correction needs 
to be made for this within-subject correlation. To test whether antibodies were associated with 
protection from severe malaria, a conditional logistic regression model was applied that takes 
into account individual matching o f  cases to controls (upto 3 controls per case).
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5.3 Results
5.3.1 Factors that influence antibody titres in children aged 0-2 years
The effect o f  age, the presence o f  detectable parasites during the three-monthly sampling 
points, cumulative exposure as measured by reactivity to schizont extract, year o f  sample 
collection and the residence o f subjects on the specific antibody titres are summarized in Table 
5.1. The coefficients indicate that for every unit increase in the predictor variable the response 
variable changes by its respective regression coefficient in the log-odds scale. Results o f  only 
one allelic type are shown since antibody titres between the two alleles o f  AM A1, MSP-2 and 
MSP-3 tested were highly correlated. Increasing age was associated with a significant decrease 
in antibody titres against all antigens tested (range o f  coefficients, -3.7 to -17.3, p<0.005). This 
reflects the decay o f  maternally transferred antibodies with increasing age. For all antigens 
tested, the presence o f parasites detected either by PCR or microscopy at any o f  the three- 
monthly visit samples was associated with a significant increase in antibody titres (range o f 
coefficients, 0.03 to 0.12; p<0.005). Similarly, increasing antibody titres to schizont extract 
were also associated with a significant increase in antibody titres to the antigens tested 
(p<0.05). Recruitment into the birth cohort and subsequent follow-ups were conducted 
between 2001 and 2008, a period o f declining malaria transmission in Kilifi county (O 'M eara 
et al. 2010, Okiro et al. 2007). We determined the influence o f year o f  falling m alaria 
transmission on antibody titres by comparing responses from samples collected between 2001 
and 2008. Periods o f low malaria transmission were associated with an overall decrease in 
antibody titres for all antigens tested. For instance, for AMA1, a significant stepwise decrease 
in antibody titres with increasing year was observed over the period o f recruitment and sample 
collection (coefficients o f -3.19, -3.75, -6.15, - 6.59 and -7.41 in 2003, 2004, 2005, 2006 and 
2007 respectively, compared to the first year o f  recruitment and sample collection - 2002).
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5.3.2 Overall age-specific antibody prevalence
Age-specific antibody prevalence was calculated using antibody measurements obtained at all 
the three-monthly time points from birth up to the incidence o f disease for cases (N=158) and 
corresponding controls (N=426). Overall, the highest antibody prevalence was against 
schizont extract (56.7%). Antigen-specific antibody prevalence was highest for AMA1 alleles 
(45% against AMA1 (FVO) and 46% against AMA1 (3D7)) whereas anti-iyRh2 antibodies 
were the least prevalent (19%). Antibody prevalence against MSP-2 (Dd2), MSP-2 
(C H I50/9), MSP-3 (3D7), MSP-3 (K l) and M SP-119 was 39%, 36%, 30%, 20% and 24%; 
respectively (Figure 5.1). Antibodies measured in cord blood samples were detectable in a 
significant proportion o f children (94% and 93% for AMA1 FVO and 3D7 respectively, 8 8 % 
and 85% for MSP-2 Dd2 and C H I50/9 respectively, 69% and 66%  for MSP-3 3D7 and K l 
respectively, 46% for M SP-119 and 34% for /yR h2) but this decreased with increasing age, 
reaching a low plateau at 5-7 months for all antigens except AMA1 allelic types and PyRh2. 
Antibodies to AMA1 allelic types continued to decline until 11-13 months o f  age whereas 
those against PfRh2 reached a low plateau by the age o f  4 months. Thereafter, a modest 
increase in antibody prevalence with age was observed for all antigens tested (Figure 5.1).
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Age - specific antibody prevalence
100-1
—  AMA1 (FVO)
—  AMA1 (3D7) 
 ^ MSP-2 (Dd2)
—  MSP-2 (CH150/9)
—  MSP-3 (3D7) 
MSP-3 (K1)
— MSP-1-jg
PfRh2
Schizont extract
O'
0 1-4 5-7 8-10 11-13 14-18 19-28
Age (months)
Figure 5.1 Age-specific antibody prevalence in children aged 0-2 years o f  age. Individual lines 
represent the antibody prevalence o f  the antigens tested across age categories grouped as; 0  
months, 1-4 months, 5-7 months, 8-10 months, 11-13 months, 14-18 months and 19-28 months.
5.3.2.1 Age-specific antibody levels am ongst the cases and controls
The highest antibody titres for all antigens tested were observed in cord blood plasma samples 
(Figure 5.2). There was a significant gradual decline in antibody titres with increasing age for 
all antigens tested (Kwallis test; P=0.0001) except MSP-119 (Kwallis test; P=0.138) and P/Rh2 
(Kwallis test; P=0.225). The decline in antibody titres reached a low plateau at 11-13 months 
for AMA1 allelic types, 8-10 months for MSP-2 allelic types, 5-7 months for MSP-3 (3D7) 
and 1-4 months for MSP-3 (Kl), MSP-119 and PfRh2. For MSP-3 (Kl ) ,  the low plateau was 
maintained upto 2  years o f  age, suggesting a lack o f  boost in antibody titres whereas for the 
other antigens there was a modest increase in antibody levels upto 2 years o f  age. Importantly,
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there was no significant difference in median antibody titres between cases and controls across 
all the age categories analysed for all antigens tested (Figure 5.2).
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F igure 5.2 The level o f antibodies to merozoite antigens by age in children aged 0-2 years. Box 
plots o f  relative antibody concentrations (in logio arbitrary units) against (A) A M A l(FV O ), (B) 
AMA1(3D7), (C) MSP-2(Dd2), (D) MSP-2(CH150/9), (E) MSP-3(3D7), (F) MSP-3(K1), (G) 
M SP-119, (H) PfRh2 and (I) schizont extract are shown for age categories 0 months, 1-4 months, 5- 
7 months, 8-10 months, 11-13 months, 14-18 months and 19-28 months. Antibody levels for cases 
(grey box plots) and controls (white box plots) at the different age categories are shown. Horizontal 
dotted lines represent the seropositivity cutoff defined as Mean+3SD antibody units o f  twenty 
European plasma samples.
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5.3.3 Individual antibody profiles in relation to the presence or absence of infection
The profiles o f antibodies were assessed in all children (both cases and controls) who had
antibody and infection status data available at two or more sampling timepoints (N=190).
There was considerable variability in the pattern o f responses observed to some antigens, in
particular against P/Rh2 and M S P -I19 (Figure 5.3). Consequently, the various profiles
observed were grouped into five broad categories; (i) Children whose antibodies declined
between 0-6 months (Figure 5.3 A-C); Children whose antibodies declined between 0-9
months but remained relatively stable thereafter (Figure 5.3 D-F); (iii) Children whose
antibodies declined between 0-9 months but showed evidence o f  a boost in antibody titres to
all antigens tested, in the presence o f an infection (Figure 5.3 G-I); (iv) Children whose
antibodies declined during the first 9 months o f  life but showed no evidence o f  a boost in
antibody titres to all antigens tested, in the presence o f an infection (Figure 5.3 J-L); and (v)
children whose antibody titres declined between 0-9 months o f  age and showed evidence o f
boosting o f  antibody titres in the absence o f a confirmed infection (Figure 5.3 M-O). In a large
proportion o f  the children 72/190 (37%), there was evidence o f declining antibody titres
between 0 - 6  months o f  age, although in a few o f  the children the converse effect was
observed, e.g. individuals 85, 116 and 132. Forty out o f  195 (20%) o f  the children acquired an
infection during the follow-up period, a proportion o f  whom either had evidence o f  boosting o f
antibody titres to all antigens tested (17/40, 42%), boosting o f titres to particular antigens
(12/40, 30%) or lack o f  boosting o f antibody titres (11/40, 28%) to all antigens tested in the
presence o f an infection. O f particular interest was the observation that responses to at least
one allele o f MSP-2 were always boosted in the presence o f  an infection. There was also
evidence o f boosting o f  antibody titres in the absence o f  an infection in 47/190 (25%) o f  the
children, although this observation could be explained by missing data on the infection status
o f 24/47 (51%) o f individuals (Figure 5.3 M-O). In 36/190 (19%) o f  the children, antibody
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titres declined during the first 6 months o f life but remained stable over the follow-up period 
and there was no evidence o f an infection in this group o f children (Figure 5.3 D-F).
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Figure 5.3 Individual profiles o f  IgG responses to merozoite antigens tested. Each panel represents the 
pattern o f  antibody responses observed in an individual during follow-up period. Individual lines 
represent responses to each antigen tested. The patterns o f  responses were grouped as follows: (A-C) 
Children with declining antibody titres between 0-6 months; (D-F) Children with declining antibody 
titres between 0-9 months and stable responses thereafter; (G-I) Children with declining antibody titres 
between 0-9 months followed by evidence o f  antibody boosting to all antigens tested in the presence o f 
an infection; (J-L) Children with declining antibody titres between 0-9 months followed by no 
evidence o f  antibody boosting to all antigens tested in the presence o f  an infection; and (M-O) children 
with declining titres between 0-9 months followed by evidence o f antibody boosting in the absence o f 
an infection. Red, black and green arrows show presence o f a P. falciparum  infection confirmed by 
PCR only, PCR and microscopy, and microscopy only, respectively.
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5.3.4 The profiles of antibody responses for individual risk sets
The longitudinal patterns o f antibody responses were analyzed in individual risk sets. A risk 
set was defined as a group consisting o f an index case and their individually matched controls. 
The profiles o f antibody responses for individual risk sets were generated for 42 out o f 61 
(67%) risk sets following availability o f data on antibody levels and infection status 
(Lundblom et al. 2013) at two or more consecutive sampling points. Three broad patterns o f  
responses were observed for each risk set; (i) index cases maintaining relatively higher 
antibody titres over time compared to their matched controls (Group 1); (ii) index cases and 
controls maintaining similar antibody titres over time (Group 2); and (iii) index cases 
maintaining relatively lower antibody titres compared to their matched controls at the different 
sampling points (Group 3). Following previous reports showing that antibody responses are 
highly variable over time and are relatively short-lived in young children (Fonjungo et al. 
1999, Kinyanjui et al. 2007, Akpogheneta et al. 2008), maintaining a relatively high antibody 
titre over the follow-up period was arbitrarily defined as achieving a titre above the cutoff 
point for seropositivity at more than 50% o f the sampling points. As previously demonstrated 
in Figure 5.2, a majority o f the risk sets had low antibody titres (below the seropositivity 
cutoff) at the different sampling points There was a bias towards controls maintaining 
relatively higher antibody titres over time compared to cases (Group III responses) for AMA1 
(FVO), MSP-3(3D7) and M S P -I19 (52.4%, 47.6% and 42.9%; respectively) although these 
findings may be explained by the bias in comparing the pattern o f responses o f  a single case 
against more than one control. The lowest proportion o f risk sets (<20%) were classified into 
Group I (cases having higher antibodies compared to controls) for all antigens tested (Table 
5.2).
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Figure 5.4. Representative patterns o f  IgG responses to merozoite antigens in defined risk sets. 
Each panel shows the profile o f antibody responses in an individual risk set (defined as a group o f  
an index case and individually matched controls). The three broad classifications o f  responses 
observed for individual antigens are shown in each column. Group I (panels A, D. G, J, M and P) 
represents antibody profiles where cases had relatively higher antibody responses over time 
compared to controls; Group II (panels B. E. H, K, N and Q) represents antibody profiles where 
antibody responses were similar in the cases and controls; and Group III (panels C, F, I, L, O and 
R) represents antibody profile where controls had relatively higher antibody responses over time 
compared to cases. Each row represents a specific antigen.
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Table 5.2. The proportion o f risk sets classified into three groups according to the profile of 
antibody responses for each antigen tested.
Antigen G roup  I G roup  II G roup  III
AMA1 (FVO) 6(14.3%) 14(33.3%) 22 (52.4%)
MSP-2 (Dd2) 6(14.3%) 22 (52.4%) 14(33.3%)
MSP-3 (3D7) 7(16.6%) 15 (35.7%) 20 (47.6%)
MSP-1,9 8(19.0%) 16(38.1%) 1 8 (42.9%)
PfRh2 5(11.9%) 24 (57.1%) 13 (31.0%)
Schizont ex tract 6(14.3%) 22 (52.4%) 14(33.3%)
Total number of risk sets included in the analysis (N=42).
5.3.5 Dynamics o f antibody responses over the follow-up period
Although a large proportion o f children had low antibody titres, often below the seropositivity 
cutoff at all time points, some children had detectable antibody levels that often fluctuated 
either above the cutoff (they were always seropositive but the actual levels varied) or around 
the cutoff (they were occasionally seropositive or seronegative at the different time points). 
Given this finding, I explored the maintenance o f  antibody responses over time to determine 
whether children generated either high or low levels of antibodies that were dynamic (highly 
fluctuant) or stable over time. Dynamic and stable responses were defined as achieving a 
standard deviation greater or less than 1; respectively, i.e. how far an individual’s antibody 
response fluctuated from their mean antibody response (Fowkes et al. 2012). This analysis was 
restricted to samples collected at >0 months to minimize the high standard deviation value
obtained when maternal antibodies were included in the analysis. With the exception o f  MSP- 
119 and P /R h 2 , a large proportion o f  children (>60%) had relatively stable antibody responses, 
often maintained below the seropositivity cutoff for all antigens tested (Figure 5.5.1 B, D, F, 
H, J and L). In contrast, a significant proportion o f children classified as having dynamic 
responses had antibody titres fluctuating above the seropositivity cutoff, although this was less 
clear for M S P -I19 and E/Rh2 (Figure 5.5.1 A, C, E, G, I and K). Comparisons o f  dynamic 
antibody responses between the cases and controls revealed no significant differences between 
the proportions o f  responders in the two groups for all antigens tested (Figure 5.5.2) although 
there was a trend towards a higher proportion o f dynamic responders amongst the control 
group for AMA1, MSP-3 alleles, fyRh2 and schizont extract compared to cases.
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Figure 5.5.1. Antibody profiles over the follow-up period categorized as being relatively stable or dynam ic . 
Representative graphs one allele o f  A MA I  (A-B), M SP-2(C-D), M SP-3(E-F). M S P - I 19 (G -H ), / 5/R h2  (I-J) and 
schizont extract (K-L) are shown. Horizontal red lines represent the seropositivity cu to f f  defined as m ean + 3 S D  o f  
tw enty  European plasma. Stable and dynam ic responses were defined as having a standard deviation less or g reater  
than 1 AU; respectively, i.e. how far an individual’s antibody response fluctuated from their mean response.
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Figure 5.5.2. Proportion o f cases and controls demonstrating dynamic versus stable 
responses over the follow-up period, to each antigen tested. Black bars and shaded bars 
represent the proportion o f cases and controls with dynamic responses; respectively. Grey 
bars show the proportion o f individuals with stable responses.
5.3.6 Association between antibodies and odds o f developing severe m alaria
The association between specific antibodies and the odds of developing severe malaria was 
assessed in the serum sample collected immediately prior to the disease episode (timepoint 1) 
or at consecutive three-monthly sampling time points (excluding antibodies measured at birth) 
for cases and corresponding controls as illustrated in Figure 5.6.
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Figure 5.6 Illustration o f the different time points that an antibody titre measurement was taken 
and used to calculate the protective efficacy of specific antibodies against severe malaria. 
Timepoint 1 and timepoint 4 represent the time points closest and farthest from the severe malaria 
episode, respectively.
The protective efficacy o f specific pre-existing antibodies measured at the time point closest to 
admission for severe malaria cases and their corresponding controls are shown in table 5.3.1.
As demonstrated in Figure 5.5.1. children classified as responders often had highly fluctuating 
antibody levels with levels dropping significantly by their subsequent follow-up visit. 
Previous studies have also demonstrated short-lived responses to blood-stage antigens in 
young children (Fonjungo et al. 1999, Kinyanjui et al. 2007, Akpogheneta et al. 2008) 
resulting in antibodies being more likely protective only within a limited duration o f  follow 
up. Taking this into consideration, separate analyses were conducted for i) all severe malaria 
admissions (N=53, median admission age 16.8 (range 5-74.06 months) and their 
corresponding controls (N=147, median age at case admission 18.2 (range 3.4-74.03 months)
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and (ii) children admitted with severe malaria during the first 28 months o f  life (N=42, median 
admission age 10.76 (range 5-27.7 months)) and their corresponding controls (N=l 12, median 
age at case admission 9.5 (range 3.4-28.2 months)). In both analyses, only antibodies to 
A M Al alleles were associated with a significant reduction in odds o f  developing severe 
malaria, (OR 0.39 (0.16-0.92) p-0.03 for A M A l (FVO), OR 0.43 (0.19-0.99) p=0.04 for 
A M Al (3D7) and OR 0.38 (0.16-0.90) p=0.028 for A M A l (HB3)), in all severe malaria 
admissions. Similarly, antibodies to AM Al (FVO and HB3) alleles were also associated with 
a significant reduction in odds o f  developing severe malaria in children followed up for 28 
months from birth (OR 0.40 (0.17-0.98) p=0.04 for A M Al (FVO) and OR 0.40 (0.16-0.98) 
p=0.04 for AM Al (HB3). Antibodies to all other antigens tested were not associated with 
protection from severe malaria (Table 5.3.1).
To determine whether antibody measurements obtained at multiple time points prior to the 
disease episode are better predictors o f protection compared to those measured at the time 
point closest to the disease episode, mean antibody titres were calculated for each individuals’ 
follow-up data, up to the incidence o f  disease for cases and their corresponding controls. 
Children whose mean antibody responses were above the seropositivity cutoff for each antigen 
were classified as responders. For most antigens tested, the antibody prevalence was 
overestimated based on the mean antibody response compared to the single time point 
measurement (53% versus 33% for A M A l (FVO), 37% versus 27% for M SP-2(Dd2), 25% 
versus 21% for MSP-2(K1), 19% versus 5% for M S P -I19 and 16% versus 11% for 7yRh2, 
respectively). Antibodies to AM Al alleles were associated with reduced odds o f  developing 
severe malaria in analyses including all children (OR 0.58 95% Cl 0.30-1.13, p= 0.11 and OR 
0.77 95% Cl 0.40-1.47, p=0.43, for FVO and 3D7 alleles, respectively) and in analyses 
including children admitted within 28 months o f life (OR 0.61 95% Cl 0.29-1.28, p=0.20 and 
OR 0.68 95% Cl 0.33-1.41, p=0.30, for FVO and 3D7 alleles, respectively). All other antigens
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tested were not associated with protection (Table 5.3.2). Strikingly, the odds ratio estimates 
obtained in analysis using the single time point closest to admission (Table 5.3.1) and using 
the mean response o f  multiple time points (Table 5.3.2) were similar in directionality.
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5.3.7 Association betw een the b read th  o f an tibody  responses and  odds o f developing 
severe m alaria .
Previously, we have shown that the breadth and depth o f anti-merozoite responses was 
associated with a reduced risk o f  developing clinical episodes o f  malaria (Osier et al. 2008). 
To demonstrate the role o f breadth o f  antibody responses in protection from severe malaria as 
an outcome, the proportion o f  cases and controls responding to a given number o f  antigens 
(N=5) was calculated (Figure 5.7A). The only differences observed between the two groups 
were in the proportion o f  children responding to at least one antigen (16% versus 27%) and 
those responding to none o f  the antigens tested (44% versus 32%), in cases and controls 
respectively. Increasing breadth o f  antibody responses was associated with a stepwise increase 
in risk o f  developing severe malaria (Figure 5.7B). Responses to at least one antigen were 
associated with a significant decrease in risk o f developing severe m alaria (OR 0.36, 95%CI
0.13-0.98, p=0.04).
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Figure 5.7 The breadth of anti-merozoite antibody responses in cases and controls (A). A total o f  
five antigens (AM A l, MSP-2, MSP-3, P/Rh2 and M SP-fg) were tested. Black, light grey, dark 
grey, white and shaded bars represent the proportion o f individuals responding to 0, l, 2, 3 and >4 
antigens respectively. (B) Protective efficacy o f  increasing breadth o f  antibody responses. The odds 
ratios and 95% Cl are shown.
5.4 Discussion
Two major strengths o f  this study were, first, the availability o f  samples collected at multiple
three-monthly intervals from birth upto 2 years o f  age to assess the cumulative contribution o f
an individual’s history and/or profile of antibody responses to protection from severe malaria.
Contemporarily, pre-existing antibodies have often been measured at one time point prior to
the disease episode and prospectively associated with the risk o f developing malaria over a
defined duration of follow-up, however this approach assumes that an individual’s ability to
mount an antibody response can be potentially assessed at only one time point whereas for
anti-malarial antibodies, the levels vary with exposure (Kinyanjui et al. 2009), they are
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relatively short-lived in children (Kinyanjui et al. 2007, Akpogheneta et al. 2008) and their 
longevity varies depending on the antigen (Akpogheneta et al. 2008, Drakeley et al. 2005); 
hence some individuals may be incorrectly classified as being non-responders when sampled 
at a single time point. Thus far, to the best o f  my knowledge, no study has compared the 
protective efficacy o f  antibodies measured at a single time point versus the overall/mean 
antibody response for the same individual against episodes o f severe malaria and this study 
therefore provides evidence for the first time that in this age-group o f children, the odds o f  
developing severe m alaria conferred by antibodies measured at a single time point are 
predictive o f  the odds likely to be obtained based on an individual’s overall pattern o f 
responses. These findings suggest that sampling o f  antibodies at the time point immediately 
prior to the disease episode accurately reflects an individuals’ overall antibody response. I 
interpret these findings with caution particularly because the majority o f  the children in this 
cohort had low and stable antibody responses over time such that a mean o f  cumulatively low 
antibody responses would be captured nonetheless at any single time point. In a separate study 
conducted in Kilifi in which two cross-sectional surveys o f  children aged less than ten years 
were carried out each year between 2002 and 2004, they showed that in the cross-sectional 
survey o f May 2002, antibody responses to AMA1 (W 2m ef allele) were associated w ith an 
increased risk o f  developing uncomplicated malaria during the ensuing 6 months o f  follow-up 
and yet this was not the case in October 2002 and May 2003 possibly due to declining malaria 
transmission intensity during the period o f their study. A longitudinal analysis o f  responses 
measured at all the sampling points revealed that anti-AM Al (W2mef) antibodies were 
associated with a significantly increased risk o f  developing uncomplicated m alaria during the 
follow-up period, a finding which is in contrast to what was observed in this chapter 
(Cleopatra Mugyenyi, 2010, PhD Thesis). Although this study focused on responses to similar 
merozoite antigens and samples were also collected during a period o f declining m alaria
transmission, it is not possible to perform a head to head comparison between their findings 
and mine because o f  differences in the age ranges studied, the sampling framework, analytical 
methods and the clinical outcome o f  uncomplicated malaria that was evaluated.
Overall there was a lack o f  association between antibodies to the panel o f  merozoite antigens 
measured at multiple or at a single time point from birth with protection against severe malaria 
during the first two years o f  life, with the exception o f AMA1 antibodies which were 
associated with a 40-50% reduced odds o f developing severe malaria. Previous studies have 
looked at responses to schizont extract (Ndungu et al. 2002) and to infected erythrocyte 
surface antigens (Bull et al. 2002), in a broader age range o f  children (1-5 years) and showed 
that anti-schizont extract IgG l antibodies were associated with a reduced risk o f  developing 
severe malaria whereas agglutinating antibodies against 3 isolates obtained from children 
admitted to hospital with malaria were not associated with protection from severe malaria, 
respectively. Although in the study by Ndungu et al, 2002, they demonstrated a role for IgG l 
in protection against severe malaria as an endpoint o f  interest, it is difficult to demonstrate the 
targets o f  protective antibodies from the antigen specificities contained in a crude parasite 
lysate and my data therefore provides, for the first time, i) an assessment o f  a much broader 
panel o f merozoite antigens in a longitudinally monitored birth cohort; and ii) included a much 
larger sample size o f  61 severe malaria cases rather than the 21 assessed in the above studies. 
Findings from similar studies conducted in this region (Polley et al. 2004, Osier et al. 2008) 
and others (Stanisic et al. 2009, Gray et al. 2007) have shown that naturally-acquired 
antibodies against AMA1 are associated with protection against uncomplicated clinical 
episodes o f malaria. Following the paucity o f data on the targets o f  protective responses 
against severe malaria as a clinical endpoint, the findings presented in this chapter lend 
support for the development o f an AMA1 vaccine which will not only protect against
uncomplicated clinical episodes but also the severe form in the most vulnerable age group.
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Antibody prevalence and titres were highest at birth but gradually decayed to a low plateau at 
5-7 months o f age for most antigens tested. Thereafter, antibody titres and prevalence were 
maintained at relatively low and stable levels with some evidence o f a slow but steady increase 
in prevalence with age. This is consistent with findings from a birth cohort o f  Gambian (Duah 
et al. 2010) and Kenyan (M alhotra et al. 2009) children. The observation o f  low antibody 
prevalence in this group o f children probably reflects inadequate exposure to infection due to 
young host age and the declining malaria transmission intensity in this area between 2002 and 
2008 (Okiro et al. 2007, O 'M eara et al. 2008). Only 19% o f the children harbored 
asymptomatic infections during the six year follow-up period, an estimate which is 
significantly below the 40% cutoff proposed by some studies as the cross-sectional parasite 
prevalence rate in children aged 2-10 years (P/PR 2-10) that reflects a population under low 
malaria transmission intensity (Noor et al. 2009, Smith et al. 2007, Hay et al. 2008). In a 
malaria holo-endemic area in Western Kenya, antibody prevalence to M SP-I42, AMA1 (FVO) 
and EBA175 was between 10% and 30% in children aged 6 - 3 6  months (M alhotra et al. 
2009). In a separate study in the same area, Branch et a l ,  examined the pattern o f responses o f  
24 infants from birth up to 1 year o f age and showed that despite documented evidence o f 
exposure to multiple infections, which was accompanied by peaks in M SP-119 antibody levels, 
the duration o f antibody responses and overall antibody levels did not increase over time 
(Branch et al. 1998). I would argue that the findings from these studies and the data presented 
in this chapter suggest that, despite evidence o f exposure to infection, there are intrinsic age- 
dependent factors that impair the ability o f  young children to mount high antibody titres to the 
panel o f  antigens tested in children o f this age range. In contrast, a study conducted in a low 
altitude area in Tanzania argues against this notion by showing that M SP-119 antibody 
prevalence in children aged 12-24 months was approximately 70% (Drakeley et al. 2005), an
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estimate that was significantly higher that what was observed in this thesis and in Western 
Kenya (M alhotra et al. 2009). ,
Despite the frequent low reactivity to individual antigens, antibody titres in this study were 
highly dependent on concomitant exposure to infection, consistent with previous studies 
(Proietti et al. 2013, Kinyanjui et al. 2004, Akpogheneta et al. 2008, al-Yaman et al. 1995). A 
positive association between asymptomatic infection, previous exposure (as measured by 
schizont extract reactivity), and year o f  sample collection with antibody titres was observed. 
Transient peaks in antibody titres that rapidly declined during the subsequent three-months o f 
follow-up were noted among individuals that had a documented P. falciparum  infection, 
similar to what has been observed in other studies (Branch et al. 1998, Fonjungo et al. 1999, 
Taylor et al. 1996, Cavanagh et al. 1998). It is plausible that the transient peaks derive from 
short-lived plasma cells generated from immature B cells rather than pre-existing long-lived 
plasma cells (LLPCs) or memory B cells (mBCs), following the observation that many o f  
these children were experiencing their first infections and mounted antibody responses that 
rapidly declined following parasite clearance together with supporting data from mathematical 
models demonstrating inefficient generation o f long-lived plasma cells in Ghanaian children 
aged 0-2 years (White et al. 2014a). Although the development o f  immune memory to m alaria 
in children o f a similar age group has so far not been studied, there is evidence that mBCs are 
efficiently acquired even following single infections in mice (Ndungu et al. 2009) and 
maintained in the absence o f exposure (Ndungu et al. 2012, W ipasa et al. 2010).
I also observed diverse longitudinal patterns o f responses in which some children had peaks in 
antibody responses to some antigens in the absence or presence o f asymptomatic infections. 
These findings could be explained by several factors such as insufficient sampling for 
asymptomatic infections, the nature o f the antigens (some antigens may be more
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immunodominant than others), clonai imprinting (original antigenic sin) as seen in influenza 
infection (W rammert et al. 2011), bystander polyclonal activation by mitogens (Bernasconi, 
Traggiai and Lanzavecchia 2002), host genetic differences, hemoglobinopathies or 
environmental factors. However, direct evidence for some o f  these factors remains elusive. In 
a study by Taylor et a l ,  they genotyped HLA class-II alleles in a population and showed that 
genetic differences did not play any role in explaining non-responsiveness to particular 
antigens (Taylor et al. 1996). There are considerable disparities between studies regarding 
whether IgG levels to merozoite antigens are lower (Sarr et al. 2006, Le Hesran et al. 1999, 
M iura et al. 2013a), higher (Diatta et al. 2004, Cabrera et al. 2005) or similar (Tan et al. 2011) 
in children with sickle cell trait compared to normal Hb. Further, it remains to be determined 
why antibodies to MSP-2 in the work presented here were preferentially boosted following 
infection as opposed to antibodies to other polymorphic and more immunogenic antigens such 
as AMA1 or a conserved antigen such as M SP-119. My observation is in contrast w ith two 
recent studies, one conducted in a low-transmission setting (Clark et al. 2012) and the other a 
controlled human malaria infection (CHMI) study that mirrors low dose, single exposure 
infections (Elias et al. 2014) that found preferential boosting o f M SP-119-specific antibodies 
relative to other merozoite antigens.
Serological studies have provided evidence that the repertoire o f  targets o f  the antibody
response increase with age and exposure, with the number o f recognized antigens and
magnitude o f responses being correlated with age and immunity to uncomplicated episodes o f
malaria (Osier et al. 2008, John et al. 2005, Gray et al. 2007). Contrary to our previous finding
that antibody breadth was associated with protection from uncomplicated m alaria (Osier et al.
2008), the breadth o f merozoite-specific antibody responses in this cohort was associated with
a stepwise increase in risk o f developing severe malaria. However, important differences
between this study and our previous one were that: i) the age range studied was wider ( 1 - 1 0
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years) and the highest proportion o f children who had high titre responses to the least number 
o f  antigens were aged less than two years; ii) the antigens selected for inclusion in the breadth 
analysis in our previous study were individually associated with a reduced risk o f developing 
clinical malaria, a result which was not replicated in this current study except against AMA1 
alleles; iii) the number o f recognized antigens was based on a cut o ff o f  high titre antibodies 
for each antigen in our previous study which could not be applied here since a large proportion 
o f  the children had low antibody levels; iv) the study was a cross-sectional survey at a specific 
time point with longitudinal monitoring for incidence o f  uncomplicated m alaria episodes 
conducted during a fixed period o f one transmission season whereas in the study presented 
here, sample collection and monitoring o f children admitted to hospital with severe m alaria 
was spread out over a period o f  eight years; and v) the study was conducted during a period o f 
relatively higher malaria transmission intensity compared to the study presented here. One 
interpretation o f  the observed correlation between breadth o f  responses with increased risk o f  
disease is that in this age group, the breadth o f  responses simply acts as a m arker o f  exposure 
to infection but the level o f exposure is insufficient and does not lead to induction o f  the 
adequate amounts o f antibodies associated with immunity to malaria.
It is also clear that a proportion o f children were less at risk o f  developing severe m alaria 
compared to others despite the absence o f  merozoite-specific antibodies to the antigens studied 
here. The panel o f merozoite antigens selected for this study was small and it remains 
plausible that there may be other potential targets o f  protective antibodies against severe 
malaria in young children. Such targets include antigens on the infected RBC surface which 
are plausible targets given the proposition that only a restricted subset o f variants are 
expressed during severe malaria (Bull et al. 2005, Kaestli et al. 2006, Kyriacou et al. 2006, 
Jensen et al. 2004) to which antibodies are acquired more rapidly (reviewed in (Chan et al. 
2014)). Towards this end, some studies have measured pre-existing agglutinating antibodies to
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various infecting parasite isolates and demonstrated an association with protection against 
clinical malaria (Marsh et al. 1989, Dodoo et al. 2001, Giha et al. 2000, Chan et al. 2014) or 
severe malaria (Bull et al. 1998) albeit inconsistently (Bull et al. 2002). Others have examined 
antibody responses to various domains o f the most studied PfEM Pl antigen (M ackintosh et al. 
2008b, Dodoo et al. 2001, Magistrado et al. 2007) and also reported inconsistent findings. The 
contribution o f other antibody unrelated factors should also be explored in future studies. For 
instance, we have demonstrated in this same cohort o f  children that asymptomatic infections 
detected at least once from birth during the three-monthly visits were associated with 
increased odds o f developing severe malaria (Lundblom et al. 2013). Others have shown that 
prenatal exposure to parasite antigens could lead to acquisition o f  a tolerant phenotype 
characterized by low levels o f  pro-inflammatory cytokines and high levels o f  IL-10, which 
increases the risk o f infection during infancy (M alhotra et al. 2009). A recent birth cohort 
study has also shown that IL -ip  levels are associated with a 42% reduction in risk o f  
developing severe malaria during infancy (Kabyemela et al. 2013). These studies point 
towards an important role o f pro-inflammatory cytokines, which are released by innate and 
adaptive immune cells in reduction o f parasite densities and risk o f developing severe malaria. 
However, increasing evidence points towards the timing and fine balance between the pro and 
anti inflammatory responses in clearance o f parasites and prevention o f  inflammation- 
mediated pathology (reviewed in (Riley et al. 2006).
In conclusion, I found no association between antibodies to most o f  the antigens tested here 
with protection against severe malaria and this could be explained by insufficient antibody 
titres which were influenced by the combination o f young host age and low transmission 
intensity during the period the study. However the finding that AMA1 antibodies could play a 
role in protection against severe malaria in infancy encourages the hope that a vaccine
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administered early in life could protect the population most at risk o f dying from severe 
malaria.
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CHAPTER SIX
The role of transplacentally acquired antibodies in protection against infection and 
severe malaria during the first six months of life
6.0 Introduction
Infants living in malaria endemic areas are resistant to malaria during the first few months o f 
life. There is evidence o f a low incidence o f clinical episodes o f  malaria (M cGuinness et al. 
1998, Klein Klouwenberg et al. 2005, Larru et al. 2009), low density asymptomatic 
parasitemia (McGuinness et al. 1998, Wagner et al. 1998) and relatively few cases o f  severe 
malaria (Snow et al. 1998). Susceptibility to clinical episodes o f malaria and high density 
parasitemia increases gradually after the age o f  18 weeks (W agner et al. 1998) which suggests 
that protection may be due to innate factors present in the infant that gradually wane with age. 
Among the factors that potentially contribute to malaria resistance in infancy are maternal 
antibodies which are transferred in ntero via an Fc receptor mediated pathway (Sim ister 1998) 
and reach peak levels during the third trimester o f pregnancy (Simister 2003). IgG l is 
transported more efficiently due to its high affinity for neonatal Fc receptors expressed on 
syncytiotrophoblast cells in the placenta (Costa-Carvalho et al. 1996, M alek 2003, M alek et al. 
1996). Although several studies have demonstrated that malaria-specific antibodies measured 
in cord blood are present in high concentrations and correlate with antibodies present in 
maternal circulation (reviewed in (Riley et al. 2001)), the association between maternally 
transferred antibodies and protection against malaria during the first few months o f  life is 
inconsistent across studies (reviewed in (Riley et al. 2001) and Table 6.1 below).
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This discrepancy may be explained by the varying duration o f follow-up from birth adopted by 
different studies, ranging between 20 weeks (Riley et al. 2000) and one year (Hogh et al. 1995, 
Achidi et al. 1996), differences in antigens tested and differences in the primary outcomes 
examined (Table 6.1). However in at least two studies, M S P -I19 antibodies measured at birth 
were consistently associated with a reduced risk o f developing a clinical episode o f  malaria 
(Hogh et al. 1995) or delaying time to first infection (Branch et al. 1998), although in both 
studies children were followed up for upto one year o f  age, a duration over which maternal 
antibodies are unlikely to persist.
Susceptibility to clinical episodes o f  malaria has also been shown to increase as the level o f  
fetal hemoglobin (HbF) decreases in circulation. This lends support to the hypothesis that HbF 
may play a role in protection against malaria during the first few months o f life. In in vitro 
experiments, Pasvol et al. demonstrated a significant inhibition o f parasite growth in red blood 
cells containing HbF in comparison to cells containing adult hemoglobin (HbA) (Pasvol, 
Weatherall and Wilson 1977). These findings were corroborated by experiments done in 
transgenic mice expressing fetal hemoglobin, a study which also demonstrated that impaired 
parasite growth occurs as a result o f HbF resistance to digestion by malarial hemoglobinases 
(Shear et al. 1998). However, in contrast to these findings, a recent study has shown that 
parasites grow efficiently in HbF containing erythrocytes but display altered expression o f  the 
major antigen expressed on the surface o f the infected red blood cell (P fEM Pl) and they 
propose a mechanism by which HbF acts cooperatively with maternal IgG leading to impaired 
binding o f these cells to human microvascular endothelial cells (Amaratunga et al. 2011). This 
mechanism remains to be clearly demonstrated using cord blood IgG and erythrocytes 
obtained from infants born to mothers living in malaria endemic areas, given that in their 
study, Amaratunga et al., used a pool o f immune IgG obtained from adults resident in Mali 
and not maternal or cord blood samples.
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In addition, there is evidence that p-aminobenzoic acid (pABA), a folate precursor that is 
required for parasite growth but is present at low levels in breast milk, limits growth o f 
parasites in breastfeeding infants (Kicska et al. 2003, Kretschmar 1966). Presence o f 
lactoferrin in breast milk which binds iron has also been shown to inhibit the in vitro growth o f 
parasites (Kassim et al. 2000). Taken together, these studies demonstrate a potential 
independent role for non-antibody mediated protection against malaria during the first few 
months o f life.
In contrast, there’s a general trend towards lack o f protection conferred by transplacentally 
acquired antibodies to a majority o f  merozoite antigens tested (Riley et al. 2001), although 
only few studies have evaluated the quality o f  the antibody response (W ilson et al. 2013, Duah 
et al. 2010) and none so far has examined the protective efficacy o f these antibodies taking 
into account recent evidence that the breadth (Osier et al. 2008) and concentration (Osier et al. 
2008, Murungi et al. 2013) o f merozoite-specific antibodies may be more important in 
protection against clinical episodes o f malaria or infection than responses to single antigens or 
the mere presence o f  these antibodies in cord blood, assessed using seropositivity cutoffs. 
Besides, no study has systematically examined the kinetics o f decay o f  maternal antibodies to 
merozoite antigens or evaluated their role in protection against the severe form o f  m alaria 
during infancy.
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6.1 Objectives
1. To determine the kinetics o f  decay o f  maternal antibodies against a panel o f merozoite 
antigens.
2. To compare pristine antibody levels between children who subsequently acquired an
asymptomatic infection and those who remained uninfected during the first six months 
o f  life.
3. To compare pristine antibody levels in children who subsequently developed severe
malaria and those who did not, during the first six months o f life.
4. To determine the protective efficacy o f specific-antibodies against acquisition o f
asymptomatic infections and development o f  severe malaria during the first six months 
o f life.
6.2 Methods
6.2.1 Serum samples
A total o f one hundred and thirty cord blood samples were collected from mothers who 
delivered their infants at Kilifi District Hospital between 2001 and 2006. The infants were 
recruited into a birth cohort and followed up every 3 months until 2 years o f  age. During the 
three-monthly visits, a blood sample was collected, separated into plasma and RBC pellet 
fractions and stored at -80°C for ELISA and PCR assays, respectively.
6.2.2 Recombinant antigens and Multiplex ELISAs.
IgG levels to a panel o f recombinant merozoite antigens; AMA1 (FVO and 3D7 allelic types), 
MSP-2(Dd2 and CH150/9 allelic types), MSP-3 (3D7 and K1 allelic types), P /R h2 and MSP-
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119 were measured using a multiplex bead-based ELISA platform, as previously described in 
Chapter two. IgG responses to schizont extract were measured using a standard ELISA 
technique, as previously described (Ndungu et al. 2002).
6.2.3 Statistical analysis
All analyses were performed in Stata 11.0 (StataCorp, Texas, USA) and GraphPad prism 6 
(GraphPad Software, Inc). A linear regression model was used to determine the influence o f 
maternal age, parity, birth weight, year o f birth, residential location and cumulative exposure 
to malaria infection (reactivity to schizont extract) on the levels o f  specific-antibodies. The 
M ann-W hitney U test was used to compare antibody titres measured at birth between children 
who prospectively acquired an infection and those who remained uninfected during six months 
o f  follow-up from birth. The rate o f  antibody decay was determined using a longitudinal 
mixed-effects model with a random intercept and slope component (Amanna, Carlson and 
Slifka 2007, Fowkes et al. 2012). The model accounts for repeated measurements per 
individual and was fitted to the logio transformed values o f the antibody titres collected at age 
0, 3 and 6 months. Maternal antibodies were expected to decay following an exponential 
decay model represented by the equation;-
L, = L0 e ~kt
Where Lt and Lo are the antibody concentrations at age t and at birth; respectively, k represents 
the decay rate constant. Half-life estimates were calculated using the equation:
T 1/2 = In 2/ k,
Where Ti/2 is the estimated half-life and k is the slope component o f the mixed-effects model 
(Kinyanjui et al. 2007, Fowkes et al. 2012, Amanna et al. 2007, Ochola et al. 2009).
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A logistic regression model was used to calculate the association between specific-antibodies 
and protection against acquiring asymptomatic infections or developing severe malaria during 
the first six months o f life. Antibodies were fitted as categorical variables in the model based 
on two different cutoffs: (i) seropositivity cutoff defined as ELISA OD value above the mean 
+ 3SD o f  twenty European plasma; and ii) threshold concentrations defined in chapter four 
(Murungi et al. 2013) and by Rono et al. (Rono et al. 2013).
6.3 Results
6.3.1 Descriptive analyses of mothers and infants at enrollment
The baseline characteristics o f  mothers and their newborns at enrollment are shown in Table 
6.2. The mean maternal age and number o f previous pregnancies were 26.67 years (IQR 
14.77-48.03) and 4 (range 0-13), respectively. The mean birth weight was 2.79 kg (range 1.63 
-  4.36) and the majority o f  the mothers were residents o f  Kilifi township area (34%) and 
Takaungu location (21.5%). The proportion o f male to female births was similar (Table 6.2).
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Tab le  6.2 Baseline characteristics o f  mothers and infants at enrollment
Maternal age (N =128), mean (range) 26.67 ( 1 4 . 7 7 - 4 8 .0 3 )
No. o f  previous pregnancies (N :=:92), mean (range) 4 (0 -13)
Sex fem ale, n/N (% ) 62/130 (47.7% )
Birth weight (N=66), m ean(range) 2.79 (1.63 - 4 . 3 6 )
R esidence, n (% )
Banda ra salam a, Junju 10(7.6)
Ziani 5(3.8)
T akaungu 28(21.5)
C hasim ba 15(11.5)
Kilifi tow nship, Konjora 34(26.1)
Jaribuni, Kaum a 4(3.1)
Tezo 20(15.3)
N gerenya, Sokoke, Roka 14(10.7)
6.3.2 Factors th a t influence the level o f antibodies m easured  in cord blood.
Among the factors examined that influence the levels o f  specific-antibodies measured in cord 
blood, only antibody titres to schizont extract was associated with a significant increase in 
antibody levels to the antigens tested (p<0.05) (Table 6.3). A significant positive correlation 
between antibody titres to specific antigens and schizont extract was also observed, with the 
exception of responses to PfK\\2 which showed a weak positive correlation (correlation 
coefficients; 0.70, 0.74, 0.69, 0.51 and 0.22 for AMA1(3D7), MSP-2(Dd2), MSP-3(3D7), 
M SP-119 and PfRh2, respectively). Maternal age, birth weight, parity, year o f  birth and
209
residence o f the mothers did not significantly influence the levels o f specific antibodies 
measured in cord blood (Table 6.3)
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6.3.3 P ro p o rtio n  o f ch ild ren  acqu iring  asym ptom atic infections o r  developing severe 
m alaria  du ring  the study  period.
Among the children that had a cord blood and three-monthly follow-up samples obtained 
(N=130), fy infections and severe malaria cases were recorded in 27/130 (20.7%) and 25/122 
(20.5%) children, respectively, during two years o f follow-up from birth. Out o f  the 25 
children who developed severe malaria, 9 o f them had experienced previous asymptomatic 
infections. The number o f children with a documented infection or developing an episode o f 
severe malaria during the first six months o f life was 10/130 (7.6%) and 5/130 (4.1%), 
respectively (Figure 6.1). Only one out o f  the five children who developed severe m alaria 
during the first six months o f  life had evidence o f a previos asymptomatic infection.
A. B.
Time to first infection
0 .2 .6 .8 1 1.2 1.4 1.6 1.8 2.4
Number at risk
analysis time
130 129 124 120 110 109 107 105 103 103 103
Severe malaria episodesOO
otoo
to<N
o
ooo'
0 1 1.2 1.4 1.6 1.8 2.2 .4 .6 .8
Number at risk
analysis time
122 122 122 115 111 106 106 103 99 99 97
Figure 6.1 Kaplan-M eier curves o f (A) time to first infection and (B) time to severe malaria 
episode in children who were recruited at birth and had a cord blood sample taken.
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6.3.4 Decay of transplacentally acquired antibodies
The decay rate o f  antibodies to specific antigens was determined using a longitudinal mixed- 
effects model (Amanna et al. 2007, Fowkes et al. 2012). A regression line was fitted through 
logio transformed antibody titres for children aged less than six months. Antibody levels 
decreased exponentially with increasing age, as shown in Figure 6.2. Excluding children who 
experienced an infection, which is known to alter the natural decay o f antibodies by boosting 
antibody levels, did not alter the overall decay rate in this population. This finding is expected 
given that only 10 out o f  130 (7.6%) infants acquired infections in less than six months o f  age. 
Analysis o f the overall rate o f decay and duration o f persistence o f maternally transferred IgG 
revealed a relatively longer half-life for PfR hl and M S P -I19 antibodies (34.65 and 10.5 
months, respectively) compared to other antigens tested (3.01, 3.12, 2.89, 2.80, 2.52, 1.53 
months for A M A l(FV O ), AMA1(3D7), MSP-2(Dd2), MSP-2(CH 150/9), M SP-3(3D7) and 
MSP-3(K1), respectively) (Table 6.4). The antibody decay rates for individual infants 
followed a normal distribution with some infants exhibiting very rapid declines, some very 
slow and majority had decay rates around the mean estimate. There was minimal inter­
individual variation in the rate o f  decline o f  specific-antibodies as illustrated by the narrow 
confidence intervals (Table 6.4); with the exception o f  antibodies to P/Rh2 and M SP-1 19 which 
showed relatively wide variations in antibody half-life estimates (half-life was 10.5 months 
(7.45 -  17.32) for anti- PJKh2 antibodies and 34.6 months (16.90 -  866.25) for anti- M SP-1 19 
antibodies).
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Figure 6.2 S c a t t e r  p lo ts  o f  a n t ib o d y  t i t r e s  to  (A )  A M A l ( F V O ) ,  (B )  A M A 1 ( 3 D 7 ) ,  (C )  M S P -  
2 (D d 2 ) ,  (D )  M S P - 2 ( C H  150 /9 ) ,  (E )  M S P - 3 ( 3 D 7 ) ,  (F )  M S P - 3 ( K 1 ) .  (G )  M S P - 1 , 9  a n d  (H )  
P fK \\2  d u r i n g  th e  f i rs t  s ix  m o n t h s  o f  life. T h e  f i t ted  s lo p e  a n d  9 5 %  C l  a re  s h o w n .  T h e  d o t t e d  
b lu e  line r e p r e s e n ts  th e  c u t o f f  fo r  a n t ib o d y  s e r o p o s i t iv i ty  d e f in e d  as  m e a n  +  3 S D  o f  20  
E u r o p e a n  p la s m a .
Table 6.4. T h e  ra te  o f  d e c a y  a n d  a n t ib o d y  h a lf - l iv e s  o f  m a te rn a l ly  t r a n s f e r r e d  a n t ib o d ie s  to  s p e c i f ic  
a n t ig e n s  te s ted .
Antigen Rate o f  decay* ( 95% Cl) Ant ibody half-life in months
(95% Cl)
A M A l ( F V O ) -0 .230(-0.248. -0.212) 3.013(2 .794 - 3 . 2 6 8 )
AMA1 (3D 7) -0.222(-0.242, -0.203) 3.122(2 .864 - 3 . 4 1 4 )
MSP-2(Dd2) -0.239(-0.263. -0.215) 2.899(2 .635 - 3 . 2 2 3 )
MSP-2(CH150) -0.247(-0.272, -0.222) 2 .805(2 .548 - 3 . 1 2 1 )
MSP-3(3D7) -0.275(-0.308, -0.241) 2 .520(2 .250 - 2 . 8 7 6 )
MSP-3(K1) -0.451 (-0.494. -0.408) 1.537(1.403 -  1.698)
MSP-1,9 -0.066(-0.093, -0.040) 10.500(7.452 -  17.325)
P f R h2 -0 .02 0 ( -0 .0 41 ,-0 .0008) 34 .650(16.902 -  866.25)
* L o g ,o  re d u c t io n  p e r  m o n th  o f  in d ica te d  v a lu e s .
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6.3.5 Relationship between the rate of decline o f cord blood titres and initial titres
Previous studies have shown that the half-life IgG to rubella (Cloonan, Hawkes and Stevens 
1970) parainfluenza type 3 and influenza type A2 (Cloonan, Hawkes and Stevens 1971) 
passively acquired by infants from their mothers is inversely proportional to the initial titre in 
cord blood. This suggests that the rate o f decline o f  antibodies in infants with high antibody 
titres is greater than in infants with low level antibodies. To test this finding for malaria- 
specific antibodies, the rate o f  decay o f  specific-antibodies according to different pristine 
antibody levels was determined. Cord blood titres were divided into quartiles and the decay 
rate o f  antibodies within each quartile assessed. With the exception o f  anti-MSP-3 K1 
antibodies (Figure 6.3 L), cord blood titres in the 4th quartile (highest titres) decayed most 
rapidly followed by those in the 3rd, 2nd and 1st quartiles, in that order (Figure 6.3 -  B, D, F, H, 
J, N and P ). For example, the decay rate for MSP-2 Dd2 antibodies was 0.14, 0.22, 0.23 and 
0.31 logio titre reduction per month in the 1st, 2nd, 3rd and 4th cord quartiles, respectively 
(Figure 6.3 F). Although the general trend was towards a decline in cord blood titres over the 6  
months follow-up period, infants with low titres o f M SP-119 and PfKh2 exhibited a boost in 
titres as opposed to a decline and hence the negative decay rates shown in Figure 6.3 N  and P.
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T h e  d e c a y  ra te s  a n d  9 5 %  C Is  o f  c o rd  b lo o d  t i tres  (o n  the  y -a x i s )  a c c o r d i n g  to  th e  d i f f e r e n t  q u a r t i l e  lev e ls  
( o n  the  x -a x i s )  a re  s h o w n  fo r  th e  a n t ig e n s  te s ted  (B )  A M A 1  ( F V O ) ,  (D )  AIY1A1 (3 D 7 ) ,  (F )  M S P - 2 ( D d 2 ) ,  
(H )  M S P - 2 ( C H  150 /9 ) ,  (J )  M S P - 3 ( 3 D 7 ) ,  (L )  M S P - 3 ( K 1 ) ,  (N )  M S P - 1 19 a n d  (P )  P /R U 2 . P v a lu e s  < 0 .0 5  
in d ic a te  d i f f e r e n c e s  b e tw e e n  re g re s s io n  c o e f f ic i e n ts  ( d e c a y  ra te s )  th a t  w e re  s ta t i s t i c a l ly  s ig n i f i c a n t .
2 2 0
6.3.6 Comparison of maternally transferred antibody titres in children who subsequently 
acquired asymptomatic parasitemia and those who remained uninfected during the first 
six months of life
To determine whether susceptibility to asymptomatic infections during the first six months o f 
life could be explained by the levels o f  maternally transferred antibodies, median cord blood 
IgG levels against a panel o f  merozoite antigens were compared in children who acquired 
infections (N=10) and those who remained uninfected during this period (N=120). There was a 
trend towards higher median cord blood IgG titres in children who acquired asymptomatic 
infections compared to those who did not (Figure 6.4.1) and this was o f  borderline 
significance for anti M SP-119 antibodies (Figure 6.4.1G). I also hypothesized that the rate o f 
decay o f maternal antibodies after birth could potentially define the duration o f  protection in 
infants and therefore compared antibody half-lives for children who acquired asymptomatic 
infections and those who remained uninfected during the first six months o f life. There was no 
significant difference in median antibody half-lives in the two groups o f  children for all 
antigens tested (Figure 6.4.2) suggesting that the longevity o f  maternal antibodies in these two 
groups does not influence susceptibility to asymptomatic infection.
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Figure 6.4.1. C o rd  b lo o d  a n t ib o d y  leve ls  a g a in s t  (A )  A M A l ( F V O ) ,  (B )  A M A 1 ( 3 D 7 ) ,  (C )  
M S P - 2 ( D d 2 ) ,  (D )  M S P - 2 ( C H  150/9) ,  (E )  M S P - 3 ( 3 D 7 ) ,  (F )  M S P - 3 ( K 1 ) ,  (G )  M S P - 1 , 9 an d  
(H )  / 5/R h 2  in c h i ld re n  w h o  s u b s e q u e n t ly  a c q u i r e d  in f e c t io n s  ( s q u a re s )  a n d  th o s e  w h o  d id  
no t  ( c i rc le s ) ,  d u r in g  s ix  m o n t h s  o f  f o l lo w -u p .  H o r iz o n ta l  red  lines  r e p r e s e n t  th e  m e d ia n  
a n t ib o d y  level fo r  b o th  g ro u p s .  P v a lu e s  in d ic a t in g  th e  s ig n i f i c a n c e  level  f o r  c o m p a r i s o n s  
b e tw e e n  g r o u p s  a re  s h o w n  o n  to p  o f  e a c h  g ra p h .
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Figure 6.4.2. S c a t te r  p lo ts  o f  th e  d is t r ib u t io n  o f  in d iv id u a l  a n t ib o d y  h a l f - l iv e s  to  (A )  
A M A l ( F V O ) ,  (B )  A M A 1 ( 3 D 7 ) ,  (C )  M S P - 2 ( D d 2 ) ,  (D )  M S P - 2 ( C H 1 5 0 /9 ) ,  (E )  M S P -  
3 (3 D 7 ) .  (F )  M S P - 3 ( K l ) ,  (G )  M S P - I 19 a n d  (FI) P fR h 2  in c h i ld re n  w h o  s u b s e q u e n t ly  
a c q u i r e d  in fe c t io n s  ( s q u a re s )  an d  th o s e  w h o  d id  n o t  (c i r c le s )  d u r in g  s ix  m o n t h s  o f  f o l lo w -  
up. M e d ia n  a n t ib o d y  h a l f - l iv e s  a re  s h o w n  as  h o r iz o n ta l  red  lines. P v a lu e s  in d ic a t in g  the  
s ig n i f i c a n c e  level fo r  c o m p a r i s o n s  b e tw e e n  g r o u p s  a re  s h o w n  on  to p  o f  e a c h  g ra p h .
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6.3.7 Comparison of maternally transferred antibody titres in children who subsequently 
developed severe malaria during the first six months of life and those who did not
For all antigens tested, the median antibody levels in cord blood were lower in children who 
subsequently developed severe malaria (severe malaria cases) during the first six months o f 
life compared to those who did not (controls) (Figure 6.4.3). The median levels were 
significantly higher in controls compared to cases for AMA1 alleles (p=0.012 and 0.016 for 
AMA1 (FVO) and AMA1 (3D7) antibodies, respectively) (Figures 6.4.3A and 6.4.3B). In 
contrast, the median antibody half-lives were significantly higher in severe malaria cases (3.2 
months and 3.04 months) compared to controls (2.6 months and 2.6 months) for AMA1 (FVO) 
and AM Al (3D7) alleles, respectively (Figures 6.4.4A and 6.4.4B). These results corroborate 
the earlier findings shown in Figure 6.4.3 that high maternal antibody titres have a shorter half 
life than relatively lower titres. There was no significant difference in antibody half-lives 
between cases and controls for the other antigens tested (Figure 6.4.3 C to H).
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6.3.8 M atern a l antibodies and  subsequen t risk  o f acqu iring  asym ptom atic infection o r 
developing severe m ala ria  du rin g  the firs t two years o f life.
As demonstrated in chapter 5, merozoite-specific antibodies in cord blood were detectable in a 
large proportion o f infants (94% and 93% for AMA1 FVO and 3D7 respectively, 8 8 % and 
85% for MSP-2 Dd2 and C H I50/9 respectively, 69% and 6 6 % for MSP-3 3D7 and K1 
respectively, 46% for M SP-119 and 34% for 7yRh2). For this cohort o f  infants, cord blood 
titres had a half-life ranging between 1 -  3 months for most antigens tested and I therefore 
reasoned that these antibodies were likely to be protective only during the first six months o f 
life although other studies have looked at longer periods o f  follow-up upto 1 year o f  age 
(Table 6.1). In order to determine the role o f  these antibodies in infant protection against 
asymptomatic infection and severe malaria during the first six months o f  life and in 
comparison over the first two years o f  life, a logistic regression model was used to compare 
the odds o f acquiring an infection during the first six months o f life in children who had 
antibodies and those who did not. For this analysis, two cutoffs were applied: (i) a seropositive 
cutoff defined by the mean + 3SD o f twenty European plasma; and (ii) a threshold cutoff 
defined in two independent study sites as the dichotomization point that gave the best model 
fit as defined by the least log likelihood ratio (Murungi et al. 2013, Rono et al. 2013). These 
levels were 55AU for AMA1, 19AU for MSP-2, 16AU for MSP-3 (3D7) and 59AU for MSP- 
119 Threshold levels for PJRh2 have not yet been defined. The association between 
transplacentally acquired antibodies and protection against infection during the first two years 
o f life was also evaluated.
Based on the cutoff o f seropositivity, none o f the children who were seronegative for AMA1
and MSP-2 alleles acquired asymptomatic infections during the follow-up period compared to
8-9% who were seropositive but subsequently acquired an infection (Table 6.5.1). Similarly,
for the remaining antigens, presence o f specific-antibodies was associated with an increased
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risk o f acquiring an infection during the first six months o f  life in multivariate analysis (OR 
4.54(0.53-38.58, p=0.16, OR 5.27(0.62-44.34) p= 0.12 and OR 1.94(0.47-7.96), p=0.35 for 
MSP-3(3D7), MSP-3(K1) and M S P -I19), respectively (Table 6.5.1). Assessment o f the role o f 
these antibodies in protection against infection during the first two years o f  life also revealed 
an increased risk o f acquiring infections in children who were seropositive compared to those 
who were seronegative (OR 1.24(0.14-10.96), p=0.84, OR 1.46(0.16-12.65), p=0.73, OR 
3.49(0.95-12.86), OR 4.25(1.16-15.50), p=0.02 and OR 1.38(0.53-3.58), p=0.50 for 
AM A l(FVO ), AM A1(3D7), MSP-3(3D7), MSP-3(K1) and M SP-1 , 9 respectively (Table 
6.5.2). These results suggest that antibodies present in cord blood are a marker o f exposure in 
this group o f  children although the estimates were not statistically significant. There was a 
trend towards a reduced risk o f  acquiring an asymptomatic infection in children who had 
antibodies to P/Rh2 during the first six months or two years o f  follow-up (OR 0.42(0.08-2.14), 
p=0.30 and OR 0.44(0.15-1.24), p=0.12), respectively, but the estimates were not statistically 
significant.
The level o f antibodies present in cord blood plasma were above the proposed thresholds 
associated with protection against clinical episodes o f  malaria in 1 1 % and 8 % o f infants in this 
birth cohort for AMA1 (FVO and 3D7, respectively), 25% and 35% for MSP-2 (Dd2 and 
CH150/9, respectively) and 23% and 25% for MSP-3(3D7 and K l, respectively). However, 
these antibodies were associated with a non-significant increase in susceptibility to 
asymptomatic infections suggesting that they are markers o f exposure to infection (OR 
1.19(0.13-10.86), p=0.87, OR 1.78(0.19-16.12), p=0.60, OR 1.03(0.19-5.38), p=0.97, OR 
1.17(0.24-5.57), p=0.84 and OR 3.56(0.55-22.76), p=0.17 for AMA1 (FVO), AM A1(3D7), 
MSP-2(Dd2), MSP-2(CH150/9) and M S P -I19, respectively). There was a trend towards 
reduced risk in children who had antibodies above the threshold level to MSP-3 (K l) , OR 
0.39(0.04-3.57), p=0.40 but the estimates were not significant (Figure 6.5.1). In analyses o f
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two years o f follow-up from birth, presence o f antibodies above the threshold was associated 
with increased risk o f  acquiring an infection for all antigens tested (OR 1.88(0.47-7.47), 
p=0.36, OR 1.34(0.25-7.18), p=0.72, OR 1.73(0.63-4.77), p=0.28, OR 2.62(0.99-7.02), 
p=0.84, OR 0.96(0.30-3.06), p=0.94, OR 1.52(0.52-4.39), p=0.43 and OR 0.77(0.14-3.99) 
p=0.75 for AMA1 (FVO), AMA1 (3D7), M SP-2(Dd2), MSP-2(CH150/9), MSP-3(3D7), 
MSP-3(K1), P/Rh2 and MSP-1 !9, respectively (Table 6.5.2).
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6.3.9 Maternal antibodies and subsequent risk of developing severe malaria during the 
first two years of life.
Further analysis o f infant protection by maternal antibodies during the first six months o f life 
revealed a non-significant reduction in risk o f  developing severe malaria in children who had 
antibodies above the seropositivity cutoff to MSP-3(3D7), MSP-3(K1) and PfRh2 (OR 0.52 
(0.07-3.71), p=0.52, OR 0.58 (0.08-3.96), p=0.58 and 0.61 (0.06-5.82), p=0.67; respectively) 
(Table 6.6.1). Similarly, over a longer period o f follow-up (up to 2 years), antibodies to 
AMA1, MSP-3 and M S P -I19 were also associated with a reduction in risk o f developing 
severe malaria but the estimates were not statistically significant (Table 6.6.2). None o f  the 
children that had antibodies above the threshold levels to AMA1 alleles and MSP-2(Dd2) 
developed severe malaria (Table 6.6.1). Children who had cord blood titres above the 
threshold cutoffs for M SP-2(CH 150/9), MSP-3(3D7) and MSP-3(K1) had an increased 
susceptibility o f developing severe malaria during the first six months o f life suggesting that 
these high antibody titres were acting as markers that could identify children who had higher 
exposure to P f  infections and were therefore also more likely to develop severe malaria, (OR 
2.07 (0.19-22.61), p=0.55, OR 15.00 (1.63-37.96), p=0.017, OR 3.00 (0.27-32.58), p=0.36), 
respectively (Table 6.6.1). Similar findings were also observed when children were followed 
up to 2 years o f age (Table 6.6.2)
236
Ta
bl
e 
6.
6.
1.
 T
he
 
pr
ot
ec
ti
ve
 
ef
fe
ct
 
of
 
sp
ec
if
ic
-a
nt
ib
od
ie
s 
ag
ai
ns
t 
de
ve
lo
pm
en
t 
of
 
se
ve
re
 
m
al
ar
ia
 
du
ri
ng
 
the
 
fi
rs
t 
six
 
m
on
th
s 
of 
lif
e.
 
A
na
ly
se
s 
ar
e
o
o oo
0
01
o
001 
NO
O l
O oo
o o
CNoi■o o oo
Ol
Cl
c l CN
oo o
o
tj-
oi
A o
o
I Cn O  Cn
® d  o
OO ^  O '>0) 0 0  
d o  do o
NO
d TOo o
^  Ti "  T  2—; o O Tf
d o’ ( 3  d
— noco of
d d
o
d o
Ol
do o
o■'3- o
Cl
-a
S£ O TO'O
Oo o■a
0
ON
01
CL
Ol
oi
o
dTO
■a
TO
_o
<u
TO
o
p
on
o
TO<U
TO
TO<u
O-coOl
TO1>
a>
TO
d
Z
Q
-X-
Ta
bl
e 
6.
6.
2.
 
Th
e 
pr
ot
ec
ti
ve
 
ef
fe
ct
 
of
 
sp
ec
if
ic
-a
nt
i 
bo
di
es
 
ag
ai
ns
t 
de
ve
lo
pm
en
t 
of
 
se
ve
re
 
m
al
ar
ia
 
du
ri
ng
 
th
e 
fir
st
 
tw
o 
ye
ar
s 
of
 
li
fe
.
o
32
o
T3
r “
S3
>.
>
Q .
O
s
C/2
>."O
o
-C
S3-O
s—
S3
C/20/
C/2
S3
<
(N
m in cn
p  oo r! . h  4  oo
_  ON o  (N fp
C3 o  o O o o
o  
d
CNO
on  o
00 do  d  °  d
cn d(N tj-O )
d o
o
ON
lA ^
«  ^  dd 3  o
£  ^
°  d  °  d o
o _C2
—
ON
OoON o
ON
o
ON
O
ON
O
ONON
O ON
ON
o
ON
G .
VO VO
©
oi —^  i 1 '^  so ~  OO
^  ON ' P  ON
o d  ® d
©
onON ON
cn hi ^in t  oo N  io)
d  d <~’ d  !—’
O 'o  i>
— d
vo _ r--
d  d <= o-!0f
O
d oo o
ON
OX)o
vn VO i in
M 3  £  r !
S  °  d  °
CN o s  ,~ l
3  o n  ' P
o  d  °
o
o o
o
o oo
oON
oON
OON O
ON
ON ON
ONON ON
-s oo o
© oON
ON
o
ON
o
ON
Oi)o
-a<uc
-o
o
Z
d
z
6.3.10 Relationship between breadth of responses and protection against asymptomatic 
infection and severe malaria during the first six months of life
The breadth o f  anti-merozoite responses present in cord blood plasma was compared between: 
i) infants who subsequently got asymptomatic infections during the first six months o f  life and 
those who did not (Figure 6.5 A); and ii) infants who subsequently developed severe malaria 
during the first six months o f  life and those who did not (Figure 6.5 B). Cord blood plasma 
from a large proportion o f  children who acquired asymptomatic infections (90%) recognized 
three or more antigens compared to children who did not acquire asym ptom atic infections 
(75%) suggesting that antibody breadth was a marker o f  exposure in this group o f  infants. 
Also noted was that all the children who acquired asymptomatic infections had responses to at 
least two antigens or more (Figure 6.5 A). In contrast, only 40%  o f  the children who 
developed severe m alaria recognized three or more antigens compared to 77% o f  the children 
who did not develop severe malaria suggesting that antibody breadth could be protective 
against development o f severe malaria (Figure 6.5 B). It was not possible to determ ine the 
protective efficacy according to different levels o f  antibody breadth due to the very small 
numbers obtained in the sub group analysis.
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F igure 6.5 The breadth o f anti-merozoite antibody responses in cord blood plasma samples from children 
who acquired asymptomatic infections during the first six months o f  life versus those who did (A) and 
from children who developed severe malaria during the first six months of life versus those who 
remained disease free (B). A total o f  five antigens (A M A f  MSP-2, MSP-3. P fR h l  and M SP-1 19) were 
tested. Black, light grey, dark grey, white and shaded bars represent the proportion o f  individuals 
responding to 0. 1, 2. 3 and >4 antigens, respectively.
6.4 Discussion
In this chapter, 1 have evaluated the role o f  the concentration o f transplacentally acquired 
antibodies against merozoite antigens in protection against acquisition o f  infection and 
development o f  severe malaria during the first six months o f life and also extended the 
analysis to a follow up of up to two years o f  age. The analyses are based on a limited sample 
set o f  one hundred and thirty cord blood plasma samples and a very small proportion o f
children acquiring infections or developing severe malaria during the first six months o f
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follow up (7.6% and 4.1%, respectively) therefore lacking adequate statistical power to detect
significant differences and at best only able to infer trends from the data.
The prevalence o f transplacentally acquired antibodies against m erozoite antibodies in this
cohort o f  infants was high and com parable to what has previously been reported for AM A1,
and M SP-2 (Riley et al. 2000) but m uch lower for M SP-119 compared to other studies (Hogh et
al. 1995, Kitua et al. 1999), suggesting that M SP-1 19 is not very im munogenic in this
population. Infants who were seropositive for the panel o f  antigens tested had an increased risk
o f  acquiring asymptomatic infections during the first six months o f  life, a period in which
maternal antibodies are more likely to persist and also when the analysis was extended to a
longer period o f  follow-up o f  2 years o f  age. Similarly, a greater proportion o f  children who
subsequently got infected had responses to a broader range o f the m erozoite targets tested.
These results therefore suggest that maternally acquired anti-merozoite antibodies are markers
o f  exposure to infection and predict the likelihood o f  acquiring asymptomatic infections in the
first two years o f life. These findings are consistent with most studies showing lack o f
protection by maternal antibodies against malaria antigens in children followed up for upto 6
months (Riley et al. 2000, Riley et al. 2001) or one year o f  age (Achidi et al. 1996, Hogh et al.
1995, K itua et al. 1999). In contrast, only one study has demonstrated a protective role for
maternal M SP-119 IgG in prolonging the time to first infection in infants followed up for up to
one year o f  age (Branch et al. 1998). A lthough I did not detect any differences in directionality
o f  odds ratio estimates between analyses conducted when maternally derived antibodies would
be expected to play a protective role ( 6  months o f  life) and when extended beyond this period
(2 years o f age), I would argue that studies should take into account the precise duration over
which these antibodies are likely to persist in the infant. However, thus far, there has been a
paucity o f  such data and I have, to the best o f  my knowledge, provided the first description o f
half-life estimates o f  m aternally transferred anti-m erozoite IgG. Furthermore, regardless o f  the
few previous descriptions o f the short duration o f  maternal antibodies in term s o f  the tim e it
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takes for the levels to fall to a minimum level, which ranges across studies between 2 months 
(Kitua et al. 1999), 14 weeks (Riley et al. 2000) and 4-6 months (Achidi et al. 1996), many 
studies have continued to assess the protective efficacy o f  maternal antibodies for up to 1 year 
o f  age (Kitua et al. 1999, Branch et al. 1998, Hogh et al. 1995).
T have previously described threshold concentrations o f  anti-m erozoite antibodies associated 
with a reduced risk o f  developing clinical episodes o f  malaria (M urungi et al. 2013, Rono et al. 
2013). Although these thresholds were specifically defined for clinical episodes o f  malaria as 
an endpoint o f  interest (and were not defined with maternally acquired antibodies but a child’s 
own naturally-acquired antibodies), I explored whether these exact cutoffs as measured in cord 
blood could also be important for protection against infection and developm ent o f severe 
m alaria in infants. However, I found no evidence o f  their role in protection against infection 
and severe malaria. From these findings, it is plausible that the threshold levels against the 
different outcomes o f  an infection are different but this remains to be dem onstrated in a bigger 
study with adequate cases o f  severe malaria and an adequate num ber o f  individuals with 
asymptomatic infections.
I have also demonstrated, to my knowledge, the first investigation o f  the role o f  these
antibodies in protection against severe malaria during the first six months o f  life and also
extended the analysis to two years o f age and showed that maternal antibodies against MSP-3
alleles and PjRh2 conferred a reduced odds o f  developing severe malaria, whereas AMA1 and
MSP-2 antibodies were associated with an increased odds. However, the estim ates were not
statistically significant and the odds o f developing severe m alaria in children aged less than six
months in this population was very low (3.8%), as previously described in an early study
(Snow et al. 1998). When the analysis was extended to two years o f  follow-up, AM A1, M SP-
3(3D7) and PJRh2 antibodies showed a trend towards reduced odds o f developing severe
malaria. These findings, together with the observation that children who developed severe
malaria generally had lower cord blood antibody levels and also had a narrower breath o f
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responses compared to children who did not develop severe malaria, suggest that these 
antibodies could be protective but the very small numbers in this study precluded a conclusive 
analysis o f  their protective efficacy.
The kinetics o f  decay o f maternal antibodies to the antigens tested was also examined in detail 
and was generally shown to decline to ha lf the original concentration within 1.5 months to 3 
m onths to most antigens tested with the exception o f  an ti-M S P-li9 and P /R h2 antibodies 
which declined at a much slower rate, up to 34 months. Antibodies to the different antigens 
declined to a median o f  10% - 1% o f  initial levels by six months o f  age. A lthough previous 
studies have not described the duration o f  persistence o f  maternal in term s o f  the antibody 
half-life or rates o f  decay, my findings are consistent with what was shown, that maternal 
antibodies have a m edian duration o f  14 weeks (range 6-22) (Riley et al. 2000). M oreover, the 
antibodies fall to minimal levels by 4 months to 10 months o f  age (Achidi et al. 1996, Sehgal, 
Siddjiqui and Alpers 1989, Riley et al. 2001), although one study showed a much shorter 
duration o f  persistence o f  two months (Kitua et al. 1999). I also observed that antibody decay 
rates were inversely proportional to the initial titres present in cord blood, a finding which was 
in contrast to a study by Riley et a l,  showing that cord blood antibody titres in Ghanaian 
infants persisted for a long duration in infants who had high antibody levels at birth (Riley et 
al. 2000). However, other studies have shown that maternally transferred antibodies to viral 
antigens, declined rapidly in children with high titres at birth (Cloonan et al. 1970, C loonan et 
al. 1971) suggesting that children with moderate to low initial antibody titres would be 
protected for a longer duration in comparison to those with high antibody titres at birth. 
Similarly, following acute malaria infection in children, m erozoite-specific IgG subclasses 
were boosted to high levels and displayed a more rapid decline than the theoretical half-life 
given for these antibodies (Kinyanjui et al. 2007). These data have important im plications for 
malaria vaccines administered in infants. If  these vaccines potentially protect by inducing high
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titre antibodies and yet are expected to wane very rapidly following immunization, they would 
require constant boosting during infancy to maintain their levels.
Other factors that may influence the levels o f transplacentally acquired m erozoite-specific 
antibodies were also investigated and, sim ilar to a previous observation (Achidi et al. 1996), 
antibody concentrations measured in cord blood were not associated with parity, m aternal age, 
birth weight or residential location but with previous cumulative exposure to infection by the 
mother. In contrast, other studies have shown that parity (M ayor et al. 2011, Ricke et al. 2000) 
and placental infection (M ayor et al. 2011) are associated with increased levels o f  total IgG to 
CSA and m erozoite antigens, respectively. The unavailability o f data on placental infection, 
intermittent preventive treatment during pregnancy, use o f insecticide treated nets and 
gestational age at delivery was a m ajor limitation o f  my study. These factors have been shown 
to influence levels o f  malaria-specific antibodies in pregnancy, which in turn contributes to the 
titres transferred from the mother to the infant.
In summary these data show that maternally transferred antibody concentrations do not 
account for the immunity against severe m alaria and asymptomatic infections observed during 
the first six months o f  life. Further investigation to; i) determine the role o f  other factors such 
HbF present in young infants, acting in cooperation with cord blood antibodies that could 
mediate protection; ii) determine the role o f other antibody specificities such as IgG subclasses 
and antibody function and; iii) determine the role o f  less well-studied antigens in protection, 
could potentially contribute to our understanding o f  the mechanisms associated w ith immunity 
to m alaria early in life.
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CHAPTER SEVEN
The role of antibody-mediated effector functions in protection against severe malaria
7.0 Introduction
Functional immunoassays are important tools used to prioritize antigens for developm ent and 
testing in vaccine trials. For the well-studied merozoite antigens, antibodies that may be 
important in clearing parasites (Cohen et al. 1961, Sabchareon et al. 1991) have been shown to 
act by: i) blocking merozoite dispersal after schizont rupture (Green et al. 1981); ii) blocking 
m erozoite invasion into red blood cells (Blackman et al. 1990, Kocken et al. 2002); or iii) 
inhibiting replication within the infected red blood cell (Locher et al. 1996) in in vitro 
experiments. The relative contribution o f these mechanisms to clinical protection in human 
studies is however less clear.
In vitro invasion assays and growth inhibition activity assays (IIA and GIA) are widely used to 
measure the ability o f  antibodies induced following vaccination or those acquired naturally, to 
block invasion and limit multiplication o f  laboratory adapted isolates or transgenic parasite 
lines expressing specific merozoite antigens. Interestingly, GIA is detectable in children aged 
less than five years o f  age and either declines or remains stable with increasing age (Duncan, 
Hill and Ellis 2012, M arsh et al. 1989, Dent et al. 2008, M cCallum et al. 2008, Bejon et al. 
2011a, Courtin et al. 2009) which is paradoxical to the observed age-related increase in 
antibody titres to most blood-stage antigens. The studies that have measured GIA in children 
under the age o f five years have found variable median GIA levels, for instance, in a study 
conducted in Western Kenya, the median GIA levels against three laboratory isolates and one 
field isolate in children aged less than 12 months were less than 20% (W ilson et al. 2013). In 
another study, the mean GIA level in children aged 2-4 years was 60% (M cCallum  et al. 2008)
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and the levels were even higher in a separate study which reported 70% GIA in children aged 
1-4 years (Dent et al. 2008). Despite the demonstration that young children have antibodies 
that mediate GIA, it has been inconsistently associated with protection from uncomplicated 
clinical episodes o f malaria or parasitization (reviewed in (Duncan et al. 2012)). Furthermore, 
no study so far has examined the contribution o f  GIA to protection against severe episodes o f 
malaria. Antibodies that mediate GIA are acquired at a time when children are at a risk o f  
developing severe m alaria and it remains to be determined w hether GIA may be protective in 
this group o f  children.
For the widely tested m erozoite candidates, such as AMA1 and MSP-1, antibodies with potent 
GIA are efficiently induced following immunization in vaccine trials (M alkin et al. 2005, 
M ullen et al. 2008) and the assay continues to form the basis for screening the biological 
activity o f antibodies induced by novel blood stage antigens (Douglas et al. 2011, Bustam ante 
et al. 2013, Reddy et al. 2014). However, trials o f  the most promising blood-stage candidates 
tested in endemic populations have not proven efficacious (Ogutu et al. 2009, Thera et al. 
2011) and protection, if  observed at all, was predominantly strain-specific. These findings 
therefore raise the concern whether GIA serves as an accurate assay for prioritizing vaccine 
candidates for testing in endemic populations. Furthermore, individuals continuously exposed 
to infection acquire antibodies that can interfere with the biological activity o f  neutralizing 
antibodies (M iura et al. 2008b). There is therefore a need to develop and evaluate other 
functional assays that better predict protection in malaria exposed individuals, in order to 
hasten the down-selection o f  antigens to put forward for clinical testing in endemic 
populations.
The interaction between antibodies and monocytes and/or neutrophils via Fc receptors 
expressed on these cells has also been shown to clear circulating parasites either by triggering 
the release o f  toxic molecules (Allison and Eugui 1983, Clark and Hunt 1983), soluble
mediators (Bouharoun-Tayoun et al. 1995) or prom oting phagocytic uptake and destruction by 
these cells (Khusmith, Druilhe and Gentilini 1982, Khusmith and Druilhe 1983, Celada, 
Cruchaud and Perrin 1983, Hill et al. 2012). Assays have been developed that m easure the 
effector function o f  antibodies in cooperation with m onocytes (antibody-dependent cellular 
inhibition -  ADCI assay and opsono-phagocytic assay), or neutrophils (antibody-dependent 
respiratory burst ADRB assay) in order to evaluate the importance o f  these m echanisms in 
predicting in vivo protection. Naturally-acquired antibodies against MSP-1 block 2 (Galamo et 
al. 2009), MSP-3 (Oeuvray et al. 1994), GLURP (Theisen et al. 1998), SERA (Soe et al. 2002) 
and those induced following immunization with MSP-3 (Druilhe et al. 2005) have been shown 
to induce ADCI by monocytes. However, this assay has not been w idely adopted by m any 
laboratories and its importance as a correlate o f  protection in longitudinal studies o f  naturally 
acquired immunity to malaria, has not been established.
Recently, a reproducible, high throughput opsono-phagocytic assay in the presence o f  immune 
sera and merozoites has been developed (Hill et al. 2012) and shown to be strongly associated 
with protection against uncomplicated clinical episodes o f  malaria and high-density 
parasitem ia in Papua New Guinean children (Hill et al. 2013). A similar study conducted at the 
coast o f  Kenya has also shown that children with antibodies that promote opsono-phagocytosis 
have a significantly reduced risk o f  developing uncomplicated m alaria (Osier et al. 2014a). 
These findings however remain to be tested against the clinical endpoint o f  severe episodes o f 
malaria.
In a study conducted in Gabon, the ability o f  neutrophils to release high levels o f  potent 
reactive oxygen species (ROS) was correlated with enhanced parasite removal in children 
acutely infected with malaria (Greve et al. 1999). On the other hand, the same group also 
showed a correlation between severe m alaria anemia and the levels o f  ROS produced by 
granulocytes (Greve et al. 2000) suggesting that ROS production could also have a detrim ental
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effect to the host. In their study Greve et a l ,  did not assess the interaction between opsonising 
antibodies and neutrophils in prom oting ROS release as a mechanism o f  protection, but in a 
recent study conducted in Senegalese children, an important role o f  ADRB induced by 
merozoites opsonized with human serum in protection against uncomplicated clinical episodes 
o f  m alaria has been dem onstrated (Joos et al. 2010).
Although m erozoite-specific antibodies are present at very low levels in children aged 0-2 
years, the demonstration by several studies that GIA is detectable in some children very early 
in life provided the rationale for examining whether it may be associated with protection 
against episodes o f  severe m alaria during the first two years o f  life. I also adapted the ADRB 
assay described by Joos et a l  (Joos et al. 2010) and assessed its role in protection against 
severe m alaria in infants. The importance o f these mechanisms in acquisition o f  immunity 
against severe malaria in this age group has not yet been demonstrated.
7.1 Objectives
1. To develop and validate the ADRB assay for screening plasma samples obtained from 
children aged 0-2 years and adults resident in Kilifi County.
2. To examine the acquisition o f  antibodies that m ediate ADRB activity in young 
children and assess the role o f  this m echanism  in protection against severe m alaria 
during the first two years o f  life.
3. To compare the growth inhibition activity o f  plasma samples obtained from children 
aged 0-2 years and adults resident in Kilifi County using two methodologies.
4. To examine the acquisition o f  growth inhibitory antibodies in young children and 
determine their association with protection against severe malaria during the first two 
years o f  life.
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7.2 Methods
7.2.1 Serum samples
A total o f  one hundred and ninety five serum samples collected during the three-m onthly 
follow-up visit immediately prior to the disease episode from cases (N=59) and from 
corresponding matched controls who never developed severe m alaria (N=136) were evaluated. 
A panel o f sera from seventy five adults enrolled during cross-sectional surveys conducted in 
Decem ber 2007 (N=25) and Decem ber 2009 (N=50) were also tested in parallel to compare 
responses in adults and infants as described in Section 2.2.3.
7.2.2 GIA and ADRB assays
GIA activity against the 3D7 laboratory adapted parasite line was tested in one or two growth 
cycles as described in the methods chapter (Section 2.3.2.5.1). Polym orphonuclear cell 
respiratory burst induced by parasitophorous vacuole enclosed merozoite structures (PEM S), 
isolated from 3D7 parasites opsonized with plasma from adults and children, was also tested 
as detailed in the methods chapter (Section 2.3.2.5.3).
7.2.3 Statistical analysis
The M ann-W hitney U test was used to compare levels o f  GIA and ADRB in the cases versus 
controls or in infants versus adults. The Kruskal-W allis test was used to com pare continuous 
variables between more than two groups. Spearm an’s rank correlation coefficients were used 
to determine the relationship between two continuous variables. According to the STROBE 
recommendations (www.strobe-statement.org), information for cases and controls should be 
given separately when reporting findings o f  case-control studies and therefore com parisons o f
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cases and controls are reported separately in this chapter. A conditional logistic regression 
model was used to compare the odds o f  developing severe malaria in children who either had 
GIA or ADRB to that o f  not developing severe malaria. A P value <0.05 was considered 
statistically significant.
7.3 Results
7.3.1 ADRB assay development
W hile the ADRB assay has been well described previously and optimized for large scale 
testing (Joos et al. 2010), inherent variability between laboratories in i) m erozoite isolation, 
purification, yield and quantification techniques, and ii) donor-dependent activity and yield o f 
neutrophils necessitated independent optimization. Here, I sought to: -
a) Determine an optimal merozoite isolation technique that gave high ADRB activity and 
large yields o f PEMS suitable for large scale testing.
b) Quantify the yield o f  PEMS obtained and standardize the amount o f  PEM S added in 
individual wells.
c) Test the effect o f  repeated freeze-thawing o f  PEMS on ADRB activity.
d) Examine the effect o f  donor-dependent variability in PM N activity on ADRB activity.
e) Compare ADRB activity using coated PEMS versus PEMS in solution.
f) Determine the optimal coating concentration o f  PEMS.
g) Determine the optimal serum dilution for use in the assay.
h) Assess ADRB inter-assay variability.
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7.3.1.1 A comparison of ADRB activity induced by merozoites isolated using two 
techniques.
First, I compared the ADRB levels obtained using merozoites isolated using two published 
protocols. One protocol yielded parasitophorous vacuole enclosed merozoite structures 
(PEM S) (Salmon, Oksman and Goldberg 2001) whereas the other yielded pure merozoites 
(Boyle et al. 2010). Two PEMS preparations that were isolated on different dates were tested 
in parallel with the pure merozoites. The induction o f  ADRB activity using neutrophils 
isolated from a healthy donor was tested against: i) two Kilifi adult serum samples (F 031 and 
F033), ii) a pool o f  sera from Kilifi adults (PHIS), iii) serum from a donor resident in the UK 
(UK) and iv) a pool o f  sera from donors resident in the UK (UK pool). Results are presented 
as the maximum relative light units (RLU) obtained (absolute RLU values) for every sample 
tested or indexed according to a positive reference serum, which was included each time the 
assay was run (indexed RLU). The positive reference serum was a pool o f  purified IgG 
obtained from Malawian adults (MIG).
There was a significant reduction in ADRB activity in the presence o f non-im m une serum 
(UK and UK pool) compared to immune serum (F031, F033 and PHIS) and this was 
consistent across the merozoite preparations when assessed using the absolute RLU  values 
(Figure 7.1.1a) and indexed relative to the activity o f  M IG (Figure 7.1.1b). The ADRB activity 
obtained using PEMS (blue bars) and pure merozoites (green bars) isolated on the same day 
were higher than that o f  PEMS that had been prepared on a separate day (red bars). In this 
experiment, the number o f  PEMS or merozoites added to each well was not quantified and this 
could also explain the differences in ADRB activity.
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F igure 7.1.1 ADRB activity induced by three different merozoite preparations against a panel o f  sera. 
Red, blue and green bars represent PEMS (isolated and frozen on 13/7/2011 ), PEMS (isolated and frozen 
on 02/1 1/201 1) and pure merozoites (isolated and frozen on 02/11/201 1). Merozoite opsonised with i) 
sera from malaria exposed individuals resident in Kilifi (F031 and F033), ii) pooled serum from a panel 
o f  malaria-exposed individuals (PHIS), iii) sera from a non-exposed individual resident in the UK (UK) 
and iv) pooled serum from a panel o f  non-exposed individuals (UK pool) were examined. Absolute RLU 
values are shown in (A) and values indexed relative to an IgG pool from Malawian adults (MIG) as 
shown in (B). Individual bars represent the mean o f  duplicates o f  one assay.
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7.3.1.2 Quantifying the number of PEMS isolated and added to individual wells.
To standardize the num ber o f  PEMS added to each well, two PEMS were prepared on separate 
days (2/11/2011 and 16/11/2011) and the num ber o f  schizonts enumerated prior to freezing as 
described in the methods chapter (Section 2.3.2.4). Approxim ately 1.85 x 105 schizonts/ml o f 
each PEMS preparation was added to each well and tested against a panel o f  serum. In parallel 
pure m erozoites isolated as previously described (Boyle et al. 2010) were also tested but I 
could not conclusively enumerate the number o f pure merozoites isolated as outlined by Boyle 
et al., as the m erozoite pellet obtained was very small.
In two separate experiments, there was significant variability in ADRB activity between the 
two PEMS batches (Figure 7.1.2a and Figure 7.1.2b). In Figure 7.1.2a, ADRB activity induced 
by pure merozoites was consistently lower than that o f  the two PEM S preparations but in Fig 
7.1.2b, there was no consistent pattern in ADRB activity between the m erozoite preparations. 
The ADRB activity for individual samples in the second experim ent was relatively lower 
compared to the first experiment. For example, there was a three-fold reduction in ADRB 
activity for sample F033 in the second experiment (0.62 versus 0.23 RLU). In addition, 
reactivity o f  the UK serum pool (HSP) was similar to the malaria exposed serum sam ples in 
both experiments. It was not clear why I was not seeing differences in ADRB activity between 
the malaria exposed and non-exposed samples and the following set o f  experim ents were 
conducted to evaluate the conditions that could explain these findings, w ith the aim  o f 
enhancing ADRB activity o f  m alaria exposed individuals.
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serum from a panel o f  non-exposed individuals (HSP) were examined. The experiments were 
conducted on two separate days (A) 29/11/11 and (B) 13/12/2011
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7.3.1.3 The effect of repeated freeze-thawing on ADRB activity
A possible explanation for reduced ADRB activity by serum from malaria-exposed donors 
could be the degradation o f PEMS as a result o f  repeated freeze-thawing. To test the effect o f  
freeze-thawing on ADRB activity, PEMS were isolated and tested following one, two or three 
freeze-thaw cycles in the presence o f  malaria-exposed (PHIS and Kilifi pool) and non-exposed 
sera (UK and HSP). An aliquot o f  the PEMS was also frozen in glycerol and tested following 
one freeze-thaw cycle. For the Kilifi pool and M IG samples, there was a decrease in absolute 
RLU values with increase in the num ber o f  freeze thaw cycles (Figure 7.1.3a). However, when 
the absolute values were indexed relative to MIG, there was no significant difference in 
ADRB activity induced by PEMS that had undergone one, two or three freeze-thaw cycles 
(Figure 7.1.3b) suggesting that the PEM S were still intact after several freeze thaw  cycles. 
PEMS frozen in glycerol induced a lower respiratory burst. Variability in ADRB activity 
between the two PEMS preparations was also noted in this experiment despite adding a sim ilar 
concentration o f  PEMS in each well.
Although ADRB activity induced by m alaria non-exposed sera was lower com pared to m alaria 
exposed sera, I could not reproduce the high ADRB activity induced by m alaria exposed 
serum as was previously observed in Figure 7.1.1 (indexed RLU values were 0.5, 0.6, 0.5 for 
F031, PHIS and a Kilifi serum pool compared to 1.05, 1.23 1.11, respectively) (Figure 7.1.1 
and Figure 7.1.3).
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Figure 7.1.3. The effect o f  repeated freeze-thawing o f  PEMS on ADRB activity. PEMS were 
isolated and tested in the assay following one (red bars), two (blue bars) and three (green bars) 
freeze-thaw cycles. In comparison, PEMS were frozen in glycerol (orange bars) and tested 
after one freeze-thaw cycle. A batch o f  PEMS tested in a previous experiment (Purple bars) 
was also included to compare ADRB activity from different batches. Two serum pools from 
malaria-exposed individuals (PHIS and Kilifi pool), sera from a non-exposed individual 
resident in the UK (UK) and pooled serum from a panel o f  non-exposed individuals (HSP)
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7.3.1.4 The effect of donor dependen t  variability  on ADRB activity
Next, the variability in ADRB activity by polymorphonuclear cells (PMNs) obtained from 
different donors was examined. PMNs were isolated from three healthy donors and tested in 
the presence o f  a pool o f  IgG from Malawian adults (MIG) and a pool o f  sera from UK adults 
(UK). Two PEMS preparations used in the previous experiment were also tested to compare 
batch to batch variability.
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F igure 7.1.4. ADRB induction by PMNs obtained from different donors. PMNs isolated from 
three individual donors and a pool prepared by mixing the three donor PMNs were tested in the 
assay against two PEMS preparations (PEMS1 and PEMS2) opsonized with IgG from a pool o f  
Malawian adults (MIG) and serum from a non-exposed individual (UK). The absolute values 
(maximum relative light units) are shown in figure (A) and values indexed relative to reactivity o f  
MIG on PEMS I are shown in figure (B).
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Based on the absolute values, there was substantial donor dependent variability in absolute 
RLU values obtained using PM Ns from different donors either against malaria exposed or 
non-exposed serum (Figure 7.1.4a). PMNs from donor 1 had the highest absolute RLU values 
(blue bars) whereas those obtained from donor 3 had the lowest values (green bars) across the 
samples tested. Absolute RLU values obtained using PMNs pooled from the three donors had 
ADRB activity second to PM Ns from donor 1 (Figure 7.1.4a). When the ADRB activity o f 
different PMN donors was examined relative to the activity o f MIG on PEM S 2, there was no 
significant difference between the three donors’ PM Ns for the two serum samples tested 
(Figure 7.1.4b). However, the indexed ADRB activity o f  pooled PM Ns was lower than the 
individual donors’ PM Ns and the difference was significant when compared against donor 2 ’s 
PMNs. Based on these findings, different PMN donors could be used on different days without 
eliciting significant variability in the assay.
7.3.1.5 Comparing ADRB activity of coated PEMS versus PEMS in solution
In order to enhance the ADRB activity induced by m alaria-exposed serum, I next compared 
the reactivity o f  PEMS in solution versus coated PEMS. The rationale for testing this was 
based on previous optimization steps dem onstrating that antigen in solution does not induce 
respiratory burst in the presence o f  immune human serum (David Llewellyn, PhD thesis) and 
mouse sera (Llewellyn et al. 2014).
ADRB activity induced by PEMS in solution, coated PEMS, coated recom binant M S P -119 
protein and ovalbumin (a non-malaria protein) opsonized with m alaria non-exposed (HSP, 
UK1 and UK5) or malaria exposed sera (PHIS and F042) were tested. The level o f  ADRB by 
malaria-specific antigens was significantly lower in malaria non-exposed versus exposed 
adults (Figure 7.1.5). ADRB activity induced by coated PEMS was higher than the reactivity
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of  PEMS in solution suggesting that there is enhanced co-localization o f  Fc receptors on the 
surface of PMNs when PEMS are coated onto the plate as opposed to floating in solution.
HI Mz coat 
c a  Mzsol 
EE MSP1
F igure  7.1.5 A comparison between ADRB activity induced by coated PEMS versus PEMS 
in solution. ADRB activity induced by malaria exposed (PHIS and F042) and non-exposed 
(HSP, UK1 and UK5) sera against PEMS coated onto a plate (red bars), PEMS in solution 
(blue bars), coated recombinant M S P -119 protein (green bars) and ovalbumin (orange bars). 
Values are indexed relative to MIG.
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7.3.1.6 Determ ining the optimal coating concentra tion  of PEM S p repara tions
Having established that PEMS coated onto a plate induce higher ADRB activity compared to 
PEMS in solution, the optimal coating dilution o f  PEMS in the assay was determined by 
titrating PEMS at two doubling dilutions starting at 1.85 x 1 (E schizonts/ml. In the malaria 
exposed serum samples (F008, F042 and F070), the highest ADRB activity was induced by 
PEMS coated at 1.85 x 1(R schizonts/ml (neat PEMS). There was no significant difference in 
ADRB activity by PEMS diluted 10-fold or 20-fold for all samples tested with the exception 
of serum sample F042 (Figure 7.1.6 ).
cm Neat 
m  1:10 
cm  1:20
D-I . _1.5-
Figure 7.1.6 Determining the optimal coating concentration o f PEMS. ADRB activity induced 
by malaria exposed (F008. F042 and F070) and non-exposed (HSP. UK01 and UK05) sera 
against doubling dilutions o f PEMS coated onto a plate. Two-fold doubling dilutions were 
tested starting at 1.85 x 10 schizonts/ml.
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7.3.1.7 Determining the optimal serum dilution
The optimal serum dilution was also determined by titrating a pool o f serum from malaria- 
exposed adults (Kilifi pool) starting at 1:25 to 1:1000 dilution in PBS (Figure 7.1.7). The 
dynamic range o f  serum dilution was between 1:25 to 1:100, therefore a mid-range dilution o f 
1:50 was ideal in this assay to accurately distinguish between responders versus non­
responders.
Kilifi Pool UK
_ i
■o
S e ru m  d ilu t io n
F ig u re  7.1.7. Determining the optimal serum dilution. A pool o f  serum from m alaria 
exposed adults (Kilifi pool) was tested at increasing serum dilutions (1:25 to 1:1000). In 
parallel, the ADRB activity o f  a serum sample from a non-exposed donor was tested at 
1:100 dilution. Values o f  duplicate wells are shown.
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7.3.1.8 Determ ining A DRB inter-assay variability
To assess the level o f  variability when the assays were conducted on different days, a panel of 
sera was tested for induction o f ADRB activity in five separate experiments using neutrophils 
from different donors. There was significant inter-assay variability for most samples tested 
(Figure 7.1.8). Despite this observation, the inherent differences between samples were 
consistent between experiments and with the exception o f sample K6 , the majority o f  the 
malaria exposed individuals were consistently classified as being ADRB positive (based on a 
cutoff o f  mean plus three standard deviations o f the seven UK sera tested across five 
experiments). Only one malaria exposed serum sample was ADRB negative (K4) and this was 
consistent across all the experiments. 6/7 (85%) o f all the malaria non-exposed sera were 
classified as ADRB negative across the five experiments.
2.5-1
Q  Expt 1 
m  Expt 2
□  Expt 3
□  Expt 4 
■ I  Expt 5
F igure 7.1.8 ADRB assay reproducibility. Serum samples obtained from six malaria exposed 
adults (K1 to K6 ), serum and IgG pooled from exposed adults (PHIS and MIG, respectively), 
six serum samples from malaria non-exposed individuals (UK1 to UK 6 ) and a pool o f  serum 
from non-exposed adults (HSP) were assayed on five separate days to assess inter-assay 
variability. The values are indexed relative to a pool o f  IgG from Kilifi adults (PHIS) and
individual bars indicate the mean activity o f  two assay replicates.
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The optimal set o f  param eters established for subsequent experiments were as follows: -
(i) Preparation o f a single PEMS batch sufficient to test all samples in a cohort since I
could not resolve the variability observed when different PEMS batches were tested.
(ii) Coating PEMS onto the plate at 1.85 x 105 schizonts/ml concentration followed by an 
overnight incubation at room temperature.
(iii) Addition o f individual serum samples diluted at 1:50 in PBS and assayed in duplicate.
(iv) Addition o f 50pl o f  5x105 PMNs isolated from different donors.
7.3.2 Comparison of ADRB activity between malaria-exposed children and adults versus 
malaria non-exposed adults
To determine the range o f  responses observed in young children and adults resident in Kilifi 
county, the level o f  ADRB induced by serum from malaria-exposed adults (N=100), infants 
aged 0-2 years recruited into a birth cohort (N=195) and m alaria naive adults enrolled in Phase 
la m alaria vaccine trials at the Jenner Institute (N=13) were compared. There was a significant 
difference in ADRB activity between malaria-exposed adults and children (PO .O O l) and 
between malaria-exposed and non-exposed adults (PO .O O l) (Figure 7.2). How ever no 
significant difference in ADRB activity was noted between malaria-exposed children and 
m alaria non-exposed adults (P=0.376).
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F igure 7.2 Comparison o f  ADRB levels induced by serum obtained from adults resident in 
Kilifi county (dark circles), children aged 0-2 years (dark squares) and malaria naive adults 
(dark triangles). Horizontal red lines indicate the median ADRB level for each group. 
Values are indexed relative to MIG.
7.3.3 Age-specific ADRB activ ity  in in fan ts aged 0-2 years
Overall, the highest median ADRB activity was observed in plasma samples collected from 
infants aged 0-3 months. Thereafter, there was a significant decline in ADRB activity upto 6  
months o f  age followed by a modest but gradual increase with age upto 28 months (Kruskal 
Wallis test; P 0 .0 0 0 1 )  (Figure 7.3a). A similar trend was observed when ADRB activity by 
age was grouped into children who subsequently developed severe malaria during the first two 
years o f  life (Kruskal Wallis test; P=0.334) and those who did not (Kruskal Wallis test; 
P 0 .0 0 0 1 )  (Figure 7.3b).
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Age-specific comparisons o f ADRB activity in cases versus controls revealed no significant 
differences between the two groups although the median ADRB levels were consistently 
higher in the cases compared to controls (Figure 7.3b)
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F igure 7.3. Age-specific ADRB levels in infants aged 0-2 years. The box plots represent (A) the 
overall range o f  responses observed in children grouped into five age categories (0-3, 4-6. 7-12, 13- 
18 and 19-28 months) and (B) responses in children who developed severe malaria during the first 
two years o f  life (grey bars) and their corresponding controls who did not develop severe malaria 
(white bars). ** P-value <0.05.
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7.3.4 C o rre la tio n  betw een A D RB activ ity  an d  an tibody  titre s  ag a in st specific an tigens in 
adu lts
The correlations between ADRB levels and ELISA OD values against AMA1 (HB3), MSP- 
2(Dd2), M SP-3(3D7) and the RO fragm ent o f  GLURP were assessed. For all antigens tested, 
there was a significant positive correlation between ADRB activity and antibody levels 
(correlation coefficients 0.31, 0.39, 0.59 and 0.40 for AMA1 (HB3), M SP-2(Dd2), M SP- 
3(3D7) and GLURP-R0, respectively) (Figure 7.4).
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F ig u re  7.4. Correlation analysis between ADRB levels and antibody titres against (A) AMA1 
(HB3), (B) MSP-2 (Dd2), (C) MSP-3 (3D7) and (D) GLURP-R0 fragment measured in plasm a 
samples collect from adults resident in Kilifi (N=75). Correlation coefficients were determ ined
by Spearm an’s rank test. P<0.05 was considered statistically significant.
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7.3.5 Correlation between ADRB activity and antibody titres to specific antigens in 
children who developed severe malaria (cases) and those who did not (controls).
The correlations between levels o f  ADRB and IgG to specific antigens were determined 
separately for the cases and controls. Plasm a samples collected at the three-m onthly time point 
that was closest to the disease episode for the severe m alaria cases (N=59) and corresponding 
controls (N=147) were analysed. For all antigens tested, there was a positive correlation 
between ADRB activity and antibody titres in the cases (Correlation coefficients 0.67, 0.70, 
0.62, 0.60, 0.18, 0.21 for schizont extract, AM A1, MSP-2, M SP-3, M S P -I19 and P/R h2, 
respectively) and controls (correlation coefficients were 0.57, 0.49, 0.44, 0.33, 0.20, 0.04 for 
schizont extract, AM A1, MSP-2, MSP-3, M S P -I19 and PJPh2, respectively). The correlation 
between ADRB and M S P -I19 and PfRh2 antibodies was weak and not statistically significant 
in both the cases and controls (correlation coefficients were 0.18, 0 . 2 1  in the cases and 0 . 2 0  
and 0.04 in the controls for M S P -I19 and PjPKL antibodies, respectively) (Figure 7.5).
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F ig u re  7.5 Correlation analysis between antibody titres to specific antigens and ADRB 
activity in children who developed severe malaria (cases) versus their corresponding controls. 
Scatter plots show the relationships between titres against schizont extract, AM A1, MSP-2, 
M SP-3, M S P -I19, P /Rh2 and ADRB activity o f  the plasma samples o f  cases (A, C, E, G, I 
and K) and controls (B, D, F, H, J and L), respectively.
7.3.6 C o m p arin g  grow th  inh ib ition  o f P. fa lciparum  3D7 parasites  by hum an  se ra  in a 
one-grow th cycle assay (pLD H  detection) versus a tw o-grow th cycle assay (flow 
cytom etry)
The ability o f  serum obtained from adults resident in Kilifi country (N=75) and children aged 
0-2 years (N=189) to inhibit growth o f  3D7 parasites in vitro was assessed using two 
methodologies: i) flow cytometry analysis o f trophozoite stage parasites stained with ethidium 
bromide after two growth cycles or ii) quantification o f parasite lactate dehydrogenase 
(pLDH) enzyme production after a single growth cycle. GIA levels were significantly higher 
in the 2-growth cycle assay compared to the single cycle assay in serum samples collected 
from the children (median GIA levels were 7.75% and 10.56% by pLDH and flow cytometry, 
respectively) (Figure 7.6.1a). A three-fold increase in median growth inhibition level was also 
noted in the adult samples (median GIA levels o f 6.19% versus 19.98% by pLDFI and flow 
cytometry, respectively) (Figure 7.6. lb).
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F igure  7.6.1 A comparison between GIA levels assessed by measuring pLDH production 
following a single growth cycle (black circles) or flow cytometry analysis o f  ethidium 
bromide stained parasites following two growth cycles (black squares) in (A) a subset o f  KBC 
children aged 0-2 years (N=189) and (B) adults resident in Kilifi county (N=75). Horizontal 
red lines represent the median GIA levels o f  each group.
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The correlation between GIA levels determined either by measuring pLDH production or by 
flow cytometry was determined using the spearm an’s rank test. There was a strong positive 
correlation between GIA activity by both methods in plasma samples collected from children 
aged 0-2 years (correlation coefficient, 0.65, P<0.0001) (Figure 7.6.2a) and adults resident in 
Kilifi (Correlation coefficient, 0.72, PO.OOOl) (Figure 7.6.2b)
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F ig u re  7.6.2. Correlation analysis between growth inhibition determined by m easuring pLDH 
production after one growth cycle (y-axis) or by flow cytometry after two growth cycles (x- 
axis) in plasma samples collected from children aged 0-2 years (A) and adults resident in Kilifi 
county (B). Scatter plots show the correlation between results obtained using the two 
methodologies. The spearm an’s rank test was used to calculate the correlation coefficients.
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A comparison o f  GIA levels by plasma obtained from children, malaria exposed and naive 
adults revealed significantly higher GIA levels in plasma from children compared to malaria 
exposed and naive (UK) adults using pLDH detection after a single growth cycle (Figure 
7.6.3a). In contrast, plasma from malaria-exposed adults elicited a significantly higher median 
GIA level compared to plasma from children and UK adults after two growth cycles (Figure 
7.6.3b)
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Figure 7.6.3 Distribution o f GIA levels o f plasma obtained from adults resident in Kilifi 
County (black circles), children aged 0-2 years recruited into a birth cohort (black squares) 
and malaria naive adults resident in the UK (black triangles). Comparisons between GIA 
assessed by pLDH measurement after a single growth cycle (A) and flow cytometry analysis 
o f  mature parasites after two growth cycles (B) are shown. ** represents P values <0.05.
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7.3.7 Age-spccific grow th  inhib ition  levels in ch ildren  aged 0-2 years.
Comparisons o f GIA levels among children aged 0-2 years revealed no significant difference 
in median GIA levels with increase in age (Kruskal Wallis test; P=0.112) (Figure 7.7a). The 
levels were highest in children aged 0-3 months. A similar trend was also observed when GIA 
levels in the different age groups were categorized into children who developed severe malaria 
(P=0.86) and those who did not (Kruskal Wallis; P=0.07) (Figure 7.7b). The median GIA 
levels between the cases and controls were similar across all age-categories (Figure 7.7b).
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Figure 7.7. Age-specific GIA levels in infants aged 0-2 years. The box plots represent (A) the 
overall range o f responses observed in children grouped into five age categories (0-3. 4-6. 7-12, 
13-18 and 19-28 months) and (B) responses in children who developed severe malaria during the 
first two years o f  life (grey bars) and their corresponding controls who did not develop severe 
malaria (white bars). ** P-value <0.05. Data obtained from the two-cycle GIA.
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7.3.8. Association between GIA and antibody titres against specific antigens in adult 
serum samples
GIA levels obtained from the two growth cycle assay were used to assess the relationship 
between GIA and IgG levels against AMA1 (HB3), M SP-2(Dd2), M SP-3(3D7) and the RO 
fragment o f GLURP protein (GLURP-RO) in adult serum samples. There was a weak and non­
significant association between growth inhibition levels and antibody titres to all the antigens 
tested (correlation coefficients obtained were 0.11, -0.01, 0.01 and 0.02 for AMA1 (HB3), 
M SP-2(Dd2), M SP-3(3D7) and GLURP-RO, respectively, P values >0.05) (Figure 7.8). 
Similar associations were observed using GIA data assessed by quantifying pLDH production 
in a one growth cycle assay (Correlation coefficients 0.03, -0.02, 0.11 and -0.01 for AMA1 
(HB3), M SP-2(Dd2), M SP-3(3D7) and GLURP-RO, respectively, P values >0.05).
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F ig u re  7.8 Correlation analysis between GIA levels quantified by flow cytom etry in a two 
growth cycle assay and antibody titres against (A) AMA1 (HB3), (B) M SP-2 (Dd2), (C) 
MSP-3 (3D7) and (D) GLURP-RO fragm ent measured in plasma samples collected from 
adults resident in Kilifi (N=75). Correlation coefficients were determined by Spearm an’s 
rank test. P<0.05 was considered statistically significant.
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7.3.9 Association between GIA and antibody titres against specific antigens in plasma 
samples collected from children aged 0-2 years.
Serum samples collected from children aged 0-2 years were grouped into those who 
subsequently developed severe malaria (N=59) and those who did not (N=147). Sim ilar to the 
findings in adults (Figure 7.9), the correlation between GIA levels and antibody titres against 
AM A1, MSP-2, M SP-3, M S P -I19 and P/Rh2 was weak and only evident am ong the controls 
(Figure 7.9).
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F igure  7.9 Correlation analysis between antibody titres to specific antigens and GIA activity 
measured in a one growth cycle assay in children who developed severe m alaria (cases) 
versus their corresponding controls. Scatter plots show the relationships between titres against 
schizont extract, AM A1, MSP-2, MSP-3, M S P -I 19, 7^Rh2 and GIA levels o f  the plasma 
samples o f cases (A, C, E, G, I and K) and controls (B, D, F, H, J and L), respectively.
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7.3.10 Correlation between GIA and ADRB
The correlation between the 2-growth cycle assay GIA and ADRB was examined in both 
children and adults. There was no correlation between both assays when examined in serum 
samples collected from the index cases prior to developm ent o f severe malaria (Fig 7.10a) and 
matched controls (Fig 7.10b). Similarly, no correlation between both assays was also observed 
in the adult serum samples (Fig 7.10c).
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Next, the levels o f  ADRB and GIA were examined relative to the num ber o f  antigens that an 
individual made responses to (breadth o f  antibody responses). Only responses to one allelic 
type were examined for each antigen. A total o f  8 children made responses to more than three 
antigens and these were classified as responders to 4&5 antigens. There was no clear trend 
between GIA levels and breadth o f  antibody responses (Kruskal W allis test, P=0.14) (Figure 
7.11a). In contrast the ADRB levels increased with increase in antibody breadth and the trend 
was statistically significant (Kruskal Wallis test, PO .O O l) (Figure 7.1 lb).
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7.3.12 The association between ADRB and GIA and protection against severe malaria 
during the first two years of life
The association between pre-existing antibodies that induce ADRB and/or mediate GIA and 
protection against severe m alaria during the first two years o f life was assessed using a 
conditional logistic regression model. Assays were performed using plasma collected prior to 
the disease episode from cases (N=42) and their corresponding controls m atched on age, 
residence and visit date (N=127). Children were classified as responders in the ADRB assay if 
they achieved levels above the mean plus three standard deviation values o f  thirteen UK adult 
sera. Positive GIA responders were classified as individuals who had GIA levels above the 
median level. Children classified as responders in the ADRB and GIA assays alone had a 
reduced odds o f developing severe m alaria (OR 0.51 95%CI (0.14 -  1.88), p=0.319 and OR
0.55 95%  Cl (0.26 -  1.20), p=0.136), although the estimates were not statistically significant.
A more important and striking observation was that children who had antibodies that mediated 
both mechanisms had a significant reduction in odds o f  developing severe m alaria during the 
first two years o f  life (OR 0.07; 95% Cl 0.006 -  0.82; p=0.035).
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7.4 Discussion
The rapid development o f  blood-stage vaccine candidates has been hampered in part by the 
lack o f suitable pre-clinical screening methods and the prohibitive cost o f conducting vaccine 
trials. The evaluation o f  in vitro functional assays that correlate with in vivo protection (both 
naturally-acquired and vaccine-induced) could accelerate the down-selection o f  potential 
candidate antigens to be put forward for testing in the clinic. The m ost advanced candidate 
antigens that have been tested in malaria endemic areas were partly selected based on the 
ability o f antibodies induced against these antigens to neutralize parasite growth in the widely 
used GIA assay. For example, AM A1, a leading candidate antigen was shown to induce potent 
GIA in Aotas monkeys (Dutta et al. 2009) and in Phase 1 vaccine trials in malaria naive adults 
(Polhemus et al. 2007). However, the vaccine only conferred strain-specific efficacy when 
tested in children living in a m alaria endemic area (Thera et al. 2011) raising the question 
whether this assay serves as an accurate correlate o f  protection in individuals continuously 
exposed to multiple parasite strains.
Similarly several immuno-epidemiological studies correlating GIA with protection have 
yielded conflicting results (reviewed in (Duncan et al. 2012)), although there is considerable 
heterogeneity in the GIA methodologies utilized, transm ission intensities in different settings, 
age groups tested and outcome measures examined. Here, two GIA assay m ethods were 
assessed to confirm whether, in my study, the GIA assay methodology and num ber o f  growth 
cycles, (factors which potentially influence the outcome o f  the assay) affected the inhibitory 
activity o f  sera collected from infants aged 0-2 years and adults resident in Kilifi County. I 
show that GIA activity in both children and adult sera is significantly enhanced in a tw o-cycle 
assay compared to a single-cycle assay as previously reported (Dent et al. 2008), possibly due 
to the amplification o f the inhibitory effect o f  antibodies in the second cycle. My findings o f  
higher median levels in the two-growth cycle assay compared to the one-growth cycle assay
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are in contrast to those reported by Dent et cil, where they showed no difference between the 
median GIA levels in the two assays (Dent et al. 2008). In their study they suggest that this 
could be explained by the w ider range o f responses seen in the pLDH assay compared to the 
FACS assays but I found no evidence o f  this in my setting as the range o f  responses by both 
assays was similar. I provide evidence that differences in assay m ethodology significantly 
impact on the levels o f  GIA reported in different settings, and there is need for standardization 
across laboratories to enable accurate comparison o f  findings. For instance, GIA assays 
adopted by different laboratories should be validated against the well-established GIA 
methodology outlined by the GIA assay reference center at the US National Institute o f  
A llergy and Infectious Diseases (NIAID), National Institutes o f  Health.
GIA levels were significantly higher in adults compared to infants in the two-growth cycle 
assay. These findings suggest that GIA levels in very young infants (0-2 years) are generally 
low and this is independent o f the num ber o f  growth cycles. In contrast, lower GIA levels 
were observed in adults compared to children in the one growth cycle assay, consistent with a 
previous study (Dent et al. 2008) that used a sim ilar methodology but tested slightly older 
children (1-4 years). The range o f  GIA observed in the two-growth cycle m atches what has 
been reported in other studies more closely, for both adults (Dent et al. 2008, Crom pton et al. 
2010b) and children aged less than 12 months (W ilson et al. 2013). Studies that have 
compared GIA levels in adults versus children have examined a w ider age classification o f 
children ranging between 1-4 years (Dent et al. 2008), 2-5 years (M cCallum et al. 2008), 1-8 
years (John et al. 2004) and 8-14 years (Courtin et al. 2009) and reported relatively higher 
median GIA levels in children. It is difficult to compare my findings with these studies since 
the children examined here are aged less than 2 years.
In both children and adults, there was a negative correlation between GIA activity and 
antibody levels against all antigens tested as previously reported in other studies (John et al.
2004, M cCallum et al. 2008, Rono et al. 2012, Dent et al. 2008). The obvious explanation for 
this is that the antigens studied here are not targets o f  naturally acquired neutralizing 
antibodies. This proposition has been challenged by findings from vaccine trials and animal 
model studies showing a clear correlation between antibody titres and GIA. It is likely that 
adults and children in endemic areas acquire blocking antibodies that interfere with the 
function o f neutralizing antibodies (M iura et al. 2008b, M iura et al. 2011) and this could 
partially explain the lack o f a positive association between antibody titres, age and GIA. M y 
findings support the notion that GIA alone may not be a useful tool for screening targets o f 
naturally acquired immunity. An important finding here and in one other study (W ilson et al. 
2013) is that although studies report acquisition o f  growth inhibitory antibodies at an early 
age, this certainly excludes children aged 0-2 years. The low median GIA levels seen in 
children studied in this cohort could be explained by inadequate exposure and low host age. 
To the best o f  my knowledge, this is the first demonstration o f  the relationship between GIA 
and protection against severe m alaria in children and we found no evidence that this 
mechanism was associated with a significant reduction in odds o f  developing severe m alaria in 
analyses o f both the one and two growth cycle GIA assays. This result is not surprising as the 
median GIA level in this cohort o f  children was very low.
The ADRB assay that has recently been described as a potential correlate o f  naturally acquired 
immunity (Joos et al. 2010) was also assessed in this chapter. I show that ADRB activity was 
mediated specifically by PEMS opsonised with serum from m alaria exposed donors and the 
activity using coated PEM S as opposed to PEMS in solution, was more reproducible and 
eliminated non-specific reactivity. 1 also demonstrate that although there is donor-dependent 
variability in ADRB activity from different neutrophil donors in term s o f  the absolute RLU 
values, the ADRB activity is comparable when indexed relative to a positive control serum 
sample hence elim inating the variability and justifying the use o f  different independent donors
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across experiments. The assay requires a minimal amount o f  serum, which supports its uptake 
for high-throughput screening in cohorts o f  individuals living in malaria endemic areas.
However, a few limitations were encountered during assay development. First, I observed 
substantial variability o f  different PEM S preparations on ADRB activity, which was 
minimized by obtaining a large yield o f  PEMS from one large volume o f  culture. This was 
sufficient to screen one hundred Kilifi adult samples and two hundred infant sera in duplicate. 
This limitation could be overcome by adopting the recently described m erozoite isolation, 
purification and quantification method (Boyle et al. 2010), which yields pure m erozoites and 
possibly eliminates m ajority o f  the red blood cell debris. My attem pt to adapt and optimize 
this technique yielded insufficient m erozoite yields and further optimization o f  this isolation 
method is required. Second, a substantial degree o f  interassay variability was noted when a 
similar set o f serum samples were assayed on different days. Despite this, I would argue that 
the distinction between responders and non-responders (based on a cu toff o f  m ean plus three 
standard deviations o f  m alaria naive sera) was consistent across the different experiments. 
Comprehensive validation o f the assay to overcome this variability and enhance 
reproducibility is ongoing (Llewellyn et a l ,  m anuscript in preparation).
With the exception o f M S P -I19 and RyRh2, ADRB activity and IgG levels to AM A1, M SP-2, 
MSP-3 and GLURP were positively correlated in both children and adults but the correlations 
were moderate suggesting that these antigens are potential targets o f  antibodies that m ediate 
ADRB activity but do not on their own entirely contribute to this m echanism. The finding that 
ADRB activity levels increased with increasing breadth o f  antibody responses supports the 
hypothesis that multiple, as opposed to single, merozoite targets are more im portant for this 
response. Identifying the antigen combinations associated with ADRB activity will improve 
our understanding o f acquisition o f naturally acquired protection. Based on the set o f 
conditions optimized for the ADRB assay, ADRB activity in sera collected prior to the disease
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episode from children who subsequently developed severe malaria and their corresponding 
controls was sim ilar and I found no evidence o f a significant association o f this mechanism 
with a reduced odds o f  developing severe m alaria although the trend was towards reduced risk. 
Cytophilic antibodies, which bind Fc-receptors with a much greater affinity, have been shown 
to mediate ADRB activity in both humans (Joos et al. 2010) and mice (Llewellyn et al. 2014). 
However, I did not test the relative contribution o f  antibody subclasses in m ediating ADRB in 
this chapter.
Overall, the m ost striking finding was that children who had both ADRB and GIA activity had 
a significant reduction in odds o f  subsequently developing severe m alaria during the first two 
years o f life. These findings suggest that antibodies are likely to protect young children from 
severe episodes o f malaria via multiple m echanisms and the assessm ent o f  the breadth o f 
functional immune responses may be more valuable for evaluating protective immunity 
against severe m alaria than single mechanisms or serological measures o f  antibody titres. To 
the best o f  my knowledge, this is the first demonstration that these two functional antibody 
assays are prospectively associated with protection from severe malaria. Further studies on 
these responses in different populations are therefore needed to validate these findings.
In addition, the wider application o f these assays in other clinical outcom es such as 
uncomplicated malaria episodes and parasitization would also be useful. My observation o f  a 
lack o f correlation between the ADRB and GIA assay outputs, which m easure distinct 
antibody-mediated anti-parasite effector mechanisms, together with the dem onstration o f  an 
increase in ADRB activity with increasing antibody breadth, highlights the involvem ent o f 
separate and possibly multiple protective antigenic targets o f  both assays. Screening these 
targets will inform vaccine development efforts and improve our understanding o f targets o f 
NAI.
286
In summary, my findings provide useful insights into potential m echanisms that protect 
against severe malaria in young infants, and encourage the assessment o f  various functional 
assays that measure distinct components o f  the antibody responses.
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CHAPTER EIGHT
C onclusions an d  recom m endations
8.0 S u m m ary  o f findings
Antibodies contribute a large part o f  the natural defence against m alaria episodes as 
dem onstrated by passive transfer experiments, but a m ajor issue in understanding naturally- 
acquired immunity to malaria, as well as the developm ent o f  vaccines, has been the lack o f 
agreem ent on the protective effects o f  different antibody responses to m alarial antigens and the 
lack o f focus on responses associated with immunity against severe malaria. The analyses and 
experiments presented in this thesis aimed to address the above issues and I sum m arize the 
findings for each o f them.
First, the finding in our own setting that antibodies to merozoite targets (that had previously 
been associated with protection in a cohort o f children recruited during a high transm ission 
period) were not associated with protection in a separate cohort (recruited several years later 
during a period o f  moderate malaria transmission) was intriguing, and provided the impetus 
for resolving this paradox. I used a common reference standard reagent to quantify and 
standardize measurem ent antibodies to a panel o f  m erozoite antigens in both cohorts and I 
have demonstrated in chapter four that: -
• Age-m atched children recruited in the moderate transm ission cohort had significantly 
lower antibody titres to the antigens tested compared to those recruited in the high 
transm ission cohort and this was a possible explanation for the lack o f  protection seen 
in the moderate transmission cohort. These findings drew my attention to the 
importance o f  generating not only a detectable antibody response, but a high titre 
response. Previously, descriptions o f so-called “high titre responses” have largely been
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study site specific, but here I have provided estimates o f  the specific levels that should 
be achieved and evaluated in other settings.
• Achieving high antibody titres above specific threshold concentrations was associated 
w ith a reduced risk o f  developing clinical episodes o f malaria. I have provided 
evidence for this by showing that despite the relatively lower antibody titres in 
children recruited in the low transmission cohort, those who achieved antibody levels 
above the specific threshold concentrations defined in the high transm ission cohort 
had a reduced risk o f  developing a clinical episode o f  malaria.
• Intriguingly, threshold concentrations derived independently in three independent 
cohorts were comparable lending support to a possible clinical and/or biological 
relevance. The proposed threshold levels could be useful correlates o f  protection 
against clinical episodes o f  malaria. Further, the anti-parasite effector m echanism(s) 
conferred in the individual by achieving these threshold titres remains to be 
determined, but should help to further support the biological plausibility o f  these 
thresholds.
Second, there is a paucity o f data on protective m echanisms and targets o f  im munity to severe 
malaria. W hilst this, in part, results from the logistical challenges o f  following up a fairly large 
num ber o f  children for a relatively rare outcome, the few published studies o f  the association 
between antibody responses to blood-stage antigens and protection from severe malaria have 
yielded inconclusive results. Using a longitudinally m onitored birth cohort o f  children aged 0- 
2 years, the findings presented in this thesis dem onstrate that: -
• Anti-merozoite antibodies are infrequently found in children below the age o f two 
years with the exception o f  those aged less than 6 months.
• Children with asymptomatic infections were relatively few and such infections were 
characterized by transient peaks in antibody levels. Importantly, there was no
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difference in antibody titres at all time-points, between cases and age-matched controls 
to all the antigens tested.
• There is a lack o f  association between antibody responses to a panel o f  merozoite 
antigens and developm ent o f  severe malaria during the first two years o f  life with the 
exception o f  IgG to AMA1 alleles. Anti-m erozoite antibody levels may thus have been 
too low to confer any significant protective effect.
• There is a consistency o f  the association between antibodies measured at a single time- 
point versus m ultiple-time points prior to a disease episode, hence supporting the 
utility o f  single time-point antibody m easurem ents in im muno-epidemiological studies 
assessing the relationship between antibodies and protection against disease in this age 
group o f  children.
• The first systematic analysis o f the longevity o f  maternal antibodies against a panel o f  
m erozoite antigens. The half-life estimates are informative in deciding when to 
administer m alaria vaccines to this group o f  children, based on the evidence that 
maternal antibodies may interfere with a child’s ability to mount an effective response 
vaccines (reviewed in (Siegrist 2001) and (Siegrist 2003)).
• The rate o f  decay o f maternal antibodies is dependent on the concentration o f 
antibodies present at birth. Children who acquired high titre antibodies from their 
mothers had the highest decay rate. Such kinetics o f antibody decay suggest that 
m alaria vaccines that protect via induction o f  high titre antibodies will require constant 
boosting in this group o f  children in order to maintain their protective levels.
• Reduced susceptibility to severe m alaria was associated with a com bination o f 
antibodies that can limit growth o f  parasites as measured by both GIA and ADRB 
assays. These assays will be useful as potential correlates o f  protection against severe 
malaria. These findings also provide evidence that multiple, as opposed to single,
functional mechanisms may be more important in protection from malaria.
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Our previous work dem onstrating that children who developed severe m alaria had more 
asymptomatic infections and harbored diverse parasites compared to their age-matched 
controls (Lundblom et al. 2013), reflects a higher degree o f  exposure in this group o f  children 
at an age when anti-merozoite antibodies have not attained concentrations required for 
protection against severe malaria. 1 have extended these findings by showing that age-matched 
controls were more likely to have a combination o f  antibodies that mediated GIA and ADRB 
compared to cases, lending support to a role o f  antibody-mediated function being more 
im portant for protection against severe m alaria as opposed to the ability to generate high titre 
responses to these antigens. The question o f  what might be the targets o f  these functional 
antibodies is o f considerable importance and interest towards identifying potential vaccine 
targets. M ore detailed studies are needed to elucidate the merozoite targets o f  functional 
antibodies.
The studies presented in this thesis thus enhance our knowledge o f the acquisition o f  immunity 
to malaria and provide insights that may be valuable for advancing m alaria vaccine 
developm ent and testing.
8.1 Recommendations for future studies
This work could be extended in future studies by: -
i) Examining the threshold concentrations proposed in this thesis in other settings with 
varying transmission intensities and converting these into absolute concentrations for 
direct comparison in vaccine trials.
ii) M easuring responses to additional and novel merozoite antigens, or antigens expressed
by other parasite stages. Given the complexity o f the malaria parasite, it is likely that a
broad repertoire o f  immune responses targeted against multiple antigens are required to
achieve immunity to malaria. Recent advances in genomics and protein expression
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systems have facilitated the identification and expression o f a broader panel o f novel 
antigens or combinations o f antigens that are targets o f  protective cellular (Cardoso et 
al. 2011) and antibody (Raj et al. 2014, Richards et al. 2013, Crompton et al. 2010a, 
Doolan et al. 2008, Osier et al. 2014b) responses. The work presented in this thesis 
could be extended further by probing whole proteom e arrays with pooled plasm a from 
cases and corresponding controls who do not develop severe malaria. Such a screening 
approach would accelerate the identification o f  combinations o f  antigens that are 
targets o f  protective antibody responses in my setting.
iii) Adoption o f  unbiased approaches such as systems biology to screen immunological 
parameters associated with resistance or susceptible to disease. The systems approach 
combines predictive computational modeling with high-throughput cellular and 
molecular assays such as whole-blood transcriptomics, m ultiple-plasm a 
cytokine/chemokine assays, multicolor flow cytometry and antibody profiling using 
proteome-based chips. A  few studies have adopted this approach and identified early 
molecular signatures that predict/correlate with immune responses induced after 
vaccination against yellow fever (Querec et al. 2009, Gaucher et al. 2008), influenza 
(Nakaya et al. 2011) and meningitis (Li et al. 2014).
Thus far, only one study has utilized a systems biology approach to analyse immune 
responses induced following natural exposure to m alaria infection in a longitudinally 
monitored cohort (Portugal et al. 2014). Adoption o f  a sim ilar approach in my setting 
and others could provide a more comprehensive definition o f  immune responses that 
are protective from those that are markers o f  exposure and hence improve our 
understanding o f  the mechanisms associated with NAI.
iv) D istinguishing responses and targets associated with protection against the individual 
symptoms o f severe malaria. Due to the relatively small numbers o f  cases with single
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symptoms o f  cerebral malaria, severe m alaria anemia and respiratory distress, I did not 
assess them in this thesis as separate outcomes o f severe malaria,
v) Evaluating the combination o f  GIA and ADRB assays in protection against the 
outcomes o f  severe m alaria and uncomplicated m alaria in other settings. In addition, 
evaluate the merozoite targets o f  these mechanisms.
293
R E F E R E N C E S
Abdalla, S. H. & G. Pasvol (2004) Malaria: a hematological perspective. Tropical medicine, London, 
River Edge, NJ.
Achidi, E. A., L. S. Salimonu, H. Perlmann, P. Perlmann, K. Berzins & A. 1. Williams (1996) Lack of  
association between levels o f transplacentally acquired Plasmodium falciparum-specific 
antibodies and age o f onset o f  clinical malaria in infants in a malaria endemic area of Nigeria. 
Acta Trop, 61, 315-26.
Agak, G. W., P. Bejon, G. Fegan, N. Gicheru, V. Villard, A. V. Kajava, K. Marsh & G. Corradin 
(2008) Longitudinal analyses o f immune responses to Plasmodium falciparum derived peptides 
corresponding to novel blood stage antigens in coastal Kenya. Vaccine, 26, 1963-71.
Agnandji, S. T., B. Lell, J. F. Fernandes, B. P. Abossolo, B. G. Methogo, A. L. Kabwende, A. A. 
Adegnika, B. Mordmuller, S. Issifou, P. G. Kremsner, J. Sacarlal, P. Aide, M. Lanaspa, J. J. 
Aponte, S. Machevo, S. Acacio, H. Bulo, B. Sigauque, E. Macete, P. Alonso, S. Abdulla, N. 
Salim, R. Minja, M. Mpina, S. Ahmed, A. M. Ali, A. T. Mtoro, A. S. Hamad, P. Mutani, M. 
Tanner, H. Tinto, U. D'Alessandro, H. Sorgho, I. Valea, B. Bihoun, I. Guiraud, B. Kabore, O. 
Sombie, R. T. Guiguemde, J. B. Ouedraogo, M. J. Hamel, S. Kariuki, M. Oneko, C. Odero, K. 
Otieno, N. Awino, M. McMorrow, V. Muturi-Kioi, K. F. Laserson, L. Slutsker, W. Otieno, L. 
Otieno, N. Otsyula, S. Gondi, A. Otieno, V. Owira, E. Oguk, G. Odongo, J. B. Woods, B. 
Ogutu, P. Njuguna, R. Chilengi, P. Akoo, C. Kerubo, C. Maingi, T. Lang, A. Olotu, P. Bejon, 
K. Marsh, G. Mwambingu, S. Owusu-Agyei, K. P. Asante, K. Osei-Kwakye, O. Boahen, D. 
Dosoo, 1. Asante, G. Adjei, E. Kwara, D. Chandramohan, B. Greenwood, J. Lusingu, S. 
Gesase, A. Malabeja, O. Abdul, C. Mahende, E. Liheluka, L. Malle, M. Lemnge, T. G. 
Theander, C. Drakeley, D. Ansong, T. Agbenyega, S. Adjei, H. O. Boateng, T. Rettig, J. Bawa, 
J. Sylverken, D. Sambian, A. Sarfo, A. Agyekum, et al. (2012) A phase 3 trial o f  RTS,S/AS0I 
malaria vaccine in African infants. N Engl J Med, 367,2284-95.
Agnandji, S. T., B. Lell, S. S. Soulanoudjingar, J. F. Fernandes, B. P. Abossolo, C. Conzelmann, B. G. 
Methogo, Y. Doucka, A. Flamen, B. Mordmuller, S. Issifou, P. G. Kremsner, J. Sacarlal, P. 
Aide, M. Lanaspa, J. J. Aponte, A. Nhamuave, D. Quelhas, Q. Bassat, S. Mandjate, E. Macete, 
P. Alonso, S. Abdulla, N. Salim, O. Juma, M. Shomari, K. Shubis, F. Machera, A. S. Hamad, 
R. Minja, A. Mtoro, A. Sykes, S. Ahmed, A. M. Urassa, A. M. Ali, G. Mwangoka, M. Tanner,
H. Tinto, U. D'Alessandro, H. Sorgho, I. Valea, M. C. Tahita, W. Kabore, S. Ouedraogo, Y. 
Sandrine, R. T. Guiguemde, J. B. Ouedraogo, M. J. Hamel, S. Kariuki, C. Odero, M. Oneko, 
K. Otieno, N. Awino, J. Omoto, J. Williamson, V. Muturi-Kioi, K. F. Laserson, L. Slutsker, W. 
Otieno, L. Otieno, O. Nekoye, S. Gondi, A. Otieno, B. Ogutu, R. Wasuna, V. Owira, D. Jones, 
A. A. Onyango, P. Njuguna, R. Chilengi, P. Akoo, C. Kerubo, J. Gitaka, C. Maingi, T. Lang, 
A. Olotu, B. Tsofa, P. Bejon, N. Peshu, K. Marsh, S. Owusu-Agyei, K. P. Asante, K. Osei- 
Kwakye, O. Boahen, S. Ayamba, K. Kayan, R. Owusu-Ofori, D. Dosoo, I. Asante, G. Adjei, 
G. Adjei, D. Chandramohan, B. Greenwood, J. Lusingu, S. Gesase, A. Malabeja, O. Abdul, H. 
Kilavo, C. Mahende, E. Liheluka, et al. (2011) First results o f phase 3 trial o f RTS,S/AS01 
malaria vaccine in African children. N Engl J Med, 365, 1863-75.
Aguiar, J. C., G. R. Albrecht, P. Cegielski, B. M. Greenwood, J. B. Jensen, G. Lallinger, A. Martinez,
I. A. McGregor, J. N. Minjas, J. Neequaye, M. E. Patarroyo, J. A. Sherwood & R. J. Howard 
(1992) Agglutination o f Plasmodium falciparum-infected erythrocytes from east and west 
African isolates by human sera from distant geographic regions. Am J Trop Med Hyg, 47, 621 - 
32.
Ahmed Ismail, H., U. Ribacke, L. Reiling, J. Normark, T. Egwang, F. Kironde, J. G. Beeson, M. 
Wahlgren & K. E. Persson (2013) Acquired antibodies to merozoite antigens in children from 
Uganda with uncomplicated or severe Plasmodium falciparum malaria. Clin Vaccine Immunol, 
20, 1170-80.
Akpogheneta, O. J., N. O. Duah, K. K. Tetteh, S. Dunyo, D. E. Lanar, M. Pinder & D. J. Conway 
(2008) Duration o f naturally acquired antibody responses to blood-stage Plasmodium 
falciparum is age dependent and antigen specific. Infect Immun, 76, 1748-55.
294
al-Yaman, F., B. Genton, K. J. Kramer, S. P. Chang, G. S. Hui, M. Baisor & M. P. Alpers (1996) 
Assessment o f the role o f naturally acquired antibody levels to Plasmodium falciparum 
merozoite surface protein-1 in protecting Papua New Guinean children from malaria 
morbidity. Am J Trop Med Hyg, 54,443-8.
al-Yaman, F., B. Genton, K. J. Kramer, J. Taraika, S. P. Chang, G. S. Hui & M. P. Alpers (1995) 
Acquired antibody levels to Plasmodium falciparum merozoite surface antigen 1 in residents o f  
a highly endemic area o f Papua New Guinea. Trans R Soc Trop Med Hyg, 89, 555-9.
Al-Yaman, F., B. Genton, J. C. Reeder, D. Mokela, R. F. Anders & M. P. Alpers (1997) Humoral 
response to defined Plasmodium falciparum antigens in cerebral and uncomplicated malaria 
and their relationship to parasite genotype. Am J  Trop Med Hyg, 56,430-5.
Alexander, D. L., S. Arastu-Kapur, J. F. Dubremetz & J. C. Boothroyd (2006) Plasmodium falciparum 
AMA1 binds a rhoptry neck protein homologous to TgRON4, a component o f  the moving 
junction in Toxoplasma gondii. Eukaryot Cell, 5, 1169-73.
Allison, A. C. & E. M. Eugui (1983) The role o f cell-mediated immune responses in resistance to 
malaria, with special reference to oxidant stress. Annu Rev Immunol, 1, 361-92.
Amanna, I. J., N. E. Carlson & M. K. Slifka (2007) Duration of humoral immunity to common viral 
and vaccine antigens. N Engl J  Med, 357, 1903-15.
Amaratunga, C., T. M. Lopera-Mesa, N. J. Brittain, R. Cholera, T. Arie, H. Fujioka, J. R. Keefer & R. 
M. Fairhurst (2011) A role for fetal hemoglobin and maternal immune IgG in infant resistance 
to Plasmodium falciparum malaria. PLoS One, 6, el4798.
Amin, A. A., D. Zurovac, B. B. Kangwana, J. Greenfield, D. N. Otieno, W. S. Akhwale & R. W. Snow 
(2007) The challenges o f changing national malaria drug policy to artemisinin-based 
combinations in Kenya. Malar J, 6, 72.
Amino, R., S. Thiberge, S. Shorte, F. Frischknecht & R. Menard (2006) Quantitative imaging o f  
Plasmodium sporozoites in the mammalian host. C R Biol, 329, 858-62.
Anders, R. F., P. E. Crewther, S. Edwards, M. Margetts, M. L. Matthew, B. Pollock & D. Pye (1998) 
Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium 
chabaudi. Vaccine, 16,240-7.
Andre, F. E., R. Booy, H. L. Bock, J. Clemens, S. K. Datta, T. J. John, B. W. Lee, S. Lolekha, H. 
Peltola, T. A. Ruff, M. Santosham & H. J. Schmitt (2008) Vaccination greatly reduces disease, 
disability, death and inequity worldwide. Bull World Health Organ, 86, 140-6.
Anstey, N. M., J. B. Weinberg, M. Y. Hassanali, E. D. Mwaikambo, D. Manyenga, M. A. Misukonis,
D. R. Amelle, D. Hollis, M. I. McDonald & D. L. Granger (1996) Nitric oxide in Tanzanian 
children with malaria: inverse relationship between malaria severity and nitric oxide 
production/nitric oxide synthase type 2 expression. J Exp Med, 184, 557-67.
Aponte, J. J., D. Schellenberg, A. Egan, A. Breckenridge, I. Cameiro, J. Critchley, I. Danquah, A. 
Dodoo, R. Kobbe, B. Lell, J. May, Z. Premji, S. Sanz, E. Sevene, R. Soulaymani-Becheikh, P. 
Winstanley, S. Adjei, S. Anemana, D. Chandramohan, S. Issifou, F. Mockenhaupt, S. Owusu- 
Agyei, B. Greenwood, M. P. Grobusch, P. G. Kremsner, E. Macete, H. Mshinda, R. D. 
Newman, L. Slutsker, M. Tanner, P. Alonso & C. Menendez (2009) Efficacy and safety o f  
intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African 
infants: a pooled analysis o f six randomised, placebo-controlled trials. Lancet, 374, 1533-42.
Avril, M., M. M. Cartwright, M. J. Hathaway, M. Hommel, S. R. Elliott, K. Williamson, D. L. Narum, 
P. E. Duffy, M. Fried, J. G. Beeson & J. D. Smith (2010) Immunization with VAR2CSA- 
DBL5 recombinant protein elicits broadly cross-reactive antibodies to placental Plasmodium 
falciparum-infected erythrocytes. Infect Immun, 78,2248-56.
Bai, T., M. Becker, A. Gupta, P. Strike, V. J. Murphy, R. F. Anders & A. H. Batchelor (2005) Structure 
o f AM A1 from Plasmodium falciparum reveals a clustering o f polymorphisms that surround a 
conserved hydrophobic pocket. Proc Natl Acad Sci USA,  102, 12736-41.
Baird, J. K. (1995) Host age as a determinant o f naturally acquired immunity to Plasmodium 
falciparum. Parasitol Today, 11, 105-11.
Baird, J. K., Pumomo, H. Basri, M. J. Bangs, E. M. Andersen, T. R. Jones, S. Masbar, S. 
Harjosuwamo, B. Subianto & P. R. Arbani (1993) Age-specific prevalence o f Plasmodium 
falciparum among six populations with limited histories o f exposure to endemic malaria. Am J  
Trop Med Hyg, 49, 707-19.
295
Baldridge, J. R. & R. T. Crane (1999) Monophosphoryl lipid A (MPL) formulations for the next 
generation o f vaccines. Methods, 19, 103-7.
Bannister, L. H., J. M. Hopkins, A. R. Dluzewski, G. Margos, 1. T. Williams, M. J. Blackman, C. H. 
Kocken, A. W. Thomas & G. H. Mitchell (2003) Plasmodium falciparum apical membrane 
antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules 
during merozoite development. J  Cell Sci, 116, 3825-34.
Barragan, A., P. G. Kremsner, W. Weiss, M. Wahlgren & J. Carlson (1998) Age-related buildup of 
humoral immunity against epitopes for rosette formation and agglutination in African areas of  
malaria endemicity. Infect Immiin, 66, 4783-7.
Barry, A. E., L. Schultz, C. O. Buckee & J. C. Reeder (2009) Contrasting population structures o f the 
genes encoding ten leading vaccine-candidate antigens o f the human malaria parasite, 
Plasmodium falciparum. PLoS One, 4, e8497.
Bartholdson, S. J., C. Crosnier, L. Y. Bustamante, J. C. Rayner & G. J. Wright (2013) Identifying 
novel Plasmodium falciparum erythrocyte invasion receptors using systematic extracellular 
protein interaction screens. Cell Microbiol, 15, 1304-12.
Beare, N. A., C. Southern, C. Chalira, T. E. Taylor, M. E. Molyneux & S. P. Harding (2004) 
Prognostic significance and course o f retinopathy in children with severe malaria. Arch 
Ophthalmol, 122, 1141-7.
Beier, J. C., J. Keating, J. I. Githure, M. B. Macdonald, D. E. Impoinvil & R. J. Novak (2008) 
Integrated vector management for malaria control. Malar J, 7 Suppl 1, S4.
Bejon, P., J. Cook, E. Bergmann-Leitner, A. Olotu, J. Lusingu, J. Mwacharo, J. Vekemans, P. Njuguna, 
A. Leach, M. Lievens, S. Dutta, L. von Seidlein, B. Savarese, T. Villafana, M. M. Lemnge, J. 
Cohen, K. Marsh, P. H. Corran, E. Angov, E. M. Riley & C. J. Drakeley (201 la) Effect o f the 
pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young 
children. J Infect Dis, 204, 9-18.
Bejon, P., J. Mwacharo, O. Kai, T. Mwangi, P. Milligan, S. Todryk, S. Keating, T. Lang, B. Lowe, C. 
Gikonyo, C. Molyneux, G. Fegan, S. C. Gilbert, N. Peshu, K. Marsh & A. V. Hill (2006) A 
phase 2b randomised trial o f the candidate malaria vaccines FP9 ME-TRAP and MVA ME- 
TRAP among children in Kenya. PLoS Clin Trials, 1, e29.
Bejon, P., L. Turner, T. Lavstsen, G. Cham, A. Olotu, C. J. Drakeley, M. Lievens, J. Vekemans, B. 
Savarese, J. Lusingu, L. von Seidlein, P. C. Bull, K. Marsh & T. G. Theander (2011b) 
Serological evidence o f discrete spatial clusters o f Plasmodium falciparum parasites. PLoS 
One, 6, e21711.
Bejon, P., T. N. Williams, A. Liljander, A. M. Noor, J. Wambua, E. Ogada, A. Olotu, F. H. Osier, S. I. 
Hay, A. Farnert & K. Marsh (2010) Stable and unstable malaria hotspots in longitudinal cohort 
studies in Kenya. PLoS Med, 7, el 000304.
Belard, S., S. Issifou, A. B. Hounkpatin, F. Schaumburg, U. A. Ngoa, M. Esen, R. Fendel, P. M. de 
Salazar, R. E. Murbeth, P. Milligan, N. Imbault, E. B. Imoukhuede, M. Theisen, S. Jepsen, R. 
A. Noor, B. Okech, P. G. Kremsner & B. Mordmuller (2011) A randomized controlled phase 
lb trial o f the malaria vaccine candidate GMZ2 in African children. PLoS One, 6, e22525.
Bemasconi, N. L., E. Traggiai & A. Lanzavecchia (2002) Maintenance o f serological memory by 
polyclonal activation o f human memory B cells. Science, 298, 2199-202.
Bijker, E. M., A. C. Teirlinck, R. Schats, G. J. van Gemert, M. van de Vegte-Bolmer, L. van Lieshout, 
J. IntHout, C. C. Hermsen, A. Scholzen, L. G. Visser & R. W. Sauerwein (2014) Cytotoxic 
Markers Associate With Protection Against Malaria in Human Volunteers Immunized With 
Plasmodium falciparum Sporozoites. J Infect Dis, 210, 1605-15.
Blackman, M. J., H. G. Heidrich, S. Donachie, J. S. McBride & A. A. Holder (1990) A single fragment 
of a malaria merozoite surface protein remains on the parasite during red cell invasion and is 
the target o f invasion-inhibiting antibodies. J Exp Med, 172, 379-82.
Blackman, M. J. & A. A. Holder (1992) Secondary processing o f the Plasmodium falciparum 
merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: 
shedding o f MSP 133 as a noncovalently associated complex with other fragments o f the 
MSP1. Mol Biochem Parasitol, 50, 307-15.
Blackman, M. J., T. J. Scott-Finnigan, S. Shai & A. A. Holder (1994) Antibodies inhibit the protease- 
mediated processing o f a malaria merozoite surface protein. J  Exp Med, 180, 389-93.
296
Blackman, M. J., H. Whittle & A. A. Holder (1991) Processing o f the Plasmodium falciparum major 
merozoite surface protein-1: identification o f a 33-kilodalton secondary processing product 
which is shed prior to erythrocyte invasion. Mol Biochem Parasitol, 49, 35-44.
Bouchaud, O., M. Cot, S. Kony, R. Durand, R. Schiemann, P. Ralaimazava, J. P. Coulaud, J. Le Bras 
& P. Deloron (2005) Do African immigrants living in France have long-term malarial 
immunity? Am J Trop Med Hyg, 72,21-5.
Bouharoun-Tayoun, H., C. Oeuvray, F. Lunel & P. Druilhe (1995) Mechanisms underlying the 
monocyte-mediated antibody-dependent killing o f Plasmodium falciparum asexual blood 
stages. J Exp Med, 182, 409-18.
Bousema, J. T., W. Roeffen, M. van der Kolk, S. J. de Vlas, M. van de Vegte-Bolmer, M. J. Bangs, K. 
Teelen, L. Kumiawan, J. D. Maguire, J. K. Baird & R. W. Sauerwein (2006) Rapid onset o f  
transmission-reducing antibodies in javanese migrants exposed to malaria in papua, indonesia. 
Am J Trop Med Hyg, 74,425-31.
Bousema, T., C. Drakeley, S. Gesase, R. Hashim, S. Magesa, F. Mosha, S. Otieno, I. Cameiro, J. Cox,
E. Msuya, I. Kleinschmidt, C. Maxwell, B. Greenwood, E. Riley, R. Sauerwein, D. 
Chandramohan & R. Gosling (2010) Identification o f hot spots o f malaria transmission for 
targeted malaria control. J Infect Dis, 201, 1764-74.
Bouyou-Akotet, M. K., D. P. Mawili-Mboumba, E. Kendjo, M. Mabika-Mamfoumbi, E. B. Ngoungou, 
A. Dzeing-Ella, M. Pemba-Mihindou, E. Ibinga, E. Efame-Eya, M. team, T. Planche, P. G. 
Kremsner & M. Kombila (2009) Evidence o f  decline o f malaria in the general hospital o f  
Libreville, Gabon from 2000 to 2008. Malar J, 8, 300.
Boyle, M. J., D. W. Wilson, J. S. Richards, D. T. Riglar, K. K. Tetteh, D. J. Conway, S. A. Ralph, J. 
Baum & J. G. Beeson (2010) Isolation o f viable Plasmodium falciparum merozoites to define 
erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci U 
SA, 107, 14378-83.
Branch, O. H., V. Udhayakumar, A. W. Hightower, A. J. Oloo, W. A. Hawley, B. L. Nahlen, P. B. 
Bloland, D. C. Kaslow & A. A. Lai (1998) A longitudinal investigation o f IgG and IgM 
antibody responses to the merozoite surface protein-1 19-kiloDalton domain o f  Plasmodium 
falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and 
anemia. Am J Trop Med Hyg, 58, 211-9.
Brasseur, P., M. Badiane, M. Cisse, P. Agnamey, M. T. Vaillant & P. L. Olliaro (2011) Changing 
patterns o f malaria during 1996-2010 in an area o f moderate transmission in southern Senegal. 
Malar J, 10,203.
Brouqui, P., P. Parola & D. Raoult (2012) Insecticide resistance in mosquitoes and failure o f malaria 
control. Expert Rev Anti Infect Ther, 10, 1379-81.
Brown, H., G. Turner, S. Rogerson, M. Tembo, J. Mwenechanya, M. Molyneux & T. Taylor (1999) 
Cytokine expression in the brain in human cerebral malaria. J Infect Dis, 180, 1742-6.
Brown, K. N. & I. N. Brown (1965) Immunity to malaria: antigenic variation in chronic infections o f  
Plasmodium knowlesi. Nature, 208, 1286-8.
Bull, P. C., M. Berriman, S. Kyes, M. A. Quail, N. Hall, M. M. Kortok, K. Marsh & C. I. Newbold 
(2005) Plasmodium falciparum variant surface antigen expression patterns during malaria. 
PLoSPathog, l,e2 6 .
Bull, P. C., M. Kortok, O. Kai, F. Ndungu, A. Ross, B. S. Lowe, C. I. Newbold & K. Marsh (2000) 
Plasmodium falciparum-infected erythrocytes: agglutination by diverse Kenyan plasma is 
associated with severe disease and young host age. J Infect Dis, 182,252-9.
Bull, P. C., B. S. Lowe, N. Kaleli, F. Njuga, M. Kortok, A. Ross, F. Ndungu, R. W. Snow & K. Marsh
(2002) Plasmodium falciparum infections are associated with agglutinating antibodies to 
parasite-infected erythrocyte surface antigens among healthy Kenyan children. J  Infect Dis, 
185, 1688-91.
Bull, P. C., B. S. Lowe, M. Kortok, C. S. Molyneux, C. I. Newbold & K. Marsh (1998) Parasite 
antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. 
Nat Med, 4,358-60.
Burghaus, P. A. & A. A. Holder (1994) Expression o f the 19-kilodalton carboxy-terminal fragment o f  
the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly 
folded protein. Mol Biochem Parasitol, 64, 165-9.
297
Burghaus, P. A., B. T. Wellde, T. Hall, R. L. Richards, A. F. Egan, E. M. Riley, W. R. Ballou & A. A. 
Holder (1996) Immunization o f Aotus nancymai with recombinant C terminus o f Plasmodium 
falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce 
protection against a challenge infection. Infect Immitn, 64, 3614-9.
Bustamante, L. Y., S. J. Bartholdson, C. Crosnier, M. G. Campos, M. Wanaguru, C. Nguon, D. P. 
Kwiatkowski, G. J. Wright & J. C. Rayner (2013) A full-length recombinant Plasmodium 
falciparum PfRH5 protein induces inhibitory antibodies that are effective across common 
PfRH5 genetic variants. Vaccine, 31, 373-9.
Butler, D. (2011) Mosquitoes score in chemical war. Nature, 475, 19.
Cabrera, G., M. Cot, F. Migot-Nabias, P. G. Kremsner, P. Deloron & A. J. Luty (2005) The sickle cell 
trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium 
falciparum variant surface antigens. J Infect Dis, 191, 1631-8.
Cardoso, F. C., J. S. Roddick, P. Groves & D. L. Doolan (2011) Evaluation o f approaches to identify 
the targets o f cellular immunity on a proteome-wide scale. PLoS One, 6, e27666.
Carlson, J., H. Helmby, A. V. Hill, D. Brewster, B. M. Greenwood & M. Wahlgren (1990) Human 
cerebral malaria: association with erythrocyte rosetting and lack o f anti-rosetting antibodies. 
Lancet, 336, 1457-60.
Cameiro, I., A. Roca-Feltrer, J. T. Griffin, L. Smith, M. Tanner, J. A. Schellenberg, B. Greenwood & 
D. Schellenberg (2010) Age-pattems o f malaria vary with severity, transmission intensity and 
seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS One, 5, 
e8988.
Carter, J. A., V. Mung'ala-Odera, B. G. Neville, G. Murira, N. Mturi, C. Musumba & C. R. Newton 
(2005) Persistent neurocognitive impairments associated with severe falciparum malaria in 
Kenyan children. J  Neurol Neurosurg Psychiatry, 76, 476-81.
Carter, R., K. N. Mendis, L. H. Miller, L. Molineaux & A. Saul (2000) Malaria transmission-blocking 
vaccines—how can their development be supported? Nat Med, 6, 241-4.
Cavanagh, D. R., D. Dodoo, L. Hviid, J. A. Kurtzhals, T. G. Theander, B. D. Akanmori, S. Polley, D. J. 
Conway, K. Koram & J. S. McBride (2004) Antibodies to the N-terminal block 2 o f  
Plasmodium falciparum merozoite surface protein 1 are associated with protection against 
clinical malaria. Infect Immun, 72, 6492-502.
Cavanagh, D. R., I. M. Elhassan, C. Roper, V. J. Robinson, H. Giha, A. A. Holder, L. Hviid, T. G. 
Theander, D. E. Arnot & J. S. McBride (1998) A longitudinal study o f type-specific antibody 
responses to Plasmodium falciparum merozoite surface protein-1 in an area o f unstable malaria 
in Sudan .J  Immunol, 161, 347-59.
Cavanagh, D. R., C. H. Kocken, J. H. White, G. J. Cowan, K. Samuel, M. A. Dubbeld, A. Voorberg- 
van der Wei, A. W. Thomas, J. S. McBride & D. E. Arnot (2014) Antibody responses to a 
novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection 
against experimental malaria infection in Aotus monkeys. PLoS One, 9, e83704.
Ceesay, S. J., C. Casals-Pascual, D. C. Nwakanma, M. Walther, N. Gomez-Escobar, A. J. Fulford, E. 
N. Takem, S. Nogaro, K. A. Bojang, T. Corrah, M. C. Jaye, M. A. Taal, A. A. Sonko & D. J. 
Conway (2010) Continued decline o f malaria in The Gambia with implications for elimination. 
PLoS One, 5, e l2242.
Celada, A., A. Cruchaud & L. H. Perrin (1982) Opsonic activity o f human immune serum on in vitro 
phagocytosis o f Plasmodium falciparum infected red blood cells by monocytes. Clin Exp 
Immunol, 47, 635-44.
(1983) Phagocytosis o f Plasmodium falciparum-parasitized erythrocytes by human 
polymorphonuclear leukocytes. J Parasitol, 69,49-53.
Chakravarty, S., I. A. Cockburn, S. Kuk, M. G. Overstreet, J. B. Sacci & F. Zavala (2007) CD8+ T 
lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. 
Nat Med, 13, 1035-41.
Chan, J. A., F. J. Fowkes & J. G. Beeson (2014) Surface antigens of Plasmodium falciparum-infected 
erythrocytes as immune targets and malaria vaccine candidates. Cell Mol Life Sci.
Chan, J. A., K. B. Howell, L. Reiling, R. Ataide, C. L. Mackintosh, F. J. Fowkes, M. Petter, J. M. 
Chesson, C. Langer, G. M. Warimwe, M. F. Duffy, S. J. Rogerson, P. C. Bull, A. F. Cowman, 
K. Marsh & J. G. Beeson (2012) Targets o f antibodies against Plasmodium falciparum-infected 
erythrocytes in malaria immunity. J Clin Invest, 122, 3227-38.
Chang, K. H., M. Tam & M. M. Stevenson (2004) Inappropriately low reticulocytosis in severe 
malarial anemia correlates with suppression in the development o f late erythroid precursors. 
Blood, 103,3727-35.
Chang, S. P., S. E. Case, W. L. Gosnell, A. Hashimoto, K. J. Kramer, L. Q. Tam, C. Q. Hashiro, C. M. 
Nikaido, H. L. Gibson, C. T. Lee-Ng, P. J. Barr, B. T. Yokota & G. S. Hut (1996) A 
recombinant baculovirus 42-kilodalton C-terminal fragment o f Plasmodium falciparum 
merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immnn, 64, 253-61. 
Chang, S. P., H. L. Gibson, C. T. Lee-Ng, P. J. Barr & G. S. Hui (1992) A carboxyl-terminal fragment 
o f Plasmodium falciparum g p l95 expressed by a recombinant baculovirus induces antibodies 
that completely inhibit parasite growth. J  Immunol, 149, 548-55.
Chappel, J. A. & A. A. Holder (1993) Monoclonal antibodies that inhibit Plasmodium falciparum 
invasion in vitro recognise the first growth factor-like domain o f merozoite surface protein-1. 
Mol Biochem Parasitol, 60, 303-11.
Chattopadhyay, R., A. Sharma, V. K. Srivastava, S. S. Pati, S. K. Sharma, B. S. Das & C. E. Chitnis
(2003) Plasmodium falciparum infection elicits both variant-specific and cross-reactive 
antibodies against variant surface antigens. Infect Immun, 71, 597-604.
Cissoko, Y., M. Daou, K. E. Lyke, A. Dicko, I. Diarra, A. Kone, A. Guindo, K. Traore, G. 
Krishnegowda, D. A. Diallo, O. K. Doumbo, C. V. Plowe, D. C. Gowda & M. B. Sztein (2006) 
Serum antibody levels to glycosylphosphatidylinositols in specimens derived from matched 
Malian children with severe or uncomplicated Plasmodium falciparum malaria and healthy 
controls. Am J  Trop Med Hyg, 75, 199-204.
Clark, E. H., C. J. Silva, G. E. Weiss, S. Li, C. Padilla, P. D. Crompton, J. N. Hernandez & O. H. 
Branch (2012) Plasmodium falciparum malaria in the Peruvian Amazon, a region o f low 
transmission, is associated with immunologic memory. Infect Immun, 80, 1583-92.
Clark, I. A. & N. H. Hunt (1983) Evidence for reactive oxygen intermediates causing hemolysis and 
parasite death in malaria. Infect Immun, 39, 1-6.
Cloonan, M. J., R. A. Hawkes & L. H. Stevens (1970) Postnatal decline o f maternally acquired rubella 
antibodies. J  Hyg (Lond), 68,461-8.
— (1971) Postnatal decline o f maternally acquired viral antibodies o f different specificities. J  Hyg
(Lond), 69,435-44.
Clyde, D. F., H. Most, V. C. McCarthy & J. P. Vanderberg (1973) Immunization o f man against 
sporozite-induced falciparum malaria. Am J Med Sci, 266, 169-77.
Coban, C., K. J. Ishii, T. Kawai, H. Hemmi, S. Sato, S. Uematsu, M. Yamamoto, O. Takeuchi, S. 
Itagaki, N. Kumar, T. Horii & S. Akira (2005) Toll-like receptor 9 mediates innate immune 
activation by the malaria pigment hemozoin. J Exp Med, 201, 19-25.
Cohen, J., S. Benns, J. Vekemans & A. Leach (2010) [The malaria vaccine candidate RTS,S/AS is in 
phase III clinical trials]. Ann Pharm Fr, 68, 370-9.
Cohen, S., G. I. Me & S. Carrington (1961) Gamma-globulin and acquired immunity to human malaria. 
Nature, 192,733-7.
Collins, W. E. & G. M. Jeffery (1999a) A retrospective examination o f secondary sporozoite- and 
trophozoite-induced infections with Plasmodium falciparum: development o f parasitologic and 
clinical immunity following secondary infection. Am J Trop Med Hyg, 61,20-35.
— (1999b) A retrospective examination o f the patterns of recrudescence in patients infected with
Plasmodium falciparum. Am J  Trop Med Hyg, 61, 44-8.
Collins, W. E., D. Pye, P. E. Crewther, K. L. Vandenberg, G. G. Galland, A. J. Sulzer, D. J. Kemp, S. 
J. Edwards, R. L. Coppel, J. S. Sullivan & et al. (1994) Protective immunity induced in squirrel 
monkeys with recombinant apical membrane antigen-1 o f Plasmodium fragile. Am J  Trop Med 
Hyg, 51,711-9.
Conroy, A. L., S. J. Glover, M. Hawkes, L. K. Erdman, K. B. Seydel, T. E. Taylor, M. E. Molyneux & 
K. C. Kain (2012) Angiopoietin-2 levels are associated with retinopathy and predict mortality 
in Malawian children with cerebral malaria: a retrospective case-control study*. Crit Care 
Med, 40, 952-9.
Conway, D. J. (1997) Natural selection on polymorphic malaria antigens and the search for a vaccine.
Parasitol Today, 13,26-9.
Conway, D. J., D. R. Cavanagh, K. Tanabe, C. Roper, Z. S. Mikes, N. Sakihama, K. A. Bojang, A. M. 
Oduola, P. G. Kremsner, D. E. Arnot, B. M. Greenwood & J. S. McBride (2000) A principal
target of human immunity to malaria identified by molecular population genetic and 
immunological analyses. Nat Med, 6, 689-92.
Conway, D. J., B. M. Greenwood & J. S. McBride (1992) Longitudinal study of Plasmodium 
falciparum polymorphic antigens in a malaria-endemic population. Infect Immun, 60, 1122-7.
Corran, P. H., J. Cook, C. Lynch, H. Leendertse, A. Manjurano, J. Griffin, J. Cox, T. Abeku, T. 
Bousema, A. C. Ghani, C. Drakeley & E. Riley (2008) Dried blood spots as a source of anti- 
malarial antibodies for epidemiological studies. Malar J, 7, 195.
Cortes, A., M. Mellombo, R. Masciantonio, V. J. Murphy, J. C. Reeder & R. F. Anders (2005) Allele 
specificity of naturally acquired antibody responses against Plasmodium falciparum apical 
membrane antigen 1. Infect Immun, 73,422-30.
Costa-Carvalho, B. T., H. M. Vieria, R. B. Dimantas, C. Arslanian, C. K. Naspitz, D. Sole & M. M. 
Cameiro-Sampaio (1996) Transfer of IgG subclasses across placenta in term and preterm 
newborns. BrazJ Med Biol Res, 29,201-4.
Courtin, D., M. Oesterholt, H. Huismans, K. Kusi, J. Milet, C. Badaut, O. Gaye, W. Roeffen, E. J. 
Remarque, R. Sauerwein, A. Garcia & A. J. Luty (2009) The quantity and quality of African 
children's IgG responses to merozoite surface antigens reflect protection against Plasmodium 
falciparum malaria. PLoS One, 4, e7590.
Crawley, J., C. Chu, G. Mtove & F. Nosten (2010) Malaria in children. Lancet, 375, 1468-81.
Crawley, J., C. Waruiru, S. Mithwani, I. Mwangi, W. Watkins, D. Ouma, P. Winstanley, T. Peto & K. 
Marsh (2000) Effect of phenobarbital on seizure frequency and mortality in childhood cerebral 
malaria: a randomised, controlled intervention study. Lancet, 355,701-6.
Crompton, P. D., M. A. Kayala, B. Traore, K. Kayentao, A. Ongoiba, G. E. Weiss, D. M. Molina, C. R. 
Burk, M. Waisberg, A. Jasinskas, X. Tan, S. Doumbo, D. Doumtabe, Y. Kone, D. L. Narum, 
X. Liang, O. K. Doumbo, L. H. Miller, D. L. Doolan, P. Baldi, P. L. Feigner & S. K. Pierce 
(2010a) A prospective analysis of the Ab response to Plasmodium falciparum before and after 
a malaria season by protein microarray. Proc Natl Acad Sci USA,  107, 6958-63.
Crompton, P. D., K. Miura, B. Traore, K. Kayentao, A. Ongoiba, G. Weiss, S. Doumbo, D. Doumtabe, 
Y. Kone, C. Y. Huang, O. K. Doumbo, L. H. Miller, C. A. Long & S. K. Pierce (2010b) In 
vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun, 78, 
737-45.
Crosnier, C., L. Y. Bustamante, S. J. Bartholdson, A. K. Bei, M. Theron, M. Uchikawa, S. Mboup, O. 
Ndir, D. P. Kwiatkowski, M. T. Duraisingh, J. C. Rayner & G. J. Wright (2011) Basigin is a 
receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature, 480, 534-7.
Crosnier, C., M. Wanaguru, B. McDade, F. H. Osier, K. Marsh, J. C. Rayner & G. J. Wright (2013) A 
library of functional recombinant cell-surface and secreted P. falciparum merozoite proteins. 
Mol Cell Proteomics, 12, 3976-86.
D'Ombrain, M. C., L. J. Robinson, D. I. Stanisic, J. Taraika, N. Bernard, P. Michon, I. Mueller & L. 
Schofield (2008) Association of early interferon-gamma production with immunity to clinical 
malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis, 47, 1380-7.
Day, N. P., T. T. Hien, T. Schollaardt, P. P. Loc, L. V. Chuong, T. T. Chau, N. T. Mai, N. H. Phu, D. 
X. Sinh, N. J. White & M. Ho (1999) The prognostic and pathophysiologic role of pro- and 
antiinflammatory cytokines in severe malaria. J Infect Dis, 180, 1288-97.
Day, N. P., N. H. Phu, N. T. Mai, T. T. Chau, P. P. Loc, L. V. Chuong, D. X. Sinh, P. Holloway, T. T. 
Hien & N. J. White (2000) The pathophysiologic and prognostic significance of acidosis in 
severe adult malaria. Crit Care Med, 28, 1833-40.
De Caterina, R., P. Libby, H. B. Peng, V. J. Thannickal, T. B. Rajavashisth, M. A. Gimbrone, Jr., W. S. 
Shin & J. K. Liao (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric 
oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory 
cytokines. J Clin Invest, 96, 60-8.
de Souza, J. B., J. Todd, G. Krishegowda, D. C. Gowda, D. Kwiatkowski & E. M. Riley (2002) 
Prevalence and boosting of antibodies to Plasmodium falciparum 
glycosylphosphatidylinositols and evaluation of their association with protection from mild and 
severe clinical malaria. Infect Immun, 70, 5045-51.
Del Giudice, G., H. D. Engers, C. Tougne, S. S. Biro, N. Weiss, A. S. Verdini, A. Pessi, A. A. 
Degremont, T. A. Freyvogel, P. H. Lambert & et al. (1987) Antibodies to the repetitive epitope
300
of Plasmodium falciparum circumsporozoite protein in a rural Tanzanian community: a 
longitudinal study of 132 children. Am J  Trop Med Hyg, 36, 203-12.
Deloron, P. & C. Chougnet (1992) Is immunity to malaria really short-lived? Parasitol Today, 8, 375- 
8 .
Deloron, P., B. Dubois, J. Y. Le Hesran, D. Riche, N. Fievet, M. Comet, P. Ringwald & M. Cot (1997) 
Isotypic analysis of maternally transmitted Plasmodium falciparum-specific antibodies in 
Cameroon, and relationship with risk of P. falciparum infection. Clin Exp Immunol, 110, 212- 
8 .
Dent, A. E., E. S. Bergmann-Leitner, D. W. Wilson, D. J. Tisch, R. Kimmel, J. Vulule, P. O. Sumba, J.
G. Beeson, E. Angov, A. M. Moormann & J. W. Kazura (2008) Antibody-mediated growth
inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in 
Kenyan children and adults. PLoS One, 3, e3557.
Desai, M., F. O. ter Kuile, F. Nosten, R. McGready, K. Asamoa, B. Brabin & R. D. Newman (2007) 
Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis, 7, 93-104.
Diatta, A. M., L. Marrama, A. Tall, J. F. Trape, A. Dieye, O. Garraud, O. Mercereau-Puijalon & R.
Perraut (2004) Relationship of binding of immunoglobulin G to Plasmodium falciparum-
infected erythrocytes with parasite endemicity and antibody responses to conserved antigen in 
immune individuals. Clin Diagn Lab Immunol, 11,6-11.
Dicko, A., I. Sagara, R. D. Ellis, K. Miura, O. Guindo, B. Kamate, M. Sogoba, M. B. Niambele, M. 
Sissoko, M. Baby, A. Dolo, G. E. Mullen, M. P. Fay, M. Pierce, D. A. Diallo, A. Saul, L. H. 
Miller & O. K. Doumbo (2008) Phase 1 study of a combination AMA1 blood stage malaria 
vaccine in Malian children. PLoS One, 3, el 563.
Dobano, C., S. J. Rogerson, M. J. Mackinnon, D. R. Cavanagh, T. E. Taylor, M. E. Molyneux & J. S. 
McBride (2008) Differential antibody responses to Plasmodium falciparum merozoite proteins 
in Malawian children with severe malaria. J Infect Dis, 197, 766-74.
Dodoo, D., A. Aikins, K. A. Kusi, H. Lamptey, E. Remarque, P. Milligan, S. Bosomprah, R. Chilengi, 
Y. D. Osei, B. D. Akanmori & M. Theisen (2008) Cohort study o f the association of antibody 
levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in 
Ghanaian children. Malar J, 7, 142.
Dodoo, D., M. R. Hollingdale, D. Anum, K. A. Koram, B. Gyan, B. D. Akanmori, J. Ocran, S. Adu- 
Amankwah, H. Geneshan, E. Abot, J. Legano, G. Banania, R. Sayo, D. Brambilla, S. Kumar,
D. L. Doolan, W. O. Rogers, J. Epstein, T. L. Richie & M. Sedegah (2011) Measuring 
naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults. 
Malar J, 10, 168.
Dodoo, D., F. M. Omer, J. Todd, B. D. Akanmori, K. A. Koram & E. M. Riley (2002) Absolute levels 
and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict 
clinical immunity to Plasmodium falciparum malaria. J  Infect Dis, 185, 971-9.
Dodoo, D., T. Staalsoe, H. Giha, J. A. Kurtzhals, B. D. Akanmori, K. Koram, S. Dunyo, F. K. 
Nkrumah, L. Hviid & T. G. Theander (2001) Antibodies to variant antigens on the surfaces of 
infected erythrocytes are associated with protection from malaria in Ghanaian children. Infect 
Immun, 69, 3713-8.
Dodoo, D., M. Theisen, J. A. Kurtzhals, B. D. Akanmori, K. A. Koram, S. Jepsen, F. K. Nkrumah, T.
G. Theander & L. Hviid (2000) Naturally acquired antibodies to the glutamate-rich protein are 
associated with protection against Plasmodium falciparum malaria. J  Infect Dis, 181, 1202-5. 
Dondorp, A. M., B. J. Angus, M. R. Hardeman, K. T. Chotivanich, K. Silamut, R. Ruangveerayuth, P.
A. Kager, N. J. White & J. Vreeken (1997) Prognostic significance of reduced red blood cell 
deformability in severe falciparum malaria. Am J Trop Med Hyg, 57, 507-11.
Dondorp, A. M., C. I. Fanello, I. C. Hendriksen, E. Gomes, A. Seni, K. D. Chhaganlal, K. Bojang, R. 
Olaosebikan, N. Anunobi, K. Maitland, E. Kivaya, T. Agbenyega, S. B. Nguah, J. Evans, S. 
Gesase, C. Kahabuka, G. Mtove, B. Nadjm, J. Deen, J. Mwanga-Amumpaire, M. Nansumba, 
C. Karema, N. Umulisa, A. Uwimana, O. A. Mokuolu, O. T. Adedoyin, W. B. Johnson, A. K. 
Tshefu, M. A. Onyamboko, T. Sakulthaew, W. P. Ngum, K. Silamut, K. Stepniewska, C. J. 
Woodrow, D. Bethell, B. Wills, M. Oneko, T. E. Peto, L. von Seidlein, N. P. Day & N. J. 
White (2010) Artesunate versus quinine in the treatment of severe falciparum malaria in 
African children (AQUAMAT): an open-label, randomised trial. Lancet, 376, 1647-57.
301
Dondorp, A. M., S. J. Lee, M. A. Faiz, S. Mishra, R. Price, E. Tjitra, M. Than, Y. Htut, S. Mohanty, E.
B. Yunus, R. Rahman, F. Nosten, N. M. Anstey, N. P. Day & N. J. White (2008) The 
relationship between age and the manifestations of and mortality associated with severe 
malaria. Clin Infect Dis, 47, 151-7.
Dondorp, A. M., F. Nosten, P. Yi, D. Das, A. P. Phyo, J. Taming, K. M. Lwin, F. Ariey, W. 
Hanpithakpong, S. J. Lee, P. Ringwald, K. Silamut, M. Imwong, K. Chotivanich, P. Lim, T. 
Herdman, S. S. An, S. Yeung, P. Singhasivanon, N. P. Day, N. Lindegardh, D. Socheat & N. J. 
White (2009) Artemisinin resistance in Plasmodium falciparum malaria. N Engl J  Med, 361, 
455-67.
Dondorp, A. M., M. Nyanoti, P. A. Kager, S. Mithwani, J. Vreeken & K. Marsh (2002) The role of 
reduced red cell deformability in the pathogenesis of severe falciparum malaria and its 
restoration by blood transfusion. Trans R Soc Trop Med Hyg, 96,282-6.
Dondorp, A. M., E. Pongponratn & N. J. White (2004) Reduced microcirculatory flow in severe 
falciparum malaria: pathophysiology and electron-microscopic pathology. Acta Trop, 89, 309- 
17.
Doolan, D. L., C. Dobano & J. K. Baird (2009) Acquired immunity to malaria. Clin Microbiol Rev, 22, 
13-36, Table of Contents.
Doolan, D. L., Y. Mu, B. Unal, S. Sundaresh, S. Hirst, C. Valdez, A. Randall, D. Molina, X. Liang, D. 
A. Freilich, J. A. Oloo, P. L. Blair, J. C. Aguiar, P. Baldi, D. H. Davies & P. L. Feigner (2008) 
Profiling humoral immune responses to P. falciparum infection with protein microarrays. 
Proteomics, 8,4680-94.
Douglas, A. D., A. R. Williams, J. J. Illingworth, G. Kamuyu, S. Biswas, A. L. Goodman, D. H. 
Wyllie, C. Crosnier, K. Miura, G. J. Wright, C. A. Long, F. H. Osier, K. Marsh, A. V. Turner, 
A. V. Hill & S. J. Draper (2011) The blood-stage malaria antigen PfRH5 is susceptible to 
vaccine-inducible cross-strain neutralizing antibody. Nat Commun, 2, 601.
Drakeley, C. J., P. H. Corran, P. G. Coleman, J. E. Tongren, S. L. McDonald, I. Cameiro, R. Malima, J. 
Lusingu, A. Manjurano, W. M. Nkya, M. M. Lemnge, J. Cox, H. Reybum & E. M. Riley 
(2005) Estimating medium- and long-term trends in malaria transmission by using serological 
markers of malaria exposure. Proc Natl Acad Sci USA,  102, 5108-13.
Drew, D. R., A. N. Hodder, D. W. Wilson, M. Foley, I. Mueller, P. M. Siba, A. E. Dent, A. F. Cowman 
& J. G. Beeson (2012) Defining the antigenic diversity of Plasmodium falciparum apical 
membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS 
One, 7, e51023.
Druilhe, P., O. Pradier, J. P. Marc, F. Miltgen, D. Mazier & G. Parent (1986) Levels of antibodies to 
Plasmodium falciparum sporozoite surface antigens reflect malaria transmission rates and are 
persistent in the absence of reinfection. Infect Immun, 53, 393-7.
Druilhe, P., F. Spertini, D. Soesoe, G. Corradin, P. Mejia, S. Singh, R. Audran, A. Bouzidi, C. Oeuvray 
& C. Roussilhon (2005) A malaria vaccine that elicits in humans antibodies able to kill 
Plasmodium falciparum. PLoS Med, 2, e344.
Duah, N. O., D. J. Miles, H. C. Whittle & D. J. Conway (2010) Acquisition o f antibody isotypes 
against Plasmodium falciparum blood stage antigens in a birth cohort. Parasite Immunol, 32, 
125-34.
Duan, J., J. Mu, M. A. Thera, D. Joy, S. L. Kosakovsky Pond, D. Diemert, C. Long, H. Zhou, K. 
Miura, A. Ouattara, A. Dolo, O. Doumbo, X. Z. Su & L. Miller (2008) Population structure of 
the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: 
implications for vaccine design. Proc Natl Acad Sci U S A, 105, 7857-62.
Dufour, C., A. Corcione, J. Svahn, R. Haupt, V. Poggi, A. N. Beka’ssy, R. Scime, A. Pistorio & V. 
Pistoia (2003) TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi 
anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood, 102, 2053-9.
Duncan, C. J., A. V. Hill & R. D. Ellis (2012) Can growth inhibition assays (GIA) predict blood-stage 
malaria vaccine efficacy? Hum Vaccin Immunother, 8, 706-14.
Duraisingh, M. T., T. Triglia, S. A. Ralph, J. C. Rayner, J. W. Barnwell, G. I. McFadden & A. F. 
Cowman (2003) Phenotypic variation of Plasmodium falciparum merozoite proteins directs 
receptor targeting for invasion of human erythrocytes. EMBOJ, 22, 1047-57.
Dutta, S., L. S. Dlugosz, D. R. Drew, X. Ge, D. Ababacar, Y. I. Rovira, J. K. Moch, M. Shi, C. A. 
Long, M. Foley, J. G. Beeson, R. F. Anders, K. Miura, J. D. Haynes & A. H. Batchelor (2013)
Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on 
the malaria vaccine candidate apical membrane antigen-1. PLoS Pcithog, 9, e l003840.
Dutta, S., P. V. Lalitha, L. A. Ware, A. Barbosa, J. K. Moch, M. A. Vassell, B. B. Fileta, S. Kitov, N. 
Kolodny, D. G. Heppner, J. D. Haynes & D. E. Lanar (2002) Purification, characterization, and 
immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane 
antigen 1 expressed in Escherichia coli. Infect Immun, 70, 3101-10.
Dutta, S., J. S. Sullivan, K. K. Grady, J. D. Haynes, J. Komisar, A. H. Batchelor, L. Soisson, C. L. 
Diggs, D. G. Heppner, D. E. Lanar, W. E. Collins & J. W. Barnwell (2009) High antibody titer 
against apical membrane antigen-1 is required to protect against malaria in the Aotus model. 
PLoS One, 4, e8138.
Edozien, J. C., H. M. Gilles & I. O. K. Udeozo (1962) Adult and cord-blood gamma-globulin and 
immunity to malaria in Nigerians. Lancet.
Egan, A., M. Waterfall, M. Pinder, A. Holder & E. Riley (1997) Characterization of human T- and B- 
cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: 
evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect 
Immun, 65, 3024-31.
Egan, A. F., P. Burghaus, P. Druilhe, A. A. Holder & E. M. Riley (1999) Human antibodies to the 
19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit 
parasite growth in vitro. Parasite Immunol, 21, 133-9.
Egan, A. F., J. Morris, G. Barnish, S. Allen, B. M. Greenwood, D. C. Kaslow, A. A. Holder & E. M. 
Riley (1996) Clinical immunity to Plasmodium falciparum malaria is associated with serum 
antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J 
Infect Dis, 173,765-9.
Ehreth, J. (2003) The global value of vaccination. Vaccine, 21, 596-600.
Ekvall, H. (2003) Malaria and anemia. Curr Opin Hematol, 10, 108-14.
El Sahly, H. M., S. M. Patel, R. L. Atmar, T. A. Lanford, T. Dube, D. Thompson, B. K. Sim, L. C. & 
W. A. Keitel (2010) Safety and immunogenicity o f a recombinant nonglycosylated erythrocyte 
binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria 
is not endemic. Clinical and vaccine immunology, 17, 1552-9.
Elias, S. C., P. Choudhary, S. C. de Cassan, S. Biswas, K. A. Collins, F. D. Halstead, C. M. Bliss, K. J. 
Ewer, S. H. Hodgson, C. J. Duncan, A. V. Hill & S. J. Draper (2014) Analysis of human B-cell 
responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria 
infection. Immunology, 141, 628-44.
Ellis, R. D., L. B. Martin, D. Shaffer, C. A. Long, K. Miura, M. P. Fay, D. L. Narum, D. Zhu, G. E. 
Mullen, S. Mahanty, L. H. Miller & A. P. Durbin (2010) Phase 1 trial of the Plasmodium 
falciparum blood stage vaccine MSPl(42)-Cl/Alhydrogel with and without CPG 7909 in 
malaria naive adults. PLoS One, 5, e8787.
Ellis, R. D., G. E. Mullen, M. Pierce, L. B. Martin, K. Miura, M. P. Fay, C. A. Long, D. Shaffer, A. 
Saul, L. H. Miller & A. P. Durbin (2009) A Phase 1 study of the blood-stage malaria vaccine 
candidate AMAl-Cl/Alhydrogel with CPG 7909, using two different formulations and dosing 
intervals. Vaccine, 27,4104-9.
Ellis, R. D., Y. Wu, L. B. Martin, D. Shaffer, K. Miura, J. Aebig, A. Orcutt, K. Rausch, D. Zhu, A. 
Mogensen, M. P. Fay, D. L. Narum, C. Long, L. Miller & A. P. Durbin (2012) Phase 1 study in 
malaria naive adults of BSAM2/Alhydrogel(R)+CPG 7909, a blood stage vaccine against P. 
falciparum malaria. PLoS One, 7, e46094.
Engvall, E. & P. Perlmann (1971) Enzyme-linked immunosorbent assay (ELISA). Quantitative assay 
of immunoglobulin G. Immunochemistry, 8, 871-4.
— (1972) Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by 
enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J  Immunol, 109, 129-35.
Epping, R. J., S. D. Goldstone, L. T. Ingram, J. A. Upcroft, R. Ramasamy, J. A. Cooper, G. R. Bushell 
& H. M. Geysen (1988) An epitope recognised by inhibitory monoclonal antibodies that react 
with a 51 kilodalton merozoite surface antigen in Plasmodium falciparum. Mol Biochem 
Parasitol, 28, 1-10.
Epstein, J. E., K. Tewari, K. E. Lyke, B. K. Sim, P. F. Billingsley, M. B. Laurens, A. Gunasekera, S. 
Chakravarty, E. R. James, M. Sedegah, A. Richman, S. Velmurugan, S. Reyes, M. Li, K. 
Tucker, A. Ahumada, A. J. Ruben, T. Li, R. Stafford, A. G. Eappen, C. Tamminga, J. W.
Bennett, C. F. Ockenhouse, J. R. Murphy, J. Komisar, N. Thomas, M. Loyevsky, A. Birkett, C. 
V. Plowe, C. Loucq, R. Edelman, T. L. Richie, R. A. Seder & S. L. Hoffman (2011) Live 
attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. 
Science, 334,475-80.
Ernst, K. C., S. O. Adoka, D. O. Kowuor, M. L. Wilson & C. C. John (2006) Malaria hotspot areas in a 
highland Kenya site are consistent in epidemic and non-epidemic years and are associated with 
ecological factors. Malar J, 5, 78.
Erunkulu, O. A., A. V. Hill, D. P. Kwiatkowski, J. E. Todd, J. Iqbal, K. Berzins, E. M. Riley & B. M. 
Greenwood (1992) Severe malaria in Gambian children is not due to lack of previous exposure 
to malaria. Clin Exp Immunol, 89,296-300.
Ewer, K. J., G. A. O'Hara, C. J. Duncan, K. A. Collins, S. H. Sheehy, A. Reyes-Sandoval, A. L. 
Goodman, N. J. Edwards, S. C. Elias, F. D. Halstead, R. J. Longley, R. Rowland, I. D. Poulton, 
S. J. Draper, A. M. Blagborough, E. Berrie, S. Moyle, N. Williams, L. Siani, A. Folgori, S. 
Colloca, R. E. Sinden, A. M. Lawrie, R. Cortese, S. C. Gilbert, A. Nicosia & A. V. Hill (2013) 
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA 
immunisation. Nat Commun, 4, 2836.
Felger, I., S. Steiger, C. Hatz, T. Smith & H. P. Beck (2003) Antigenic cross-reactivity between 
different alleles of the Plasmodium falciparum merozoite surface protein 2. Parasite Immunol, 
25, 531-43.
Felli, N., F. Pedini, A. Zeuner, E. Petrucci, U. Testa, C. Conticello, M. Biffoni, A. Di Cataldo, J. A. 
Winkles, C. Peschle & R. De Maria (2005) Multiple members of the TNF superfamily 
contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol, 175, 1464-72. 
Fenton, B., J. T. Clark, C. M. Khan, J. V. Robinson, D. Walliker, R. Ridley, J. G. Scaife & J. S. 
McBride (1991) Structural and antigenic polymorphism of the 35- to 48-kilodalton merozoite 
surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum. Mol Cell Biol, 11, 
963-71.
Fonjungo, P. N., I. M. Elhassan, D. R. Cavanagh, T. G. Theander, L. Hviid, C. Roper, D. E. Arnot & J. 
S. McBride (1999) A longitudinal study of human antibody responses to Plasmodium 
falciparum rhoptry-associated protein 1 in a region of seasonal and unstable malaria 
transmission. Infect Immun, 67,2975-85.
Fouda, G. G., R. F. Leke, C. Long, P. Druilhe, A. Zhou, D. W. Taylor & A. H. Johnson (2006) 
Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium 
falciparum antigens. Clin Vaccine Immunol, 13, 1307-13.
Fowkes, F. J., R. McGready, N. J. Cross, M. Hommel, J. A. Simpson, S. R. Elliott, J. S. Richards, K. 
Lackovic, J. Viladpai-Nguen, D. Narum, T. Tsuboi, R. F. Anders, F. Nosten & J. G. Beeson
(2012) New insights into acquisition, boosting, and longevity of immunity to malaria in 
pregnant women. J  Infect Dis, 206, 1612-21.
Fowkes, F. J., J. S. Richards, J. A. Simpson & J. G. Beeson (2010) The relationship between anti- 
merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review 
and meta-analysis. PLoS Med, 7, e l000218.
Frey, A., J. Di Canzio & D. Zurakowski (1998) A statistically defined endpoint titer determination 
method for immunoassays. J  Immunol Methods, 221, 35-41.
Fried, M., M. Avril, R. Chaturvedi, P. Fernandez, J. Lograsso, D. Narum, M. A. Nielsen, A. V. 
Oleinikov, M. Resende, A. Salanti, T. Saveria, K. Williamson, A. Dicko, A. Scherf, J. D. 
Smith, T. G. Theander & P. E. Duffy (2013) Multilaboratory approach to preclinical evaluation 
of vaccine immunogens for placental malaria. Infect Immun, 81,487-95.
Fried, M. & P. E. Duffy (1996) Adherence of Plasmodium falciparum to chondroitin sulfate A in the 
human placenta. Science, 272, 1502-4.
Galamo, C. D., A. Jafarshad, C. Blanc & P. Druilhe (2009) Anti-MSPl block 2 antibodies are effective 
at parasite killing in an allele-specific manner by monocyte-mediated antibody-dependent 
cellular inhibition. J Infect Dis, 199, 1151-4.
Gardner, M. J., N. Hall, E. Fung, O. White, M. Berriman, R. W. Hyman, J. M. Carlton, A. Pain, K. E. 
Nelson, S. Bowman, I. T. Paulsen, K. James, J. A. Eisen, K. Rutherford, S. L. Salzberg, A. 
Craig, S. Kyes, M. S. Chan, V. Nene, S. J. Shallom, B. Suh, J. Peterson, S. Angiuoli, M. 
Pertea, J. Allen, J. Selengut, D. Haft, M. W. Mather, A. B. Vaidya, D. M. Martin, A. H. 
Fairlamb, M. J. Fraunholz, D. S. Roos, S. A. Ralph, G. I. McFadden, L. M. Cummings, G. M.
Subramanian, C. Mungall, J. C. Venter, D. J. Carucci, S. L. Hoffman, C. Newbold, R. W. 
Davis, C. M. Fraser & B. Barrell (2002) Genome sequence of the human malaria parasite 
Plasmodium falciparum. Nature, 419,498-511.
Gaucher, D., R. Therrien, N. Kettaf, B. R. Angermann, G. Boucher, A. Filali-Mouhim, J. M. Moser, R. 
S. Mehta, D. R. Drake, 3rd, E. Castro, R. Akondy, A. Rinffet, B. Yassine-Diab, E. A. Said, Y. 
Chouikh, M. J. Cameron, R. Clum, D. Kelvin, R. Somogyi, L. D. Greller, R. S. Balderas, P. 
Wilkinson, G. Pantaleo, J. Tartaglia, E. K. Haddad & R. P. Sekaly (2008) Yellow fever vaccine 
induces integrated multilineage and polyfunctional immune responses. J  Exp Med, 205, 3119- 
31.
Gaudart, J., B. Poudiougou, A. Dicko, S. Ranque, O. Toure, I. Sagara, M. Diallo, S. Diawara, A. 
Ouattara, M. Diakite & O. K. Doumbo (2006) Space-time clustering of childhood malaria at 
the household level: a dynamic cohort in a Mali village. BMC Public Health, 6, 286.
Genton, B., I. Betuela, I. Felger, F. Al-Yaman, R. F. Anders, A. Saul, L. Rare, M. Baisor, K. Lorry, G. 
V. Brown, D. Pye, D. O. Irving, T. A. Smith, H. P. Beck & M. P. Alpers (2002) A recombinant 
blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective 
pressure on parasite populations in a phase 1 -2b trial in Papua New Guinea. J  Infect Dis, 185, 
820-7.
Genton, B., G. Pluschke, L. Degen, A. R. Kammer, N. Westerfeld, S. L. Okitsu, S. Schroller, P. 
Vounatsou, M. M. Mueller, M. Tanner & R. Zurbriggen (2007) A randomized placebo- 
controlled phase la malaria vaccine trial of two virosome-formulated synthetic peptides in 
healthy adult volunteers. PLoS One, 2, el018.
Ghumra, A., P. Khunrae, R. Ataide, A. Raza, S. J. Rogerson, M. K. Higgins & J. A. Rowe (2011) 
Immunisation with recombinant PfEMPl domains elicits functional rosette-inhibiting and 
phagocytosis-inducing antibodies to Plasmodium falciparum. PLoS One, 6, el6414.
Giha, H. A., T. Staalsoe, D. Dodoo, C. Roper, G. M. Satti, D. E. Amot, L. Hviid & T. G. Theander
(2000) Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are 
associated with protection from novel malaria infections. Immunol Lett, 71,117-26.
Gitau, E. N., J. Tuju, L. Stevenson, E. Kimani, H. Karanja, K. Marsh, P. C. Bull & B. C. Urban (2012) 
T-cell responses to the DBLalpha-tag, a short semi-conserved region o f the Plasmodium 
falciparum membrane erythrocyte protein 1. PLoS One, 7, e30095.
Gowda, D. C. (2007) TLR-mediated cell.signaling by malaria GPIs. Trends Parasitol, 23, 596-604.
Grau, G. E., C. D. Mackenzie, R. A. Carr, M. Redard, G. Pizzolato, C. Allasia, C. Cataldo, T. E. Taylor 
& M. E. Molyneux (2003) Platelet accumulation in brain microvessels in fatal pediatric 
cerebral malaria. J  Infect Dis, 187, 461 -6.
Gray, J. C., P. H. Corran, E. Mangia, M. W. Gaunt, Q. Li, K. K. Tetteh, S. D. Polley, D. J. Conway, A. 
A. Holder, T. Bacarese-Hamilton, E. M. Riley & A. Crisanti (2007) Profiling the antibody 
immune response against blood stage malaria vaccine candidates. Clin Chem, 53, 1244-53.
Green, T. J., M. Morhardt, R. G. Brackett & R. L. Jacobs (1981) Serum inhibition of merozoite 
dispersal from Plasmodium falciparum schizonts: indicator of immune status. Infect Immun, 
31, 1203-8.
Greve, B., P. G. Kremsner, B. Lell, D. Luckner & D. Schmid (2000) Malarial anaemia in African 
children associated with high oxygen-radical production. Lancet, 355, 40-1.
Greve, B., L. G. Lehman, B. Lell, D. Luckner, R. Schmidt-Ott & P. G. Kremsner (1999) High oxygen 
radical production is associated with fast parasite clearance in children with Plasmodium 
falciparum malaria. J Infect Dis, 179, 1584-6.
Griffin, J. T., N. M. Ferguson & A. C. Ghani (2014) Estimates of the changing age-burden of 
Plasmodium falciparum malaria disease in sub-Saharan Africa. Nat Commun, 5, 3136.
Gupta, S., R. W. Snow, C. A. Donnelly, K. Marsh & C. Newbold (1999) Immunity to non-cerebral 
severe malaria is acquired after one or two infections. Nat Med, 5, 340-3.
Gwadz, R. W., A. H. Cochrane, V. Nussenzweig & R. S. Nussenzweig (1979) Preliminary studies on 
vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and 
characterization of surface antigens of these parasites. Bull World Health Organ, 57 Suppl 1, 
165-73.
Hay, S. I., D. L. Smith & R. W. Snow (2008) Measuring malaria endemicity from intense to 
interrupted transmission. Lancet Infect Dis, 8, 369-78.
305
Healer, J., S. Crawford, S. Ralph, G. McFadden & A. F. Cowman (2002) Independent translocation of 
two micronemal proteins in developing Plasmodium falciparum merozoites. Infect Immun, 70, 
5751-8.
Healer, J., V. Murphy, A. N. Hodder, R. Masciantonio, A. W. Gemmill, R. F. Anders, A. F. Cowman 
& A. Batchelor (2004) Allelic polymorphisms in apical membrane antigen-1 are responsible 
for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol, 52, 
159-68.
Hero, M., S. P. Harding, C. E. Riva, P. A. Winstanley, N. Peshu & K. Marsh (1997) Photographic and 
angiographic characterization of the retina of Kenyan children with severe malaria. Arch 
Ophthalmol, 115,997-1003.
Hill, D. L., E. M. Eriksson, A. B. Carmagnac, D. W. Wilson, A. F. Cowman, D. S. Hansen & L. 
Schofield (2012) Efficient measurement of opsonising antibodies to Plasmodium falciparum 
merozoites. PLoS One, 7, e51692.
Hill, D. L., E. M. Eriksson, C. S. Li Wai Suen, C. Y. Chiu, V. Ryg-Comejo, L. J. Robinson, P. M. 
Siba, 1. Mueller, D. S. Hansen & L. Schofield (2013) Opsonising antibodies to P. falciparum 
merozoites associated with immunity to clinical malaria. PLoS One, 8, e74627.
Himeidan, Y. E., H. M. Muzamil, C. M. Jones & H. Ranson (2011) Extensive permethrin and DDT 
resistance in Anopheles arabiensis from eastern and central Sudan. Parasit Vectors, 4, 154.
Hodder, A. N., P. E. Crewther & R. F. Anders (2001) Specificity of the protective antibody response to 
apical membrane antigen 1. Infect Immun, 69, 3286-94.
Hodder, A. N., P. E. Crewther, M. L. Matthew, G. E. Reid, R. L. Moritz, R. J. Simpson & R. F. Anders 
(1996) The disulfide bond structure of Plasmodium apical membrane antigen-1. J  Biol Chem, 
271,29446-52.
Hoffman, S. L., P. F. Billingsley, E. James, A. Richman, M. Loyevsky, T. Li, S. Chakravarty, A. 
Gunasekera, R. Chattopadhyay, M. Li, R. Stafford, A. Ahumada, J. E. Epstein, M. Sedegah, S. 
Reyes, T. L. Richie, K. E. Lyke, R. Edelman, M. B. Laurens, C. V. Plowe & B. K. Sim (2010) 
Development of a metabolically active, non-replicating sporozoite vaccine to prevent 
Plasmodium falciparum malaria. Hum Vaccin, 6, 97-106.
Hogh, B., N. T. Marbiah, P. A. Burghaus & P. K. Andersen (1995) Relationship between maternally 
derived anti-Plasmodium falciparum antibodies and risk of infection and disease in infants 
living in an area of Liberia, west Africa, in which malaria is highly endemic. Infect Immun, 63, 
4034-8.
Holder, A. A., M. J. Blackman, P. A. Burghaus, J. A. Chappel, I. T. Ling, N. McCallum-Deighton & S. 
Shai (1992) A malaria merozoite surface protein (MSPl)-structure, processing and function. 
Mem Inst Oswaldo Cruz, 87 Suppl 3, 37-42.
Hollestelle, M. J., C. Donkor, E. A. Mantey, S. J. Chakravorty, A. Craig, A. O. Akoto, J. O'Donnell, J. 
A. van Mourik & J. Bunn (2006) von Willebrand factor propeptide in malaria: evidence of 
acute endothelial cell activation. Br J  Haematol, 133, 562-9.
Horii, T., H. Shirai, L. Jie, K. J. Ishii, N. Q. Palacpac, T. Tougan, M. Hato, N. Ohta, A. Bobogare, N. 
Arakaki, Y. Matsumoto, J. Namazue, T. Ishikawa, S. Ueda & M. Takahashi (2010) Evidences 
of protection against blood-stage infection of Plasmodium falciparum by the novel protein 
vaccine SE36. Parasitol Int, 59, 380-6.
Howell, S. A., C. Withers-Martinez, C. H. Kocken, A. W. Thomas & M. J. Blackman (2001) 
Proteolytic processing and primary structure of Plasmodium falciparum apical membrane 
antigen-1. J Biol Chem, 276, 31311 -20.
Hu, J., Z. Chen, J. Gu, M. Wan, Q. Shen, M. P. Kieny, J. He, Z. Li, Q. Zhang, Z. H. Reed, Y. Zhu, W. 
Li, Y. Cao, L. Qu, Z. Cao, Q. Wang, H. Liu, X. Pan, X. Huang, D. Zhang, X. Xue & W. Pan 
(2008) Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA- 
1/MSP-l chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS One, 3, 
el952.
Huber, W., I. Felger, H. Matile, H. J. Lipps, S. Steiger & H. P. Beck (1997) Limited sequence 
polymorphism in the Plasmodium falciparum merozoite surface protein 3. Mol Biochem 
Parasitol, 87,231-4.
Idro, R., N. E. Jenkins & C. R. Newton (2005) Pathogenesis, clinical features, and neurological 
outcome of cerebral malaria. Lancet Neurol, 4, 827-40.
306
Idro, R., M. Ndiritu, B. Ogutu, S. Mithwani, K. Maitland, J. Berkley, J. Crawley, G. Fegan, E. Bauni, 
N. Peshu, K. Marsh, B. Neville & C. Newton (2007) Burden, features, and outcome of 
neurological involvement in acute falciparum malaria in Kenyan children. JAMA, 297, 2232- 
40.
Iriemenam, N. C., A. H. Khirelsied, A. Nasr, G. ElGhazali, H. A. Giha, A. E. T. M. Elhassan, A. A. 
Agab-Aldour, S. M. Montgomery, R. F. Anders, M. Theisen, M. Troye-Blomberg, M. I. 
Elbashir & K. Berzins (2009) Antibody responses to a panel of Plasmodium falciparum 
malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine, 27, 62- 
71.
Jagannathan, P., I. Eccles-James, K. Bowen, F. Nankya, A. Auma, S. Wamala, C. Ebusu, M. K. 
Muhindo, E. Arinaitwe, J. Briggs, B. Greenhouse, J. W. Tappero, M. R. Kamya, G. Dorsey & 
M. E. Feeney (2014) IFNgamma/IL-10 co-producing cells dominate the CD4 response to 
malaria in highly exposed children. PLoS Pathog, 10, el003864.
Jelinek, T., C. Schulte, R. Behrens, M. P. Grobusch, J. P.- Coulaud, Z. Bisoffi, A. Matteelli, J. Clerinx, 
M. Corachan, S. Puente, I. Gjorup, G. Harms, H. Kollaritsch, A. Kotlowski, A. Bjorkmann, J. 
P. Delmont, J. Knobloch, L. N. Nielsen, J. Cuadros, C. Hatz, J. Beran, M. L. Schmid, M. 
Schulze, R. Lopez-Velez, K. Fleischer, A. Kapaun, P. McWhinney, P. Kern, J. Atougia, G. 
Fry, S. da Cunha & G. Boecken (2002) Imported Falciparum malaria in Europe: sentinel 
surveillance data from the European network on surveillance of imported infectious diseases. 
Clin Infect Dis, 34, 572-6.
Jensen, A. T., P. Magistrado, S. Sharp, L. Joergensen, T. Lavstsen, A. Chiucchiuini, A. Salanti, L. S. 
Vestergaard, J. P. Lusingu, R. Hermsen, R. Sauerwein, J. Christensen, M. A. Nielsen, L. Hviid,
C. Sutherland, T. Staalsoe & T. G. Theander (2004) Plasmodium falciparum associated with 
severe childhood malaria preferentially expresses PfEMPl encoded by group A var genes. J  
Exp Med, 199, 1179-90.
Jepsen, M. P., P. S. Jogdand, S. K. Singh, M. Esen, M. Christiansen, S. Issifou, A. B. Hounkpatin, U. 
Ateba-Ngoa, P. G. Kremsner, M. H. Dziegiel, S. Olesen-Larsen, S. Jepsen, B. Mordmuller & 
M. Theisen (2013) The malaria vaccine candidate GMZ2 elicits functional antibodies in 
individuals from malaria endemic and non-endemic areas. J  Infect Dis, 208, 479-88.
John, C. C., E. Kutamba, K. Mugarura & R. O. Opoka (2010) Adjunctive therapy for cerebral malaria 
and other severe forms of Plasmodium falciparum malaria. Expert Rev Anti Infect Ther, 8, 997- 
1008.
John, C. C., A. M. Moormann, D. C. Pregibon, P. O. Sumba, M. M. McHugh, D. L. Narum, D. E. 
Lanar, M. D. Schluchter & J. W. Kazura (2005) Correlation of high levels o f antibodies to 
multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J
Trop Med Hyg, 73, 222-8.
John, C. C., R. A. O'Donnell, P. O. Sumba, A. M. Moormann, T. F. de Koning-Ward, C. L. King, J. W. 
Kazura & B. S. Crabb (2004) Evidence that invasion-inhibitory antibodies specific for the 19- 
kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against 
blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of 
A frica.. Journal o f Immunology, 173, 666-672.
John, C. C., A. J. Tande, A. M. Moormann, P. O. Sumba, D. E. Lanar, X. M. Min & J. W. Kazura
(2008) Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical 
malaria in Kenyan children. J Infect Dis, 197, 519-26.
John, C. C., J. S. Zickafoose, P. O. Sumba, C. L. King & J. W. Kazura (2003) Antibodies to the 
Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive 
protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of 
Kenya. Infect Immun, 71, 4320-5.
Joos, C., L. Marrama, H. E. Poison, S. Corre, A. M. Diatta, B. Diouf, J. F. Trape, A. Tall, S. Longacre 
& R. Perraut (2010) Clinical protection from falciparum malaria correlates with neutrophil 
respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One, 
5,e9871.
Kabyemela, E., B. P. Goncalves, D. R. Prevots, R. Morrison, W. Harrington, M. Gwamaka, J. D. 
Kurtis, M. Fried & P. E. Duffy (2013) Cytokine profiles at birth predict malaria severity during 
infancy. PLoS One, 8, e77214.
307
Kaestli, M., I. A. Cockbum, A. Cortes, K. Baea, J. A. Rowe & H. P. Beck (2006) Virulence of malaria 
is associated with differential expression of Plasmodium falciparum var gene subgroups in a 
case-control study. J Infect Dis, 193, 1567-74.
Kassim, O. O., K. A. Ako-Anai, S. E. Torimiro, G. P. Hollowell, V. C. Okoye & S. K. Martin (2000) 
Inhibitory factors in breastmilk, maternal and infant sera against in vitro growth of 
Plasmodium falciparum malaria parasite. J Trop Pediatr, 46, 92-6.
Kendjo, E., T. Agbenyega, K. Bojang, C. R. Newton, M. Bouyou-Akotet, F. Pedross, M. Kombila, R. 
Helbok & P. G. Kremsner (2013) Mortality patterns and site heterogeneity of severe malaria in 
African children. PLoS One, 8, e58686.
Kensil, C. R., J. Y. Wu & S. Soltysik (1995) Structural and immunological characterization of the 
vaccine adjuvant QS-21. Pharm Biotechnol, 6, 525-41.
Kester, K. E., J. F. Cummings, O. Ofori-Anyinam, C. F. Ockenhouse, U. Krzych, P. Moris, R. 
Schwenk, R. A. Nielsen, Z. Debebe, E. Pinelis, L. Juompan, J. Williams, M. Dowler, V. A. 
Stewart, R. A. Wirtz, M. C. Dubois, M. Lievens, J. Cohen, W. R. Ballou & D. G. Heppner, Jr.
(2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B 
and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of 
protection. J  Infect Dis, 200, 337-46.
Khusmith, S. & P. Druilhe (1983) Antibody-dependent ingestion of P. falciparum merozoites by 
human blood monocytes. Parasite Immunol, 5, 357-68.
Khusmith, S., P. Druilhe & M. Gentilini (1982) Enhanced Plasmodium falciparum merozoite 
phagocytosis by monocytes from immune individuals. Infect Immun, 35, 874-9.
Kicska, G. A., L. M. Ting, V. L. Schramm & K. Kim (2003) Effect of dietary p-aminobenzoic acid on 
murine Plasmodium yoelii infection. J  Infect Dis, 188, 1776-81.
Kiguli, S., S. O. Akech, G. Mtove, R. O. Opoka, C. Engoru, P. Olupot-Olupot, R. Nyeko, J. Evans, J. 
Crawley, N. Prevatt, H. Reybum, M. Levin, E. C. George, A. South, A. G. Babiker, D. M. 
Gibb & K. Maitland (2014) WHO guidelines on fluid resuscitation in children: missing the 
FEAST data. BMJ, 348, f7003.
Kim, I., S. O. Moon, S. H. Kim, H. J. Kim, Y. S. Koh & G. Y. Koh (2001) Vascular endothelial growth 
factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion 
molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial 
cells. J  Biol Chem, 276, 7614-20.
Kinyanjui, S. M., P. Bejon, F. H. Osier, P. C. Bull & K. Marsh (2009) What you see is not what you 
get: implications of the brevity of antibody responses to malaria antigens and transmission 
heterogeneity in longitudinal studies of malaria immunity. Malar J, 8, 242.
Kinyanjui, S. M., D. J. Conway, D. E. Lanar & K. Marsh (2007) IgG antibody responses to 
Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar J, 
6, 82.
Kinyanjui, S. M., T. Mwangi, P. C. Bull, C. I. Newbold & K. Marsh (2004) Protection against clinical 
malaria by heterologous immunoglobulin G antibodies against malaria-infected erythrocyte 
variant surface antigens requires interaction with asymptomatic infections. J  Infect Dis, 190, 
1527-33.
Kitua, A. Y., H. Urassa, M. Wechsler, T. Smith, P. Vounatsou, N. A. Weiss, P. L. Alonso & M. Tanner 
(1999) Antibodies against Plasmodium falciparum vaccine candidates in infants in an area of 
intense and perennial transmission: relationships with clinical malaria and with entomological 
inoculation rates. Parasite Immunol, 21, 307-17.
Klein Klouwenberg, P. M., S. Oyakhirome, N. G. Schwarz, B. Glaser, S. Issifou, G. Kiessling, A. 
Klopfer, P. G. Kremsner, M. Langin, B. Lassmann, M. Necek, M. Potschke, A. Ritz & M. P. 
Grobusch (2005) Malaria and asymptomatic parasitaemia in Gabonese infants under the age of 
3 months. Acta Trop, 95, 81-5.
Kobayashi, T., S. Chishimba, T. Shields, H. Hamapumbu, S. Mharakurwa, P. E. Thuma, G. Glass & 
W. J. Moss (2012) Temporal and spatial patterns of serologic responses to Plasmodium 
falciparum antigens in a region of declining malaria transmission in southern Zambia. Malar J, 
11,438.
Kocken, C. H., C. Withers-Martinez, M. A. Dubbeld, A. van der Wei, F. Hackett, A. Valderrama, M. J. 
Blackman & A. W. Thomas (2002) High-level expression of the malaria blood-stage vaccine
308
candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that 
inhibit erythrocyte invasion. Infect Immun, 70,4471-6.
Kohler, C., A. E. Tebo, B. Dubois, P. Deloron, P. G. Kremsner & A. J. Luty (2003) Temporal 
variations in immune responses to conserved regions of Plasmodium falciparum merozoite 
surface proteins related to the severity of a prior malaria episode in Gabonese children. Trans R 
Soc Trop Med Hyg, 97, 455-61.
Kretschmar, W. (1966) [The importance o f p-aminobenzoic acid to the course and immunity of malaria 
in animals (Plasmodium berghei) and in man (PI. falciparum). II. Studies on naturally fed small 
children]. Z Tropenmed Parasitol, 17, 369-74.
Kumar, N. & R. Carter (1984) Biosynthesis o f the target antigens o f antibodies blocking transmission 
of Plasmodium falciparum. Mol Biochem Parasitol, 13,333-42.
Kumar, S., W. Collins, A. Egan, A. Yadava, O. Garraud, M. J. Blackman, J. A. Guevara Patino, C. 
Diggs & D. C. Kaslow (2000) Immunogenicity and efficacy in aotus monkeys of four 
recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 
19-kilodalton C terminus of merozoite surface protein 1. Infect Immun, 68,2215-23.
Kumar, S., A. Yadava, D. B. Keister, J. H. Tian, M. Ohl, K. A. Perdue-Greenfield, L. H. Miller & D.
C. Kaslow (1995) Immunogenicity and in vivo efficacy of recombinant Plasmodium 
falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med, 1, 325-32.
Kurtzhals, J. A., V. Adabayeri, B. Q. Goka, B. D. Akanmori, J. O. Oliver-Commey, F. K. Nkrumah, C. 
Behr & L. Hviid (1998) Low plasma concentrations of interleukin 10 in severe malarial 
anaemia compared with cerebral and uncomplicated malaria. Lancet, 351, 1768-72.
Kwiatkowski, D., A. V. Hill, I. Sambou, P. Twumasi, J. Castracane, K. R. Manogue, A. Cerami, D. R. 
Brewster & B. M. Greenwood (1990) TNF concentration in fatal cerebral, non-fatal cerebral, 
and uncomplicated Plasmodium falciparum malaria. Lancet, 336, 1201-4.
Kyriacou, H. M., G. N. Stone, R. J. Challis, A. Raza, K. E. Lyke, M. A. Thera, A. K. Kone, O. K. 
Doumbo, C. V. Plowe & J. A. Rowe (2006) Differential var gene transcription in Plasmodium 
falciparum isolates from patients with cerebral malaria compared to hyperparasitaemia. Mol 
Biochem Parasitol, 150,211-8.
Lamarque, M., S. Besteiro, J. Papoin, M. Roques, B. Vulliez-Le Normand, J. Morlon-Guyot, J. F. 
Dubremetz, S. Fauquenoy, S. Tomavo, B. W. Faber, C. H. Kocken, A. W. Thomas, M. J. 
Boulanger, G. A. Bentley & M. Lebrun (2011) The RON2-AMA1 interaction is a critical step 
in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog, 7, el 001276.
Lamikanra, A. A., D. Brown, A. Potocnik, C. Casals-Pascual, J. Langhome & D. J. Roberts (2007) 
Malarial anemia: of mice and men. Blood, 110, 18-28.
Langhome, J., F. M. Ndungu, A. M. Sponaas & K. Marsh (2008) Immunity to malaria: more questions 
than answers. Nat Immunol, 9, 725-32.
Larru, B., E. Molyneux, F. O. Ter Kuile, T. Taylor, M. Molyneux & D. J. Terlouw (2009) Malaria in 
infants below six months of age: retrospective surveillance of hospital admission records in 
Blantyre, Malawi. Malar J, 8, 310.
Le Hesran, J. Y., I. Personne, P. Personne, N. Fievet, B. Dubois, M. Beyeme, C. Boudin, M. Cot & P. 
Deloron (1999) Longitudinal study of Plasmodium falciparum infection and immune responses 
in infants with or without the sickle cell trait. Int J  Epidemiol, 28, 793-8.
Lengeler, C. (2004) Insecticide-treated bed nets and curtains for preventing malaria. Cochrane 
Database Syst Rev, CD000363.
Leoratti, F. M., R. R. Durlacher, M. V. Lacerda, M. G. Alecrim, A. W. Ferreira, M. C. Sanchez & S. L. 
Moraes (2008) Pattern of humoral immune response to Plasmodium falciparum blood stages in 
individuals presenting different clinical expressions of malaria. Malar J, 7, 186.
Levine, M. M. & R. Robins-Browne (2009) Vaccines, global health and social equity. Immunol Cell 
Biol, 87,274-8.
Lewallen, S., H. Bakker, T. E. Taylor, B. A. Wills, P. Courtright & M. E. Molyneux (1996) Retinal 
findings predictive of outcome in cerebral malaria. Trans R Soc Trop Med Hyg, 90, 144-6.
Li, S., N. Rouphael, S. Duraisingham, S. Romero-Steiner, S. Presnell, C. Davis, D. S. Schmidt, S. E. 
Johnson, A. Milton, G. Rajam, S. Kasturi, G. M. Carlone, C. Quinn, D. Chaussabel, A. K. 
Palucka, M. J. Mulligan, R. Ahmed, D. S. Stephens, H. I. Nakaya & B. Pulendran (2014) 
Molecular signatures of antibody responses derived from a systems biology study of five 
human vaccines. Nat Immunol, 15, 195-204.
309
Liljander, A., L. Wiklund, N. Falk, M. Kweku, A. Martensson, I. Felger & A. Famert (2009) 
Optimization and validation of multi-coloured capillary electrophoresis for genotyping of 
Plasmodium falciparum merozoite surface proteins (mspl and 2). Malar J, 8, 78.
Llewellyn, D., S. C. de Cassan, A. R. Williams, A. D. Douglas, E. K. Forbes, J. R. Adame-Gallegos, J. 
Shi, R. J. Pleass & S. J. Draper (2014) Assessment of antibody-dependent respiratory burst 
activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome. J Leukoc 
Biol', 95, 369-82.
Locher, C. P., L. Q. Tam, S. P. Chang, J. S. McBride & W. A. Siddiqui (1996) Plasmodium 
falciparum: gpl95 tripeptide repeat-specific monoclonal antibody inhibits parasite growth in 
vitro. Exp Parasitol, 84, 74-83.
Looareesuwan, S., M. Ho, Y. Wattanagoon, N. J. White, D. A. Warrell, D. Bunnag, T. Harinasuta & D. 
J. Wyler (1987) Dynamic alteration in splenic function during acute falciparum malaria. N 
Engl J  Med, 317, 675-9.
Lopansri, B. K., N. M. Anstey, J. B. Weinberg, G. J. Stoddard, M. R. Hobbs, M. C. Levesque, E. D. 
Mwaikambo & D. L. Granger (2003) Low plasma arginine concentrations in children with 
cerebral malaria and decreased nitric oxide production. Lancet, 361, 676-8.
Lovegrove, F. E., N. Tangpukdee, R. O. Opoka, E. I. Lafferty, N. Rajwans, M. Hawkes, S. Krudsood, 
S. Looareesuwan, C. C. John, W. C. Liles & K. C. Kain (2009) Serum angiopoietin-1 and -2 
levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome 
in African children. PLoS One, 4, e4912.
Lundblom, K., L. Murungi, V. Nyaga, D. Olsson, J. Rono, F. Osier, E. Ogada, S. Montgomery, J. A. 
Scott, K. Marsh & A. Farnert (2013) Plasmodium falciparum infection patterns since birth and 
risk of severe malaria: a nested case-control study in children on the coast of Kenya. PLoS 
One, 8, e56032.
Lusingu, J. P., L. S. Vestergaard, M. Aliffangis, B. P. Mmbando, M. Theisen, A. Y. Kitua, M. M. 
Lemnge & T. G. Theander (2005) Cytophilic antibodies to Plasmodium falciparum glutamate 
rich protein are associated with malaria protection in an area of holoendemic transmission. 
Malar J, 4,48.
Luty, A. J., B. Lell, R. Schmidt-Ott, L. G. Lehman, D. Luckner, B. Greve, P. Matousek, K. Herbich, D. 
Schmid, F. Migot-Nabias, P. Deloron, R. S. Nussenzweig & P. G. Kremsner (1999) Interferon- 
gamma responses are associated with resistance to reinfection with Plasmodium falciparum in 
young African children. J Infect Dis, 179, 980-8.
Luty, A. J., S. Ulbert, B. Lell, L. Lehman, R. Schmidt-Ott, D. Luckner, B. Greve, P. Matousek, D. 
Schmid, K. Herbich, B. Dubois, P. Deloron & P. G. Kremsner (2000) Antibody responses to 
Plasmodium falciparum: evolution according to the severity of a prior clinical episode and 
association with subsequent reinfection. Am J Trop Med Hyg, 62, 566-72.
Lyke, K. E., R. Burges, Y. Cissoko, L. Sangare, M. Dao, I. Diarra, A. Kone, R. Harley, C. V. Plowe, O. 
K. Doumbo & M. B. Sztein (2004) Serum levels of the proinflammatory cytokines interleukin- 
1 beta (IL-lbeta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian 
children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or 
healthy controls. Infect Immun, 72, 5630-7.
Mackintosh, C. L., J. G. Beeson & K. Marsh (2004) Clinical features and pathogenesis o f severe 
malaria. Trends Parasitol, 20, 597-603.
Mackintosh, C. L., Z. Christodoulou, T. W. Mwangi, M. Kortok, R. Pinches, T. N. Williams, K. Marsh 
& C. I. Newbold (2008a) Acquisition of naturally occurring antibody responses to recombinant 
protein domains of Plasmodium falciparum erythrocyte membrane protein 1. Malar J, 7, 155.
Mackintosh, C. L., T. Mwangi, S. M. Kinyanjui, M. Mosobo, R. Pinches, T. N. Williams, C. I. 
Newbold & K. Marsh (2008b) Failure to respond to the surface of Plasmodium falciparum 
infected erythrocytes predicts susceptibility to clinical malaria amongst African children. Int J 
Parasitol, 38, 1445-54.
MacPherson, G. G., M. J. Warrell, N. J. White, S. Looareesuwan & D. A. Warrell (1985) Human 
cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte 
sequestration. Am J  Pathol, 119, 385-401.
Magistrado, P. A., J. Lusingu, L. S. Vestergaard, M. Lemnge, T. Lavstsen, L. Turner, L. Hviid, A. T. 
Jensen & T. G. Theander (2007) Immunoglobulin G antibody reactivity to a group A
310
Plasmodium falciparum erythrocyte membrane protein 1 and protection from P. falciparum 
malaria. Infect Immun, 75,2415-20.
Maitland, K., S. Kiguli, R. O. Opoka, C. Engoru, P. Olupot-Olupot, S. O. Akech, R. Nyeko, G. Mtove,
H. Reybum, T. Lang, B. Brent, J. A. Evans, J. K. Tibenderana, J. Crawley, E. C. Russell, M. 
Levin, A. G. Babiker & D. M. Gibb (2011) Mortality after fluid bolus in African children with 
severe infection. N Engl J Med, 364, 2483-95.
Malek, A. (2003) Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. 
Vaccine, 21, 3362-4.
Malek, A., R. Sager, P. Kuhn, K. H. Nicolaides & H. Schneider (1996) Evolution of matemofetal 
transport of immunoglobulins during human pregnancy. Am J Reprod Immunol, 36,248-55. 
Malhotra, 1., A. Dent, P. Mungai, A. Wamachi, J. H. Ouma, D. L. Narum, E. Muchiri, D. J. Tisch & C. 
L. King (2009) Can prenatal malaria exposure produce an immune tolerant phenotype? A 
prospective birth cohort study in Kenya. PLoS Med, 6, el 000116.
Malkin, E., J. Hu, Z. Li, Z. Chen, X. Bi, Z. Reed, F. Dubovsky, J. Liu, Q. Wang, X. Pan, T. Chen, B. 
Giersing, Y. Xu, X. Kang, J. Gu, Q. Shen, K. Tucker, E. Tierney, W. Pan, C. Long & Z. Cao
(2008) A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for 
Plasmodium falciparum malaria. Vaccine, 26, 6864-73.
Malkin, E. M., D. J. Diemert, J. H. McArthur, J. R. Perreault, A. P. Miles, B. K. Giersing, G. E. 
Mullen, A. Orcutt, O. Muratova, M. Awkal, H. Zhou, J. Wang, A. Stowers, C. A. Long, S. 
Mahanty, L. H. Miller, A. Saul & A. P. Durbin (2005) Phase 1 clinical trial of apical 
membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. 
Infect Immun, 73, 3677-85.
Marsh, K., D. Forster, C. Waruiru, I. Mwangi, M. Winstanley, V. Marsh, C. Newton, P. Winstanley, P. 
Warn, N. Peshu & et al. (1995) Indicators of life-threatening malaria in African children. N 
Engl J  Med, 332,1399-404.
Marsh, K., R. H. Hayes, D. C. Carson, L. Otoo, F. Shenton, P. Byass, F. Zavala & B. M. Greenwood 
(1988) Anti-sporozoite antibodies and immunity to malaria in a rural Gambian population. 
Trans R Soc Trop Med Hyg, 82, 532-7.
Marsh, K. & R. J. Howard (1986) Antigens induced on erythrocytes by P. falciparum: expression of 
diverse and conserved determinants. Science, 231, 150-3.
Marsh, K. & S. Kinyanjui (2006) Immune effector mechanisms in malaria. Parasite Immunol, 28, 51- 
60.
Marsh, K., L. Otoo, R. J. Hayes, D. C. Carson & B. M. Greenwood (1989) Antibodies to blood stage 
antigens of Plasmodium falciparum in rural Gambians and their relation to protection against 
infection. Trans R Soc Trop Med Hyg, 83,293-303.
Mascarello, M., B. Allegranzi, A. Angheben, M. Anselmi, E. Concia, S. Lagana, L. Manzoli, S. 
Marocco, G. Monteiro & Z. Bisoffi (2008) Imported malaria in adults and children: 
epidemiological and clinical characteristics of 380 consecutive cases observed in Verona, Italy. 
J Travel Med, 15, 229-36.
Matteelli, A., P. Colombini, M. Gulletta, F. Castelli & G. Carosi (1999) Epidemiological features and 
case management practices of imported malaria in northern Italy 1991-1995. Trop Med Int 
Health, 4, 653-7.
Mayor, A., E. Rovira-Vallbona, S. Machevo, Q. Bassat, R. Aguilar, L. Quinto, A. Jimenez, B. 
Sigauque, C. Dobano, S. Kumar, B. Singh, P. Gupta, V. S. Chauhan, C. E. Chitnis, P. L. 
Alonso & C. Menendez (2011) Parity and placental infection affect antibody responses against 
Plasmodium falciparum during pregnancy. Infect Immun, 79, 1654-9.
Mbogo, C. M., J. M. Mwangangi, J. Nzovu, W. Gu, G. Yan, J. T. Gunter, C. Swalm, J. Keating, J. L. 
Regens, J. I. Shililu, J. I. Githure & J. C. Beier (2003) Spatial and temporal heterogeneity of 
Anopheles mosquitoes and Plasmodium falciparum transmission along the Kenyan coast. Am J 
Trop Med Hyg, 68, 734-42.
McBride, J. S. & H. G. Heidrich (1987) Fragments of the polymorphic Mr 185,000 glycoprotein from 
the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. Mol 
Biochem Parasitol, 23, 71-84.
McCall, M. B. & R. W. Sauerwein (2010) Interferon-gamma-central mediator of protective immune 
responses against the pre-erythrocytic and blood stage of malaria. J Leukoc Biol, 88, 1131-43.
311
McCallum, F. J., K. E. Persson, C. K. Mugyenyi, F. J. Fowkes, J. A. Simpson, J. S. Richards, T. N. 
Williams, K. Marsh & J. G. Beeson (2008) Acquisition of growth-inhibitory antibodies against 
blood-stage Plasmodium falciparum. PLoS One, 3, e3571.
McCarra, M. B., G. Ayodo, P. O. Sumba, J. W. Kazura, A. M. Moormann, D. L. Narum & C. C. John 
(2011) Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated 
with protection from clinical malaria. Pediatr Infect DisJ, 30, 1037-42.
McCarthy, J. S., J. Marjason, S. Elliott, P. Fahey, G. Bang, E. Malkin, E. Tierney, H. Aked-Hurditch,
C. Adda, N. Cross, J. S. Richards, F. J. Fowkes, M. J. Boyle, C. Long, P. Druilhe, J. G. Beeson 
& R. F. Anders (2011) A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 
isoforms of MSP2 formulated with Montanide(R) ISA 720. PLoS One, 6, e24413.
McColl, D. J., A. Silva, M. Foley, J. F. Kun, J. M. Favaloro, J. K. Thompson, V. M. Marshall, R. L. 
Coppel, D. J. Kemp & R. F. Anders (1994) Molecular variation in a novel polymorphic antigen 
associated with Plasmodium falciparum merozoites. Mol Biochem Parasitol, 68, 53-67.
McGuinness, D., K. Koram, S. Bennett, G. Wagner, F. Nkrumah & E. Riley (1998) Clinical case 
definitions for malaria: clinical malaria associated with very low parasite densities in African 
infants. Trans R Soc Trop Med Hyg, 92, 527-31.
Meraldi, V., I. Nebie, A. B. Tiono, D. Diallo, E. Sanogo, M. Theisen, P. Druilhe, G. Corradin, R. 
Moret & B. S. Sirima (2004) Natural antibody response to Plasmodium falciparum Exp-1, 
MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol, 
26,265-72.
Metzger, W. G., D. M. Okenu, D. R. Cavanagh, J. V. Robinson, K. A. Bojang, H. A. Weiss, J. S. 
McBride, B. M. Greenwood & D. J. Conway (2003) Serum IgG3 to the Plasmodium 
falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of 
malaria. Parasite Immunol, 25, 307-12.
Midega, J. T., D. L. Smith, A. Olotu, J. M. Mwangangi, J. G. Nzovu, J. Wambua, G. Nyangweso, C. 
M. Mbogo, G. K. Christophides, K. Marsh & P. Bejon (2012) Wind direction and proximity to 
larval sites determines malaria risk in Kilifi District in Kenya. Nat Commun, 3, 674.
Miettinen, O. S. (1969) Individual matching with multiple controls in the case of all-or-none responses. 
Biometrics, 25, 339-55.
Migot-Nabias, F., P. Deloron, P. Ringwald, B. Dubois, J. Mayombo, T. N. Minh, N. Fievet, P. Millet & 
A. Luty (2000) Immune response to Plasmodium falciparum liver stage antigen-1: 
geographical variations within Central Africa and their relationship with protection from 
clinical malaria. Trans R Soc Trop Med Hyg, 94, 557-62.
Miller, L. H., D. I. Baruch, K. Marsh & O. K. Doumbo (2002) The pathogenic basis of malaria. Nature, 
415, 673-9.
Miller, L. H., T. Roberts, M. Shahabuddin & T. F. McCutchan (1993) Analysis of sequence diversity in 
the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol, 59, 
1-14.
Mills, K. E., J. A. Pearce, B. S. Crabb & A. F. Cowman (2002) Truncation of merozoite surface protein 
3 disrupts its trafficking and that of acidic-basic repeat protein to the surface o f Plasmodium 
falciparum merozoites. Mol Microbiol, 43, 1401-11.
Mitchell, G. H., A. W. Thomas, G. Margos, A. R. Dluzewski & L. H. Bannister (2004) Apical 
membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of 
invasive merozoites to host red blood cells. Infect Immun, 72, 154-8.
Miura, K., M. Diakite, A. Diouf, S. Doumbia, D. Konate, A. S. Keita, S. E. Moretz, G. Tullo, H. Zhou, 
T. M. Lopera-Mesa, J. M. Anderson, R. M. Fairhurst & C. A. Long (2013a) Relationship 
between malaria incidence and IgG levels to Plasmodium falciparum merozoite antigens in 
Malian children: impact of hemoglobins S and C. PLoS One, 8, e60182.
Miura, K., R. Herrera, A. Diouf, H. Zhou, J. Mu, Z. Hu, N. J. MacDonald, K. Reiter, V. Nguyen, R. L. 
Shimp, Jr., K. Singh, D. L. Narum, C. A. Long & L. H. Miller (2013b) Overcoming allelic 
specificity by immunization with five allelic forms of Plasmodium falciparum apical 
membrane antigen 1. Infect Immun, 81, 1491-501.
Miura, K., A. C. Orcutt, O. V. Muratova, L. H. Miller, A. Saul & C. A. Long (2008a) Development and 
characterization of a standardized ELISA including a reference serum on each plate to detect 
antibodies induced by experimental malaria vaccines. Vaccine, 26, 193-200.
312
Miura, K., H. Zhou, A. Diouf, S. E. Moretz, M. P. Fay, L. H. Miller, L. B. Martin, M. A. Pierce, R. D. 
Ellis, G. E. Mullen & C. A. Long (2009) Anti-apical-membrane-antigen-1 antibody is more 
effective than anti-42-kilodalton-merozoite-surface-protein-l antibody in inhibiting 
plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin 
Vaccine Immunol, 16,963-8.
Miura, K., H. Zhou, A. Diouf, G. Tullo, S. E. Moretz, J. A. Aebig, M. P. Fay, L. H. Miller, O. K. 
Doumbo, I. Sagara, A. Dicko, C. A. Long & R. D. Ellis (2011) Immunological responses 
against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the 
population immunized. Vaccine, 29, 2255-61.
Miura, K., H. Zhou, S. E. Moretz, A. Diouf, M. A. Thera, A. Dolo, O. Doumbo, E. Malkin, D. Diemert, 
L. H. Miller, G. E. Mullen & C. A. Long (2008b) Comparison of biological activity of human 
anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J 
Immunol, 181, 8776-83.
Mmbando, B. P., L. S. Vestergaard, A. Y. Kitua, M. M. Lemnge, T. G. Theander & J. P. Lusingu
(2010) A progressive declining in the burden of malaria in north-eastern Tanzania. Malar J, 9, 
216.
Moormann, A. M., P. O. Sumba, K. Chelimo, FI. Fang, D. J. Tisch, A. E. Dent, C. C. John, C. A. Long,
, J. Vulule & J. W. Kazura (2013) Humoral and cellular immunity to Plasmodium falciparum 
merozoite surface protein 1 and protection from infection with blood-stage parasites. J Infect 
Dis, 208, 149-58.
Moorthy, V. S., M. Pinder, W. H. Reece, K. Watkins, S. Atabani, C. Hannan, K. Bojang, K. P. 
McAdam, J. Schneider, S. Gilbert & A. V. Hill (2003) Safety and immunogenicity of 
DNA/modified vaccinia virus ankara malaria vaccination in African adults. J Infect Dis, 188, 
1239-44.
Mordmuller, B., K. Szywon, B. Greutelaers, M. Esen, L. Mewono, C. Treut, R. E. Murbeth, R. 
Chilengi, R. Noor, W. L. Kilama, E. B. Imoukhuede, N. Imbault, O. Leroy, M. Theisen, S. 
Jepsen, P. Milligan, R. Fendel, P. G. Kremsner & S. Issifou (2010) Safety and immunogenicity 
of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, 
Gabon. Vaccine, 28, 6698-703.
Mouchet, J., S. Laventure, S. Blanchy, R. Fioramonti, A. Rakotonjanabelo, P. Rabarison, J. Sircoulon 
& J. Roux (1997) [The reconquest of the Madagascar highlands by malaria]. Bull Soc Pathol 
Exot, 90, 162-8.
Mullen, G. E., R. D. Ellis, K. Miura, E. Malkin, C. Nolan, M. Hay, M. P. Fay, A. Saul, D. Zhu, K. 
Rausch, S. Moretz, H. Zhou, C. A. Long, L. H. Miller & J. Treanor (2008) Phase 1 trial of 
AMAl-Cl/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium 
falciparum malaria. PLoS One, 3, e2940.
Murungi, L. M., G. Kamuyu, B. Lowe, P. Bejon, M. Theisen, S. M. Kinyanjui, K. Marsh & F. H. Osier
(2013) A threshold concentration of anti-merozoite antibodies is required for protection from 
clinical episodes of malaria. Vaccine, 31, 3936-42.
Mwangi, T. W., A. Ross, R. W. Snow & K. Marsh (2005) Case definitions of clinical malaria under 
different transmission conditions in Kilifi District, Kenya. J Infect Dis, 191, 1932-9.
Nakaya, H. I., J. Wrammert, E. K. Lee, L. Racioppi, S. Marie-Kunze, W. N. Haining, A. R. Means, S. 
P. Kasturi, N. Khan, G. M. Li, M. McCausland, V. Kanchan, K. E. Kokko, S. Li, R. Elbein, A. 
K. Mehta, A. Aderem, K. Subbarao, R. Ahmed & B. Pulendran (2011) Systems biology of 
vaccination for seasonal influenza in humans. Nat Immunol, 12, 786-95.
Nardin, E. H., R. S. Nussenzweig, I. A. McGregor & J. H. Bryan (1979) Antibodies to sporozoites: 
their frequent occurrence in individuals living in an area of hyperendemic malaria. Science, 
206, 597-9.
Narum, D. L. & A. W. Thomas (1994) Differential localization of full-length and processed forms of 
PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol 
Biochem Parasitol, 67, 59-68.
Ndungu, F. M., P. C. Bull, A. Ross, B. S. Lowe, E. Kabiru & K. Marsh (2002) Naturally acquired 
immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: 
evidence for association with protection for IgG 1 and disease for IgG2. Parasite Immunol, 24, 
77-82.
313
Ndungu, F. M., E. T. Cadman, J. Coulcher, E. Nduati, E. Couper, D. W. Macdonald, D. Ng & J. 
Langhome (2009) Functional memory B cells and long-lived plasma cells are generated after a 
single Plasmodium chabaudi infection in mice. PLoS Pathog, 5, e l000690.
Ndungu, F. M., A. Olotu, J. Mwacharo, M. Nyonda, J. Apfeld, L. K. Mramba, G. W. Fegan, P. Bejon 
& K. Marsh (2012) Memory B cells are a more reliable archive for historical antimalarial 
responses than plasma antibodies in no-longer exposed children. Proc Natl Acad Sci US A ,  
109,8247-52.
Nebie, I., A. Diarra, A. Ouedraogo, I. Soulama, E. C. Bougouma, A. B. Tiono, A. T. Konate, R. 
Chilengi, M. Theisen, D. Dodoo, E. Remarque, S. Bosomprah, P. Milligan & S. B. Sirima 
(2008a) Humoral responses to Plasmodium falciparum blood-stage antigens and association 
with incidence of clinical malaria in children living in an area of seasonal malaria transmission 
in Burkina Faso, West Africa. Infect Immun, 76, 759-66.
Nebie, I., A. B. Tiono, D. A. Diallo, S. Samandoulougou, A. Diarra, A. T. Konate, N. Cuzin-Ouattara, 
M. Theisen, G. Corradin, S. Cousens, A. S. Ouattara, E. Ilboudo-Sanogo & B. S. Sirima 
(2008b) Do antibody responses to malaria vaccine candidates influenced by the level of 
malaria transmission protect from malaria? Trop Med Int Health, 13, 229-37.
Nebl, T., M. J. De Veer & L. Schofield (2005) Stimulation of innate immune responses by malarial 
glycosylphosphatidylinositol via pattern recognition receptors. Parasitology, 130 Suppl, S45- 
62.
Newton, C. R., P. A. Warn, P. A. Winstanley, N. Peshu, R. W. Snow, G. Pasvol & K. Marsh (1997) 
Severe anaemia in children living in a malaria endemic area of Kenya. Trop Med Int Health, 2, 
165-78.
Nielsen, M. A., T. Staalsoe, J. A. Kurtzhals, B. Q. Goka, D. Dodoo, M. Alifrangis, T. G. Theander, B.
D. Akanmori & L. Hviid (2002) Plasmodium falciparum variant surface antigen expression 
varies between isolates causing severe and nonsevere malaria and is modified by acquired 
immunity. J Immunol, 168, 3444-50.
Nielsen, M. A., L. S. Vestergaard, J. Lusingu, J. A. Kurtzhals, H. A. Giha, B. Grevstad, B. Q. Goka, M. 
M. Lemnge, J. B. Jensen, B. D. Akanmori, T. G. Theander, T. Staalsoe & L. Hviid (2004) 
Geographical and temporal conservation of antibody recognition of Plasmodium falciparum 
variant surface antigens. Infect Immun, 72, 3531-5.
Noedl, H., Y. Se, K. Schaecher, B. L. Smith, D. Socheat, M. M. Fukuda & C. Artemisinin Resistance 
in Cambodia 1 Study (2008) Evidence of artemisinin-resistant malaria in western Cambodia. N  
Engl J  Med, 359,2619-20.
Noor, A. M., A. A. Amin, W. S. Akhwale & R. W. Snow (2007) Increasing coverage and decreasing 
inequity in insecticide-treated bed net use among rural Kenyan children. PLoS Med, 4, e255.
Noor, A. M., P. W. Gething, V. A. Alegana, A. P. Patil, S. I. Hay, E. Muchiri, E. Juma & R. W. Snow
(2009) The risks of malaria infection in Kenya in 2009. BMC Infect Dis, 9, 180.
Noor, A. M., D. K. Kinyoki, C. W. Mundia, C. W. Kabaria, J. W. Mutua, V. A. Alegana, I. S. Fall & R. 
W. Snow (2014) The changing risk of Plasmodium falciparum malaria infection in Africa: 
2000-10: a spatial and temporal analysis of transmission intensity. The Lancet, 383, 1739- 
1747.
Noor, A. M., M. B. Mohamed, C. K. Mugyenyi, M. A. Osman, H. H. Guessod, C. W. Kabaria, I. A. 
Ahmed, M. Nyonda, J. Cook, C. J. Drakeley, M. J. Mackinnon & R. W. Snow (2011) 
Establishing the extent of malaria transmission and challenges facing pre-elimination in the 
Republic of Djibouti. BMC Infect Dis, 11, 121.
Nussenzweig, R. S., J. Vanderberg, H. Most & C. Orton (1967) Protective immunity produced by the 
injection of x-irradiated sporozoites ofplasmodium berghei. Nature, 216, 160-2.
O'Donnell, R. A., T. F. de Koning-Ward, R. A. Burt, M. Bockarie, J. C. Reeder, A. F. Cowman & B. S. 
Crabb (2001) Antibodies against merozoite surface protein (MSP)-1(19) are a major 
component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med, 
193,1403-12.
O'Garra, A. & P. Vieira (2007) T(H)1 cells control themselves by producing interleukin-10. Nat Rev 
Immunol, 7, 425-8.
O'Meara, W. P., P. Bejon, T. W. Mwangi, E. A. Okiro, N. Peshu, R. W. Snow, C. R. Newton & K. 
Marsh (2008) Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, 
Kenya. Lancet, 372, 1555-62.
314
O'Meara, W. P., J. N. Mangeni, R. Steketee & B. Greenwood (2010) Changes in the burden of malaria 
in sub-Saharan Africa. Lancet Infect Dis, 10, 545-55.
Ochola, R., C. Sande, G. Fegan, P. D. Scott, G. F. Medley, P. A. Cane & D. J. Nokes (2009) The level 
and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One, 4, e8088. 
Ockenhouse, C. F., E. Angov, K. E. Kester, C. Diggs, L. Soisson, J. F. Cummings, A. V. Stewart, D. R. 
Palmer, B. Mahajan, U. Krzych, N. Tornieporth, M. Delchambre, M. Vanhandenhove, O. 
Ofori-Anyinam, J. Cohen, J. A. Lyon & D. G. Heppner (2006) Phase I safety and 
immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage 
vaccine. Vaccine, 24,3009-17.
Oeuvray, C., H. Bouharoun-Tayoun, H. Gras-Masse, E. Bottius, T. Kaidoh, M. Aikawa, M. C. 
Filgueira, A. Tartar & P. Druilhe (1994) Merozoite surface protein-3: a malaria protein 
inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood 
monocytes. Blood, 84, 1594-602.
Ofori, M. F., D. Dodoo, T. Staalsoe, J. A. Kurtzhals, K. Koram, T. G. Theander, B. D. Akanmori & L. 
Hviid (2002) Malaria-induced acquisition of antibodies to Plasmodium falciparum variant 
surface antigens. Infect Immun, 70,2982-8.
Ogutu, B. R., O. J. Apollo, D. McKinney, W. Okoth, J. Siangla, F. Dubovsky, K. Tucker, J. N. 
Waitumbi, C. Diggs, J. Wittes, E. Malkin, A. Leach, L. A. Soisson, J. B. Milman, L. Otieno, C. 
A. Holland, M. Polhemus, S. A. Remich, C. F. Ockenhouse, J. Cohen, W. R. Ballou, S. K. 
Martin, E. Angov, V. A. Stewart, J. A. Lyon, D. G. Heppner & M. R. Withers (2009) Blood 
stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no 
protection to young children in Western Kenya. PLoS One, 4, e4708.
Ogwang, C., M. Afolabi, D. Kimani, Y. J. Jagne, S. H. Sheehy, C. M. Bliss, C. J. Duncan, K. A. 
Collins, M. A. Garcia Knight, E. Kimani, N. A. Anagnostou, E. Berrie, S. Moyle, S. C. Gilbert, 
A. J. Spencer, P. Soipei, J. Mueller, J. Okebe, S. Colloca, R. Cortese, N. K. Viebig, R. Roberts, 
K. Gantlett, A. M. Lawrie, A. Nicosia, E. B. Imoukhuede, P. Bejon, B. C. Urban, K. L. 
Flanagan, K. J. Ewer, R. Chilengi, A. V. Hill & K. Bojang (2013) Safety and immunogenicity 
of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate 
vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. 
PLoS One, 8, e57726.
Oh, H., H. Takagi, K. Suzuma, A. Otani, M. Matsumura & Y. Honda (1999) Hypoxia and vascular 
endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular 
endothelial cells. J  Biol Chem, 274, 15732-9.
Okech, B., G. Mujuzi, A. Ogwal, H. Shirai, T. Horii & T. G. Egwang (2006) High titers of IgG 
antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with 
protection against severe malaria in Ugandan children. Am J Trop Med Hyg, 74, 191-7.
Okiro, E. A., V. A. Alegana, A. M. Noor, J. J. Mutheu, E. Juma & R. W. Snow (2009) Malaria 
paediatric hospitalization between 1999 and 2008 across Kenya. BMC Med, 7, 75.
Okiro, E. A., D. Bitira, G. Mbabazi, A. Mpimbaza, V. A. Alegana, A. O. Talisuna & R. W. Snow 
(2011) Increasing malaria hospital admissions in Uganda between 1999 and 2009. BMC Med, 
9,37.
Okiro, E. A., S. I. Hay, P. W. Gikandi, S. K. Sharif, A. M. Noor, N. Peshu, K. Marsh & R. W. Snow
(2007) The decline in paediatric malaria admissions on the coast of Kenya. Malar J, 6, 151. 
Okiro, E. A., L. N. Kazembe, C. W. Kabaria, J. Ligomeka, A. M. Noor, D. Ali & R. W. Snow (2013) 
Childhood malaria admission rates to four hospitals in Malawi between 2000 and 2010. PLoS 
One, 8, e62214.
Oliveira, G. A., K. A. Kumar, J. M. Calvo-Calle, C. Othoro, D. Altszuler, V. Nussenzweig & E. H. 
Nardin (2008) Class II-restricted protective immunity induced by malaria sporozoites. Infect 
Immun, 76, 1200-6.
Olotu, A., G. Fegan, J. Wambua, G. Nyangweso, K. O. Awuondo, A. Leach, M. Lievens, D. 
Leboulleux, P. Njuguna, N. Peshu, K. Marsh & P. Bejon (2013) Four-year efficacy of 
RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med, 368, 1111-20.
Olotu, A., J. Lusingu, A. Leach, M. Lievens, J. Vekemans, S. Msham, T. Lang, J. Gould, M. C. 
Dubois, E. Jongert, P. Vansadia, T. Carter, P. Njuguna, K. O. Awuondo, A. Malabeja, O. 
Abdul, S. Gesase, N. Mturi, C. J. Drakeley, B. Savarese, T. Villafana, D. Lapierre, W. R. 
Ballou, J. Cohen, M. M. Lemnge, N. Peshu, K. Marsh, E. M. Riley, L. von Seidlein & P. Bejon
(2011) Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti- 
circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and 
Tanzania: a randomised controlled trial. Lancet Infect Dis, 11, 102-9.
Osier, F. H., G. Fegan, S. D. Polley, L. Murungi, F. Verra, K. K. Tetteh, B. Lowe, T. Mwangi, P. C. 
Bull, A. W. Thomas, D. R. Cavanagh, J. S. McBride, D. E. Lanar, M. J. Mackinnon, D. J. 
Conway & K. Marsh (2008) Breadth and magnitude of antibody responses to multiple 
Plasmodium falciparum merozoite antigens are associated with protection from clinical 
malaria. Infect Immun, 76,2240-8.
Osier, F. H., G. Feng, M. J. Boyle, C. Langer, J. Zhou, J. S. Richards, F. J. McCallum, L. Reiling, A. 
Jaworowski, R. F. Anders, K. Marsh & J. G. Beeson (2014a) Opsonic phagocytosis of 
Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of 
protection against malaria. BMC Med, 12, 108.
Osier, F. FL, M. J. Mackinnon, C. Crosnier, G. Fegan, G. Kamuyu, M. Wanaguru, E. Ogada, B. 
McDade, J. C. Rayner, G. J. Wright & K. Marsh (2014b) New antigens for a multicomponent 
blood-stage malaria vaccine. Sci Transl Med, 6 ,247ral02.
Osier, F. FL, L. M. Murungi, G. Fegan, J. Tuju, K. K. Tetteh, P. C. Bull, D. J. Conway & K. Marsh 
(2010a) Allele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and 
protection against clinical malaria. Parasite Immunol, 32, 193-201.
Osier, F. FL, S. D. Polley, T. Mwangi, B. Lowe, D. J. Conway & K. Marsh (2007) Naturally acquired 
antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite 
surface protein 3. Parasite Immunol, 29, 387-94.
Osier, F. FL, G. D. Weedall, F. Verra, L. Murungi, K. K. Tetteh, P. Bull, B. W. Faber, E. Remarque, A. 
Thomas, K. Marsh & D. J. Conway (2010b) Allelic diversity and naturally acquired allele- 
specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in Kenya. 
Infect Immun, 78,4625-33.
Othoro, C., A. A. Lai, B. Nahlen, D. Koech, A. S. Orago & V. Udhayakumar (1999) A low interleukin- 
10 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a 
holoendemic malaria region in western Kenya. J  Infect Dis, 179, 279-282.
Otten, M., M. Aregawi, W. Were, C. Karema, A. Medin, W. Bekele, D. Jima, K. Gausi, R. Komatsu, E. 
Korenromp, D. Low-Beer & M. Grabowsky (2009) Initial evidence of reduction of malaria 
cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria prevention and 
treatment. Malar J, 8, 14.
Pasvol, G., D. J. Weatherall & R. J. Wilson (1977) Effects of foetal haemoglobin on susceptibility of 
red cells to Plasmodium falciparum. Nature, 270, 171-3.
Patnaik, J. K., B. S. Das, S. K. Mishra, S. Mohanty, S. K. Satpathy & D. Mohanty (1994) Vascular 
clogging, mononuclear cell margination, and enhanced vascular permeability in the 
pathogenesis of human cerebral malaria. Am J Trop Med Hyg, 51, 642-7.
Perkins, D. J., T. Were, G. C. Davenport, P. Kempaiah, J. B. Hittner & J. M. Ong'echa (2011) Severe 
malarial anemia: innate immunity and pathogenesis. Int J  Biol Sci, 7, 1427-42.
Perlmann, P., H. Perlmann, S. Looareesuwan, S. Krudsood, S. Kano, Y. Matsumoto, G. Brittenham, M. 
Troye-Blomberg & M. Aikawa (2000) Contrasting functions of IgG and IgE antimalarial 
antibodies in uncomplicated and severe Plasmodium falciparum malaria. Am J Trop Med Hyg, 
62, 373-7.
Perraut, R., B. Diatta, L. Marrama, O. Garraud, R. Jambou, S. Longacre, G. Krishnegowda, A. Dieye &
D. C. Gowda (2005a) Differential antibody responses to Plasmodium falciparum 
glycosylphosphatidylinositol anchors in patients with cerebral and mild malaria. Microbes 
Infect, 7, 682-7.
Perraut, R., L. Marrama, B. Diouf, C. Sokhna, A. Tall, P. Nabeth, J. F. Trape, S. Longacre & O. 
Mercereau-Puijalon (2005b) Antibodies to the conserved C-terminal domain o f the 
Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their 
relationship with in vitro inhibitory antibodies and protection against clinical malaria in a 
Senegalese village. J Infect Dis, 191, 264-71.
Persson, K. E., C. T. Lee, K. Marsh & J. G. Beeson (2006) Development and optimization of high- 
throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. 
J  Clin Microbiol, 44, 1665-73.
316
Phu, N. H., T. T. Hien, N. T. Mai, T. T. Chau, L. V. Chuong, P. P. Loc, C. Winearls, J. Farrar, N. 
White & N. Day (2002) Hemofiltration and peritoneal dialysis in infection-associated acute 
renal failure in Vietnam. N Engl J Med, 347, 895-902.
Pierce, M. A., R. D. Ellis, L. B. Martin, E. Malkin, E. Tierney, K. Miura, M. P. Fay, J. Marjason, S. L. 
Elliott, G. E. Mullen, K. Rausch, D. Zhu, C. A. Long & L. H. Miller (2010) Phase 1 safety and 
immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1- 
Cl/ISA 720 in Australian adults. Vaccine, 28, 2236-42.
Plested, J. S., P. A. Coull & M. A. Gidney (2003) Elisa. Methods Mol Med, 71,243-61.
Plotkin, S. A. (2008) Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis, 47,401-9.
Polhemus, M. E., A. J. Magill, J. F. Cummings, K. E. Kester, C. F. Ockenhouse, D. E. Lanar, S. Dutta, 
A. Barbosa, L. Soisson, C. L. Diggs, S. A. Robinson, J. D. Haynes, V. A. Stewart, L. A. Ware,
C. Brando, U. Krzych, R. A. Bowden, J. D. Cohen, M. C. Dubois, O. Ofori-Anyinam, E. De- 
Kock, W. R. Ballou & D. G. Heppner, Jr. (2007) Phase 1 dose escalation safety and 
immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, 
adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of 
Research. Vaccine, 25,4203-12.
Polhemus, M. E., S. A. Remich, B. R. Ogutu, J. N. Waitumbi, L. Otieno, S. Apollo, J. F. Cummings, 
K. E. Kester, C. F. Ockenhouse, A. Stewart, O. Ofori-Anyinam, I. Ramboer, C. P. Cahill, M. 
Lievens, M. C. Dubois, M. A. Demoitie, A. Leach, J. Cohen, W. R. Ballou & D. G. Heppner, 
Jr. (2009) Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria 
transmission area. PLoS One, 4, e6465.
Polley, S. D., W. Chokejindachai & D. J. Conway (2003a) Allele frequency-based analyses robustly 
map sequence sites under balancing selection in a malaria vaccine candidate antigen. Genetics, 
165, 555-61.
Polley, S. D. & D. J. Conway (2001) Strong diversifying selection on domains of the Plasmodium 
falciparum apical membrane antigen 1 gene. Genetics, 158, 1505-12.
Polley, S. D., D. J. Conway, D. R. Cavanagh, J. S. McBride, B. S. Lowe, T. N. Williams, T. W. 
Mwangi & K. Marsh (2006) High levels of serum antibodies to merozoite surface protein 2 of 
Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. 
Vaccine, 24, 4233-46.
Polley, S. D., T. Mwangi, C. H. Kocken, A. W. Thomas, S. Dutta, D. E. Lanar, E. Remarque, A. Ross, 
T. N. Williams, G. Mwambingu, B. Lowe, D. J. Conway & K. Marsh (2004) Human 
antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane 
Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine, 23, 718-28.
Polley, S. D., K. K. Tetteh, D. R. Cavanagh, R. J. Pearce, J. M. Lloyd, K. A. Bojang, D. M. Okenu, B. 
M. Greenwood, J. S. McBride & D. J. Conway (2003b) Repeat sequences in block 2 of 
Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with 
protection from malaria. Infect Immun, 71, 1833-42.
Polley, S. D., K. K. Tetteh, J. M. Lloyd, O. J. Akpogheneta, B. M. Greenwood, K. A. Bojang & D. J. 
Conway (2007) Plasmodium falciparum merozoite surface protein 3 is a target of allele- 
specific immunity and alleles are maintained by natural selection. J Infect Dis, 195, 279-87.
Pombo, D. J., G. Lawrence, C. Hirunpetcharat, C. Rzepczyk, M. Bryden, N. Cloonan, K. Anderson, Y. 
Mahakunkijcharoen, L. B. Martin, D. Wilson, S. Elliott, S. Elliott, D. P. Eisen, J. B. Weinberg, 
A. Saul & M. F. Good (2002) Immunity to malaria after administration of ultra-low doses of 
red cells infected with Plasmodium falciparum. Lancet, 360, 610-7.
Portugal, S., J. Moebius, J. Skinner, S. Doumbo, D. Doumtabe, Y. Kone, S. Dia, K. Kanakabandi, D.
E. Sturdevant, K. Virtaneva, S. F. Porcella, S. Li, O. K. Doumbo, K. Kayentao, A. Ongoiba, B. 
Traore & P. D. Crompton (2014) Exposure-dependent control of malaria-induced inflammation 
in children. PLoS Pathog, 10, e l004079.
Pradel, G. (2007) Proteins of the malaria parasite sexual stages: expression, function and potential for 
transmission blocking strategies. Parasitology, 134, 1911-29.
Proietti, C., F. Verra, M. T. Bretscher, W. Stone, B. N. Kanoi, B. Balikagala, T. G. Egwang, P. Corran, 
R. Ronca, B. Area, E. M. Riley, A. Crisanti, C. Drakeley & T. Bousema (2013) Influence of 
infection on malaria-specific antibody dynamics in a cohort exposed to intense malaria 
transmission in northern Uganda. Parasite Immunol, 35, 164-73.
317
Quataert, S. A., C. S. Kirch, L. J. Wiedl, D. C. Phipps, S. Strohmeyer, C. O. Cimino, J. Skuse & D. V. 
Madore (1995) Assignment of weight-based antibody units to a human antipneumococcal 
standard reference serum, lot 89-S. Clin Diagn Lab Immunol, 2, 590-7.
Querec, T. D., R. S. Akondy, E. K. Lee, W. Cao, H. 1. Nakaya, D. Teuwen, A. Pirani, K. Gernert, J. 
Deng, B. Marzolf, K. Kennedy, H. Wu, S. Bennouna, H. Oluoch, J. Miller, R. Z. Vencio, M. 
Mulligan, A. Aderem, R. Ahmed & B. Pulendran (2009) Systems biology approach predicts 
immunogenicity of the yellow fever vaccine in humans. Nat Immunol, 10, 116-25.
Raj, D. K., C. P. Nixon, C. E. Nixon, J. D. Dvorin, C. G. DiPetrillo, S. Pond-Tor, H. W. Wu, G. Jolly, 
L. Pischel, A. Lu, I. C. Michelow, L. Cheng, S. Conteh, E. A. McDonald, S. Absalon, S. E. 
Holte, J. F. Friedman, M. Fried, P. E. Duffy & J. D. Kurtis (2014) Antibodies to PfSEA-1 
block parasite egress from RBCs and protect against malaria infection. Science, 344, 871-7.
Ramasamy, R., K. Nagendran & M. S. Ramasamy (1994) Antibodies to epitopes on merozoite and 
sporozoite surface antigens as serologic markers of malaria transmission: studies at a site in the 
dry zone of Sri Lanka. Am J Trop Med Hyg, 50, 537-47.
Ranson, FL, R. N'Guessan, J. Lines, N. Moiroux, Z. Nkuni & V. Corbel (2011) Pyrethroid resistance in 
African anopheline mosquitoes: what are the implications for malaria control? Trends 
Parasitol, 27, 91-8.
Rayner, J. C., M. R. Galinski, P. Ingravallo & J. W. Barnwell (2000) Two Plasmodium falciparum 
genes express merozoite proteins that are related to Plasmodium vivax and Plasmodium yoelii 
adhesive proteins involved in host cell selection and invasion. Proc Natl Acad Sci US A,  97, 
9648-53.
Rayner, J. C., T. M. Tran, V. Corredor, C. S. Fluber, J. W. Barnwell & M. R. Galinski (2005) Dramatic 
difference in diversity between Plasmodium falciparum and Plasmodium vivax reticulocyte 
binding-like genes. Am J  Trop Med Hyg, 72, 666-74.
Reddy, K. S., A. K. Pandey, FI. Singh, T. Sahar, A. Emmanuel, C. E. Chitnis, V. S. Chauhan & D. 
Gaur (2014) Bacterially expressed full-length recombinant Plasmodium falciparum RH5 
protein binds erythrocytes and elicits potent strain-transcending parasite-neutralizing 
antibodies. Infect Immun, 82, 152-64.
Reece, W. H., M. Pinder, P. K. Gothard, P. Milligan, K. Bojang, T. Doherty, M. Plebanski, P. 
Akinwunmi, S. Everaere, K. R. Watkins, G. Voss, N. Tomieporth, A. Alloueche, B. M. 
Greenwood, K. E. Kester, K. P. McAdam, J. Cohen & A. V. Hill (2004) A CD4(+) T-cell 
immune response to a conserved epitope in the circumsporozoite protein correlates with 
protection from natural Plasmodium falciparum infection and disease. Nat Med, 10, 406-10.
Reiling, L., J. S. Richards, F. J. Fowkes, A. E. Barry, T. Triglia, W. Chokejindachai, P. Michon, L. 
Tavul, P. M. Siba, A. F. Cowman, I. Mueller & J. G. Beeson (2010) Evidence that the 
erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium 
falciparum malaria. J Immunol, 185, 6157-67.
Rener, J., P. M. Graves, R. Carter, J. L. Williams & T. R. Burkot (1983) Target antigens of 
transmission-blocking immunity on gametes o f plasmodium falciparum. J  Exp Med, 158, 976- 
81.
Reybum, H., R. Mbatia, C. Drakeley, J. Bruce, I. Cameiro, R. Olomi, J. Cox, W. M. Nkya, M. 
Lemnge, B. M. Greenwood & E. M. Riley (2005) Association of transmission intensity and 
age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. 
JAMA, 293,1461-70.
Richard, D., C. A. MacRaild, D. T. Riglar, J. A. Chan, M. Foley, J. Baum, S. A. Ralph, R. S. Norton & 
A. F. Cowman (2010) Interaction between Plasmodium falciparum apical membrane antigen 1 
and the rhoptry neck protein complex defines a key step in the eiythrocyte invasion process of 
malaria parasites. J Biol Chem, 285, 14815-22.
Richards, J. S., T. U. Arumugam, L. Reiling, J. Healer, A. N. Hodder, F. J. Fowkes, N. Cross, C. 
Langer, S. Takeo, A. D. Uboldi, J. K. Thompson, P. R. Gilson, R. L. Coppel, P. M. Siba, C. L. 
King, M. Torii, C. E. Chitnis, D. L. Narum, I. Mueller, B. S. Crabb, A. F. Cowman, T. Tsuboi 
& J. G. Beeson (2013) Identification and prioritization of merozoite antigens as targets of 
protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker 
development. J Immunol, 191, 795-809.
Richards, J. S., D. I. Stanisic, F. J. Fowkes, L. Tavul, E. Dabod, J. K. Thompson, S. Kumar, C. E. 
Chitnis, D. L. Narum, P. Michon, P. M. Siba, A. F. Cowman, I. Mueller & J. G. Beeson (2010)
Association between naturally acquired antibodies to erythrocyte-binding antigens of 
Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect 
Dis, 51,e50-60.
Ricke, C. H., T. Staalsoe, K. Koram, B. D. Akanmori, E. M. Riley, T. G. Theander & L. Hviid (2000) 
Plasma antibodies from malaria-exposed pregnant women recognize variant surface antigens 
on Plasmodium falciparum-infected erythrocytes in a parity-dependent manner and block 
parasite adhesion to chondroitin sulfate A. J  Immunol, 165, 3309-16.
Riley, E. M., G. E. Wagner, B. D. Akanmori & K. A. Koram (2001) Do maternally acquired antibodies 
protect infants from malaria infection? Parasite Immunol, 23, 51-9.
Riley, E. M., G. E. Wagner, M. F. Ofori, J. G. Wheeler, B. D. Akanmori, K. Tetteh, D. McGuinness, S. 
Bennett, F. K. Nkrumah, R. F. Anders & K. A. Koram (2000) Lack of association between 
maternal antibody and protection of African infants from malaria infection. Infect Immun, 68, 
5856-63.
Riley, E. M., S. Wahl, D. J. Perkins & L. Schofield (2006) Regulating immunity to malaria. Parasite 
Immunol, 28, 35-49.
Robinson, L. J., M. C. D'Ombrain, D. I. Stanisic, J. Taraika, N. Bernard, J. S. Richards, J. G. Beeson, 
L. Tavul, P. Michon, I. Mueller & L. Schofield (2009) Cellular tumor necrosis factor, gamma 
interferon, and interleukin-6 responses as correlates of immunity and risk of clinical 
Plasmodium falciparum malaria in children from Papua New Guinea. Infect Immun, 77, 3033- 
43.
Roca-Feltrer, A., I. Carneiro, L. Smith, J. R. Schellenberg, B. Greenwood & D. Schellenberg (2010) 
The age patterns o f severe malaria syndromes in sub-Saharan Africa across a range of 
transmission intensities and seasonality settings. Malar J, 9, 282.
Roca-Feltrer, A., C. J. Kwizombe, M. A. Sanjoaquin, S. S. Sesay, B. Faragher, J. Harrison, K. Geukers, 
S. Kabuluzi, D. P. Mathanga, E. Molyneux, M. Chagomera, T. Taylor, M. Molyneux & R. S. 
Heyderman (2012) Lack of decline in childhood malaria, Malawi, 2001-2010. Emerg Infect 
Dis, 18,272-8.
Rodrigues, E. G., F. Zavala, D. Eichinger, J. M. Wilson & M. Tsuji (1997) Single immunizing dose of 
recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against 
malaria .J  Immunol, 158, 1268-74.
Roestenberg, M., A. C. Teirlinck, M. B. McCall, K. Teelen, K. N. Makamdop, J. Wiersma, T. Arens, P. 
Beckers, G. van Gemert, M. van de Vegte-Bolmer, A. J. van der Ven, A. J. Luty, C. C. 
Hermsen & R. W. Sauerwein (2011) Long-term protection against malaria after experimental 
sporozoite inoculation: an open-label follow-up study. Lancet, 377, 1770-6.
Rono, J., A. Famert, D. Olsson, F. Osier, I. Rooth & K. E. Persson (2012) Plasmodium falciparum line- 
dependent association of in vitro growth-inhibitory activity and risk of malaria. Infect Immun, 
80, 1900-8.
Rono, J., F. H. Osier, D. Olsson, S. Montgomery, L. Mhoja, I. Rooth, K. Marsh & A. Farnert (2013) 
Breadth of anti-merozoite antibody responses is associated with the genetic diversity of 
asymptomatic Plasmodium falciparum infections and protection against clinical malaria. Clin 
Infect Dis, 57, 1409-16.
Rottmann, M., T. Lavstsen, J. P. Mugasa, M. Kaestli, A. T. Jensen, D. Muller, T. Theander & H. P. 
Beck (2006) Differential expression of var gene groups is associated with morbidity caused by 
Plasmodium falciparum infection in Tanzanian children. Infect Immun, 74, 3904-11.
Sabchareon, A., T. Burnouf, D. Ouattara, P. Attanath, H. Bouharoun-Tayoun, P. Chantavanich, C. 
Foucault, T. Chongsuphajaisiddhi & P. Druilhe (1991) Parasitologic and clinical human 
response to immunoglobulin administration in falciparum malaria. Am J  Trop Med Hyg, 45, 
297-308.
Sagara, I., A. Dicko, R. D. Ellis, M. P. Fay, S. I. Diawara, M. H. Assadou, M. S. Sissoko, M. Kone, A. 
I. Diallo, R. Saye, M. A. Guindo, O. Kante, M. B. Niambele, K. Miura, G. E. Mullen, M. 
Pierce, L. B. Martin, A. Dolo, D. A. Diallo, O. K. Doumbo, L. H. Miller & A. Saul (2009) A 
randomized controlled phase 2 trial of the blood stage AMAl-Cl/Alhydrogel malaria vaccine 
in children in Mali. Vaccine, 27, 3090-8.
Sahar, T., K. S. Reddy, M. Bharadwaj, A. K. Pandey, S. Singh, C. E. Chitnis & D. Gaur (2011) 
Plasmodium falciparum reticulocyte binding-like homologue protein 2 (PfRH2) is a key 
adhesive molecule involved in erythrocyte invasion. PLoS One, 6, e l7102.
319
Salanti, A., T. Staalsoe, T. Lavstsen, A. T. Jensen, M. P. Sowa, D. E. Arnot, L. Hviid & T. G. Theander 
(2003) Selective upregulation of a single distinctly structured var gene in chondroitin sulphate 
A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol, 
49, 179-91.
Salmon, B. L., A. Oksman & D. E. Goldberg (2001) Malaria parasite exit from the host erythrocyte: a 
two-step process requiring extraerythrocytic proteolysis. Proc Ncitl Acad Sci USA,  98,271-6.
Sarr, J. B., S. Pelleau, C. Toly, J. Guitard, L. Konate, P. Deloron, A. Garcia & F. Migot-Nabias (2006) 
Impact of red blood cell polymorphisms on the antibody response to Plasmodium falciparum in 
Senegal. Microbes Infect, 8, 1260-8.
Saul, A. (2008) Efficacy model for mosquito stage transmission blocking vaccines for malaria. 
Parasitology, 135, 1497-506.
Saul, A., R. Lord, G. L. Jones & L. Spencer (1992) Protective immunization with invariant peptides of 
the Plasmodium falciparum antigen MSA2. J  Immunol, 148,208-11.
Saveria, T., A. V. Oleinikov, K. Wiliamson, R. Chaturvedi, J. Lograsso, G. J. Keitany, M. Fried & P. 
Duffy (2013) Antibodies to Escherichia coli-expressed C-terminal domains of Plasmodium 
falciparum variant surface antigen 2-chondroitin sulfate A (VAR2CSA) inhibit binding of 
CSA-adherent parasites to placental tissue. Infect Immun, 81, 1031-9.
Scarselli, E., R. Tolle, O. Koita, M. Diallo, H. M. Muller, K. Fruh, O. Doumbo, A. Crisanti & H. 
Bujard (1993) Analysis of the human antibody response to thrombospondin-related anonymous 
protein of Plasmodium falciparum. Infect Immun, 61, 3490-5.
Scherf, A., J. J. Lopez-Rubio & L. Riviere (2008) Antigenic variation in Plasmodium falciparum. Annu 
Rev Microbiol, 62, 445-70.
Schmidt, N. W., R. L. Podyminogin, N. S. Butler, V. P. Badovinac, B. J. Tucker, K. S. Bahjat, P. 
Lauer, A. Reyes-Sandoval, C. L. Hutchings, A. C. Moore, S. C. Gilbert, A. V. Hill, L. C. 
Bartholomay & J. T. Harty (2008) Memory CD8 T cell responses exceeding a large but 
definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci US A ,  105, 
14017-22.
Schofield, L. & G. E. Grau (2005) Immunological processes in malaria pathogenesis. Nat Rev 
Immunol, 5, 722-35.
Schreiber, N., N. Brattig, J. Evans, A. Tsiri, R. D. Horstmann, J. May & M. Q. Klinkert (2006) 
Cerebral malaria is associated with IgG2 and lgG4 antibody responses to recombinant 
Plasmodium falciparum RIFIN antigen. Microbes Infect, 8, 1269-76.
Schwartz, L., G. V. Brown, B. Genton & V. S. Moorthy (2012) A review of malaria vaccine clinical 
projects based on the WHO rainbow table. Malar J, 11,11.
Scopel, K. K., M. da Silva-Nunes, R. S. Malafronte, E. M. Braga & M. U. Ferreira (2007) Variant- 
specific antibodies to merozoite surface protein 2 and clinical expression of Plasmodium 
falciparum malaria in rural Amazonians. Am J Trop Med Hyg, 76, 1084-91.
Scopel, K. K., C. J. Fontes, M. U. Ferreira & E. M. Braga (2006) Factors associated with 
immunoglobulin G subclass polarization in naturally acquired antibodies to Plasmodium 
falciparum merozoite surface proteins: a cross-sectional survey in Brazilian Amazonia. Clin 
Vaccine Immunol, 13,810-3.
Scott, J. A., E. Bauni, J. C. Moisi, J. Ojal, H. Gatakaa, C. Nyundo, C. S. Molyneux, F. Kombe, B. 
Tsofa, K. Marsh, N. Peshu & T. N. Williams (2012) Profile: The Kilifi Health and 
Demographic Surveillance System (KHDSS). Int J  Epidemiol, 41, 650-7.
Seder, R. A., L. J. Chang, M. E. Enama, K. L. Zephir, U. N. Sarwar, I. J. Gordon, L. A. Holman, E. R. 
James, P. F. Billingsley, A. Gunasekera, A. Richman, S. Chakravarty, A. Manoj, S. 
Velmurugan, M. Li, A. J. Ruben, T. Li, A. G. Eappen, R. E. Stafford, S. H. Plummer, C. S. 
Hendel, L. Novik, P. J. Costner, F. H. Mendoza, J. G. Saunders, M. C. Nason, J. H. 
Richardson, J. Murphy, S. A. Davidson, T. L. Richie, M. Sedegah, A. Sutamihardja, G. A, 
Fahle, K. E. Lyke, M. B. Laurens, M. Roederer, K. Tewari, J. E. Epstein, B. K. Sim, J. E. 
Ledgerwood, B. S. Graham & S. L. Hoffman (2013) Protection against malaria by intravenous 
immunization with a nonreplicating sporozoite vaccine. Science, 341, 1359-65.
Sehgal, V. M., W. A. Siddjiqui & M. P. Alpers (1989) A seroepidemiological study to evaluate the role 
of passive maternal immunity to malaria in infants. Trans R Soc Trop Med Hyg, 83 Suppl, 105- 
6 .
320
Seo, J. H., J. S. Jun, H. S. Youn, J. S. Yeom, J. S. Park, C. H. Park, H. O. Woo, W. K. Lee, M. J. Cho 
& K. H. Rhee (2013) Development of an ELISA for Quantitative Detection of 
Immunoglobulin G (IgG) and IgA Antibodies to Helicobacter pylori for Use in Korean Patients 
with H. pylori-Associated Diseases. Gat Liver, 7, 437-42.
Shear, H. L., L. Grinberg, J. Gilman, M. E. Fabry, G. Stamatoyannopoulos, D. E. Goldberg & R. L. 
Nagel (1998) Transgenic mice expressing human fetal globin are protected from malaria by a 
novel mechanism. Blood, 92, 2520-6.
Sheehy, S. H., C. J. Duncan, S. C. Elias, S. Biswas, K. A. Collins, G. A. O'Hara, F. D. Halstead, K. J. 
Ewer, T. Mahungu, A. J. Spencer, K. Miura, I. D. Poulton, M. D. Dicks, N. J. Edwards, E. 
Berrie, S. Moyle, S. Colloca, R. Cortese, K. Gantlett, C. A. Long, A. M. Lawrie, S. C. Gilbert, 
T. Doherty, A. Nicosia, A. V. Hill & S. J. Draper (2012a) Phase la clinical evaluation of the 
safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in 
ChAd63 and MVA vaccine vectors. PLoS One, 7, e31208.
Sheehy, S. H., C. J. Duncan, S. C. Elias, P. Choudhary, S. Biswas, F. D. Halstead, K. A. Collins, N. J. 
Edwards, A. D. Douglas, N. A. Anagnostou, K. J. Ewer, T. Havelock, T. Mahungu, C. M. 
Bliss, K. Miura, I. D. Poulton, P. J. Lillie, R. D. Antrobus, E. Berrie, S. Moyle, K. Gantlett, S. 
Colloca, R. Cortese, C. A. Long, R. E. Sinden, S. C. Gilbert, A. M. Lawrie, T. Doherty, S. N. 
Faust, A. Nicosia, A. V. Hill & S. J. Draper (2012b) ChAd63-MVA-vectored blood-stage 
malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite 
challenge in humans. Mol Ther, 20, 2355-68.
Sheehy, S. H., C. J. Duncan, S. C. Elias, K. A. Collins, K. J. Ewer, A. J. Spencer, A. R. Williams, F. D. 
Halstead, S. E. Moretz, K. Miura, C. Epp, M. D. Dicks, I. D. Poulton, A. M. Lawrie, E. Berrie, 
S. Moyle, C. A. Long, S. Colloca, R. Cortese, S. C. Gilbert, A. Nicosia, A. V. Hill & S. J. 
Draper (2011) Phase la clinical evaluation of the Plasmodium falciparum blood-stage antigen 
MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther, 19, 2269-76.
Shulman, C. E. & E. K. Dorman (2003) Importance and prevention of malaria in pregnancy. Trans R 
Soc Trop Med Hyg, 97, 30-5.
Siegrist, C. A. (2001) Neonatal and early life vaccinology. Vaccine, 19, 3331-46.
— (2003) Mechanisms by which maternal antibodies influence infant vaccine responses: review of
hypotheses and definition of main determinants. Vaccine, 21, 3406-12.
Silamut, K., N. H. Phu, C. Whitty, G. D. Turner, K. Louwrier, N. T. Mai, J. A. Simpson, T. T. Hien & 
N. J. White (1999) A quantitative analysis of the microvascular sequestration of malaria 
parasites in the human brain. Am J Pathol, 155, 395-410.
Simister, N. E. (1998) Human placental Fc receptors and the trapping of immune complexes. Vaccine, 
16, 1451-5.
— (2003) Placental transport of immunoglobulin G. Vaccine, 21, 3365-9.
Singh, B., L. Kim Sung, A. Matusop, A. Radhakrishnan, S. S. Shamsul, J. Cox-Singh, A. Thomas & D. 
J. Conway (2004) A large focus of naturally acquired Plasmodium knowlesi infections in 
human beings. Lancet, 363, 1017-24.
Sinnis, P. & A. Coppi (2007) A long and winding road: the Plasmodium sporozoite's journey in the 
mammalian host. Parasitol Int, 56,171-8.
Sirima, S. B., I. Nebie, A. Ouedraogo, A. B. Tiono, A. T. Konate, A. Gansane, A. I. Derme, A. Diarra,
I. Soulama, N. Cuzzin-Ouattara, S. Cousens & O. Leroy (2007) Safety and immunogenicity of 
the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) 
malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine, 
25, 2723-32.
Sirima, S. B., A. B. Tiono, A. Ouedraogo, A. Diarra, A. L. Ouedraogo, J. B. Yaro, E. Ouedraogo, A. 
Gansane, E. C. Bougouma, A. T. Konate, Y. Kabore, A. Traore, R. Chilengi, I. Soulama, A. J. 
Luty, P. Druilhe, S. Cousens & I. Nebie (2009) Safety and immunogenicity of the malaria 
vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS 
One, 4, e7549.
Smith, D. L., C. A. Guerra, R. W. Snow & S. I. Hay (2007) Standardizing estimates o f the Plasmodium 
falciparum parasite rate. Malar J, 6,131.
Smith, D. L. & S. I. Hay (2009) Endemicity response timelines for Plasmodium falciparum 
elimination. Malar J, 8, 87.
321
Smythe, J. A., R. L. Coppel, K. P. Day, R. K. Martin, A. M. Oduola, D. J. Kemp & R. F. Anders 
(1991) Structural diversity in the Plasmodium falciparum merozoite surface antigen 2. Proc 
Natl Acad Sci U S A, 88, 1751-5.
Snow, R. W., I. Bastos de Azevedo, B. S. Lowe, E. W. Kabiru, C. G. Nevill, S. Mwankusye, G. 
Kassiga, K. Marsh & T. Teuscher (1994) Severe childhood malaria in two areas of markedly 
different falciparum transmission in east Africa. Acta Trop, 57,289-300.
Snow, R. W., B. Nahlen, A. Palmer, C. A. Donnelly, S. Gupta & K. Marsh (1998) Risk of severe 
malaria among African infants: direct evidence of clinical protection during early infancy. J  
Infect Dis, 177,819-22.
Soe, S., S. Singh, D. Camus, T. Horii & P. Druilhe (2002) Plasmodium falciparum serine repeat 
protein, a new target of monocyte-dependent antibody-mediated parasite killing. Infect Immun, 
70, 7182-4.
Soe, S., M. Theisen, C. Roussilhon, K. S. Aye & P. Druilhe (2004) Association between protection 
against clinical malaria and antibodies to merozoite surface antigens in an area of 
hyperendemicity in Myanmar: complementarity between responses to merozoite surface 
protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun, 72, 247-52.
Spring, M. D., J. F. Cummings, C. F. Ockenhouse, S. Dutta, R. Reidler, E. Angov, E. Bergmann- 
Leitner, V. A. Stewart, S. Bittner, L. Juompan, M. G. Kortepeter, R. Nielsen, U. Krzych, E. 
Tierney, L. A. Ware, M. Dowler, C. C. Hermsen, R. W. Sauerwein, S. J. de Vlas, O. Ofori- 
Anyinam, D. E. Lanar, J. L. Williams, K. E. Kester, K. Tucker, M. Shi, E. Malkin, C. Long, C. 
L. Diggs, L. Soisson, M. C. Dubois, W. R. Ballou, J. Cohen & D. G. Heppner, Jr. (2009) Phase 
l/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered 
in adjuvant system AS01B or AS02A. PLoS One, 4, e5254.
Stanisic, D. I., J. S. Richards, F. J. McCallum, P. Michon, C. L. King, S. Schoepflin, P. R. Gilson, V. J.
Murphy, R. F. Anders, I. Mueller & J. G. Beeson (2009) Immunoglobulin G subclass-specific 
responses against Plasmodium falciparum merozoite antigens are associated with control of 
parasitemia and protection from symptomatic illness. Infect Immun, 77, 1165-74.
Stoute, J. A., J. Gombe, M. R. Withers, J. Siangla, D. McKinney, M. Onyango, J. F. Cummings, J. 
Milman, K. Tucker, L. Soisson, V. A. Stewart, J. A. Lyon, E. Angov, A. Leach, J. Cohen, K.
E. Kester, C. F. Ockenhouse, C. A. Holland, C. L. Diggs, J. Wittes & D. G. Heppner, Jr. (2007) 
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum 
malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western 
Kenya. Vaccine, 25, 176-84.
Stowers, A. W., V. Cioce, R. L. Shimp, M. Lawson, G. Hui, O. Muratova, D. C. Kaslow, R. Robinson,
C. A. Long & L. H. Miller (2001) Efficacy of two alternate vaccines based on Plasmodium 
falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun, 69, 1536-46.
Stowers, A. W., M. C. Kennedy, B. P. Keegan, A. Saul, C. A. Long & L. H. Miller (2002) Vaccination 
of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers
protection against blood-stage malaria. Infect Immun, 70, 6961-7.
Sturm, A., R. Amino, C. van de Sand, T. Regen, S. Retzlaff, A. Rennenberg, A. Krueger, J. M. Pollok, 
R. Menard & V. T. Heussler (2006) Manipulation of host hepatocytes by the malaria parasite 
for delivery into liver sinusoids. Science, 313, 1287-90.
Takala, S. L., D. Coulibaly, M. A. Thera, A. H. Batchelor, M. P. Cummings, A. A. Escalante, A. 
Ouattara, K. Traore, A. Niangaly, A. A. Djimde, O. K. Doumbo & C. V. Plowe (2009) 
Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for 
vaccine development. Sci Transl Med, 1 ,2ra5.
Tan, X., B. Traore, K. Kayentao, A. Ongoiba, S. Doumbo, M. Waisberg, O. K. Doumbo, P. L. Feigner, 
R. M. Fairhurst & P. D. Crompton (2011) Hemoglobin S and C heterozygosity enhances 
neither the magnitude nor breadth of antibody responses to a diverse array o f Plasmodium 
falciparum antigens. J Infect Dis, 204, 1750-61.
Tanabe, K., M. Mackay, M. Goman & J. G. Scaife (1987) Allelic dimorphism in a surface antigen gene 
of the malaria parasite Plasmodium falciparum. J Mol Biol, 195, 273-87.
Tangteerawatana, P., S. M. Montgomery, H. Perlmann, S. Looareesuwan, M. Troye-Blomberg & S. 
Khusmith (2007) Differential regulation of IgG subclasses and IgE antimalarial antibody 
responses in complicated and uncomplicated Plasmodium falciparum malaria. Parasite 
Immunol, 29,475-83.
322
Taylor, R. R., S. J. Allen, B. M. Greenwood & E. M. Riley (1998) lgG3 antibodies to Plasmodium 
falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and 
association with clinical immunity to malaria. Am J Trop Med Hyg, 58,406-13.
Taylor, R. R., A. Egan, D. McGuinness, A. Jepson, R. Adair, C. Drakely & E. Riley (1996) Selective 
recognition of malaria antigens by human serum antibodies is not genetically determined but 
demonstrates some features of clonal imprinting. Int Immunol, 8, 905-15.
Taylor, R. R., D. B. Smith, V. J. Robinson, J. S. McBride & E. M. Riley (1995) Human antibody 
response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and 
predominantly of the immunoglobulin G3 subclass. Infect Immun, 63,4382-8.
Taylor, T. E., W. J. Fu, R. A. Carr, R. O. Whitten, J. S. Mueller, N. G. Fosiko, S. Lewallen, N. G. 
Liomba & M. E. Molyneux (2004) Differentiating the pathologies of cerebral malaria by 
postmortem parasite counts. Nat Med, 10, 143-5.
Taylor, T. E., M. E. Molyneux, J. J. Wirima, A. Borgstein, J. D. Goldring & M. Hommel (1992) 
Intravenous immunoglobulin in the treatment of paediatric cerebral malaria. Clin Exp 
Immunol, 90, 357-62.
Tchinda, V. H., A. D. Tadem, E. A. Tako, G. Tene, J. Fogako, P. Nyonglema, G. Sama, A. Zhou & R.
G. Leke (2007) Severe malaria in Cameroonian children: correlation between plasma levels of 
three soluble inducible adhesion molecules and TNF-alpha. Acta Trop, 102, 20-8.
Tebo, A. E., P. G. Kremsner, K. P. Piper & A. J. Luty (2002) Low antibody responses to variant 
surface antigens of Plasmodium falciparum are associated with severe malaria and increased 
susceptibility to malaria attacks in Gabonese children. Am J  Trop Med Hyg, 67, 597-603. 
Tharavanij, S., M. J. Warrell, S. Tantivanich, P. Tapchaisri, M. Chongsa-Nguan, V. Prasertsiriroj & J. 
Patarapotikul (1984) Factors contributing to the development of cerebral malaria. I. Humoral 
immune responses. Am J  Trop Med Hyg, 33, 1-11.
Theisen, M., S. Soe, C. Oeuvray, A. W. Thomas, J. Vuust, S. Danielsen, S. Jepsen & P. Druilhe (1998) 
The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody- 
dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun, 66, 11-7. 
Theisen, M., J. Vuust, A. Gottschau, S. Jepsen & B. Hogh (1995) Antigenicity and immunogenicity of 
recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. 
Clin Diagn Lab Immunol, 2, 30-4.
Thera, M. A., O. K. Doumbo, D. Coulibaly, D. A. Diallo, A. K. Kone, A. B. Guindo, K. Traore, A. 
Dicko, I. Sagara, M. S. Sissoko, M. Baby, M. Sissoko, I. Diarra, A. Niangaly, A. Dolo, M. 
Daou, S. I. Diawara, D. G. Heppner, V. A. Stewart, E. Angov, E. S. Bergmann-Leitner, D. E. 
Lanar, S. Dutta, L. Soisson, C. L. Diggs, A. Leach, A. Owusu, M. C. Dubois, J. Cohen, J. N. 
Nixon, A. Gregson, S. L. Takala, K. E. Lyke & C. V. Plowe (2008) Safety and 
immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 
randomized controlled trial. PLoS One, 3, el465.
Thera, M. A., O. K. Doumbo, D. Coulibaly, D. A. Diallo, I. Sagara, A. Dicko, D. J. Diemert, D. G. 
Heppner, Jr., V. A. Stewart, E. Angov, L. Soisson, A. Leach, K. Tucker, K. E. Lyke & C. V. 
Plowe (2006) Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: 
results of a phase 1 randomized trial. PLoS Clin Trials, 1, e34.
Thera, M. A., O. K. Doumbo, D. Coulibaly, M. B. Laurens, A. K. Kone, A. B. Guindo, K. Traore, M. 
Sissoko, D. A. Diallo, I. Diarra, B. Kouriba, M. Daou, A. Dolo, M. Baby, M. S. Sissoko, I. 
Sagara, A. Niangaly, I. Traore, A. Olotu, O. Godeaux, A. Leach, M. C. Dubois, W. R. Ballou, 
J. Cohen, D. Thompson, T. Dube, L. Soisson, C. L. Diggs, S. L. Takala, K. E. Lyke, B. House,
D. E. Lanar, S. Dutta, D. G. Heppner & C. V. Plowe (2010) Safety and immunogenicity of an 
AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. 
PLoS One, 5, e9041.
Thera, M. A., O. K. Doumbo, D. Coulibaly, M. B. Laurens, A. Ouattara, A. K. Kone, A. B. Guindo, K. 
Traore, I. Traore, B. Kouriba, D. A. Diallo, I. Diarra, M. Daou, A. Dolo, Y. Tolo, M. S. 
Sissoko, A. Niangaly, M. Sissoko, S. Takala-Harrison, K. E. Lyke, Y. Wu, W. C. Blackwelder, 
O. Godeaux, J. Vekemans, M. C. Dubois, W. R. Ballou, J. Cohen, D. Thompson, T. Dube, L. 
Soisson, C. L. Diggs, B. House, D. E. Lanar, S. Dutta, D. G. Heppner, Jr. & C. V. Plowe
(2011) A field trial to assess a blood-stage malaria vaccine. N Engl J  Med, 365, 1004-13.
323
TM, A. E., M. I. Elbashir, K. Berzins, E. M. Masuadi, A. E. IE, G. ElGhazali & H. A. Giha (2008) The 
profile of IgG-antibody response against merozoite surface proteins 1 and 2 in severe 
Plasmodium falciparum malaria in Eastern Sudan. Parasitol Res, 102,401-9.
Todryk, S. M., P. Bejon, T. Mwangi, M. Plebanski, B. Urban, K. Marsh, A. V. Hill & K. L. Flanagan
(2008) Correlation of memory T cell responses against TRAP with protection from clinical 
malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One, 3, e2027.
Tongren, J. E., P. H. Corran, W. Jarra, J. Langhome & E. M. Riley (2005) Epitope-specific regulation 
of immunoglobulin class switching in mice immunized with malarial merozoite surface 
proteins. Infect Immun, 73, 8119-29.
Tonkin, M. L., M. Roques, M. H. Lamarque, M. Pugniere, D. Douguet, J. Crawford, M. Lebrun & M. 
J. Boulanger (2011) Host cell invasion by apicomplexan parasites: insights from the co­
structure of AMA1 with a RON2 peptide. Science, 333,463-7.
Tran, T. M., S. Li, S. Doumbo, D. Doumtabe, C. Y. Huang, S. Dia, A. Bathily, J. Sangala, Y. Kone, A. 
Traore, M. Niangaly, C. Dara, K. Kayentao, A. Ongoiba, O. K. Doumbo, B. Traore & P. D. 
Crompton (2013) An intensive longitudinal cohort study of Malian children and adults reveals 
no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis, 57, 40- 
7.
Trieu, A., M. A. Kayala, C. Burk, D. M. Molina, D. A. Freilich, T. L. Richie, P. Baldi, P. L. Feigner &
D. L. Doolan (2011) Sterile protective immunity to malaria is associated with a panel of novel 
P. falciparum antigens. Mol Cell Proteomics, 10, Mi l l  007948.
Triglia, T., J. Thompson, S. R. Caruana, M. Delorenzi, T. Speed & A. F. Cowman (2001) Identification 
of proteins from Plasmodium falciparum that are homologous to reticulocyte binding proteins 
in Plasmodium vivax. Infect Immun, 69, 1084-92.
Tsuji, M., P. Romero, R. S. Nussenzweig & F. Zavala (1990) CD4+ cytolytic T cell clone confers 
protection against murine malaria. J  Exp Med, 172, 1353-7.
Turner, G. D., V. C. Ly, T. H. Nguyen, T. H. Tran, H. P. Nguyen, D. Bethell, S. Wyllie, K. Louwrier, 
S. B. Fox, K. C. Gatter, N. P. Day, N. J. White & A. R. Berendt (1998) Systemic endothelial 
activation occurs in both mild and severe malaria. Correlating dermal microvascular 
endothelial cell phenotype and soluble cell adhesion molecules with disease severity. Am J  
Pathol, 152, 1477-87.
Turner, G. D., H. Morrison, M. Jones, T. M. Davis, S. Looareesuwan, I. D. Buley, K. C. Gatter, C. I. 
Newbold, S. Pukritayakamee, B. Nagachinta & et al. (1994) An immunohistochemical study of 
the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential 
role for intercellular adhesion molecule-1 in cerebral sequestration. Am J  Pathol, 145, 1057-69.
Udeinya, I. J., J. A. Schmidt, M. Aikawa, L. H. Miller & I. Green (1981) Falciparum malaria-infected 
erythrocytes specifically bind to cultured human endothelial cells. Science, 213, 555-7.
Udhayakumar, V., D. Anyona, S. Kariuki, Y. P. Shi, P. B. Bloland, O. H. Branch, W. Weiss, B. L. 
Nahlen, D. C. Kaslow & A. A. Lai (1995) Identification of T and B cell epitopes recognized by 
humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface 
protein (MSP)-l. J  Immunol, 154, 6022-30.
Uthaipibull, C., B. Aufiero, S. E. Syed, B. Hansen, J. A. Guevara Patino, E. Angov, I. T. Ling, K. 
Fegeding, W. D. Morgan, C. Ockenhouse, B. Birdsall, J. Feeney, J. A. Lyon & A. A. Holder
(2001) Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of 
the malaria parasite Plasmodium falciparum. J Mol Biol, 307, 1381-94.
Van Weemen, B. K. & A. H. Schuurs (1971) Immunoassay using antigen-enzyme conjugates. FEBS 
Lett, 15,232-236.
Vermeulen, A. N., T. Ponnudurai, P. J. Beckers, J. P. Verhave, M. A. Smits & J. H. Meuwissen (1985) 
Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to 
transmission-blocking antibodies in the mosquito. J Exp Med, 162, 1460-76.
Wagner, G., K. Koram, D. McGuinness, S. Bennett, F. Nkrumah & E. Riley (1998) High incidence of 
asymptomatic malara infections in a birth cohort of children less than one year of age in 
Ghana, detected by multicopy gene polymerase chain reaction. Am J Trop Med Hyg, 59, 115- 
23.
Wassmer, S. C., C. Lepolard, B. Traore, B. Pouvelle, J. Gysin & G. E. Grau (2004) Platelets reorient 
Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J  
Infect Dis, 189, 180-9.
324
Weiss, G. E., B. Traore, K. Kayentao, A. Ongoiba, S. Doumbo, D. Doumtabe, Y. Kone, S. Dia, A. 
Guindo, A. Traore, C. Y. Huang, K. Miura, M. Mircetic, S. Li, A. Baughman, D. L. Narum, L.
H. Miller, O. K. Doumbo, S. K. Pierce & P. D. Crompton (2010) The Plasmodium falciparum- 
specific human memory B cell compartment expands gradually with repeated malaria 
infections. PLoS Pathog, 6, e l000912.
Weiss, W. R., M. Sedegah, R. L. Beaudoin, L. H. Miller & M. F. Good (1988) CD8+ T cells 
(cytotoxic/suppressors) are required for protection in mice immunized with malaria 
sporozoites. Proc Natl Acad Sci USA,  85, 573-6.
Wernette, C. M., C. E. Frasch, D. Madore, G, Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S. A. 
Quataert, S. Hildreth, D. J. Sikkema, H. Kayhty, 1. Jonsdottir & M. H. Nahm (2003) Enzyme- 
linked immunosorbent assay for quantitation of human antibodies to pneumococcal 
polysaccharides. Clin Diagn Lab Immunol, 10, 514-9.
White, M. T., J. T. Griffin, O. Akpogheneta, D. J. Conway, K. A. Koram, E. M. Riley & A. C. Ghani 
(2014a) Dynamics of the Antibody Response to Plasmodium falciparum Infection in African 
Children. J Infect Dis.
White, N. J. (2008) Plasmodium knowlesi: the fifth human malaria parasite. Clin Infect Dis, 46, 172-3.
— (2011) Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J, 10,297.
White, N. J., S. Pukrittayakamee, T. T. Hien, M. A. Faiz, O. A. Mokuolu & A. M. Dondorp (2014b)
Malaria. The Lancet, 383, 723-735.
WHO (2004) A strategic framework for malaria prevention and control during pregnancy in the 
African region
January 2004.
— (2009) Clinical Guidelines for Management and Referral of Common Conditions at Levels 4-6:
Hospitals. Clinical management and referral guidelines, Volume III.
— (2010) Guidelines for the treatment of malaria. Second edition.
— (2012) Management of severe malaria: a practical handbook -  3rd ed.
— (2013) World Malaria Report 2013.
Willey, B. A., L. S. Paintain, L. Mangham, J. Car & J. A. Schellenberg (2012) Strategies for delivering 
insecticide-treated nets at scale for malaria control: a systematic review. Bull World Health 
Organ, 90, 672-684E.
Williams, A. R., A. D. Douglas, K. Miura, J. J. Illingworth, P. Choudhary, L. M. Murungi, J. M. Furze, 
A. Diouf, O. Miotto, C. Crosnier, G. J. Wright, D. P. Kwiatkowski, R. M. Fairhurst, C. A. 
Long & S. J. Draper (2012) Enhancing blockade of Plasmodium falciparum erythrocyte 
invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. 
PLoS Pathog, 8, e l002991.
Wilson, A. L. (2011) A systematic review and meta-analysis of the efficacy and safety of intermittent 
preventive treatment of malaria in children (IPTc). PLoS One, 6, el6976.
Wilson, P. T., I. Malhotra, P. Mungai, C. L. King & A. E. Dent (2013) Transplacentally transferred 
functional antibodies against Plasmodium falciparum decrease with age. Acta Trop, 128, 149- 
53.
Wipasa, J., C. Suphavilai, L. C. Okell, J. Cook, P. H. Corran, K. Thaikla, W. Liewsaree, E. M. Riley & 
J. C. Hafalla (2010) Long-lived antibody and B Cell memory responses to the human malaria 
parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog, 6, e l000770.
Withers, M. R., D. McKinney, B. R. Ogutu, J. N. Waitumbi, J. B. Milman, O. J. Apollo, O. G. Allen, 
K. Tucker, L. A. Soisson, C. Diggs, A. Leach, J. Wittes, F. Dubovsky, V. A. Stewart, S. A. 
Remich, J. Cohen, W. R. Ballou, C. A. Holland, J. A. Lyon, E. Angov, J. A. Stoute, S. K. 
Martin & D. G. Heppner, Jr. (2006) Safety and reactogenicity of an MSP-1 malaria vaccine 
candidate: a randomized phase lb dose-escalation trial in Kenyan children. PLoS Clin Trials, 1, 
e32.
Wongsrichanalai, C. & S. R. Meshnick (2008) Declining artesunate-mefloquine efficacy against 
falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis, 14, 716-9.
Wrammert, J., D. Koutsonanos, G. M. Li, S. Edupuganti, J. Sui, M. Morrissey, M. McCausland, I. 
Skountzou, M. Hornig, W. I. Lipkin, A. Mehta, B. Razavi, C. Del Rio, N. Y. Zheng, J. H. Lee, 
M. Huang, Z. Ali, K. Kaur, S. Andrews, R. R. Amara, Y. Wang, S. R. Das, C. D. O'Donnell, J. 
W. Yewdell, K. Subbarao, W. A. Marasco, M. J. Mulligan, R. Compans, R. Ahmed & P. C.
325
Wilson (2011) Broadly cross-reactive antibodies dominate the human B cell response against 
2009 pandemic H1N1 influenza virus infection. J Exp Med, 208, 181-93.
Wu, Y., R. D. Ellis, D. Shaffer, E. Fontes, E. M. Malkin, S. Mahanty, M. P. Fay, D. Narum, K. Rausch, 
A. P. Miles, J. Aebig, A. Orcutt, O. Muratova, G. Song, L. Lambert, D. Zhu, K. Miura, C. 
Long, A. Saul, L. H. Miller & A. P. Durbin (2008) Phase 1 trial of malaria transmission 
blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One, 
3, e2636.
Yeo, T. W., D. A. Lampah, R. Gitawati, E. Tjitra, E. Kenangalem, Y. R. McNeil, C. J. Darcy, D. L. 
Granger, J. B. Weinberg, B. K. Lopansri, R. N. Price, S. B. Duffull, D. S. Celermajer & N. M. 
Anstey (2007) Impaired nitric oxide bioavailability and L-arginine reversible endothelial 
dysfunction in adults with falciparum malaria. J  Exp Med, 204,2693-704.
Yeo, T. W., D. A. Lampah, R. Gitawati, E. Tjitra, E. Kenangalem, K. Piera, R. N. Price, S. B. Duffull,
D. S. Celermajer & N. M. Anstey (2008) Angiopoietin-2 is associated with decreased 
endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl 
AcadSciUSA,  105, 17097-102.
Yoon, 1. K., E. Angov, D. Larson, D. G. Heppner, J. F. Cummings & V. A. Stewart (2005) 
Characterization of a human reference standard for antibody to Plasmodium falciparum 
merozoite surface protein 1(42). Am J  Trop MedHyg, 72, 714-8.
326
